id,ticker,title,link,topic,published_est,market,begin_price,end_price,index_begin_price,index_end_price,daily_return,index_return,daily_alpha,actual_action,predicted_action,confidence
2,"ACIU","AC Immune Showcasing Precision Medicine Programs at AAIC 2023","https://www.globenewswire.com/news-release/2023/07/03/2698440/0/en/AC-Immune-Showcasing-Precision-Medicine-Programs-at-AAIC-2023.html","Clinical Study","2023-07-03 07:00:00","pre_market",3,3,443,443,-0,-0,-0,"short","short",NaN
3,"ACIU","AC Immune to Host Key Opinion Leader Webinar on Early Diagnosis and Prevention of Alzheimer’s Disease","https://www.globenewswire.com/news-release/2023/04/05/2641522/0/en/AC-Immune-to-Host-Key-Opinion-Leader-Webinar-on-Early-Diagnosis-and-Prevention-of-Alzheimer-s-Disease.html","Calendar of Events","2023-04-05 07:00:00","pre_market",2,2,409,408,-0,-0,-0,"short","short",NaN
4,"ACIU","AC Immune Clinical Data Published in Nature Communications Show Alpha-Synuclein PET Tracer ACI-12589 Has Potential as Neurodegenerative Disease Diagnostic","https://www.globenewswire.com/news-release/2023/10/27/2768271/0/en/AC-Immune-Clinical-Data-Published-in-Nature-Communications-Show-Alpha-Synuclein-PET-Tracer-ACI-12589-Has-Potential-as-Neurodegenerative-Disease-Diagnostic.html","Company Announcement","2023-10-27 07:00:00","pre_market",3,3,413,414,-0,0,-0,"short","short",NaN
5,"ACIU","AC Immune at AD/PD™ 2023 to Present New Clinical and Preclinical Data from its Precision Medicine Pipeline","https://www.globenewswire.com/news-release/2023/03/20/2630182/0/en/AC-Immune-at-AD-PD-2023-to-Present-New-Clinical-and-Preclinical-Data-from-its-Precision-Medicine-Pipeline.html","Calendar of Events","2023-03-20 08:00:00","pre_market",2,2,390,391,0,0,0,"long","long",NaN
6,"ACIU","AC Immune Awarded New Grants from MJFF and Target ALS Supporting Programs Targeting TDP-43","https://www.globenewswire.com/news-release/2023/02/07/2602787/0/en/AC-Immune-Awarded-New-Grants-from-MJFF-and-Target-ALS-Supporting-Programs-Targeting-TDP-43.html","Health","2023-02-07 07:00:00","pre_market",2,2,410,409,0,-0,0,"long","long",NaN
7,"ACIU","AC Immune SA Appoints New Chief Medical Officer","https://www.globenewswire.com/news-release/2023/07/26/2711171/0/en/AC-Immune-SA-Appoints-New-Chief-Medical-Officer.html","Management Changes","2023-07-26 07:00:00","pre_market",3,3,455,454,0,-0,0,"long","long",NaN
8,"ACIU","AC Immune’s ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer’s Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE Trial","https://www.globenewswire.com/news-release/2023/01/26/2595885/0/en/AC-Immune-s-ACI-24-060-Anti-Amyloid-Beta-Vaccine-for-Alzheimer-s-Shows-Positive-Initial-Interim-Safety-and-Immunogenicity-in-Phase-1b-2-ABATE-Trial.html","Clinical Study","2023-01-26 07:00:00","pre_market",2,3,400,403,0,0,0,"long","long",NaN
9,"ACIU","AC Immune Reports First Quarter 2023 Financial Results and Provides a Corporate Update","https://www.globenewswire.com/news-release/2023/04/28/2657303/0/en/AC-Immune-Reports-First-Quarter-2023-Financial-Results-and-Provides-a-Corporate-Update.html","Interim information","2023-04-28 07:00:00","pre_market",2,2,412,411,0,-0,0,"long","long",NaN
10,"ACIU","AC Immune to Host KOL Webinar on Amyloid Plaque PET Imaging in Alzheimer’s Disease as a Surrogate of Clinical Efficacy on November 9, 2023","https://www.globenewswire.com/news-release/2023/11/02/2772091/0/en/AC-Immune-to-Host-KOL-Webinar-on-Amyloid-Plaque-PET-Imaging-in-Alzheimer-s-Disease-as-a-Surrogate-of-Clinical-Efficacy-on-November-9-2023.html","Clinical Study","2023-11-02 07:00:00","pre_market",3,3,423,427,0,0,-0,"short","long",NaN
11,"ACIU","AC Immune Reports Third Quarter 2023 Financial Results and Provides a Corporate Update","https://www.globenewswire.com/news-release/2023/11/03/2773089/0/en/AC-Immune-Reports-Third-Quarter-2023-Financial-Results-and-Provides-a-Corporate-Update.html","Earnings Releases and Operating Results","2023-11-03 07:00:00","pre_market",3,3,431,433,0,0,0,"long","long",NaN
12,"ACIU","AC Immune to Present at the SVB Securities Global Biopharma Conference","https://www.globenewswire.com/news-release/2023/02/02/2600439/0/en/AC-Immune-to-Present-at-the-SVB-Securities-Global-Biopharma-Conference.html","Calendar of Events","2023-02-02 08:15:00","pre_market",2,2,411,415,-0,0,-0,"short","short",NaN
15,"ACIU","AC Immune Reports Second Quarter 2023 Financial Results and Provides a Corporate Update","https://www.globenewswire.com/news-release/2023/08/04/2718852/0/en/AC-Immune-Reports-Second-Quarter-2023-Financial-Results-and-Provides-a-Corporate-Update.html","Clinical Study","2023-08-04 07:00:00","pre_market",3,3,449,451,0,0,0,"long","short",NaN
16,"ACIU","AC Immune to Present at the Jefferies 2023 CNS & Neuro Summit in October 2023","https://www.globenewswire.com/news-release/2023/10/05/2755226/0/en/AC-Immune-to-Present-at-the-Jefferies-2023-CNS-Neuro-Summit-in-October-2023.html","Calendar of Events","2023-10-05 07:00:00","pre_market",3,3,425,424,0,-0,0,"long","long",NaN
17,"ACIU","AC Immune’s Alzheimer’s Disease Vaccine-candidate ACI-35.030 Selected for Further Development","https://www.globenewswire.com/news-release/2022/11/30/2564787/0/en/AC-Immune-s-Alzheimer-s-Disease-Vaccine-candidate-ACI-35-030-Selected-for-Further-Development.html","Clinical Study","2022-11-30 07:00:00","pre_market",3,3,395,395,0,0,0,"long","long",NaN
18,"ACIU","AC Immune Receives FDA Fast Track Designation for Anti-Amyloid-beta Active Immunotherapy, ACI-24.060, to Treat Alzheimer’s Disease","https://www.globenewswire.com/news-release/2023/06/27/2695157/0/en/AC-Immune-Receives-FDA-Fast-Track-Designation-for-Anti-Amyloid-beta-Active-Immunotherapy-ACI-24-060-to-Treat-Alzheimer-s-Disease.html","Clinical Study","2023-06-27 07:00:00","pre_market",2,2,431,432,0,0,0,"long","long",NaN
29,"ADAG","Adagene Achieves $3 Million Milestone in Collaboration with Exelixis for Successful Nomination of Second SAFEbody® Novel Masked Antibody-Drug Conjugate","https://www.globenewswire.com/news-release/2023/05/04/2661611/0/en/Adagene-Achieves-3-Million-Milestone-in-Collaboration-with-Exelixis-for-Successful-Nomination-of-Second-SAFEbody-Novel-Masked-Antibody-Drug-Conjugate.html","Product / Services Announcement","2023-05-04 09:00:00","pre_market",1,1,408,407,0,-0,0,"long","long",NaN
21,"ACIU","AC Immune to Report Full Year 2022 Financial Results and Provide Corporate Update on March 16, 2023","https://www.globenewswire.com/news-release/2023/03/08/2622870/0/en/AC-Immune-to-Report-Full-Year-2022-Financial-Results-and-Provide-Corporate-Update-on-March-16-2023.html","Calendar of Events","2023-03-08 07:00:00","pre_market",2,2,398,398,-0,0,-0,"short","short",NaN
30,"ADAG","Adagene Presents Data Demonstrating the Best-in-Class Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 at SITC 2023","https://www.globenewswire.com/news-release/2023/11/03/2773331/0/en/Adagene-Presents-Data-Demonstrating-the-Best-in-Class-Therapeutic-Index-for-Masked-Anti-CTLA-4-SAFEbody-ADG126-at-SITC-2023.html","Product / Services Announcement","2023-11-03 12:00:00","market_open",1,1,433,435,0,0,0,"long","long",NaN
19,"ACIU","AC Immune Reports Full Year 2022 Financial Results and Provides Corporate Update","https://www.globenewswire.com/news-release/2023/03/16/2628465/0/en/AC-Immune-Reports-Full-Year-2022-Financial-Results-and-Provides-Corporate-Update.html","Earnings Releases and Operating Results","2023-03-16 07:00:00","pre_market",2,2,389,387,0,-0,0,"long","long",NaN
34,"ADAG","Adagene Announces Updates to its Board of Directors","https://www.globenewswire.com/news-release/2023/04/28/2657314/0/en/Adagene-Announces-Updates-to-its-Board-of-Directors.html","Directors and Officers","2023-04-28 07:00:00","pre_market",1,1,412,411,0,-0,0,"long","long",NaN
32,"ADAG","天演药业将在第38届SITC年会上以海报形式公布其精准掩蔽型抗CTLA-4安全抗体SAFEbody® ADG126剂量优化试验结果","https://www.globenewswire.com/news-release/2023/10/12/2759195/0/zh-hans/%E5%A4%A9%E6%BC%94%E8%8D%AF%E4%B8%9A%E5%B0%86%E5%9C%A8%E7%AC%AC38%E5%B1%8ASITC%E5%B9%B4%E4%BC%9A%E4%B8%8A%E4%BB%A5%E6%B5%B7%E6%8A%A5%E5%BD%A2%E5%BC%8F%E5%85%AC%E5%B8%83%E5%85%B6%E7%B2%BE%E5%87%86%E6%8E%A9%E8%94%BD%E5%9E%8B%E6%8A%97CTLA-4%E5%AE%89%E5%85%A8%E6%8A%97%E4%BD%93SAFEbody-ADG126%E5%89%82%E9%87%8F%E4%BC%98%E5%8C%96%E8%AF%95%E9%AA%8C%E7%BB%93%E6%9E%9C.html","Calendar of Events","2023-10-12 08:00:00","pre_market",1,2,436,437,0,0,0,"long","long",NaN
33,"ADAG","Adagene to Present at Investor and Scientific Conferences in September","https://www.globenewswire.com/news-release/2023/09/07/2739093/0/en/Adagene-to-Present-at-Investor-and-Scientific-Conferences-in-September.html","Conference Calls/ Webcasts","2023-09-07 06:00:00","pre_market",1,1,446,443,-0,-0,-0,"short","short",NaN
31,"ADAG","Adagene Announces Clinical Trial Collaboration to Evaluate Anti-CTLA-4 SAFEbody® ADG126 in Combination with Roche’s Standard-of-Care for First-Line Advanced Liver Cancer","https://www.globenewswire.com/news-release/2022/12/16/2575333/0/en/Adagene-Announces-Clinical-Trial-Collaboration-to-Evaluate-Anti-CTLA-4-SAFEbody-ADG126-in-Combination-with-Roche-s-Standard-of-Care-for-First-Line-Advanced-Liver-Cancer.html","Health","2022-12-16 06:30:00","pre_market",1,1,390,385,0,-0,0,"long","long",NaN
20,"ACIU","AC Immune to Present Progress of Alzheimer’s Disease Programs targeting Abeta and Tau at the 15th CTAD Conference","https://www.globenewswire.com/news-release/2022/11/23/2561536/0/en/AC-Immune-to-Present-Progress-of-Alzheimer-s-Disease-Programs-targeting-Abeta-and-Tau-at-the-15th-CTAD-Conference.html","Clinical Study","2022-11-23 07:30:00","pre_market",3,3,400,400,0,-0,0,"long","short",NaN
51,"ADXN","Addex Announces Participation in the H.C. Wainwright 25th Annual Global Investment Conference","https://www.globenewswire.com/news-release/2023/09/06/2737990/0/en/Addex-Announces-Participation-in-the-H-C-Wainwright-25th-Annual-Global-Investment-Conference.html","European Regulatory News","2023-09-06 01:00:00","no_market",(null),(null),(null),(null),(null),(null),(null),(null),"long",NaN
22,"ACIU","AC Immune to Present at the Jefferies 2023 London Healthcare Conference","https://www.globenewswire.com/news-release/2023/11/07/2774887/0/en/AC-Immune-to-Present-at-the-Jefferies-2023-London-Healthcare-Conference.html","Calendar of Events","2023-11-07 07:00:00","pre_market",3,3,436,436,-0,0,-0,"short","short",NaN
23,"ACIU","AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson diseases","https://www.globenewswire.com/news-release/2024/01/03/2803284/0/en/AC-Immune-Progress-Update-on-Phase-2-Active-Immunotherapy-Clinical-Pipeline-for-Alzheimer-s-and-Parkinson-diseases.html","Clinical Study","2024-01-03 08:10:00","pre_market",5,5,473,470,-0,-0,-0,"short","short",NaN
24,"ACIU","AC Immune to Regain Global Rights to Crenezumab and Semorinemab","https://www.globenewswire.com/news-release/2024/01/22/2812913/0/en/AC-Immune-to-Regain-Global-Rights-to-Crenezumab-and-Semorinemab.html","Licensing Agreements","2024-01-22 07:00:00","pre_market",4,4,482,484,0,0,-0,"short","short",NaN
25,"ACIU","AC Immune Announces Pricing of Underwritten Offering of Common Shares","https://www.globenewswire.com/news-release/2023/12/15/2797008/0/en/AC-Immune-Announces-Pricing-of-Underwritten-Offering-of-Common-Shares.html","Financing Agreements","2023-12-15 07:56:00","pre_market",4,4,472,469,-0,-0,-0,"short","short",NaN
26,"ACIU","AC Immune Strengthens Management, Appoints Madiha Derouazi as CSO and Christopher Roberts as CFO","https://www.globenewswire.com/news-release/2023/12/01/2789221/0/en/AC-Immune-Strengthens-Management-Appoints-Madiha-Derouazi-as-CSO-and-Christopher-Roberts-as-CFO.html","Management Changes","2023-12-01 07:00:00","pre_market",3,3,456,456,-0,-0,-0,"short","short",NaN
27,"ACIU","AC Immune’s Targeted Anti-pTau Active Immunotherapy for Alzheimer’s Disease Advances into Phase 2b Trial","https://www.globenewswire.com/news-release/2023/12/15/2796982/0/en/AC-Immune-s-Targeted-Anti-pTau-Active-Immunotherapy-for-Alzheimer-s-Disease-Advances-into-Phase-2b-Trial.html","Financing Agreements","2023-12-15 07:22:00","pre_market",4,4,472,469,-0,-0,-0,"short","short",NaN
37,"ADAG","Adagene Announces Interim Data Demonstrating Safety and Confirmed Clinical Responses of Anti-CTLA-4 SAFEbody® ADG126 up to 10 mg/kg with Repeat Cycles in Combination with Anti-PD-1 Therapy from Dose Escalation Portion of Phase 1b/2 Trial","https://www.globenewswire.com/news-release/2023/01/09/2585049/0/en/Adagene-Announces-Interim-Data-Demonstrating-Safety-and-Confirmed-Clinical-Responses-of-Anti-CTLA-4-SAFEbody-ADG126-up-to-10-mg-kg-with-Repeat-Cycles-in-Combination-with-Anti-PD-1-.html","Clinical Study","2023-01-09 07:00:00","pre_market",2,2,388,390,0,0,0,"long","long",NaN
38,"ADAG","Adagene Reports Six Month Financial Results for 2023 and Provides Corporate Update","https://www.globenewswire.com/news-release/2023/08/31/2735151/0/en/Adagene-Reports-Six-Month-Financial-Results-for-2023-and-Provides-Corporate-Update.html","Earnings Releases and Operating Results","2023-08-31 07:32:00","pre_market",1,1,451,452,0,0,0,"long","long",NaN
48,"ADTX","Aditxt, Inc. to Present at 8th Annual Dawson James Conference","https://www.globenewswire.com/news-release/2023/10/06/2756039/0/en/Aditxt-Inc-to-Present-at-8th-Annual-Dawson-James-Conference.html","Advisory","2023-10-06 08:00:00","pre_market",12,12,424,422,-0,-0,-0,"short","short",NaN
41,"ADPT","Adaptive Biotechnologies Highlights New Data at ASCO 2023 and EHA 2023 Underscoring the clonoSEQ® Assay’s Impact as a Standard for Minimal Residual Disease Assessment in Patients with Hematologic Cancer","https://www.globenewswire.com/news-release/2023/06/02/2681086/0/en/Adaptive-Biotechnologies-Highlights-New-Data-at-ASCO-2023-and-EHA-2023-Underscoring-the-clonoSEQ-Assay-s-Impact-as-a-Standard-for-Minimal-Residual-Disease-Assessment-in-Patients-wi.html","Clinical Study","2023-06-02 07:34:00","pre_market",7,7,422,424,0,0,0,"long","long",NaN
39,"ADAG","Adagene To Present Interim Results of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at ASCO-GI Symposium","https://www.globenewswire.com/news-release/2024/01/04/2803770/0/en/Adagene-To-Present-Interim-Results-of-Masked-anti-CTLA-4-SAFEbody-ADG126-muzastotug-in-Combination-with-Pembrolizumab-in-MSS-CRC-at-ASCO-GI-Symposium.html","Health","2024-01-04 05:00:00","pre_market",2,2,469,468,0,-0,0,"long","long",NaN
42,"ADPT","Adaptive Biotechnologies Announces FDA Acceptance of Genentech’s Investigational New Drug Application for the First Neoantigen-Directed T-Cell Therapy Product in Oncology","https://www.globenewswire.com/news-release/2023/05/09/2664318/0/en/Adaptive-Biotechnologies-Announces-FDA-Acceptance-of-Genentech-s-Investigational-New-Drug-Application-for-the-First-Neoantigen-Directed-T-Cell-Therapy-Product-in-Oncology.html","Health","2023-05-09 07:30:00","pre_market",7,7,413,411,0,-0,0,"long","long",NaN
43,"ADPT","Adaptive Biotechnologies Announces New Translational Collaboration to Measure Minimal Residual Disease with clonoSEQ® Assay Across BeiGene’s Lymphoid Malignancy Pipeline","https://www.globenewswire.com/news-release/2023/11/07/2774988/0/en/Adaptive-Biotechnologies-Announces-New-Translational-Collaboration-to-Measure-Minimal-Residual-Disease-with-clonoSEQ-Assay-Across-BeiGene-s-Lymphoid-Malignancy-Pipeline.html","Clinical Study","2023-11-07 07:30:00","pre_market",5,5,436,436,-0,0,-0,"short","short",NaN
44,"ADPT","Adaptive Biotechnologies and Collaborators to Present More than 30 Abstracts Demonstrating the Actionability of clonoSEQ® MRD Testing in Blood Cancer Patient Care and Drug Development at the 65th ASH Annual Meeting","https://www.globenewswire.com/news-release/2023/12/05/2790810/0/en/Adaptive-Biotechnologies-and-Collaborators-to-Present-More-than-30-Abstracts-Demonstrating-the-Actionability-of-clonoSEQ-MRD-Testing-in-Blood-Cancer-Patient-Care-and-Drug-Developme.html","Clinical Study","2023-12-05 07:30:00","pre_market",5,5,457,455,-0,-0,-0,"short","long",NaN
45,"ADPT","Adaptive Announces Launch of Epic Integration for clonoSEQ®","https://www.globenewswire.com/news-release/2023/09/13/2742380/0/en/Adaptive-Announces-Launch-of-Epic-Integration-for-clonoSEQ.html","Product / Services Announcement","2023-09-13 07:30:00","pre_market",7,7,446,446,0,0,0,"long","long",NaN
40,"ADAG","Adagene Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with KEYTRUDA® (pembrolizumab) to Demonstrate Further Efficacy in Patients with Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)","https://www.globenewswire.com/news-release/2024/02/09/2826677/0/en/Adagene-Announces-Progress-and-Expansion-of-Clinical-Collaboration-Program-for-Masked-Anti-CTLA-4-SAFEbody-ADG126-muzastotug-in-Combination-with-KEYTRUDA-pembrolizumab-to-Demonstra.html","Product / Services Announcement","2024-02-09 06:00:00","pre_market",4,3,498,499,-0,0,-0,"short","short",NaN
46,"ADPT","Adaptive Biotechnologies to Participate in the 2023 RBC Capital Markets Global Healthcare Conference","https://www.globenewswire.com/news-release/2023/05/12/2667757/0/en/Adaptive-Biotechnologies-to-Participate-in-the-2023-RBC-Capital-Markets-Global-Healthcare-Conference.html","Calendar of Events","2023-05-12 08:00:00","pre_market",7,7,412,413,0,0,-0,"short","short",NaN
47,"ADPT","Adaptive Biotechnologies Announces Translational Collaboration with Takeda to Measure Minimal Residual Disease with Its clonoSEQ® Assay Across Its Hematologic Malignancy Pipeline","https://www.globenewswire.com/news-release/2023/04/12/2645230/0/en/Adaptive-Biotechnologies-Announces-Translational-Collaboration-with-Takeda-to-Measure-Minimal-Residual-Disease-with-Its-clonoSEQ-Assay-Across-Its-Hematologic-Malignancy-Pipeline.html","Partnerships","2023-04-12 07:30:00","pre_market",8,8,410,412,0,0,0,"long","long",NaN
54,"ADXN","Addex GABAB Positive Allosteric Modulator Program to Receive Additional CHF2.7 Million from Indivior in Extended Substance Use Disorder Research Collaboration","https://www.globenewswire.com/news-release/2023/08/03/2717597/0/en/Addex-GABAB-Positive-Allosteric-Modulator-Program-to-Receive-Additional-CHF2-7-Million-from-Indivior-in-Extended-Substance-Use-Disorder-Research-Collaboration.html","European Regulatory News","2023-08-03 01:00:00","overnight",(null),(null),(null),(null),(null),(null),(null),(null),"long",NaN
74,"ADXN","Addex Increases Issued Share Capital to Create Treasury Shares","https://www.globenewswire.com/news-release/2023/06/15/2688579/0/en/Addex-Increases-Issued-Share-Capital-to-Create-Treasury-Shares.html","European Regulatory News","2023-06-15 01:00:00","no_market",(null),(null),(null),(null),(null),(null),(null),(null),"long",NaN
66,"ADXN","Addex’s Dipraglurant Development in Post-Stroke Recovery Supported by Data Published in Brain","https://www.globenewswire.com/news-release/2023/09/04/2736453/0/en/Addex-s-Dipraglurant-Development-in-Post-Stroke-Recovery-Supported-by-Data-Published-in-Brain.html","European Regulatory News","2023-09-04 01:00:00","overnight",(null),(null),(null),(null),(null),(null),(null),(null),"long",NaN
73,"ADXN","Addex ADX71149 Epilepsy Phase 2 Study Completes Recruitment of Patients","https://www.globenewswire.com/news-release/2023/11/14/2779698/0/en/Addex-ADX71149-Epilepsy-Phase-2-Study-Completes-Recruitment-of-Patients.html","European Regulatory News","2023-11-14 01:00:00","overnight",(null),(null),(null),(null),(null),(null),(null),(null),"long",NaN
53,"ADXN","Addex Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency","https://www.globenewswire.com/news-release/2023/05/18/2671600/0/en/Addex-Receives-Nasdaq-Notification-Regarding-Minimum-Bid-Price-Deficiency.html","European Regulatory News","2023-05-18 01:00:00","overnight",(null),(null),(null),(null),(null),(null),(null),(null),"long",NaN
56,"ADXN","Addex Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency","https://www.globenewswire.com/news-release/2023/05/18/2671600/0/en/Addex-Receives-Nasdaq-Notification-Regarding-Minimum-Bid-Price-Deficiency.html","European Regulatory News","2023-05-18 01:00:00","no_market",(null),(null),(null),(null),(null),(null),(null),(null),"long",NaN
72,"ADXN","Addex Regains Nasdaq Listing Compliance","https://www.globenewswire.com/news-release/2023/11/08/2775790/0/en/Addex-Regains-Nasdaq-Listing-Compliance.html","European Regulatory News","2023-11-08 01:00:00","no_market",(null),(null),(null),(null),(null),(null),(null),(null),"long",NaN
59,"ADXN","Addex Convenes Annual General Meeting 2023","https://www.globenewswire.com/news-release/2023/05/05/2662258/0/en/Addex-Convenes-Annual-General-Meeting-2023.html","European Regulatory News","2023-05-05 01:00:00","no_market",(null),(null),(null),(null),(null),(null),(null),(null),"short",NaN
62,"ADXN","Addex Announces ADX71149 Phase 2 Epilepsy Clinical Study’s Independent Interim Review Committee Recommends Continuing Study","https://www.globenewswire.com/news-release/2023/05/10/2665174/0/en/Addex-Announces-ADX71149-Phase-2-Epilepsy-Clinical-Study-s-Independent-Interim-Review-Committee-Recommends-Continuing-Study.html","European Regulatory News","2023-05-10 01:00:00","no_market",(null),(null),(null),(null),(null),(null),(null),(null),"long",NaN
63,"ADXN","Addex Reports Full Year 2022 Financial Results and Provides Corporate Update","https://www.globenewswire.com/news-release/2023/03/30/2637303/0/en/Addex-Reports-Full-Year-2022-Financial-Results-and-Provides-Corporate-Update.html","European Regulatory News","2023-03-30 01:00:00","no_market",(null),(null),(null),(null),(null),(null),(null),(null),"long",NaN
64,"ADXN","Addex Completes $5.0 Million Equity Financing","https://www.globenewswire.com/news-release/2023/04/05/2641327/0/en/Addex-Completes-5-0-Million-Equity-Financing.html","European Regulatory News","2023-04-05 01:00:00","no_market",(null),(null),(null),(null),(null),(null),(null),(null),"long",NaN
67,"ADXN","Addex mGlu2PAM Demonstrates Potential in Substance Use Disorder","https://www.globenewswire.com/news-release/2023/07/24/2709220/0/en/Addex-mGlu2PAM-Demonstrates-Potential-in-Substance-Use-Disorder.html","European Regulatory News","2023-07-24 01:00:00","no_market",(null),(null),(null),(null),(null),(null),(null),(null),"long",NaN
60,"ADXN","Addex Announces Participation in the Bio-Europe 2023 Conference","https://www.globenewswire.com/news-release/2023/11/02/2771873/0/en/Addex-Announces-Participation-in-the-Bio-Europe-2023-Conference.html","European Regulatory News","2023-11-02 02:00:00","overnight",(null),(null),(null),(null),(null),(null),(null),(null),"long",NaN
57,"ADXN","Addex Shareholders Approve All Resolutions at Annual General Meeting","https://www.globenewswire.com/news-release/2023/06/01/2679938/0/en/Addex-Shareholders-Approve-All-Resolutions-at-Annual-General-Meeting.html","European Regulatory News","2023-06-01 01:00:00","no_market",(null),(null),(null),(null),(null),(null),(null),(null),"short",NaN
68,"ADXN","Addex Shareholders Approve All Resolutions at Annual General Meeting","https://www.globenewswire.com/news-release/2023/06/01/2679938/0/en/Addex-Shareholders-Approve-All-Resolutions-at-Annual-General-Meeting.html","European Regulatory News","2023-06-01 01:00:00","overnight",(null),(null),(null),(null),(null),(null),(null),(null),"short",NaN
71,"ADXN","Addex Reports Q3 2023 Financial Results and Provides Corporate Update","https://www.globenewswire.com/news-release/2023/11/29/2787467/0/en/Addex-Reports-Q3-2023-Financial-Results-and-Provides-Corporate-Update.html","European Regulatory News","2023-11-29 01:00:00","overnight",(null),(null),(null),(null),(null),(null),(null),(null),"long",NaN
70,"ADXN","Addex Reports 2023 Half Year and Second Quarter Financial Results and Provides Corporate Update","https://www.globenewswire.com/news-release/2023/08/10/2722288/0/en/Addex-Reports-2023-Half-Year-and-Second-Quarter-Financial-Results-and-Provides-Corporate-Update.html","European Regulatory News","2023-08-10 01:00:00","overnight",(null),(null),(null),(null),(null),(null),(null),(null),"long",NaN
225,"ANAB","AnaptysBio Announces Stock Repurchase Plan","https://www.globenewswire.com/news-release/2023/01/13/2588623/0/en/AnaptysBio-Announces-Stock-Repurchase-Plan.html","Stock Market News","2023-01-13 09:00:00","pre_market",23,24,397,394,0,-0,0,"long","short",NaN
65,"ADXN","Addex ADX71149 Phase 2 Epilepsy Study Expected to Readout Data in  Q2 2024","https://www.globenewswire.com/news-release/2023/09/05/2736936/0/en/Addex-ADX71149-Phase-2-Epilepsy-Study-Expected-to-Readout-Data-in-Q2-2024.html","European Regulatory News","2023-09-05 01:00:00","no_market",(null),(null),(null),(null),(null),(null),(null),(null),"long",NaN
85,"ADXN","Addex ADX71149 Epilepsy Phase 2 Study Completes Recruitment of Patients","https://www.globenewswire.com/news-release/2023/11/14/2779698/0/en/Addex-ADX71149-Epilepsy-Phase-2-Study-Completes-Recruitment-of-Patients.html","European Regulatory News","2023-11-14 01:00:00","no_market",(null),(null),(null),(null),(null),(null),(null),(null),"long",NaN
97,"ADXN","Addex Enters into At-The-Market ADS Offering Agreement with H.C. Wainwright & Co. LLC.","https://www.globenewswire.com/news-release/2024/01/31/2820703/0/en/Addex-Enters-into-At-The-Market-ADS-Offering-Agreement-with-H-C-Wainwright-Co-LLC.html","European Regulatory News","2024-01-31 01:00:00","overnight",(null),(null),(null),(null),(null),(null),(null),(null),"long",NaN
100,"AEON","AEON Biopharma Reports Third Quarter 2023 Financial Results","https://www.globenewswire.com/news-release/2023/11/13/2779046/0/en/AEON-Biopharma-Reports-Third-Quarter-2023-Financial-Results.html","Earnings Releases and Operating Results","2023-11-13 08:15:00","pre_market",4,4,441,439,-0,-0,-0,"short","short",NaN
98,"ADXN","Addex Shareholders Approve All Resolutions at Extraordinary General Meeting","https://www.globenewswire.com/news-release/2023/12/20/2799005/0/en/Addex-Shareholders-Approve-All-Resolutions-at-Extraordinary-General-Meeting.html","European Regulatory News","2023-12-20 01:00:00","overnight",(null),(null),(null),(null),(null),(null),(null),(null),"short",NaN
99,"ADXN","Addex to Present at Biotech Showcase™ 2024","https://www.globenewswire.com/news-release/2024/01/05/2804455/0/en/Addex-to-Present-at-Biotech-Showcase-2024.html","European Regulatory News","2024-01-05 01:30:00","overnight",(null),(null),(null),(null),(null),(null),(null),(null),"long",NaN
86,"ADXN","Addex mGlu2 NAM Cognition Program Receives €4 Million Grant","https://www.globenewswire.com/news-release/2023/09/20/2746109/0/en/Addex-mGlu2-NAM-Cognition-Program-Receives-4-Million-Grant.html","European Regulatory News","2023-09-20 01:00:00","overnight",(null),(null),(null),(null),(null),(null),(null),(null),"long",NaN
92,"ADXN","Addex mGlu2 NAM Cognition Program Receives €4 Million Grant","https://www.globenewswire.com/news-release/2023/09/20/2746109/0/en/Addex-mGlu2-NAM-Cognition-Program-Receives-4-Million-Grant.html","European Regulatory News","2023-09-20 01:00:00","no_market",(null),(null),(null),(null),(null),(null),(null),(null),"long",NaN
87,"ADXN","Addex mGlu2PAM Demonstrates Potential in Substance Use Disorder","https://www.globenewswire.com/news-release/2023/07/24/2709220/0/en/Addex-mGlu2PAM-Demonstrates-Potential-in-Substance-Use-Disorder.html","European Regulatory News","2023-07-24 01:00:00","overnight",(null),(null),(null),(null),(null),(null),(null),(null),"long",NaN
93,"ADXN","Addex’s Dipraglurant Development in Post-Stroke Recovery Supported by Data Published in Brain","https://www.globenewswire.com/news-release/2023/09/04/2736453/0/en/Addex-s-Dipraglurant-Development-in-Post-Stroke-Recovery-Supported-by-Data-Published-in-Brain.html","European Regulatory News","2023-09-04 01:00:00","no_market",(null),(null),(null),(null),(null),(null),(null),(null),"long",NaN
82,"ADXN","Addex Regains Nasdaq Listing Compliance","https://www.globenewswire.com/news-release/2023/11/08/2775790/0/en/Addex-Regains-Nasdaq-Listing-Compliance.html","European Regulatory News","2023-11-08 01:00:00","overnight",(null),(null),(null),(null),(null),(null),(null),(null),"long",NaN
80,"ADXN","Addex Reports Q1 2023 Financial Results and Provides Corporate Update","https://www.globenewswire.com/news-release/2023/05/11/2666253/0/en/Addex-Reports-Q1-2023-Financial-Results-and-Provides-Corporate-Update.html","European Regulatory News","2023-05-11 01:00:00","no_market",(null),(null),(null),(null),(null),(null),(null),(null),"long",NaN
83,"ADXN","Addex Reports Q1 2023 Financial Results and Provides Corporate Update","https://www.globenewswire.com/news-release/2023/05/11/2666253/0/en/Addex-Reports-Q1-2023-Financial-Results-and-Provides-Corporate-Update.html","European Regulatory News","2023-05-11 01:00:00","overnight",(null),(null),(null),(null),(null),(null),(null),(null),"long",NaN
84,"ADXN","Addex ADX71149 Phase 2 Epilepsy Study Expected to Readout Data in  Q2 2024","https://www.globenewswire.com/news-release/2023/09/05/2736936/0/en/Addex-ADX71149-Phase-2-Epilepsy-Study-Expected-to-Readout-Data-in-Q2-2024.html","European Regulatory News","2023-09-05 01:00:00","overnight",(null),(null),(null),(null),(null),(null),(null),(null),"long",NaN
89,"ADXN","Addex Reports Q3 2023 Financial Results and Provides Corporate Update","https://www.globenewswire.com/news-release/2023/11/29/2787467/0/en/Addex-Reports-Q3-2023-Financial-Results-and-Provides-Corporate-Update.html","European Regulatory News","2023-11-29 01:00:00","no_market",(null),(null),(null),(null),(null),(null),(null),(null),"long",NaN
90,"ADXN","Addex Announces Plan to Implement ADS Ratio Change","https://www.globenewswire.com/news-release/2023/10/06/2756301/0/en/Addex-Announces-Plan-to-Implement-ADS-Ratio-Change.html","European Regulatory News","2023-10-06 16:00:00","after_hours",(null),(null),(null),(null),(null),(null),(null),(null),"long",NaN
94,"ADXN","Addex Announces Participation in the Bio-Europe 2023 Conference","https://www.globenewswire.com/news-release/2023/11/02/2771873/0/en/Addex-Announces-Participation-in-the-Bio-Europe-2023-Conference.html","European Regulatory News","2023-11-02 02:00:00","no_market",(null),(null),(null),(null),(null),(null),(null),(null),"long",NaN
95,"ADXN","Addex to Present at the Swiss Equities Baader Conference","https://www.globenewswire.com/news-release/2024/01/09/2805955/0/en/Addex-to-Present-at-the-Swiss-Equities-Baader-Conference.html","European Regulatory News","2024-01-09 01:00:00","overnight",(null),(null),(null),(null),(null),(null),(null),(null),"long",NaN
96,"ADXN","Addex Creates Treasury Shares","https://www.globenewswire.com/news-release/2023/12/14/2795964/0/en/Addex-Creates-Treasury-Shares.html","European Regulatory News","2023-12-14 01:00:00","overnight",(null),(null),(null),(null),(null),(null),(null),(null),"long",NaN
107,"AKRO","Akero Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update","https://www.globenewswire.com/news-release/2023/11/13/2778893/0/en/Akero-Therapeutics-Reports-Third-Quarter-2023-Financial-Results-and-Provides-Business-Update.html","Earnings Releases and Operating Results","2023-11-13 07:00:00","pre_market",14,14,441,439,-0,-0,0,"long","short",NaN
108,"AKRO","Akero Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference","https://www.globenewswire.com/news-release/2023/01/04/2582867/0/en/Akero-Therapeutics-to-Present-at-the-41st-Annual-J-P-Morgan-Healthcare-Conference.html","Trade Show","2023-01-04 08:00:00","pre_market",49,50,381,383,0,0,-0,"short","short",NaN
109,"AKRO","Akero Therapeutics Announces Publication of the Harmony Phase 2b Trial Results in The Lancet Gastroenterology & Hepatology","https://www.globenewswire.com/news-release/2023/10/04/2754507/0/en/Akero-Therapeutics-Announces-Publication-of-the-Harmony-Phase-2b-Trial-Results-in-The-Lancet-Gastroenterology-Hepatology.html","Clinical Study","2023-10-04 08:00:00","pre_market",47,48,422,422,0,0,0,"long","long",NaN
110,"AKRO","Akero Therapeutics to Present Late-Breaking Oral and Poster Presentations on EFX at AASLD’s The Liver Meeting® 2023","https://www.globenewswire.com/news-release/2023/11/10/2778341/0/en/Akero-Therapeutics-to-Present-Late-Breaking-Oral-and-Poster-Presentations-on-EFX-at-AASLD-s-The-Liver-Meeting-2023.html","Clinical Study","2023-11-10 08:57:00","pre_market",14,14,434,436,0,0,0,"long","long",NaN
111,"AKRO","Akero Therapeutics Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY Study, with a Trend on Fibrosis Improvement and Statistically Significant Results for NASH Resolution, Markers of Liver Injury and Fibrosis, Insulin Sensitization and Lipoproteins","https://www.globenewswire.com/news-release/2023/10/10/2757329/0/en/Akero-Therapeutics-Reports-Encouraging-36-Week-Analysis-of-96-Week-Phase-2b-SYMMETRY-Study-with-a-Trend-on-Fibrosis-Improvement-and-Statistically-Significant-Results-for-NASH-Resol.html","Clinical Study","2023-10-10 07:00:00","pre_market",49,20,432,433,-1,0,-1,"short","short",NaN
112,"AKRO","Akero Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results","https://www.globenewswire.com/news-release/2023/03/17/2629388/0/en/Akero-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2022-Financial-Results.html","Earnings Releases and Operating Results","2023-03-17 07:00:00","pre_market",40,40,396,393,0,-0,0,"long","long",NaN
113,"AKRO","Akero Therapeutics to Present at Upcoming Healthcare Conferences in September","https://www.globenewswire.com/news-release/2023/08/31/2735089/0/en/Akero-Therapeutics-to-Present-at-Upcoming-Healthcare-Conferences-in-September.html","Calendar of Events","2023-08-31 07:00:00","pre_market",50,50,451,452,-0,0,-0,"short","short",NaN
102,"AEON","AEON Biopharma Presents Positive Results from Phase 2 Clinical Trial of ABP-450 (prabotulinumtoxinA) in Cervical Dystonia at the International Parkinson and Movement Disorders Society Congress®","https://www.globenewswire.com/news-release/2023/08/29/2733326/0/en/AEON-Biopharma-Presents-Positive-Results-from-Phase-2-Clinical-Trial-of-ABP-450-prabotulinumtoxinA-in-Cervical-Dystonia-at-the-International-Parkinson-and-Movement-Disorders-Societ.html","Research Analysis and Reports","2023-08-29 08:00:00","pre_market",4,4,443,443,0,-0,0,"long","long",NaN
114,"AKRO","Akero Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update","https://www.globenewswire.com/news-release/2023/05/15/2668591/0/en/Akero-Therapeutics-Reports-First-Quarter-2023-Financial-Results-and-Provides-Business-Update.html","Earnings Releases and Operating Results","2023-05-15 07:00:00","pre_market",46,46,412,412,-0,0,-0,"short","short",NaN
115,"AKRO","Akero Therapeutics Appoints Patrick Lamy as Senior Vice President, Commercial Strategy","https://www.globenewswire.com/news-release/2023/01/10/2586110/0/en/Akero-Therapeutics-Appoints-Patrick-Lamy-as-Senior-Vice-President-Commercial-Strategy.html","Management Changes","2023-01-10 08:00:00","pre_market",44,44,388,387,0,-0,0,"long","short",NaN
104,"AEON","AEON Biopharma Completes Enrollment in Phase 2 Study of ABP-450 (prabotulinumtoxinA) for Preventive Treatment of Chronic Migraine","https://www.globenewswire.com/news-release/2023/12/12/2794700/0/en/AEON-Biopharma-Completes-Enrollment-in-Phase-2-Study-of-ABP-450-prabotulinumtoxinA-for-Preventive-Treatment-of-Chronic-Migraine.html","Clinical Study","2023-12-12 08:00:00","pre_market",6,7,462,462,0,-0,0,"long","long",NaN
103,"AEON","Strathspey Crown Holdings Group, LLC Provides Clarifying Statement Regarding Form 4 Filing with SEC for Holdings in AEON Biopharma","https://www.globenewswire.com/news-release/2023/08/16/2726201/0/en/Strathspey-Crown-Holdings-Group-LLC-Provides-Clarifying-Statement-Regarding-Form-4-Filing-with-SEC-for-Holdings-in-AEON-Biopharma.html","Regulatory information","2023-08-16 07:00:00","pre_market",4,5,443,442,0,-0,0,"long","long",NaN
117,"AKRO","Akero Therapeutics’ Phase 2b SYMMETRY Cohort D Study Met Safety & Tolerability Endpoints and Showed Adding EFX to GLP-1 Therapy Significantly Improved Non-Invasive Markers of NASH-Related Disease","https://www.globenewswire.com/news-release/2023/06/05/2681816/0/en/Akero-Therapeutics-Phase-2b-SYMMETRY-Cohort-D-Study-Met-Safety-Tolerability-Endpoints-and-Showed-Adding-EFX-to-GLP-1-Therapy-Significantly-Improved-Non-Invasive-Markers-of-NASH-Rel.html","Clinical Study","2023-06-05 07:00:00","pre_market",47,46,428,428,-0,0,-0,"short","long",NaN
116,"AKRO","Akero Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update","https://www.globenewswire.com/news-release/2023/08/11/2723407/0/en/Akero-Therapeutics-Reports-Second-Quarter-2023-Financial-Results-and-Provides-Business-Update.html","Earnings Releases and Operating Results","2023-08-11 06:00:00","pre_market",45,46,446,444,0,-0,0,"long","long",NaN
125,"AKYA","Akoya Biosciences Introduces PhenoCode Discovery Panels to Simplify PhenoCycler-Fusion Workflow","https://www.globenewswire.com/news-release/2023/04/12/2645262/0/en/Akoya-Biosciences-Introduces-PhenoCode-Discovery-Panels-to-Simplify-PhenoCycler-Fusion-Workflow.html","Product / Services Announcement","2023-04-12 08:00:00","pre_market",7,7,410,412,0,0,0,"long","long",NaN
126,"AKYA","Akoya Biosciences to Present First-of-its-Kind Spatial Multiomics Dataset at 2023 AGBT General Meeting","https://www.globenewswire.com/news-release/2023/02/01/2599401/0/en/Akoya-Biosciences-to-Present-First-of-its-Kind-Spatial-Multiomics-Dataset-at-2023-AGBT-General-Meeting.html","Health","2023-02-01 08:00:00","pre_market",11,11,406,405,0,-0,0,"long","long",NaN
127,"AKYA","Akoya to Participate at Three Upcoming Investor Conferences","https://www.globenewswire.com/news-release/2023/11/02/2772246/0/en/Akoya-to-Participate-at-Three-Upcoming-Investor-Conferences.html","Calendar of Events","2023-11-02 08:00:00","pre_market",3,4,423,427,0,0,0,"long","long",NaN
129,"AKYA","Akoya to Report Fourth Quarter and Full Year 2022 Financial Results on March 6th, 2023 and Participate at Two Upcoming Investor Conferences","https://www.globenewswire.com/news-release/2023/02/06/2602048/0/en/Akoya-to-Report-Fourth-Quarter-and-Full-Year-2022-Financial-Results-on-March-6th-2023-and-Participate-at-Two-Upcoming-Investor-Conferences.html","Conference Calls/ Webcasts","2023-02-06 08:05:00","pre_market",12,12,412,410,-0,-0,-0,"short","short",NaN
130,"AKYA","Akoya to Report Second Quarter 2023 Financial Results on August 7th, 2023","https://www.globenewswire.com/news-release/2023/07/12/2703488/0/en/Akoya-to-Report-Second-Quarter-2023-Financial-Results-on-August-7th-2023.html","Conference Calls/ Webcasts","2023-07-12 08:05:00","pre_market",7,7,442,446,-0,0,-0,"short","short",NaN
131,"AKYA","Akoya Biosciences to Showcase New Spatial Biology 2.0 Solutions and Spatial Phenotyping Data at SITC 2023","https://www.globenewswire.com/news-release/2023/10/31/2770244/0/en/Akoya-Biosciences-to-Showcase-New-Spatial-Biology-2-0-Solutions-and-Spatial-Phenotyping-Data-at-SITC-2023.html","Calendar of Events","2023-10-31 09:00:00","pre_market",3,3,416,416,-0,0,-0,"short","short",NaN
132,"AKYA","Akoya Biosciences and Enable Medicine Introduce Cloud Platform to Power Faster Analysis of PhenoCycler-Fusion Data","https://www.globenewswire.com/news-release/2023/04/12/2645278/0/en/Akoya-Biosciences-and-Enable-Medicine-Introduce-Cloud-Platform-to-Power-Faster-Analysis-of-PhenoCycler-Fusion-Data.html","Partnerships","2023-04-12 08:00:00","pre_market",7,7,410,412,0,0,0,"long","long",NaN
133,"AKYA","Akoya Biosciences Announces Appointment of Jennifer Kamocsay as General Counsel","https://www.globenewswire.com/news-release/2023/02/28/2617008/0/en/Akoya-Biosciences-Announces-Appointment-of-Jennifer-Kamocsay-as-General-Counsel.html","Directors and Officers","2023-02-28 08:00:00","pre_market",12,12,398,397,0,-0,0,"long","long",NaN
134,"AKYA","Akoya to Report First Quarter 2023 Financial Results on May 8th, 2023","https://www.globenewswire.com/news-release/2023/04/06/2642490/0/en/Akoya-to-Report-First-Quarter-2023-Financial-Results-on-May-8th-2023.html","Calendar of Events","2023-04-06 08:00:00","pre_market",7,7,408,407,0,-0,0,"long","long",NaN
135,"AKYA","Akoya Biosciences Marks Milestone Achievement with Shipment of 1,000th Spatial Biology Instrument","https://www.globenewswire.com/news-release/2023/04/27/2656258/0/en/Akoya-Biosciences-Marks-Milestone-Achievement-with-Shipment-of-1-000th-Spatial-Biology-Instrument.html","Other News","2023-04-27 08:00:00","pre_market",7,7,404,407,0,0,-0,"short","short",NaN
118,"AKRO","Akero Therapeutics to Present Late-Breaking Oral and Poster presentations on EFX Today at AASLD’s The Liver Meeting® 2022","https://www.globenewswire.com/news-release/2022/11/07/2549564/0/en/Akero-Therapeutics-to-Present-Late-Breaking-Oral-and-Poster-presentations-on-EFX-Today-at-AASLD-s-The-Liver-Meeting-2022.html","Calendar of Events","2022-11-07 07:30:00","pre_market",38,39,376,378,0,0,0,"long","long",NaN
119,"AKRO","Akero Therapeutics Presents Analyses of Phase 2b HARMONY Study at the 2023 International Liver Congress Reinforcing and Characterizing EFX-Related Improvements in Liver Histopathology","https://www.globenewswire.com/news-release/2023/06/23/2693588/0/en/Akero-Therapeutics-Presents-Analyses-of-Phase-2b-HARMONY-Study-at-the-2023-International-Liver-Congress-Reinforcing-and-Characterizing-EFX-Related-Improvements-in-Liver-Histopathol.html","Calendar of Events","2023-06-23 07:00:00","pre_market",52,52,437,433,-0,-0,0,"long","long",NaN
120,"AKRO","Efruxifermin Granted FDA Breakthrough Therapy Designation for NASH","https://www.globenewswire.com/news-release/2022/12/08/2570081/0/en/Efruxifermin-Granted-FDA-Breakthrough-Therapy-Designation-for-NASH.html","Product / Services Announcement","2022-12-08 07:00:00","pre_market",42,43,393,395,0,0,0,"long","long",NaN
121,"AKRO","Akero Therapeutics to Present at Upcoming Healthcare Conferences in November","https://www.globenewswire.com/news-release/2023/11/08/2776046/0/en/Akero-Therapeutics-to-Present-at-Upcoming-Healthcare-Conferences-in-November.html","Calendar of Events","2023-11-08 07:00:00","pre_market",16,16,437,438,-0,0,-0,"short","short",NaN
122,"AKRO","Akero Therapeutics Announces First Patients Dosed in Efruxifermin Phase 3 SYNCHRONY Program","https://www.globenewswire.com/news-release/2023/12/18/2797681/0/en/Akero-Therapeutics-Announces-First-Patients-Dosed-in-Efruxifermin-Phase-3-SYNCHRONY-Program.html","Clinical Study","2023-12-18 07:00:00","pre_market",23,23,469,471,-0,0,-0,"short","short",NaN
123,"AKRO","Akero Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference","https://www.globenewswire.com/news-release/2024/01/03/2803286/0/en/Akero-Therapeutics-to-Present-at-the-42nd-Annual-J-P-Morgan-Healthcare-Conference.html","Calendar of Events","2024-01-03 08:15:00","pre_market",23,23,473,470,-0,-0,-0,"short","short",NaN
141,"ALERS.PA","Eurobio Scientific : l’assemblée générale approuve l’ensemble des résolutions","https://www.globenewswire.com/news-release/2023/06/16/2689837/0/fr/Eurobio-Scientific-l-assembl%C3%A9e-g%C3%A9n%C3%A9rale-approuve-l-ensemble-des-r%C3%A9solutions.html","European Regulatory News","2023-06-16 11:45:00","market_open",15,15,443,439,-0,-0,0,"long","long",NaN
142,"ALERS.PA","Eurobio Scientific formalises the appointment of Anne-Sophie Hérelle as Group CFO","https://www.globenewswire.com/news-release/2023/02/08/2604261/0/en/Eurobio-Scientific-formalises-the-appointment-of-Anne-Sophie-H%C3%A9relle-as-Group-CFO.html","European Regulatory News","2023-02-08 11:45:00","market_open",18,18,413,411,0,-0,0,"long","long",NaN
143,"ALERS.PA","Eurobio Scientific becomes one of the first European companies to obtain IVDR1 CE marking of PCR tests","https://www.globenewswire.com/news-release/2023/05/23/2674617/0/en/Eurobio-Scientific-becomes-one-of-the-first-European-companies-to-obtain-IVDR1-CE-marking-of-PCR-tests.html","European Regulatory News","2023-05-23 11:45:00","market_open",17,17,417,414,0,-0,0,"long","long",NaN
144,"ALERS.PA","EUROBIO SCIENTIFIC : RESULTATS DU 1ER SEMESTRE 2023","https://www.globenewswire.com/news-release/2023/10/11/2758684/0/fr/EUROBIO-SCIENTIFIC-RESULTATS-DU-1ER-SEMESTRE-2023.html","European Regulatory News","2023-10-11 12:52:00","market_open",13,13,436,436,0,0,-0,"short","short",NaN
145,"ALERS.PA","Eurobio Scientific : Results for the First Half of 2023","https://www.globenewswire.com/news-release/2023/10/11/2758684/0/en/Eurobio-Scientific-Results-for-the-First-Half-of-2023.html","European Regulatory News","2023-10-11 12:52:00","market_open",13,13,436,436,0,0,-0,"short","short",NaN
147,"ALERS.PA","Eurobio Scientific : MISE À DISPOSITION DU RAPPORT FINANCIER ANNUEL 2022","https://www.globenewswire.com/news-release/2023/04/28/2657647/0/fr/Eurobio-Scientific-MISE-%C3%80-DISPOSITION-DU-RAPPORT-FINANCIER-ANNUEL-2022.html","European Regulatory News","2023-04-28 11:45:00","market_open",16,16,411,416,-0,0,-0,"short","long",NaN
148,"ALERS.PA","Eurobio Scientific: Wietse Mulder, CEO of GenDx, holds a 2% stake","https://www.globenewswire.com/news-release/2023/02/14/2607947/0/en/Eurobio-Scientific-Wietse-Mulder-CEO-of-GenDx-holds-a-2-stake.html","European Regulatory News","2023-02-14 11:45:00","market_open",18,18,411,413,-0,0,-0,"short","short",NaN
149,"ALERS.PA","EUROBIO SCIENTIFIC : RAPPORT FINANCIER ANNUEL 2022","https://www.globenewswire.com/news-release/2023/04/28/2657649/0/fr/EUROBIO-SCIENTIFIC-RAPPORT-FINANCIER-ANNUEL-2022.html","European Regulatory News","2023-04-28 11:45:00","market_open",16,16,411,416,-0,0,-0,"short","long",NaN
150,"ALERS.PA","Eurobio Scientific: GenDx reduces organ matching time to 3 hours","https://www.globenewswire.com/news-release/2023/10/17/2761752/0/en/Eurobio-Scientific-GenDx-reduces-organ-matching-time-to-3-hours.html","European Regulatory News","2023-10-17 11:40:00","market_open",14,14,433,436,0,0,-0,"short","short",NaN
151,"ALERS.PA","Eurobio Scientific: CATHERINE COURBOILLET TO JOIN EUROBIO SCIENTIFIC BOARD AS AN INDEPENDENT MEMBER","https://www.globenewswire.com/news-release/2023/11/07/2775371/0/en/Eurobio-Scientific-CATHERINE-COURBOILLET-TO-JOIN-EUROBIO-SCIENTIFIC-BOARD-AS-AN-INDEPENDENT-MEMBER.html","European Regulatory News","2023-11-07 11:40:00","market_open",16,16,436,437,0,0,0,"long","long",NaN
152,"ALERS.PA","Eurobio Scientific : GenDx réduit à 3h la durée des tests de compatibilité d’organes","https://www.globenewswire.com/news-release/2023/10/17/2761752/0/fr/Eurobio-Scientific-GenDx-r%C3%A9duit-%C3%A0-3h-la-dur%C3%A9e-des-tests-de-compatibilit%C3%A9-d-organes.html","European Regulatory News","2023-10-17 11:40:00","market_open",14,14,433,436,0,0,-0,"short","short",NaN
153,"ALERS.PA","EUROBIO : ACCÉLÉRATION DU DÉPLOIEMENT STRATÉGIQUE AU PREMIER SEMESTRE 2023","https://www.globenewswire.com/news-release/2023/07/24/2709736/0/fr/EUROBIO-ACC%C3%89L%C3%89RATION-DU-D%C3%89PLOIEMENT-STRAT%C3%89GIQUE-AU-PREMIER-SEMESTRE-2023.html","European Regulatory News","2023-07-24 11:46:00","market_open",15,15,453,454,-0,0,-0,"short","short",NaN
154,"ALERS.PA","Eurobio Scientific: RESULTATS ANNUELS 2022 - Très solide performance et renforcement du Cœur d’Activité","https://www.globenewswire.com/news-release/2023/04/05/2641992/0/fr/Eurobio-Scientific-RESULTATS-ANNUELS-2022-Tr%C3%A8s-solide-performance-et-renforcement-du-C%C5%93ur-d-Activit%C3%A9.html","European Regulatory News","2023-04-05 11:41:00","market_open",16,16,408,408,-0,-0,-0,"short","short",NaN
136,"AKYA","Akoya Biosciences Sets a New Standard for Scaling Spatial Biology with the Launch of 2.0 Platforms","https://www.globenewswire.com/news-release/2023/09/19/2745518/0/en/Akoya-Biosciences-Sets-a-New-Standard-for-Scaling-Spatial-Biology-with-the-Launch-of-2-0-Platforms.html","Product / Services Announcement","2023-09-19 08:00:00","pre_market",4,4,444,443,0,-0,0,"long","long",NaN
137,"AKYA","Akoya Biosciences’ Technology Enables Queensland Spatial Biology Centre to Revolutionize the Diagnosis and Treatment of Cancer and Other Diseases","https://www.globenewswire.com/news-release/2024/01/18/2811486/0/en/Akoya-Biosciences-Technology-Enables-Queensland-Spatial-Biology-Centre-to-Revolutionize-the-Diagnosis-and-Treatment-of-Cancer-and-Other-Diseases.html","Health","2024-01-18 08:00:00","pre_market",5,5,472,474,0,0,0,"long","long",NaN
138,"AKYA","Akoya Biosciences Announces that Garry Nolan, Ph.D., James Allison, Ph.D., and Padmanee Sharma, M.D., Ph.D., Join Newly Created Scientific Advisory Board","https://www.globenewswire.com/news-release/2024/01/10/2807080/0/en/Akoya-Biosciences-Announces-that-Garry-Nolan-Ph-D-James-Allison-Ph-D-and-Padmanee-Sharma-M-D-Ph-D-Join-Newly-Created-Scientific-Advisory-Board.html","Directors and Officers","2024-01-10 08:00:00","pre_market",5,5,474,474,-0,0,-0,"short","short",NaN
139,"AKYA","Akoya to Participate at 42nd Annual J.P. Morgan Healthcare Conference","https://www.globenewswire.com/news-release/2023/12/20/2799236/0/en/Akoya-to-Participate-at-42nd-Annual-J-P-Morgan-Healthcare-Conference.html","Calendar of Events","2023-12-20 08:05:00","pre_market",5,5,475,474,-0,-0,-0,"short","short",NaN
155,"ALERS.PA","Eurobio Scientific - MISE À DISPOSITION DU RAPPORT FINANCIER SEMESTRIEL 2023","https://www.globenewswire.com/news-release/2023/10/30/2769525/0/en/Eurobio-Scientific-MISE-%C3%80-DISPOSITION-DU-RAPPORT-FINANCIER-SEMESTRIEL-2023.html","European Regulatory News","2023-10-30 12:45:00","market_open",16,16,414,416,0,0,0,"long","long",NaN
168,"ALVO","Alvotech and Islandsbanki enter into Market Making Agreement for Shares Trading on Nasdaq Iceland","https://www.globenewswire.com/news-release/2023/10/05/2755706/0/en/Alvotech-and-Islandsbanki-enter-into-Market-Making-Agreement-for-Shares-Trading-on-Nasdaq-Iceland.html","European Regulatory News","2023-10-05 13:21:00","market_open",9,9,424,424,-0,0,-0,"short","long",NaN
169,"ALVO","Alvotech og JAMP Pharma hljóta markaðsleyfi í Kanada fyrir Jamteki, líftæknilyfjahliðstæðu við Stelara","https://www.globenewswire.com/news-release/2023/11/14/2779894/0/is/Alvotech-og-JAMP-Pharma-hlj%C3%B3ta-marka%C3%B0sleyfi-%C3%AD-Kanada-fyrir-Jamteki-l%C3%ADft%C3%A6knilyfjahli%C3%B0st%C3%A6%C3%B0u-vi%C3%B0-Stelara.html","European Regulatory News","2023-11-14 07:00:00","pre_market",9,9,440,446,0,0,-0,"short","short",NaN
170,"ALVO","STADA and Alvotech receive positive CHMP opinion for Europe’s first ustekinumab biosimilar to Stelara","https://www.globenewswire.com/news-release/2023/11/10/2778378/0/en/STADA-and-Alvotech-receive-positive-CHMP-opinion-for-Europe-s-first-ustekinumab-biosimilar-to-Stelara.html","European Regulatory News","2023-11-10 09:30:00","market_open",9,9,436,441,0,0,0,"long","long",NaN
171,"ALVO","Alvotech and JAMP Pharma Announce Receipt of Marketing Authorization for Jamteki (AVT04), the First Biosimilar of Stelara® (ustekinumab)","https://www.globenewswire.com/news-release/2023/11/14/2779894/0/en/Alvotech-and-JAMP-Pharma-Announce-Receipt-of-Marketing-Authorization-for-Jamteki-AVT04-the-First-Biosimilar-of-Stelara-ustekinumab.html","European Regulatory News","2023-11-14 07:00:00","pre_market",9,9,440,446,0,0,-0,"short","short",NaN
172,"ALVO","Alvotech og Íslandsbanki gera samning um viðskiptavakt með hlutabréf í Kauphöllinni","https://www.globenewswire.com/news-release/2023/10/05/2755706/0/is/Alvotech-og-%C3%8Dslandsbanki-gera-samning-um-vi%C3%B0skiptavakt-me%C3%B0-hlutabr%C3%A9f-%C3%AD-Kauph%C3%B6llinni.html","European Regulatory News","2023-10-05 13:21:00","market_open",9,9,424,424,-0,0,-0,"short","long",NaN
167,"ALVO","Alvotech birtir nýjar upplýsingar um stöðu umsóknar um markaðsleyfi fyrir AVT04 í Bandaríkjunum","https://www.globenewswire.com/news-release/2023/10/12/2758971/0/is/Alvotech-birtir-n%C3%BDjar-uppl%C3%BDsingar-um-st%C3%B6%C3%B0u-ums%C3%B3knar-um-marka%C3%B0sleyfi-fyrir-AVT04-%C3%AD-Bandar%C3%ADkjunum.html","European Regulatory News","2023-10-12 04:00:00","pre_market",9,9,436,437,-0,0,-0,"short","long",NaN
156,"ALERS.PA","Eurobio Scientific: all resolutions approved at the Annual General Meeting","https://www.globenewswire.com/news-release/2023/06/16/2689837/0/en/Eurobio-Scientific-all-resolutions-approved-at-the-Annual-General-Meeting.html","European Regulatory News","2023-06-16 11:45:00","market_open",15,15,443,439,-0,-0,0,"long","long",NaN
157,"ALERS.PA","Eurobio Scientific devient une des premières sociétés européennes à obtenir le marquage CE IVDR1 de tests PCR","https://www.globenewswire.com/news-release/2023/05/23/2674617/0/fr/Eurobio-Scientific-devient-une-des-premi%C3%A8res-soci%C3%A9t%C3%A9s-europ%C3%A9ennes-%C3%A0-obtenir-le-marquage-CE-IVDR1-de-tests-PCR.html","European Regulatory News","2023-05-23 11:45:00","market_open",17,17,417,414,0,-0,0,"long","long",NaN
158,"ALERS.PA","EUROBIO : ACCELERATION OF STRATEGIC DEPLOYMENT IN THE FIRST HALF OF 2023","https://www.globenewswire.com/news-release/2023/07/24/2709830/0/en/EUROBIO-ACCELERATION-OF-STRATEGIC-DEPLOYMENT-IN-THE-FIRST-HALF-OF-2023.html","European Regulatory News","2023-07-24 13:45:00","market_open",15,15,453,454,-0,0,-0,"short","short",NaN
159,"ALERS.PA","Eurobio Scientific : Wietse Mulder, CEO de GenDx,  détient 2% du capital","https://www.globenewswire.com/news-release/2023/02/14/2607947/0/fr/Eurobio-Scientific-Wietse-Mulder-CEO-de-GenDx-d%C3%A9tient-2-du-capital.html","European Regulatory News","2023-02-14 11:45:00","market_open",18,18,411,413,-0,0,-0,"short","short",NaN
160,"ALERS.PA","Eurobio Scientific : 2022 ANNUAL RESULTS - Very strong performance and strengthening of the Core Business","https://www.globenewswire.com/news-release/2023/04/05/2641992/0/en/Eurobio-Scientific-2022-ANNUAL-RESULTS-Very-strong-performance-and-strengthening-of-the-Core-Business.html","European Regulatory News","2023-04-05 11:41:00","market_open",16,16,408,408,-0,-0,-0,"short","short",NaN
161,"ALERS.PA","EUROBIO SCIENTIFIC CONFIRME SON ELIGIBILITE AU DISPOSITIF PEA-PME","https://www.globenewswire.com/news-release/2024/01/17/2810996/0/fr/EUROBIO-SCIENTIFIC-CONFIRME-SON-ELIGIBILITE-AU-DISPOSITIF-PEA-PME.html","European Regulatory News","2024-01-17 11:45:00","market_open",16,16,472,472,0,0,0,"long","long",NaN
162,"ALERS.PA","Eurobio Scientific: FISCAL YEAR 2023, STRATEGIC TRANSFORMATION OF THE GROUP","https://www.globenewswire.com/news-release/2024/01/30/2820322/0/en/Eurobio-Scientific-FISCAL-YEAR-2023-STRATEGIC-TRANSFORMATION-OF-THE-GROUP.html","European Regulatory News","2024-01-30 11:45:00","market_open",16,16,491,491,0,0,0,"long","long",NaN
163,"ALERS.PA","Eurobio Scientific : BILAN SEMESTRIEL S2 DU CONTRAT DE LIQUIDITE","https://www.globenewswire.com/news-release/2024/01/17/2810998/0/fr/Eurobio-Scientific-BILAN-SEMESTRIEL-S2-DU-CONTRAT-DE-LIQUIDITE.html","European Regulatory News","2024-01-17 11:45:00","market_open",16,16,472,472,0,0,0,"long","long",NaN
164,"ALERS.PA","Eurobio Scientific : réduction de capital par annulation d’actions auto-détenues","https://www.globenewswire.com/news-release/2024/01/10/2806894/0/fr/Eurobio-Scientific-r%C3%A9duction-de-capital-par-annulation-d-actions-auto-d%C3%A9tenues.html","European Regulatory News","2024-01-10 04:48:00","pre_market",16,16,474,474,-0,0,-0,"short","long",NaN
165,"ALERS.PA","Eurobio Scientific : EXERCICE 2023, CONFIRMATION DE LA TRANSFORMATION STRATEGIQUE","https://www.globenewswire.com/news-release/2024/01/30/2820322/0/fr/Eurobio-Scientific-EXERCICE-2023-CONFIRMATION-DE-LA-TRANSFORMATION-STRATEGIQUE.html","European Regulatory News","2024-01-30 11:45:00","market_open",16,16,491,491,0,0,0,"long","long",NaN
181,"ALVO","STADA and Alvotech receive positive CHMP opinion for Europe’s first ustekinumab biosimilar to Stelara","https://www.globenewswire.com/news-release/2023/11/10/2778383/0/en/STADA-and-Alvotech-receive-positive-CHMP-opinion-for-Europe-s-first-ustekinumab-biosimilar-to-Stelara.html","Health","2023-11-10 09:30:00","market_open",9,9,436,441,0,0,0,"long","long",NaN
173,"ALVO","Alvotech mun birta uppgjör fyrstu níu mánaða 2023 þann 28. nóvember og streyma uppgjörsfundi 29. nóvember kl. 13:00 að íslenskum tíma","https://www.globenewswire.com/news-release/2023/11/21/2784014/0/is/Alvotech-mun-birta-uppgj%C3%B6r-fyrstu-n%C3%ADu-m%C3%A1na%C3%B0a-2023-%C3%BEann-28-n%C3%B3vember-og-streyma-uppgj%C3%B6rsfundi-29-n%C3%B3vember-kl-13-00-a%C3%B0-%C3%ADslenskum-t%C3%ADma.html","European Regulatory News","2023-11-21 08:00:00","pre_market",9,9,454,453,-0,-0,-0,"short","short",NaN
177,"ALVO","Alvotech to Present at the Jefferies 2023 London Healthcare Conference","https://www.globenewswire.com/news-release/2023/11/07/2775024/0/en/Alvotech-to-Present-at-the-Jefferies-2023-London-Healthcare-Conference.html","European Regulatory News","2023-11-07 08:00:00","pre_market",9,9,436,436,-0,0,-0,"short","short",NaN
175,"ALVO","Alvotech Announces Changes to the Leadership Team","https://www.globenewswire.com/news-release/2023/09/05/2737491/0/en/Alvotech-Announces-Changes-to-the-Leadership-Team.html","European Regulatory News","2023-09-05 09:30:00","market_open",10,10,451,449,-0,-0,-0,"short","short",NaN
174,"ALVO","Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®","https://www.globenewswire.com/news-release/2023/11/29/2787524/0/en/Alvotech-Announces-Positive-Top-Line-Results-from-a-Pharmacokinetic-Study-for-AVT05-a-Proposed-Biosimilar-for-Simponi-and-Simponi-Aria.html","European Regulatory News","2023-11-29 04:00:00","pre_market",10,10,455,457,0,0,0,"long","long",NaN
178,"ALVO","Alvotech tilkynnir um breytingar í framkvæmdastjórn","https://www.globenewswire.com/news-release/2023/09/05/2737491/0/is/Alvotech-tilkynnir-um-breytingar-%C3%AD-framkv%C3%A6mdastj%C3%B3rn.html","European Regulatory News","2023-09-05 09:30:00","market_open",10,10,451,449,-0,-0,-0,"short","short",NaN
180,"ALVO","Alvotech Provides Update on Status of U.S. Biologics License Application for AVT04","https://www.globenewswire.com/news-release/2023/10/12/2758971/0/en/Alvotech-Provides-Update-on-Status-of-U-S-Biologics-License-Application-for-AVT04.html","European Regulatory News","2023-10-12 04:00:00","pre_market",9,9,436,437,-0,0,-0,"short","long",NaN
182,"ALVO","Alvotech og STADA fyrst til að hljóta jákvæða afgreiðslu lyfjastofnunar Evrópu á umsókn um markaðsleyfi fyrir líftæknilyfjahliðstæðu við Stelara","https://www.globenewswire.com/news-release/2023/11/10/2778378/0/is/Alvotech-og-STADA-fyrst-til-a%C3%B0-hlj%C3%B3ta-j%C3%A1kv%C3%A6%C3%B0a-afgrei%C3%B0slu-lyfjastofnunar-Evr%C3%B3pu-%C3%A1-ums%C3%B3kn-um-marka%C3%B0sleyfi-fyrir-l%C3%ADft%C3%A6knilyfjahli%C3%B0st%C3%A6%C3%B0u-vi%C3%B0-Stelara.html","European Regulatory News","2023-11-10 09:30:00","market_open",9,9,436,441,0,0,0,"long","long",NaN
184,"ALVO","Alvotech tekur þátt í heilbrigðisráðstefnu Jefferies í London","https://www.globenewswire.com/news-release/2023/11/07/2775024/0/is/Alvotech-tekur-%C3%BE%C3%A1tt-%C3%AD-heilbrig%C3%B0isr%C3%A1%C3%B0stefnu-Jefferies-%C3%AD-London.html","European Regulatory News","2023-11-07 08:00:00","pre_market",9,9,436,436,-0,0,-0,"short","short",NaN
183,"ALVO","Alvotech kynnir jákvæðar niðurstöður úr rannsókn á lyfjahvörfum AVT05, fyrirhugaðri líftæknilyfjahliðstæðu við Simponi® og Simponi Aria®","https://www.globenewswire.com/news-release/2023/11/29/2787524/0/is/Alvotech-kynnir-j%C3%A1kv%C3%A6%C3%B0ar-ni%C3%B0urst%C3%B6%C3%B0ur-%C3%BAr-ranns%C3%B3kn-%C3%A1-lyfjahv%C3%B6rfum-AVT05-fyrirhuga%C3%B0ri-l%C3%ADft%C3%A6knilyfjahli%C3%B0st%C3%A6%C3%B0u-vi%C3%B0-Simponi-og-Simponi-Aria.html","European Regulatory News","2023-11-29 04:00:00","pre_market",10,10,455,457,0,0,0,"long","long",NaN
185,"ALVO","Alvotech to Present at the Jefferies 2023 London Healthcare Conference","https://www.globenewswire.com/news-release/2023/11/07/2775023/0/en/Alvotech-to-Present-at-the-Jefferies-2023-London-Healthcare-Conference.html","Health","2023-11-07 08:00:00","pre_market",9,9,436,436,-0,0,-0,"short","short",NaN
186,"ALVO","Alvotech and JAMP Pharma Announce Receipt of Marketing Authorization for Jamteki™ (AVT04), the First Biosimilar of Stelara® (ustekinumab)","https://www.globenewswire.com/news-release/2023/11/14/2779896/0/en/Alvotech-and-JAMP-Pharma-Announce-Receipt-of-Marketing-Authorization-for-Jamteki-AVT04-the-First-Biosimilar-of-Stelara-ustekinumab.html","Licensing Agreements","2023-11-14 07:00:00","pre_market",9,9,440,446,0,0,-0,"short","short",NaN
187,"ALVO","Alvotech Announces Changes to the Leadership Team","https://www.globenewswire.com/news-release/2023/09/05/2737492/0/en/Alvotech-Announces-Changes-to-the-Leadership-Team.html","Management Changes","2023-09-05 09:30:00","market_open",10,10,451,449,-0,-0,-0,"short","short",NaN
188,"ALVO","Alvotech Provides Update on Status of  Biologics License Applications for AVT02 and AVT04","https://www.globenewswire.com/news-release/2024/01/19/2812429/0/en/Alvotech-Provides-Update-on-Status-of-Biologics-License-Applications-for-AVT02-and-AVT04.html","European Regulatory News","2024-01-19 11:30:00","market_open",13,14,478,482,0,0,0,"long","long",NaN
189,"ALVO","Alvotech tilkynnir hvenær sala á AVT04, líftæknilyfjahliðstæðu við Stelara, getur hafist á alþjóðlegum mörkuðum","https://www.globenewswire.com/news-release/2024/02/15/2829780/0/is/Alvotech-tilkynnir-hven%C3%A6r-sala-%C3%A1-AVT04-l%C3%ADft%C3%A6knilyfjahli%C3%B0st%C3%A6%C3%B0u-vi%C3%B0-Stelara-getur-hafist-%C3%A1-al%C3%BEj%C3%B3%C3%B0legum-m%C3%B6rku%C3%B0um.html","European Regulatory News","2024-02-15 06:30:00","pre_market",16,16,499,499,0,0,0,"long","long",NaN
205,"AMRN","Amarin to Report First Quarter 2023 Financial Results and Host Conference Call on May 3, 2023","https://www.globenewswire.com/news-release/2023/04/19/2649963/18362/en/Amarin-to-Report-First-Quarter-2023-Financial-Results-and-Host-Conference-Call-on-May-3-2023.html","Conference Calls/ Webcasts","2023-04-19 08:00:00","pre_market",1,1,414,412,-0,-0,-0,"short","short",NaN
199,"AMRN","Amarin to Report Third Quarter 2023 Financial Results and Host Conference Call on November 1, 2023","https://www.globenewswire.com/news-release/2023/10/19/2763140/18362/en/Amarin-to-Report-Third-Quarter-2023-Financial-Results-and-Host-Conference-Call-on-November-1-2023.html","Conference Calls/ Webcasts","2023-10-19 08:00:00","pre_market",1,1,430,431,-0,0,-0,"short","short",NaN
200,"AMRN","Amarin Board of Directors Announces Executive Compensation Program for New President and CEO Patrick Holt","https://www.globenewswire.com/news-release/2023/07/20/2708141/18362/en/Amarin-Board-of-Directors-Announces-Executive-Compensation-Program-for-New-President-and-CEO-Patrick-Holt.html","Directors and Officers","2023-07-20 08:00:00","pre_market",1,1,455,454,0,-0,0,"long","long",NaN
201,"AMRN","Amarin Reports Third Quarter 2023 Financial Results","https://www.globenewswire.com/news-release/2023/11/01/2770981/18362/en/Amarin-Reports-Third-Quarter-2023-Financial-Results.html","Earnings Releases and Operating Results","2023-11-01 07:00:00","pre_market",1,1,418,419,0,0,-0,"short","short",NaN
202,"AMRN","Latest Research Evaluating Clinical Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the European Society of Cardiology (ESC) Congress","https://www.globenewswire.com/news-release/2023/07/26/2711275/18362/en/Latest-Research-Evaluating-Clinical-Benefits-of-VASCEPA-VAZKEPA-icosapent-ethyl-to-be-Presented-at-the-European-Society-of-Cardiology-ESC-Congress.html","Clinical Study","2023-07-26 08:00:00","pre_market",1,1,455,454,0,-0,0,"long","long",NaN
203,"AMRN","Amarin Reports First Quarter 2023 Financial Results and Provides Business Update","https://www.globenewswire.com/news-release/2023/05/03/2660168/18362/en/Amarin-Reports-First-Quarter-2023-Financial-Results-and-Provides-Business-Update.html","Earnings Releases and Operating Results","2023-05-03 07:00:00","pre_market",1,1,411,411,0,0,0,"long","long",NaN
204,"AMRN","Amarin Announces Vascepa® (Icosapent Ethyl) Approved to Reduce Cardiovascular Risk in the Kingdom of Saudi Arabia (KSA)","https://www.globenewswire.com/news-release/2023/06/21/2692114/18362/en/Amarin-Announces-Vascepa-Icosapent-Ethyl-Approved-to-Reduce-Cardiovascular-Risk-in-the-Kingdom-of-Saudi-Arabia-KSA.html","Product / Services Announcement","2023-06-21 09:00:00","pre_market",1,1,437,436,-0,-0,-0,"short","short",NaN
198,"AMRN","Amarin Partner EddingPharm Receives Regulatory Approval for Vascepa® (Icosapent Ethyl) in Mainland China","https://www.globenewswire.com/news-release/2023/06/01/2680082/18362/en/Amarin-Partner-EddingPharm-Receives-Regulatory-Approval-for-Vascepa-Icosapent-Ethyl-in-Mainland-China.html","Health","2023-06-01 06:00:00","pre_market",1,1,418,418,0,0,0,"long","long",NaN
206,"AMRN","Scottish Medicines Consortium Accepts VAZKEPA® (icosapent ethyl) to Help Reduce Cardiovascular Risk for Patients in Scotland(1)","https://www.globenewswire.com/news-release/2023/08/07/2719579/18362/en/Scottish-Medicines-Consortium-Accepts-VAZKEPA-icosapent-ethyl-to-Help-Reduce-Cardiovascular-Risk-for-Patients-in-Scotland-1.html","Product / Services Announcement","2023-08-07 07:00:00","pre_market",1,1,447,449,0,0,-0,"short","short",NaN
190,"ALVO","Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®","https://www.globenewswire.com/news-release/2024/01/29/2818530/0/en/Alvotech-Announces-Positive-Top-Line-Results-from-a-Pharmacokinetic-Study-for-AVT03-a-Proposed-Biosimilar-for-Prolia-and-Xgeva.html","European Regulatory News","2024-01-29 04:00:00","pre_market",15,15,487,488,0,0,0,"long","long",NaN
191,"ALVO","Alvotech birtir upplýsingar um stöðu umsókna um markaðsleyfi fyrir AVT02 og AVT04 í Bandaríkjunum","https://www.globenewswire.com/news-release/2024/01/19/2812429/0/is/Alvotech-birtir-uppl%C3%BDsingar-um-st%C3%B6%C3%B0u-ums%C3%B3kna-um-marka%C3%B0sleyfi-fyrir-AVT02-og-AVT04-%C3%AD-Bandar%C3%ADkjunum.html","European Regulatory News","2024-01-19 11:30:00","market_open",13,14,478,482,0,0,0,"long","long",NaN
192,"ALVO","Alvotech Provides Update on Status of Biologics License Applications for AVT02 and AVT04","https://www.globenewswire.com/news-release/2024/01/19/2812432/0/en/Alvotech-Provides-Update-on-Status-of-Biologics-License-Applications-for-AVT02-and-AVT04.html","Health","2024-01-19 11:30:00","market_open",13,14,478,482,0,0,0,"long","long",NaN
194,"ALVO","Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®","https://www.globenewswire.com/news-release/2024/01/29/2818535/0/en/Alvotech-Announces-Positive-Top-Line-Results-from-a-Pharmacokinetic-Study-for-AVT03-a-Proposed-Biosimilar-for-Prolia-and-Xgeva.html","Clinical Study","2024-01-29 04:00:00","pre_market",15,15,487,488,0,0,0,"long","long",NaN
195,"ALVO","Alvotech Announces Expected Global Market Entry Dates for AVT04 Biosimilar to Stelara® (ustekinumab)","https://www.globenewswire.com/news-release/2024/02/15/2829779/0/en/Alvotech-Announces-Expected-Global-Market-Entry-Dates-for-AVT04-Biosimilar-to-Stelara-ustekinumab.html","Financing Agreements","2024-02-15 06:30:00","pre_market",16,16,499,499,0,0,0,"long","long",NaN
196,"ALVO","Alvotech Announces Expected Global Market Entry Dates for AVT04 Biosimilar to Stelara® (ustekinumab)","https://www.globenewswire.com/news-release/2024/02/15/2829780/0/en/Alvotech-Announces-Expected-Global-Market-Entry-Dates-for-AVT04-Biosimilar-to-Stelara-ustekinumab.html","European Regulatory News","2024-02-15 06:30:00","pre_market",16,16,499,499,0,0,0,"long","long",NaN
221,"ANAB","Anaptys Announces Participation in November Investor Conferences","https://www.globenewswire.com/news-release/2023/11/01/2771329/0/en/Anaptys-Announces-Participation-in-November-Investor-Conferences.html","Conference Calls/ Webcasts","2023-11-01 09:15:00","pre_market",16,16,418,419,-0,0,-0,"short","short",NaN
222,"ANAB","Anaptys to Present Phase 1 Data on ANB032, its BTLA Agonist Antibody, at the 32nd EADV Congress","https://www.globenewswire.com/news-release/2023/10/11/2758455/0/en/Anaptys-to-Present-Phase-1-Data-on-ANB032-its-BTLA-Agonist-Antibody-at-the-32nd-EADV-Congress.html","Clinical Study","2023-10-11 09:15:00","pre_market",20,20,435,436,-0,0,-0,"short","short",NaN
223,"ANAB","AnaptysBio- and GSK-partnered immuno-oncology agent JEMPERLI (dostarlimab-gxly) meets primary endpoint in Phase 3 RUBY trial in primary advanced or recurrent endometrial cancer","https://www.globenewswire.com/news-release/2022/12/02/2566746/0/en/AnaptysBio-and-GSK-partnered-immuno-oncology-agent-JEMPERLI-dostarlimab-gxly-meets-primary-endpoint-in-Phase-3-RUBY-trial-in-primary-advanced-or-recurrent-endometrial-cancer.html","Health","2022-12-02 09:00:00","pre_market",27,27,407,402,-0,-0,0,"long","long",NaN
224,"ANAB","AnaptysBio to Participate in Upcoming November Investor Conferences","https://www.globenewswire.com/news-release/2022/11/09/2552375/0/en/AnaptysBio-to-Participate-in-Upcoming-November-Investor-Conferences.html","Calendar of Events","2022-11-09 14:10:00","market_open",30,29,380,374,-0,-0,-0,"short","short",NaN
207,"AMRN","Amarin Highlights New Data Providing Potential Mechanistic Insight into Vascepa®/Vazkepa® (Icosapent Ethyl) Reduction of Cardiovascular Events","https://www.globenewswire.com/news-release/2023/05/12/2667968/18362/en/Amarin-Highlights-New-Data-Providing-Potential-Mechanistic-Insight-into-Vascepa-Vazkepa-Icosapent-Ethyl-Reduction-of-Cardiovascular-Events.html","Health","2023-05-12 11:00:00","market_open",1,1,413,412,0,-0,0,"long","long",NaN
208,"AMRN","Amarin And Neopharm Announce Exclusive Commercialization Agreement for VAZKEPA® (Icosapent Ethyl) in Israel","https://www.globenewswire.com/news-release/2023/08/08/2720436/18362/en/Amarin-And-Neopharm-Announce-Exclusive-Commercialization-Agreement-for-VAZKEPA-Icosapent-Ethyl-in-Israel.html","Product / Services Announcement","2023-08-08 07:00:00","pre_market",1,1,451,448,-0,-0,-0,"short","short",NaN
209,"AMRN","Amarin Appoints Jonathan Provoost Executive Vice President, Chief Legal & Compliance Officer","https://www.globenewswire.com/news-release/2023/10/31/2770478/18362/en/Amarin-Appoints-Jonathan-Provoost-Executive-Vice-President-Chief-Legal-Compliance-Officer.html","Directors and Officers","2023-10-31 12:00:00","market_open",1,1,416,418,0,0,0,"long","long",NaN
210,"AMRN","Amarin and Lotus Pharmaceuticals Announce Exclusive Partnership Agreement to Commercialize Vazkepa® (Icosapent Ethyl) in Southeast Asia and South Korea","https://www.globenewswire.com/news-release/2023/07/31/2714836/18362/en/Amarin-and-Lotus-Pharmaceuticals-Announce-Exclusive-Partnership-Agreement-to-Commercialize-Vazkepa-Icosapent-Ethyl-in-Southeast-Asia-and-South-Korea.html","Partnerships","2023-07-31 08:00:00","pre_market",1,1,457,457,0,0,-0,"short","short",NaN
211,"AMRN","Amarin Announces VAZKEPA® (Icosapent Ethyl) Approved by Israel's Ministry of Health","https://www.globenewswire.com/news-release/2023/04/04/2640591/18362/en/Amarin-Announces-VAZKEPA-Icosapent-Ethyl-Approved-by-Israel-s-Ministry-of-Health.html","Product / Services Announcement","2023-04-04 08:00:00","pre_market",1,1,411,412,-0,0,-0,"short","short",NaN
212,"AMRN","Amarin Names Aaron Berg Interim President & Chief Executive Officer and Adds Oliver O’Connor to Company’s Board of Directors","https://www.globenewswire.com/news-release/2023/04/17/2647757/18362/en/Amarin-Names-Aaron-Berg-Interim-President-Chief-Executive-Officer-and-Adds-Oliver-O-Connor-to-Company-s-Board-of-Directors.html","Directors and Officers","2023-04-17 07:00:00","pre_market",1,1,412,412,0,-0,0,"long","long",NaN
213,"AMRN","Amarin to Present at the 2023 Cantor Global Healthcare Conference","https://www.globenewswire.com/news-release/2023/09/12/2741592/18362/en/Amarin-to-Present-at-the-2023-Cantor-Global-Healthcare-Conference.html","Conference Calls/ Webcasts","2023-09-12 08:00:00","pre_market",1,1,448,447,-0,-0,-0,"short","short",NaN
214,"AMRN","Amarin Reports Second Quarter 2023 Financial Results","https://www.globenewswire.com/news-release/2023/08/02/2716719/18362/en/Amarin-Reports-Second-Quarter-2023-Financial-Results.html","Earnings Releases and Operating Results","2023-08-02 07:11:00","pre_market",1,1,456,453,-0,-0,-0,"short","short",NaN
215,"AMRN","Amarin Provides Preliminary Fourth Quarter 2023 Selected Financials and Outlines Key Priorities For 2024","https://www.globenewswire.com/news-release/2024/01/10/2806970/18362/en/Amarin-Provides-Preliminary-Fourth-Quarter-2023-Selected-Financials-and-Outlines-Key-Priorities-For-2024.html","Pre-Release Comments","2024-01-10 07:00:00","pre_market",1,1,474,474,0,0,0,"long","long",NaN
216,"AMRN","Amarin Chairman & CEO Issue Letter to Shareholders","https://www.globenewswire.com/news-release/2024/01/22/2812941/18362/en/Amarin-Chairman-CEO-Issue-Letter-to-Shareholders.html","Major shareholder announcements","2024-01-22 07:30:00","pre_market",1,1,482,484,0,0,0,"long","long",NaN
217,"AMRN","Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024","https://www.globenewswire.com/news-release/2024/02/15/2829894/18362/en/Amarin-to-Report-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Host-Conference-on-February-29-2024.html","Conference Calls/ Webcasts","2024-02-15 08:00:00","pre_market",1,1,499,499,0,0,-0,"short","short",NaN
218,"AMRN","Amarin to Present at the 42nd Annual J.P. Morgan Healthcare Conference","https://www.globenewswire.com/news-release/2023/12/11/2793825/18362/en/Amarin-to-Present-at-the-42nd-Annual-J-P-Morgan-Healthcare-Conference.html","Calendar of Events","2023-12-11 08:00:00","pre_market",1,1,460,460,-0,-0,-0,"short","short",NaN
241,"ANNX","Annexon Highlights Recent Pipeline and Business Progress and Reports Second Quarter 2023 Financial Results","https://www.globenewswire.com/news-release/2023/08/07/2719531/0/en/Annexon-Highlights-Recent-Pipeline-and-Business-Progress-and-Reports-Second-Quarter-2023-Financial-Results.html","Earnings Releases and Operating Results","2023-08-07 06:30:00","pre_market",3,3,447,449,0,0,0,"long","long",NaN
232,"ANNX","Annexon Biosciences to Participate in the 43rd Annual Cowen Healthcare Conference","https://www.globenewswire.com/news-release/2023/02/27/2615857/0/en/Annexon-Biosciences-to-Participate-in-the-43rd-Annual-Cowen-Healthcare-Conference.html","Conference Calls/ Webcasts","2023-02-27 06:30:00","pre_market",5,5,396,400,0,0,0,"long","long",NaN
237,"ANNX","Annexon Biosciences to Participate in the 2023 Cantor Global Healthcare Conference","https://www.globenewswire.com/news-release/2023/09/19/2745419/0/en/Annexon-Biosciences-to-Participate-in-the-2023-Cantor-Global-Healthcare-Conference.html","Calendar of Events","2023-09-19 06:30:00","pre_market",3,3,444,443,0,-0,0,"long","long",NaN
228,"ANAB","Anaptys Announces Positive Top-Line Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)","https://www.globenewswire.com/news-release/2023/10/09/2756638/0/en/Anaptys-Announces-Positive-Top-Line-Phase-3-Clinical-Trial-Results-of-Imsidolimab-IL-36R-in-Generalized-Pustular-Psoriasis-GPP.html","Product / Services Announcement","2023-10-09 08:00:00","pre_market",19,20,430,428,0,-0,0,"long","long",NaN
231,"ANNX","Annexon Announces Clinical and Regulatory Progress for ANX005 Pivotal Program in Guillain-Barré Syndrome (GBS)","https://www.globenewswire.com/news-release/2023/10/10/2757271/0/en/Annexon-Announces-Clinical-and-Regulatory-Progress-for-ANX005-Pivotal-Program-in-Guillain-Barr%C3%A9-Syndrome-GBS.html","Clinical Study","2023-10-10 06:30:00","pre_market",2,2,432,433,0,0,0,"long","long",NaN
227,"ANAB","AnaptysBio to Present at the Stifel 2023 Immunology and Inflammation Virtual Summit","https://www.globenewswire.com/news-release/2023/09/12/2741776/0/en/AnaptysBio-to-Present-at-the-Stifel-2023-Immunology-and-Inflammation-Virtual-Summit.html","Conference Calls/ Webcasts","2023-09-12 09:15:00","pre_market",20,20,448,447,-0,-0,0,"long","long",NaN
233,"ANNX","Annexon Biosciences to Participate in 2023 Jefferies London Healthcare Conference","https://www.globenewswire.com/news-release/2023/11/09/2777120/0/en/Annexon-Biosciences-to-Participate-in-2023-Jefferies-London-Healthcare-Conference.html","Conference Calls/ Webcasts","2023-11-09 06:30:00","pre_market",2,2,437,438,-0,0,-0,"short","short",NaN
242,"ANNX","Annexon Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference","https://www.globenewswire.com/news-release/2023/12/27/2801303/0/en/Annexon-Biosciences-to-Present-at-the-42nd-Annual-J-P-Morgan-Healthcare-Conference.html","Calendar of Events","2023-12-27 06:30:00","pre_market",4,4,476,475,0,-0,0,"long","long",NaN
243,"ANVS","Annovis Bio Interview to Air on Bloomberg International on the RedChip Money Report","https://www.globenewswire.com/news-release/2020/09/03/2088309/0/en/Annovis-Bio-Interview-to-Air-on-Bloomberg-International-on-the-RedChip-Money-Report.html","Product / Services Announcement","2020-09-03 06:45:00","pre_market",5,5,358,356,-0,-0,-0,"short","long",NaN
239,"ANNX","Annexon Biosciences to Participate in the 22nd Annual Needham Virtual Healthcare Conference","https://www.globenewswire.com/news-release/2023/04/11/2644185/0/en/Annexon-Biosciences-to-Participate-in-the-22nd-Annual-Needham-Virtual-Healthcare-Conference.html","Conference Calls/ Webcasts","2023-04-11 06:30:00","pre_market",4,4,410,410,-0,0,-0,"short","long",NaN
236,"ANNX","Annexon to Report ARCHER Phase 2 Trial Results in Geographic Atrophy at ASRS 2023","https://www.globenewswire.com/news-release/2023/07/24/2709360/0/en/Annexon-to-Report-ARCHER-Phase-2-Trial-Results-in-Geographic-Atrophy-at-ASRS-2023.html","Clinical Study","2023-07-24 06:30:00","pre_market",3,3,452,453,-0,0,-0,"short","long",NaN
238,"ANNX","Annexon Biosciences Strengthens Leadership Team with Appointment of Jamie Dananberg, M.D., as Chief Medical Officer","https://www.globenewswire.com/news-release/2023/07/27/2711977/0/en/Annexon-Biosciences-Strengthens-Leadership-Team-with-Appointment-of-Jamie-Dananberg-M-D-as-Chief-Medical-Officer.html","Management Changes","2023-07-27 06:30:00","pre_market",3,3,456,459,0,0,0,"long","long",NaN
235,"ANNX","Annexon Receives PRIME Designation from the EMA for ANX007 for the Treatment of Geographic Atrophy","https://www.globenewswire.com/news-release/2023/10/24/2765415/0/en/Annexon-Receives-PRIME-Designation-from-the-EMA-for-ANX007-for-the-Treatment-of-Geographic-Atrophy.html","Health","2023-10-24 06:30:00","pre_market",2,2,420,423,0,0,0,"long","long",NaN
229,"ANAB","AnaptysBio to Participate at the Piper Sandler 34th Annual Healthcare Conference","https://www.globenewswire.com/news-release/2022/11/21/2560251/0/en/AnaptysBio-to-Participate-at-the-Piper-Sandler-34th-Annual-Healthcare-Conference.html","Calendar of Events","2022-11-21 13:56:00","market_open",27,27,395,395,-0,-0,-0,"short","short",NaN
234,"ANNX","Annexon Reports Fourth Quarter and Year-End 2022 Financial Results and Reiterates Anticipated Milestones","https://www.globenewswire.com/news-release/2023/03/06/2620852/0/en/Annexon-Reports-Fourth-Quarter-and-Year-End-2022-Financial-Results-and-Reiterates-Anticipated-Milestones.html","Earnings Releases and Operating Results","2023-03-06 06:30:00","pre_market",5,5,404,405,-0,0,-0,"short","short",NaN
230,"ANAB","Anaptys to Present at Guggenheim’s 6th Annual Biotechnology Conference","https://www.globenewswire.com/news-release/2024/01/31/2821240/0/en/Anaptys-to-Present-at-Guggenheim-s-6th-Annual-Biotechnology-Conference.html","Conference Calls/ Webcasts","2024-01-31 09:15:00","pre_market",24,24,491,489,-0,-0,-0,"short","short",NaN
250,"ANVS","Annovis Bio CEO to Present at Meridian Clinical Trials Summit","https://www.globenewswire.com/news-release/2020/11/02/2118277/0/en/Annovis-Bio-CEO-to-Present-at-Meridian-Clinical-Trials-Summit.html","Company Announcement","2020-11-02 06:45:00","pre_market",5,4,327,330,-0,0,-0,"short","short",NaN
247,"ANVS","Annovis Bio Announces Full Enrollment of Its Phase II/III Alzheimer’s Disease Trial, Exceeding Original Projections","https://www.globenewswire.com/news-release/2023/11/27/2786071/0/en/Annovis-Bio-Announces-Full-Enrollment-of-Its-Phase-II-III-Alzheimer-s-Disease-Trial-Exceeding-Original-Projections.html","Clinical Study","2023-11-27 07:30:00","pre_market",6,7,455,455,0,-0,0,"long","long",NaN
246,"ANVS","Annovis Bio Interview to Air on Bloomberg International on the RedChip Money Report","https://www.globenewswire.com/news-release/2020/12/17/2146815/0/en/Annovis-Bio-Interview-to-Air-on-Bloomberg-International-on-the-RedChip-Money-Report.html","Company Announcement","2020-12-17 06:45:00","pre_market",6,6,370,372,0,0,-0,"short","short",NaN
255,"ANVS","Annovis Bio to Present at the New York Academy of Sciences’ Alzheimer's Disease Therapeutics: Alternatives to Amyloid 2020 Virtual Conference","https://www.globenewswire.com/news-release/2020/12/03/2139244/0/en/Annovis-Bio-to-Present-at-the-New-York-Academy-of-Sciences-Alzheimer-s-Disease-Therapeutics-Alternatives-to-Amyloid-2020-Virtual-Conference.html","Calendar of Events","2020-12-03 09:15:00","pre_market",5,5,367,367,-0,-0,-0,"short","short",NaN
251,"ANVS","Annovis Bio Showcases its Unique Approach to Alzheimer’s at the New York Academy of Sciences","https://www.globenewswire.com/news-release/2020/12/15/2145170/0/en/Annovis-Bio-Showcases-its-Unique-Approach-to-Alzheimer-s-at-the-New-York-Academy-of-Sciences.html","Company Announcement","2020-12-15 06:45:00","pre_market",6,6,365,367,0,0,-0,"short","short",NaN
253,"ANVS","Annovis Bio CEO Participates in Roundtable Discussion at the Financial Times’ Outstanding Directors Exchange and Panel Discussion at the Angel Venture Fair","https://www.globenewswire.com/news-release/2020/10/20/2110894/0/en/Annovis-Bio-CEO-Participates-in-Roundtable-Discussion-at-the-Financial-Times-Outstanding-Directors-Exchange-and-Panel-Discussion-at-the-Angel-Venture-Fair.html","Calendar of Events","2020-10-20 06:45:00","pre_market",5,5,342,343,0,0,0,"long","long",NaN
256,"ANVS","Annovis Bio Reports Positive Results from Final Phase of $1.9M NIH Funded Chronic Toxicology Study for its Lead Compound for the Treatment of Alzheimer’s and Parkinson’s Diseases","https://www.globenewswire.com/news-release/2020/11/12/2125393/0/en/Annovis-Bio-Reports-Positive-Results-from-Final-Phase-of-1-9M-NIH-Funded-Chronic-Toxicology-Study-for-its-Lead-Compound-for-the-Treatment-of-Alzheimer-s-and-Parkinson-s-Diseases.html","Product / Services Announcement","2020-11-12 06:45:00","pre_market",5,5,357,356,0,-0,0,"long","long",NaN
259,"ANVS","Annovis Bio to Participate in the 139th Yale CEO Summit","https://www.globenewswire.com/news-release/2023/12/11/2794161/0/en/Annovis-Bio-to-Participate-in-the-139th-Yale-CEO-Summit.html","Calendar of Events","2023-12-11 13:00:00","market_open",10,9,460,462,-0,0,-0,"short","short",NaN
252,"ANVS","Annovis Bio to Participate in A.G.P.'s Virtual Healthcare Symposium","https://www.globenewswire.com/news-release/2020/11/16/2127426/0/en/Annovis-Bio-to-Participate-in-A-G-P-s-Virtual-Healthcare-Symposium.html","Calendar of Events","2020-11-16 09:15:00","pre_market",5,5,358,361,0,0,0,"long","short",NaN
257,"ANVS","Annovis Bio Announces Positive Interim Independent Analysis for Statistical Power in Its Alzheimer’s Study","https://www.globenewswire.com/news-release/2023/10/12/2759203/0/en/Annovis-Bio-Announces-Positive-Interim-Independent-Analysis-for-Statistical-Power-in-Its-Alzheimer-s-Study.html","Clinical Study","2023-10-12 08:02:00","pre_market",8,8,436,437,0,0,0,"long","long",NaN
248,"ANVS","Annovis Bio CEO Receives 2020 Smart Business Dealmaker Award","https://www.globenewswire.com/news-release/2020/10/22/2112633/0/en/Annovis-Bio-CEO-Receives-2020-Smart-Business-Dealmaker-Award.html","Calendar of Events","2020-10-22 06:45:00","pre_market",5,5,343,343,0,0,0,"long","long",NaN
254,"ANVS","Annovis Bio Provides Third Quarter 2020 and Year-to-Date Business Highlights","https://www.globenewswire.com/news-release/2020/10/15/2109031/0/en/Annovis-Bio-Provides-Third-Quarter-2020-and-Year-to-Date-Business-Highlights.html","Company Announcement","2020-10-15 06:45:00","pre_market",5,5,348,344,0,-0,0,"long","long",NaN
249,"ANVS","Annovis Bio Actively Recruiting Patients for its Phase 2a Trials in Alzheimer’s and Parkinson’s Diseases","https://www.globenewswire.com/news-release/2020/08/20/2081200/0/en/Annovis-Bio-Actively-Recruiting-Patients-for-its-Phase-2a-Trials-in-Alzheimer-s-and-Parkinson-s-Diseases.html","Product / Services Announcement","2020-08-20 06:45:00","pre_market",5,6,337,335,0,-0,0,"long","long",NaN
258,"ANVS","Annovis Bio Demonstrates Improved Axonal Transport in Nerve Cells and Brain of Down Syndrome Mice, an Animal Model of Alzheimer’s Disease","https://www.globenewswire.com/news-release/2020/09/29/2100426/0/en/Annovis-Bio-Demonstrates-Improved-Axonal-Transport-in-Nerve-Cells-and-Brain-of-Down-Syndrome-Mice-an-Animal-Model-of-Alzheimer-s-Disease.html","Research Analysis and Reports","2020-09-29 06:45:00","pre_market",4,4,334,334,0,-0,0,"long","long",NaN
260,"ANVS","Annovis Bio Announces Last Patient Last Visit in the Phase III Study of Buntanetap in Parkinson’s Disease","https://www.globenewswire.com/news-release/2023/12/05/2790799/0/en/Annovis-Bio-Announces-Last-Patient-Last-Visit-in-the-Phase-III-Study-of-Buntanetap-in-Parkinson-s-Disease.html","Health","2023-12-05 07:30:00","pre_market",10,10,457,455,0,-0,0,"long","long",NaN
261,"ANVS","Annovis Bio Announces Last Patient Last Visit in the Phase II/III Study of Buntanetap in Alzheimer’s Disease","https://www.globenewswire.com/news-release/2024/02/14/2828993/0/en/Annovis-Bio-Announces-Last-Patient-Last-Visit-in-the-Phase-II-III-Study-of-Buntanetap-in-Alzheimer-s-Disease.html","Clinical Study","2024-02-14 07:30:00","pre_market",10,10,494,497,0,0,0,"long","long",NaN
278,"ARQT","Arcutis Presents Positive Patient-Reported Outcome Data from the Pivotal ARRECTOR Phase 3 Trial in Scalp and Body Psoriasis at European Academy of Dermatology and Venereology (EADV) Congress","https://www.globenewswire.com/news-release/2023/10/13/2759915/0/en/Arcutis-Presents-Positive-Patient-Reported-Outcome-Data-from-the-Pivotal-ARRECTOR-Phase-3-Trial-in-Scalp-and-Body-Psoriasis-at-European-Academy-of-Dermatology-and-Venereology-EADV-.html","Clinical Study","2023-10-13 08:00:00","pre_market",4,4,434,435,-0,0,-0,"short","short",NaN
279,"ARQT","FDA Accepts Arcutis’ Supplemental New Drug Application for Roflumilast Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to Age 6","https://www.globenewswire.com/news-release/2023/11/29/2787702/0/en/FDA-Accepts-Arcutis-Supplemental-New-Drug-Application-for-Roflumilast-Cream-0-15-for-the-Treatment-of-Atopic-Dermatitis-in-Adults-and-Children-Down-to-Age-6.html","Clinical Study","2023-11-29 08:00:00","pre_market",2,2,455,457,0,0,0,"long","long",NaN
265,"APTO","Aptose to Hold Interim Clinical Update Webcast on Saturday, June 10, 2023","https://www.globenewswire.com/news-release/2023/05/31/2679281/35575/en/Aptose-to-Hold-Interim-Clinical-Update-Webcast-on-Saturday-June-10-2023.html","Conference Calls/ Webcasts","2023-05-31 07:30:00","pre_market",0,0,420,418,0,-0,0,"long","long",NaN
266,"APTO","Aptose Announces Pricing of $8.4 Million Public Offering and a Concurrent $4 Million Private Placement with Hanmi Pharmaceutical","https://www.globenewswire.com/news-release/2024/01/26/2817923/35575/en/Aptose-Announces-Pricing-of-8-4-Million-Public-Offering-and-a-Concurrent-4-Million-Private-Placement-with-Hanmi-Pharmaceutical.html","Financing Agreements","2024-01-26 08:00:00","pre_market",2,2,488,488,-0,-0,-0,"short","short",NaN
267,"APTO","Aptose Clinical and Preclinical Data to be Presented at European School of Haematology (ESH) 6th International Conference","https://www.globenewswire.com/news-release/2023/10/16/2760527/35575/en/Aptose-Clinical-and-Preclinical-Data-to-be-Presented-at-European-School-of-Haematology-ESH-6th-International-Conference.html","Research Analysis and Reports","2023-10-16 07:30:00","pre_market",2,2,432,434,0,0,0,"long","long",NaN
268,"APTO","Aptose Announces Closing of $3 Million Investment by Hanmi Pharmaceutical","https://www.globenewswire.com/news-release/2023/09/06/2738285/35575/en/Aptose-Announces-Closing-of-3-Million-Investment-by-Hanmi-Pharmaceutical.html","Financing Agreements","2023-09-06 07:45:00","pre_market",4,4,449,448,0,-0,0,"long","long",NaN
269,"APTO","Aptose to Present at the Cantor Global Healthcare Conference","https://www.globenewswire.com/news-release/2023/09/18/2744684/35575/en/Aptose-to-Present-at-the-Cantor-Global-Healthcare-Conference.html","Health","2023-09-18 07:45:00","pre_market",3,3,443,443,0,-0,0,"long","long",NaN
270,"APTO","Aptose to Report Third Quarter 2023 Financial Results and Hold Conference Call on Thursday, November 9, 2023","https://www.globenewswire.com/news-release/2023/10/26/2767370/35575/en/Aptose-to-Report-Third-Quarter-2023-Financial-Results-and-Hold-Conference-Call-on-Thursday-November-9-2023.html","Conference Calls/ Webcasts","2023-10-26 07:11:00","pre_market",3,3,418,416,0,-0,0,"long","long",NaN
271,"APTO","Aptose to Hold Clinical Update and KOL Data Review of AML Drug Tuspetinib on Monday, October 30th","https://www.globenewswire.com/news-release/2023/10/23/2764610/35575/en/Aptose-to-Hold-Clinical-Update-and-KOL-Data-Review-of-AML-Drug-Tuspetinib-on-Monday-October-30th.html","Conference Calls/ Webcasts","2023-10-23 07:30:00","pre_market",2,2,421,420,0,-0,0,"long","long",NaN
272,"APTO","Aptose Presents Highlights from Clinical Update Webcast Featuring Latest Available Data on AML Drug Tuspetinib","https://www.globenewswire.com/news-release/2023/10/30/2769327/35575/en/Aptose-Presents-Highlights-from-Clinical-Update-Webcast-Featuring-Latest-Available-Data-on-AML-Drug-Tuspetinib.html","Clinical Study","2023-10-30 09:15:00","pre_market",3,3,411,414,0,0,0,"long","long",NaN
273,"APTO","Aptose Tuspetinib Clinical Data Selected for Oral Presentation at the 2023 ASH Annual Meeting","https://www.globenewswire.com/news-release/2023/11/02/2772405/35575/en/Aptose-Tuspetinib-Clinical-Data-Selected-for-Oral-Presentation-at-the-2023-ASH-Annual-Meeting.html","Clinical Study","2023-11-02 09:00:00","pre_market",3,3,423,427,-0,0,-0,"short","short",NaN
274,"APTO","Aptose Biosciences Provides Update on Reverse Stock Split","https://www.globenewswire.com/news-release/2023/06/05/2681857/35575/en/Aptose-Biosciences-Provides-Update-on-Reverse-Stock-Split.html","Changes in company's own shares","2023-06-05 07:30:00","pre_market",0,0,428,428,0,0,0,"long","long",NaN
262,"ANVS","Annovis Bio Appoints Andrew Walsh as Vice President Finance","https://www.globenewswire.com/news-release/2023/12/01/2789245/0/en/Annovis-Bio-Appoints-Andrew-Walsh-as-Vice-President-Finance.html","Directors and Officers","2023-12-01 07:30:00","pre_market",8,9,456,456,0,-0,0,"long","long",NaN
263,"ANVS","Annovis Bio Refines Timeline for Parkinson’s Phase III Study Data Announcement","https://www.globenewswire.com/news-release/2024/01/24/2815216/0/en/Annovis-Bio-Refines-Timeline-for-Parkinson-s-Phase-III-Study-Data-Announcement.html","Clinical Study","2024-01-24 08:00:00","pre_market",12,10,485,488,-0,0,-0,"short","short",NaN
295,"BCAB","BioAtla Announces $65 Million Underwritten Offering of its Common Stock","https://www.globenewswire.com/news-release/2022/11/04/2548838/0/en/BioAtla-Announces-65-Million-Underwritten-Offering-of-its-Common-Stock.html","Stock Market News","2022-11-04 09:08:00","pre_market",6,8,371,377,0,0,0,"long","long",NaN
296,"BCAB","BioAtla to Announce Fourth Quarter and Full-Year 2022 Financial Results and Provide Business Highlights","https://www.globenewswire.com/news-release/2023/03/16/2628593/0/en/BioAtla-to-Announce-Fourth-Quarter-and-Full-Year-2022-Financial-Results-and-Provide-Business-Highlights.html","Conference Calls/ Webcasts","2023-03-16 08:00:00","pre_market",3,3,389,387,-0,-0,0,"long","long",NaN
281,"ARQT","Arcutis Launches First Television Ad for ZORYVE® (Roflumilast) Cream 0.3%","https://www.globenewswire.com/news-release/2023/08/29/2733332/0/en/Arcutis-Launches-First-Television-Ad-for-ZORYVE-Roflumilast-Cream-0-3.html","Product / Services Announcement","2023-08-29 08:00:00","pre_market",8,8,443,443,0,-0,0,"long","long",NaN
282,"ARQT","Arcutis Biotherapeutics Publishes Annual Environmental, Social, and Governance (ESG) Report","https://www.globenewswire.com/news-release/2023/08/31/2735212/0/en/Arcutis-Biotherapeutics-Publishes-Annual-Environmental-Social-and-Governance-ESG-Report.html","Environmental, Social, and Governance Criteria","2023-08-31 08:00:00","pre_market",9,9,451,452,0,0,-0,"short","long",NaN
283,"ARQT","FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for Treatment of Psoriasis in Children Ages 6 to 11","https://www.globenewswire.com/news-release/2023/10/06/2756044/0/en/FDA-Approves-Arcutis-ZORYVE-roflumilast-Cream-0-3-for-Treatment-of-Psoriasis-in-Children-Ages-6-to-11.html","Product / Services Announcement","2023-10-06 08:00:00","pre_market",4,4,424,422,0,-0,0,"long","long",NaN
284,"ARQT","Arcutis Announces Positive Results from INTEGUMENT-PED Pivotal Phase 3 Trial of Roflumilast Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5","https://www.globenewswire.com/news-release/2023/09/19/2745482/0/en/Arcutis-Announces-Positive-Results-from-INTEGUMENT-PED-Pivotal-Phase-3-Trial-of-Roflumilast-Cream-0-05-for-the-Treatment-of-Atopic-Dermatitis-in-Children-Ages-2-to-5.html","Clinical Study","2023-09-19 07:30:00","pre_market",6,6,444,443,-0,-0,-0,"short","short",NaN
285,"ARQT","Arcutis Announces Positive Long-Term Results of Roflumilast Cream 0.15% Showing Durable and Improved Efficacy Over Time and Favorable Safety Profile in Treatment of Mild to Moderate Atopic Dermatitis (AD)","https://www.globenewswire.com/news-release/2023/09/07/2739327/0/en/Arcutis-Announces-Positive-Long-Term-Results-of-Roflumilast-Cream-0-15-Showing-Durable-and-Improved-Efficacy-Over-Time-and-Favorable-Safety-Profile-in-Treatment-of-Mild-to-Moderate.html","Clinical Study","2023-09-07 08:15:00","pre_market",8,8,446,443,0,-0,0,"long","long",NaN
287,"ARQT","Arcutis Announces Third Quarter 2023 Financial Results and Provides Business Update","https://www.globenewswire.com/news-release/2023/11/03/2773109/0/en/Arcutis-Announces-Third-Quarter-2023-Financial-Results-and-Provides-Business-Update.html","Conference Calls/ Webcasts","2023-11-03 07:30:00","pre_market",2,2,431,433,0,0,0,"long","long",NaN
288,"ARQT","New Data Shows ZORYVE® (Roflumilast) Cream 0.3% Provided Measurable Improvement of Plaque Psoriasis in Nearly All Individuals in DERMIS Trials","https://www.globenewswire.com/news-release/2023/10/20/2763969/0/en/New-Data-Shows-ZORYVE-Roflumilast-Cream-0-3-Provided-Measurable-Improvement-of-Plaque-Psoriasis-in-Nearly-All-Individuals-in-DERMIS-Trials.html","Clinical Study","2023-10-20 08:00:00","pre_market",3,2,426,426,-0,-0,-0,"short","short",NaN
289,"ARQT","Arcutis Appoints L. Todd Edwards as Chief Commercial Officer","https://www.globenewswire.com/news-release/2023/09/27/2750305/0/en/Arcutis-Appoints-L-Todd-Edwards-as-Chief-Commercial-Officer.html","Directors and Officers","2023-09-27 08:00:00","pre_market",6,6,426,427,-0,0,-0,"short","short",NaN
290,"ARQT","ZORYVE® (roflumilast) Topical Foam, 0.3%, for the Treatment of Seborrheic Dermatitis Launches in the United States","https://www.globenewswire.com/news-release/2024/01/22/2813014/0/en/ZORYVE-roflumilast-Topical-Foam-0-3-for-the-Treatment-of-Seborrheic-Dermatitis-Launches-in-the-United-States.html","Health","2024-01-22 08:00:00","pre_market",3,3,482,484,0,0,0,"long","long",NaN
291,"ARQT","Arcutis to Report Fourth Quarter and Full Year 2023 Financial Results","https://www.globenewswire.com/news-release/2024/02/16/2830722/0/en/Arcutis-to-Report-Fourth-Quarter-and-Full-Year-2023-Financial-Results.html","Calendar of Events","2024-02-16 08:00:00","pre_market",8,8,502,502,0,-0,0,"long","long",NaN
292,"ARQT","Journal of the American Academy of Dermatology Publishes ZORYVE (roflumilast) Foam, 0.3% Results for Seborrheic Dermatitis from Pivotal Phase 3 Trial","https://www.globenewswire.com/news-release/2024/01/29/2818829/0/en/Journal-of-the-American-Academy-of-Dermatology-Publishes-ZORYVE-roflumilast-Foam-0-3-Results-for-Seborrheic-Dermatitis-from-Pivotal-Phase-3-Trial.html","Clinical Study","2024-01-29 08:00:00","pre_market",5,5,487,488,0,0,0,"long","long",NaN
293,"ARQT","Arcutis to Present at the Guggenheim Healthcare Talks – 6th Annual Biotechnology Conference","https://www.globenewswire.com/news-release/2024/01/31/2821035/0/en/Arcutis-to-Present-at-the-Guggenheim-Healthcare-Talks-6th-Annual-Biotechnology-Conference.html","Calendar of Events","2024-01-31 08:00:00","pre_market",6,6,491,489,-0,-0,-0,"short","short",NaN
297,"BCAB","BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3182, a CAB-EpCAMxCAB-CD3 Bispecific T-Cell Engager for the Treatment of Advanced Adenocarcinoma","https://www.globenewswire.com/news-release/2023/02/23/2614225/0/en/BioAtla-Announces-FDA-Clearance-of-Investigational-New-Drug-Application-for-BA3182-a-CAB-EpCAMxCAB-CD3-Bispecific-T-Cell-Engager-for-the-Treatment-of-Advanced-Adenocarcinoma.html","Clinical Study","2023-02-23 08:00:00","pre_market",3,3,399,402,-0,0,-0,"short","short",NaN
298,"BCAB","BioAtla to Announce Second Quarter 2023 Financial Results and Provide Business Highlights on August 1, 2023","https://www.globenewswire.com/news-release/2023/07/25/2710360/0/en/BioAtla-to-Announce-Second-Quarter-2023-Financial-Results-and-Provide-Business-Highlights-on-August-1-2023.html","Conference Calls/ Webcasts","2023-07-25 08:00:00","pre_market",3,3,454,454,-0,-0,-0,"short","short",NaN
299,"BCAB","BioAtla to Participate in the JMP Securities Hematology and Oncology Summit","https://www.globenewswire.com/news-release/2023/11/30/2788523/0/en/BioAtla-to-Participate-in-the-JMP-Securities-Hematology-and-Oncology-Summit.html","Conference Calls/ Webcasts","2023-11-30 08:00:00","pre_market",2,2,455,455,0,0,0,"long","long",NaN
300,"BCAB","BioAtla Added to Membership of U.S. Small-Cap Russell 2000® Index","https://www.globenewswire.com/news-release/2023/06/26/2694369/0/en/BioAtla-Added-to-Membership-of-U-S-Small-Cap-Russell-2000-Index.html","Trading information","2023-06-26 08:00:00","pre_market",4,3,433,433,-0,-0,-0,"short","short",NaN
301,"BCAB","BioAtla Provides Clinical Program Updates and Upcoming 2023 Milestones","https://www.globenewswire.com/news-release/2023/01/10/2586086/0/en/BioAtla-Provides-Clinical-Program-Updates-and-Upcoming-2023-Milestones.html","Clinical Study","2023-01-10 08:00:00","pre_market",8,5,388,387,-0,-0,-0,"short","short",NaN
302,"BCAB","BioAtla’s Jay M. Short, Ph.D., Selected for The Explorers Club Lowell Thomas Award","https://www.globenewswire.com/news-release/2023/10/12/2759131/0/en/BioAtla-s-Jay-M-Short-Ph-D-Selected-for-The-Explorers-Club-Lowell-Thomas-Award.html","Contests/Awards","2023-10-12 07:30:00","pre_market",2,2,436,437,0,0,0,"long","long",NaN
303,"BCAB","BioAtla to Announce First Quarter 2023 Financial Results and Provide Business Highlights on May 11, 2023","https://www.globenewswire.com/news-release/2023/05/04/2661440/0/en/BioAtla-to-Announce-First-Quarter-2023-Financial-Results-and-Provide-Business-Highlights-on-May-11-2023.html","Conference Calls/ Webcasts","2023-05-04 08:00:00","pre_market",4,4,408,407,0,-0,0,"long","short",NaN
304,"BCAB","BioAtla to Participate in the Jefferies London Healthcare Conference","https://www.globenewswire.com/news-release/2022/11/08/2550890/0/en/BioAtla-to-Participate-in-the-Jefferies-London-Healthcare-Conference.html","Calendar of Events","2022-11-08 08:00:00","pre_market",8,8,380,381,0,0,-0,"short","short",NaN
305,"BCAB","BioAtla to Host Virtual KOL Event to Review IASLC Data on BA3011 in NSCLC","https://www.globenewswire.com/news-release/2023/11/28/2786858/0/en/BioAtla-to-Host-Virtual-KOL-Event-to-Review-IASLC-Data-on-BA3011-in-NSCLC.html","Conference Calls/ Webcasts","2023-11-28 08:00:00","pre_market",1,2,454,454,0,-0,0,"long","long",NaN
306,"BCAB","BioAtla to Participate in the 41st Annual J.P. Morgan Healthcare Conference","https://www.globenewswire.com/news-release/2022/12/22/2578554/0/en/BioAtla-to-Participate-in-the-41st-Annual-J-P-Morgan-Healthcare-Conference.html","Conference Calls/ Webcasts","2022-12-22 08:00:00","pre_market",8,8,386,383,0,-0,0,"long","long",NaN
307,"BCAB","BioAtla Provides Guidance on Near-Term Milestones and Plans to Announce Third Quarter 2023 Financial Results and Business Update on November 7, 2023","https://www.globenewswire.com/news-release/2023/10/10/2757357/0/en/BioAtla-Provides-Guidance-on-Near-Term-Milestones-and-Plans-to-Announce-Third-Quarter-2023-Financial-Results-and-Business-Update-on-November-7-2023.html","Conference Calls/ Webcasts","2023-10-10 07:30:00","pre_market",2,2,432,433,0,0,-0,"short","short",NaN
308,"BCAB","BioAtla to Participate in the Jefferies Healthcare Conference","https://www.globenewswire.com/news-release/2023/05/31/2679301/0/en/BioAtla-to-Participate-in-the-Jefferies-Healthcare-Conference.html","Trade Show","2023-05-31 08:00:00","pre_market",3,3,420,418,-0,-0,-0,"short","short",NaN
309,"BCAB","BioAtla to Participate in the H.C. Wainwright 25th Annual Global Investment Conference","https://www.globenewswire.com/news-release/2023/09/06/2738343/0/en/BioAtla-to-Participate-in-the-H-C-Wainwright-25th-Annual-Global-Investment-Conference.html","Conference Calls/ Webcasts","2023-09-06 08:00:00","pre_market",3,3,449,448,0,-0,0,"long","short",NaN
310,"BCAB","BioAtla Hosting Virtual R&D Day to Highlight BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types","https://www.globenewswire.com/news-release/2023/12/13/2795508/0/en/BioAtla-Hosting-Virtual-R-D-Day-to-Highlight-BA3071-CAB-CTLA-4-Phase-1-Data-in-Multiple-Solid-Tumor-Types.html","Calendar of Events","2023-12-13 08:00:00","pre_market",2,2,464,464,0,0,0,"long","long",NaN
311,"BCAB","BioAtla Presented Phase 2 Clinical Trial Data at the IASLC 2023 North America Conference on Lung Cancer and Virtual KOL Event","https://www.globenewswire.com/news-release/2023/12/05/2790846/0/en/BioAtla-Presented-Phase-2-Clinical-Trial-Data-at-the-IASLC-2023-North-America-Conference-on-Lung-Cancer-and-Virtual-KOL-Event.html","Clinical Study","2023-12-05 08:00:00","pre_market",1,1,457,455,0,-0,0,"long","long",NaN
312,"BCAB","BioAtla to Participate in the 42nd Annual J.P. Morgan Healthcare Conference","https://www.globenewswire.com/news-release/2023/12/20/2799219/0/en/BioAtla-to-Participate-in-the-42nd-Annual-J-P-Morgan-Healthcare-Conference.html","Calendar of Events","2023-12-20 08:00:00","pre_market",2,2,475,474,0,-0,0,"long","long",NaN
313,"BCAB","BioAtla to Host Virtual R&D Day to Review BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types on Wednesday, December 13, 2023","https://www.globenewswire.com/news-release/2023/12/06/2791717/0/en/BioAtla-to-Host-Virtual-R-D-Day-to-Review-BA3071-CAB-CTLA-4-Phase-1-Data-in-Multiple-Solid-Tumor-Types-on-Wednesday-December-13-2023.html","Clinical Study","2023-12-06 08:00:00","pre_market",1,1,457,459,0,0,0,"long","long",NaN
316,"BCDA","BioCardia Announces Clarification and Next Steps on its Autologous CardiAMP Cell Therapy Programs","https://www.globenewswire.com/news-release/2023/09/06/2738243/0/en/BioCardia-Announces-Clarification-and-Next-Steps-on-its-Autologous-CardiAMP-Cell-Therapy-Programs.html","Clinical Study","2023-09-06 07:15:00","pre_market",1,1,449,448,-0,-0,-0,"short","short",NaN
317,"BCDA","BioCardia Announces Helix™ Biotherapeutic Delivery Patent Issuance in Japan","https://www.globenewswire.com/news-release/2023/06/08/2684599/0/en/BioCardia-Announces-Helix-Biotherapeutic-Delivery-Patent-Issuance-in-Japan.html","Patents","2023-06-08 07:00:00","pre_market",2,2,427,427,0,0,0,"long","long",NaN
319,"BCDA","BioCardia Announces DSMB Recommendation to Pause New Enrollment in Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial While Additional Blinded Data is Collected","https://www.globenewswire.com/news-release/2023/07/24/2709400/0/en/BioCardia-Announces-DSMB-Recommendation-to-Pause-New-Enrollment-in-Phase-III-Pivotal-CardiAMP-Cell-Therapy-Heart-Failure-Trial-While-Additional-Blinded-Data-is-Collected.html","Product / Services Announcement","2023-07-24 07:00:00","pre_market",2,1,452,453,-0,0,-0,"short","short",NaN
320,"BCDA","BioCardia Letter to Shareholders","https://www.globenewswire.com/news-release/2022/12/22/2578489/0/en/BioCardia-Letter-to-Shareholders.html","Health","2022-12-22 07:00:00","pre_market",2,2,386,383,-0,-0,-0,"short","short",NaN
321,"BCDA","BioCardia Announces US Patent on Bone Marrow Derived Neurokinin-1 Receptor Positive (NK1R+) Mesenchymal Stem Cells for Therapeutic Applications","https://www.globenewswire.com/news-release/2023/05/09/2664254/0/en/BioCardia-Announces-US-Patent-on-Bone-Marrow-Derived-Neurokinin-1-Receptor-Positive-NK1R-Mesenchymal-Stem-Cells-for-Therapeutic-Applications.html","Patents","2023-05-09 07:00:00","pre_market",2,2,413,411,-0,-0,-0,"short","short",NaN
322,"BCDA","BioCardia Announces Issuance of Two Patents Related to Technology That Guides Interventional Therapies","https://www.globenewswire.com/news-release/2023/04/04/2640452/0/en/BioCardia-Announces-Issuance-of-Two-Patents-Related-to-Technology-That-Guides-Interventional-Therapies.html","Patents","2023-04-04 07:00:00","pre_market",2,2,411,412,-0,0,-0,"short","short",NaN
323,"BCDA","BioCardia Announces FDA Approval of CardiAMP Heart Failure II Protocol for Autologous Cell Therapy for Ischemic Heart Failure","https://www.globenewswire.com/news-release/2023/11/14/2779941/0/en/BioCardia-Announces-FDA-Approval-of-CardiAMP-Heart-Failure-II-Protocol-for-Autologous-Cell-Therapy-for-Ischemic-Heart-Failure.html","Health","2023-11-14 07:15:00","pre_market",0,1,440,446,2,0,2,"long","long",NaN
324,"BCDA","BioCardia to Host 2022 Financial Results and Corporate Update Conference Call on March 29, 2023","https://www.globenewswire.com/news-release/2023/03/16/2628490/0/en/BioCardia-to-Host-2022-Financial-Results-and-Corporate-Update-Conference-Call-on-March-29-2023.html","Conference Calls/ Webcasts","2023-03-16 07:00:00","pre_market",2,2,389,387,0,-0,0,"long","long",NaN
325,"BCDA","BioCardia Announces Timing of the Next Data Safety Monitoring Board Meeting for the CardiAMP Cell Therapy in Heart Failure Pivotal Study","https://www.globenewswire.com/news-release/2023/05/23/2674138/0/en/BioCardia-Announces-Timing-of-the-Next-Data-Safety-Monitoring-Board-Meeting-for-the-CardiAMP-Cell-Therapy-in-Heart-Failure-Pivotal-Study.html","Calendar of Events","2023-05-23 07:00:00","pre_market",2,2,419,417,0,-0,0,"long","long",NaN
330,"BCDA","BioCardia Announces Expected CardiAMP Heart Failure Japan Approval Timeline Based on Pharmaceutical and Medical Device Agency Consultation Minutes","https://www.globenewswire.com/news-release/2023/12/18/2797714/0/en/BioCardia-Announces-Expected-CardiAMP-Heart-Failure-Japan-Approval-Timeline-Based-on-Pharmaceutical-and-Medical-Device-Agency-Consultation-Minutes.html","Clinical Study","2023-12-18 07:16:00","pre_market",1,1,469,471,0,0,0,"long","long",NaN
326,"BCDA","BioCardia to Host Q2 2023 Financial Results and Corporate Update Conference Call on August 9, 2023","https://www.globenewswire.com/news-release/2023/08/02/2716675/0/en/BioCardia-to-Host-Q2-2023-Financial-Results-and-Corporate-Update-Conference-Call-on-August-9-2023.html","Conference Calls/ Webcasts","2023-08-02 07:00:00","pre_market",1,1,456,453,0,-0,0,"long","long",NaN
327,"BCDA","BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure; Foreign Data Expected to be Sufficient for Product Approval","https://www.globenewswire.com/news-release/2023/11/29/2787607/0/en/BioCardia-Shares-Update-from-Japan-PMDA-Consultation-on-CardiAMP-Autologous-Cell-Therapy-for-Ischemic-Heart-Failure-Foreign-Data-Expected-to-be-Sufficient-for-Product-Approval.html","Other News","2023-11-29 07:00:00","pre_market",1,1,455,457,-0,0,-0,"short","long",NaN
349,"BICX","BioCorRx Announces First Subject Dosed in Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder","https://www.globenewswire.com/news-release/2022/06/30/2472213/0/en/BioCorRx-Announces-First-Subject-Dosed-in-Phase-I-Clinical-Trial-of-BICX104-an-Implantable-Naltrexone-Pellet-for-the-Treatment-of-Opioid-Use-Disorder.html","Health","2022-06-30 09:00:00","pre_market",2,2,380,376,0,-0,0,"long","long",NaN
328,"BCDA","BioCardia Reports Fourth Quarter and Full Year 2022 Business Highlights and Financial Results","https://www.globenewswire.com/news-release/2023/03/29/2636648/0/en/BioCardia-Reports-Fourth-Quarter-and-Full-Year-2022-Business-Highlights-and-Financial-Results.html","Conference Calls/ Webcasts","2023-03-29 08:15:00","pre_market",2,2,396,400,0,0,-0,"short","short",NaN
329,"BCDA","BioCardia Announces Completion of Enrollment in Phase III CardiAMP HF Trial and Plans for CardiAMP HF Trial II","https://www.globenewswire.com/news-release/2023/10/11/2758144/0/en/BioCardia-Announces-Completion-of-Enrollment-in-Phase-III-CardiAMP-HF-Trial-and-Plans-for-CardiAMP-HF-Trial-II.html","Clinical Study","2023-10-11 06:00:00","pre_market",0,0,435,436,0,0,0,"long","long",NaN
337,"BICX","BioCorRx Announces Completion of Treatment Phase of Study Subjects and Preliminary Safety Data from Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder","https://www.globenewswire.com/news-release/2023/01/19/2591804/0/en/BioCorRx-Announces-Completion-of-Treatment-Phase-of-Study-Subjects-and-Preliminary-Safety-Data-from-Phase-I-Clinical-Trial-of-BICX104-an-Implantable-Naltrexone-Pellet-for-the-Treat.html","Company Announcement","2023-01-19 08:30:00","pre_market",1,1,391,389,0,-0,0,"long","long",NaN
338,"BICX","BioCorRx Provides Business Update for the First Quarter of 2023","https://www.globenewswire.com/news-release/2023/05/16/2669960/0/en/BioCorRx-Provides-Business-Update-for-the-First-Quarter-of-2023.html","Company Announcement","2023-05-16 08:30:00","pre_market",2,2,413,412,0,-0,0,"long","long",NaN
339,"BICX","BioCorRx Announced Interim Positive Safety and Pharmacokinetic Results of Phase 1 Clinical Trial at 4th Annual NIH HEAL Initiative Investigator Meeting","https://www.globenewswire.com/news-release/2023/03/07/2622532/0/en/BioCorRx-Announced-Interim-Positive-Safety-and-Pharmacokinetic-Results-of-Phase-1-Clinical-Trial-at-4th-Annual-NIH-HEAL-Initiative-Investigator-Meeting.html","Clinical Study","2023-03-07 15:13:00","market_open",2,2,404,398,-0,-0,0,"long","long",NaN
340,"BICX","BioCorRx to Present at Sequire Biotechnology Conference on February 2nd","https://www.globenewswire.com/news-release/2023/01/27/2596906/0/en/BioCorRx-to-Present-at-Sequire-Biotechnology-Conference-on-February-2nd.html","Press releases","2023-01-27 08:30:00","pre_market",1,1,405,404,0,-0,0,"long","long",NaN
341,"BICX","BioCorRx Completes Final Subject Enrollment in Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder","https://www.globenewswire.com/news-release/2022/10/13/2533867/0/en/BioCorRx-Completes-Final-Subject-Enrollment-in-Phase-I-Clinical-Trial-of-BICX104-an-Implantable-Naltrexone-Pellet-for-the-Treatment-of-Opioid-Use-Disorder.html","Clinical Study","2022-10-13 08:30:00","pre_market",2,2,357,349,0,-0,0,"long","long",NaN
342,"BICX","BioCorRx Submits Fast Track Application to FDA for BICX104, an Implantable Biodegradable Naltrexone Pellet for The Treatment of Opioid Use Disorder","https://www.globenewswire.com/news-release/2023/07/18/2706412/0/en/BioCorRx-Submits-Fast-Track-Application-to-FDA-for-BICX104-an-Implantable-Biodegradable-Naltrexone-Pellet-for-The-Treatment-of-Opioid-Use-Disorder.html","Press releases","2023-07-18 08:30:00","pre_market",2,2,451,450,0,-0,0,"long","long",NaN
343,"BICX","BioCorRx Provides Business Update for the Third Quarter of 2022","https://www.globenewswire.com/news-release/2022/11/15/2556294/0/en/BioCorRx-Provides-Business-Update-for-the-Third-Quarter-of-2022.html","Earnings Releases and Operating Results","2022-11-15 09:00:00","pre_market",2,2,395,401,0,0,-0,"short","short",NaN
344,"BICX","BioCorRx Provides Business Update for the Second Quarter of 2022","https://www.globenewswire.com/news-release/2022/08/16/2499080/0/en/BioCorRx-Provides-Business-Update-for-the-Second-Quarter-of-2022.html","Company Announcement","2022-08-16 08:30:00","pre_market",2,2,429,428,0,-0,0,"long","long",NaN
345,"BICX","BioCorRx Provides Business Update for 2022","https://www.globenewswire.com/news-release/2023/04/03/2639586/0/en/BioCorRx-Provides-Business-Update-for-2022.html","Annual report","2023-04-03 08:30:00","pre_market",2,2,409,409,0,-0,0,"long","long",NaN
346,"BICX","BioCorRx Reports Business Update for the Third Quarter of 2023","https://www.globenewswire.com/news-release/2023/11/14/2780399/0/en/BioCorRx-Reports-Business-Update-for-the-Third-Quarter-of-2023.html","Earnings Releases and Operating Results","2023-11-14 12:52:00","market_open",1,1,446,449,-0,0,-0,"short","short",NaN
347,"BICX","BioCorRx Appoints Pharmaceutical & Finance Veteran Harsha Murthy to the Board of Directors","https://www.globenewswire.com/news-release/2023/01/24/2594325/0/en/BioCorRx-Appoints-Pharmaceutical-Finance-Veteran-Harsha-Murthy-to-the-Board-of-Directors.html","Directors and Officers","2023-01-24 09:00:00","pre_market",1,1,401,399,0,-0,0,"long","long",NaN
348,"BICX","BioCorRx Featured on LiveNOW from FOX","https://www.globenewswire.com/news-release/2022/06/17/2464706/0/en/BioCorRx-Featured-on-LiveNOW-from-FOX.html","Press releases","2022-06-17 09:00:00","pre_market",2,2,367,366,0,-0,0,"long","long",NaN
331,"BCDA","BioCardia Doses First Patient in CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells for the Treatment of Ischemic Heart Failure of Reduced Ejection Fraction","https://www.globenewswire.com/news-release/2023/12/19/2798416/0/en/BioCardia-Doses-First-Patient-in-CardiALLO-Phase-I-II-Clinical-Trial-of-BCDA-03-Allogeneic-Mesenchymal-Stem-Cells-for-the-Treatment-of-Ischemic-Heart-Failure-of-Reduced-Ejection-Fr.html","Clinical Study","2023-12-19 07:00:00","pre_market",1,1,472,473,0,0,-0,"short","short",NaN
332,"BCDA","BioCardia Biotherapeutic Delivery and Morph Access Innovations Business Development Update for Shareholders","https://www.globenewswire.com/news-release/2024/01/03/2803155/0/en/BioCardia-Biotherapeutic-Delivery-and-Morph-Access-Innovations-Business-Development-Update-for-Shareholders.html","Major shareholder announcements","2024-01-03 07:00:00","pre_market",1,1,473,470,-0,-0,-0,"short","short",NaN
333,"BCDA","BioCardia Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved by FDA","https://www.globenewswire.com/news-release/2024/02/08/2825876/0/en/BioCardia-Announces-Activation-of-CardiAMP-Heart-Failure-II-Phase-3-Pivotal-Study-Recently-Approved-by-FDA.html","Clinical Study","2024-02-08 07:00:00","pre_market",0,0,498,498,-0,0,-0,"short","long",NaN
334,"BCDA","BioCardia Announces Two Scientific Abstracts Have Been Accepted at the 2024 Technology and Heart Failure Therapeutics Conference","https://www.globenewswire.com/news-release/2024/01/31/2820965/0/en/BioCardia-Announces-Two-Scientific-Abstracts-Have-Been-Accepted-at-the-2024-Technology-and-Heart-Failure-Therapeutics-Conference.html","Calendar of Events","2024-01-31 07:00:00","pre_market",0,0,491,489,0,-0,0,"long","long",NaN
356,"BIIB","Biogen Appoints Adam Keeney as Head of Corporate Development","https://www.globenewswire.com/news-release/2023/04/04/2640516/0/en/Biogen-Appoints-Adam-Keeney-as-Head-of-Corporate-Development.html","Directors and Officers","2023-04-04 07:30:00","pre_market",277,277,411,412,-0,0,-0,"short","long",NaN
357,"BIIB","New Data Presented at AD/PD™ 2023 Show Biogen’s BIIB080 (MAPT ASO) Substantially Reduced Tau Protein Levels in Patients with Early-stage Alzheimer’s Disease","https://www.globenewswire.com/news-release/2023/03/29/2636687/0/en/New-Data-Presented-at-AD-PD-2023-Show-Biogen-s-BIIB080-MAPT-ASO-Substantially-Reduced-Tau-Protein-Levels-in-Patients-with-Early-stage-Alzheimer-s-Disease.html","Clinical Study","2023-03-29 08:45:00","pre_market",270,271,396,400,0,0,-0,"short","short",NaN
358,"BIIB","Biogen Appoints Jane Grogan as Head of Research","https://www.globenewswire.com/news-release/2023/09/06/2738268/0/en/Biogen-Appoints-Jane-Grogan-as-Head-of-Research.html","Management Changes","2023-09-06 07:30:00","pre_market",266,266,449,448,0,-0,0,"long","short",NaN
359,"BIIB","Biogen Appoints Monish Patolawala to its Board of Directors","https://www.globenewswire.com/news-release/2023/11/06/2773981/0/en/Biogen-Appoints-Monish-Patolawala-to-its-Board-of-Directors.html","Directors and Officers","2023-11-06 07:30:00","pre_market",250,250,435,435,0,0,-0,"short","short",NaN
360,"BIIB","FDA Grants Accelerated Approval for QALSODY™ (tofersen) for SOD1-ALS, a Major Scientific Advancement as the First Treatment to Target a Genetic Cause of ALS","https://www.globenewswire.com/news-release/2023/04/25/2654404/0/en/FDA-Grants-Accelerated-Approval-for-QALSODY-tofersen-for-SOD1-ALS-a-Major-Scientific-Advancement-as-the-First-Treatment-to-Target-a-Genetic-Cause-of-ALS.html","Clinical Study","2023-04-25 15:04:00","market_open",291,282,411,406,-0,-0,-0,"short","short",NaN
361,"BIIB","Biogen Completes Acquisition of Reata Pharmaceuticals","https://www.globenewswire.com/news-release/2023/09/26/2749581/0/en/Biogen-Completes-Acquisition-of-Reata-Pharmaceuticals.html","Mergers and Acquisitions","2023-09-26 08:59:00","pre_market",255,255,432,429,-0,-0,0,"long","long",NaN
362,"BIIB","Biogen to Acquire Reata Pharmaceuticals","https://www.globenewswire.com/news-release/2023/07/28/2713028/0/en/Biogen-to-Acquire-Reata-Pharmaceuticals.html","Health","2023-07-28 07:05:00","pre_market",263,263,452,456,0,0,-0,"short","short",NaN
363,"BIIB","Biogen to Present New Data at the Clinical Trials on Alzheimer’s Disease (CTAD) 2023 Meeting","https://www.globenewswire.com/news-release/2023/10/19/2763066/0/en/Biogen-to-Present-New-Data-at-the-Clinical-Trials-on-Alzheimer-s-Disease-CTAD-2023-Meeting.html","Clinical Study","2023-10-19 07:30:00","pre_market",264,263,430,431,-0,0,-0,"short","short",NaN
350,"BICX","BioCorRx Partners with Government Plus to Expand its Beat Addiction Recovery Program in the United States","https://www.globenewswire.com/news-release/2022/12/07/2569398/0/en/BioCorRx-Partners-with-Government-Plus-to-Expand-its-Beat-Addiction-Recovery-Program-in-the-United-States.html","Partnerships","2022-12-07 09:00:00","pre_market",2,2,394,393,0,-0,0,"long","long",NaN
351,"BICX","BioCorRx Board of Directors Approves Exploration of Potential Spin-Off of BioCorRx Pharmaceuticals, Inc.","https://www.globenewswire.com/news-release/2022/11/22/2560932/0/en/BioCorRx-Board-of-Directors-Approves-Exploration-of-Potential-Spin-Off-of-BioCorRx-Pharmaceuticals-Inc.html","Company Announcement","2022-11-22 09:00:00","pre_market",2,2,395,397,0,0,-0,"short","short",NaN
352,"BICX","BioCorRx Attended 4th Annual NIH HEAL Initiative Investigator Meeting; Shares Update on BICX104 Data","https://www.globenewswire.com/news-release/2023/02/23/2614329/0/en/BioCorRx-Attended-4th-Annual-NIH-HEAL-Initiative-Investigator-Meeting-Shares-Update-on-BICX104-Data.html","Company Announcement","2023-02-23 08:30:00","pre_market",2,2,399,402,0,0,-0,"short","short",NaN
353,"BICX","BioCorRx Appoints Renowned Investment and Capital Markets Executive Louis Lucido as President","https://www.globenewswire.com/news-release/2024/01/09/2806288/0/en/BioCorRx-Appoints-Renowned-Investment-and-Capital-Markets-Executive-Louis-Lucido-as-President.html","Directors and Officers","2024-01-09 08:30:00","pre_market",1,1,475,472,0,-0,0,"long","long",NaN
364,"BIIB","Biogen to Realign Resources for Alzheimer's Disease Franchise","https://www.globenewswire.com/news-release/2024/01/31/2821003/0/en/Biogen-to-Realign-Resources-for-Alzheimer-s-Disease-Franchise.html","Clinical Study","2024-01-31 07:30:00","pre_market",247,248,491,489,0,-0,0,"long","long",NaN
365,"BIIB","Centralized Marketing Authorizations of Generic Versions of TECFIDERA® are Revoked by the European Commission","https://www.globenewswire.com/news-release/2023/12/19/2798443/0/en/Centralized-Marketing-Authorizations-of-Generic-Versions-of-TECFIDERA-are-Revoked-by-the-European-Commission.html","Product / Services Announcement","2023-12-19 07:30:00","pre_market",250,250,472,473,0,0,-0,"short","short",NaN
354,"BICX","BioCorRx Pharmaceuticals Inc. Appoints Neuroscientist Dr. Kate DeVarney to the Board of Directors","https://www.globenewswire.com/news-release/2024/02/08/2826159/0/en/BioCorRx-Pharmaceuticals-Inc-Appoints-Neuroscientist-Dr-Kate-DeVarney-to-the-Board-of-Directors.html","Directors and Officers","2024-02-08 09:52:00","market_open",1,1,498,498,0,0,0,"long","long",NaN
366,"BIIB","ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S.","https://www.globenewswire.com/news-release/2023/12/14/2796102/0/en/ZURZUVAE-zuranolone-CIV-a-Landmark-Oral-Treatment-for-Women-with-Postpartum-Depression-PPD-is-Now-Available-in-the-U-S.html","Product / Services Announcement","2023-12-14 06:30:00","pre_market",256,257,470,472,0,0,0,"long","long",NaN
369,"BIOR","Biora Therapeutics Announces New Patents Covering its BioJet™ Systemic Oral Delivery Platform","https://www.globenewswire.com/news-release/2023/08/03/2717952/0/en/Biora-Therapeutics-Announces-New-Patents-Covering-its-BioJet-Systemic-Oral-Delivery-Platform.html","Patents","2023-08-03 08:00:00","pre_market",4,4,450,448,-0,-0,-0,"short","short",NaN
377,"BIOR","Biora Therapeutics to Report First Quarter 2023 Financial Results and Provide Corporate Update","https://www.globenewswire.com/news-release/2023/05/08/2663346/0/en/Biora-Therapeutics-to-Report-First-Quarter-2023-Financial-Results-and-Provide-Corporate-Update.html","Conference Calls/ Webcasts","2023-05-08 09:00:00","pre_market",3,3,413,413,-0,0,-0,"short","short",NaN
371,"BIOR","Biora Therapeutics Announces Submission of IND Application to the U.S. FDA for BT-600 Program","https://www.globenewswire.com/news-release/2023/09/25/2748572/0/en/Biora-Therapeutics-Announces-Submission-of-IND-Application-to-the-U-S-FDA-for-BT-600-Program.html","Health","2023-09-25 08:00:00","pre_market",2,2,430,429,0,-0,0,"long","long",NaN
372,"BIOR","Biora Therapeutics to Report Third Quarter 2023 Financial Results and Provide Corporate Update","https://www.globenewswire.com/news-release/2023/11/06/2774028/0/en/Biora-Therapeutics-to-Report-Third-Quarter-2023-Financial-Results-and-Provide-Corporate-Update.html","Conference Calls/ Webcasts","2023-11-06 08:00:00","pre_market",2,2,435,435,0,0,0,"long","short",NaN
373,"BIOR","Biora Therapeutics Announces Clinical Device Performance Study Results for its NaviCap™ Targeted Oral Delivery Platform","https://www.globenewswire.com/news-release/2023/07/27/2712117/0/en/Biora-Therapeutics-Announces-Clinical-Device-Performance-Study-Results-for-its-NaviCap-Targeted-Oral-Delivery-Platform.html","Clinical Study","2023-07-27 08:00:00","pre_market",4,4,456,459,-0,0,-0,"short","short",NaN
379,"BIOR","Biora Therapeutics Appoints Dr. Ariella Kelman as Chief Medical Officer","https://www.globenewswire.com/news-release/2023/05/01/2658330/0/en/Biora-Therapeutics-Appoints-Dr-Ariella-Kelman-as-Chief-Medical-Officer.html","Management Changes","2023-05-01 09:00:00","pre_market",2,2,416,415,-0,-0,-0,"short","short",NaN
374,"BIOR","Biora Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference","https://www.globenewswire.com/news-release/2023/09/11/2740775/0/en/Biora-Therapeutics-to-Present-at-H-C-Wainwright-25th-Annual-Global-Investment-Conference.html","Calendar of Events","2023-09-11 08:01:00","pre_market",3,3,446,448,0,0,0,"long","long",NaN
375,"BIOR","Biora Therapeutics Reduces Debt and Largest Shareholder Increases Equity Exposure","https://www.globenewswire.com/news-release/2023/09/19/2745527/0/en/Biora-Therapeutics-Reduces-Debt-and-Largest-Shareholder-Increases-Equity-Exposure.html","Interim information","2023-09-19 08:00:00","pre_market",2,2,444,443,0,-0,0,"long","long",NaN
376,"BIOR","Biora Therapeutics to Report Second Quarter 2023 Financial Results and Provide Corporate Update","https://www.globenewswire.com/news-release/2023/07/17/2705252/0/en/Biora-Therapeutics-to-Report-Second-Quarter-2023-Financial-Results-and-Provide-Corporate-Update.html","Calendar of Events","2023-07-17 06:00:00","pre_market",4,4,449,449,0,-0,0,"long","long",NaN
378,"BIOR","Biora Therapeutics Presents Data on the BioJet™ Systemic Oral Delivery Platform at the American Diabetes Association 83rd Scientific Sessions","https://www.globenewswire.com/news-release/2023/06/26/2694235/0/en/Biora-Therapeutics-Presents-Data-on-the-BioJet-Systemic-Oral-Delivery-Platform-at-the-American-Diabetes-Association-83rd-Scientific-Sessions.html","Clinical Study","2023-06-26 06:00:00","pre_market",4,4,433,433,-0,-0,-0,"short","short",NaN
380,"BIOR","Biora Therapeutics Announces New Patents for its NaviCap™ Targeted Oral Delivery Platform","https://www.globenewswire.com/news-release/2023/06/28/2696172/0/en/Biora-Therapeutics-Announces-New-Patents-for-its-NaviCap-Targeted-Oral-Delivery-Platform.html","Patents","2023-06-28 08:30:00","pre_market",4,4,436,435,0,-0,0,"long","long",NaN
381,"BIOR","Biora Therapeutics Presents Data on the BioJet™ Systemic Oral Delivery Platform at the 59th Annual Meeting of the European Association for the Study of Diabetes","https://www.globenewswire.com/news-release/2023/10/05/2755345/0/en/Biora-Therapeutics-Presents-Data-on-the-BioJet-Systemic-Oral-Delivery-Platform-at-the-59th-Annual-Meeting-of-the-European-Association-for-the-Study-of-Diabetes.html","Health","2023-10-05 08:00:00","pre_market",2,2,425,424,0,-0,0,"long","long",NaN
382,"BIOR","Biora Therapeutics Announces $8 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules","https://www.globenewswire.com/news-release/2023/06/13/2687091/0/en/Biora-Therapeutics-Announces-8-Million-Registered-Direct-Offering-Priced-At-the-Market-Under-Nasdaq-Rules.html","Initial Public Offerings","2023-06-13 08:00:00","pre_market",6,5,434,435,-0,0,-0,"short","short",NaN
383,"BIOR","Biora Therapeutics Announces Participation in Canaccord Genuity Inflammatory Bowel Disease Symposium","https://www.globenewswire.com/news-release/2024/02/08/2825975/0/en/Biora-Therapeutics-Announces-Participation-in-Canaccord-Genuity-Inflammatory-Bowel-Disease-Symposium.html","Calendar of Events","2024-02-08 08:00:00","pre_market",1,1,498,498,-0,0,-0,"short","long",NaN
384,"BIOR","Biora Therapeutics Announces New Research Collaboration for the BioJet™ Systemic Oral Delivery Platform","https://www.globenewswire.com/news-release/2023/12/11/2793791/0/en/Biora-Therapeutics-Announces-New-Research-Collaboration-for-the-BioJet-Systemic-Oral-Delivery-Platform.html","Product / Services Announcement","2023-12-11 08:00:00","pre_market",1,1,460,460,0,-0,0,"long","long",NaN
385,"BIOR","Biora Therapeutics Announces Participation in Fireside Chat Hosted by H.C. Wainwright & Co.","https://www.globenewswire.com/news-release/2024/01/22/2812999/0/en/Biora-Therapeutics-Announces-Participation-in-Fireside-Chat-Hosted-by-H-C-Wainwright-Co.html","Conference Calls/ Webcasts","2024-01-22 08:00:00","pre_market",1,1,482,484,-0,0,-0,"short","long",NaN
397,"BIVI","BioVie To Present of NE3017 in Alzheimer’s Disease Data at 83rd Scientific Sessions of the American Diabetes Association","https://www.globenewswire.com/news-release/2023/06/21/2691942/0/en/BioVie-To-Present-of-NE3017-in-Alzheimer-s-Disease-Data-at-83rd-Scientific-Sessions-of-the-American-Diabetes-Association.html","Product / Services Announcement","2023-06-21 08:00:00","pre_market",6,6,437,436,0,-0,0,"long","long",NaN
398,"BIVI","BioVie Presents Positive Clinical Safety Data from Phase 2b Trial of BIV201 in Refractory Ascites at the American Association for the Study of Liver Disease (AASLD) - The Liver Meeting® 2023","https://www.globenewswire.com/news-release/2023/11/13/2779020/0/en/BioVie-Presents-Positive-Clinical-Safety-Data-from-Phase-2b-Trial-of-BIV201-in-Refractory-Ascites-at-the-American-Association-for-the-Study-of-Liver-Disease-AASLD-The-Liver-Meeting.html","Clinical Study","2023-11-13 08:00:00","pre_market",3,3,441,439,-0,-0,-0,"short","short",NaN
399,"BIVI","BioVie To Present Data from NE3107 Phase 2 Open-Label Trial at Society of Biological Psychiatry Annual Meeting","https://www.globenewswire.com/news-release/2023/04/20/2650993/0/en/BioVie-To-Present-Data-from-NE3107-Phase-2-Open-Label-Trial-at-Society-of-Biological-Psychiatry-Annual-Meeting.html","Clinical Study","2023-04-20 08:30:00","pre_market",8,8,414,411,-0,-0,-0,"short","short",NaN
400,"BIVI","BioVie Announces Late-Breaking Abstract Presenting Clinical Safety Data from the Company’s Ascites Phase 2 Trial Accepted for Presentation at AASLD – The Liver Meeting® 2023","https://www.globenewswire.com/news-release/2023/10/26/2767473/0/en/BioVie-Announces-Late-Breaking-Abstract-Presenting-Clinical-Safety-Data-from-the-Company-s-Ascites-Phase-2-Trial-Accepted-for-Presentation-at-AASLD-The-Liver-Meeting-2023.html","Calendar of Events","2023-10-26 08:00:00","pre_market",3,3,418,416,-0,-0,-0,"short","short",NaN
401,"BIVI","BioVie Announces Data Abstracts from NE3107 Phase 2 Trials Accepted for Presentation at AAN 2023","https://www.globenewswire.com/news-release/2023/04/17/2647867/0/en/BioVie-Announces-Data-Abstracts-from-NE3107-Phase-2-Trials-Accepted-for-Presentation-at-AAN-2023.html","Trade Show","2023-04-17 08:00:00","pre_market",8,8,412,412,-0,-0,-0,"short","short",NaN
402,"BIVI","BioVie to Participate in the Truist Securities BioPharma Symposium","https://www.globenewswire.com/news-release/2023/11/02/2772222/0/en/BioVie-to-Participate-in-the-Truist-Securities-BioPharma-Symposium.html","Calendar of Events","2023-11-02 08:00:00","pre_market",5,5,423,427,-0,0,-0,"short","long",NaN
389,"BIOS.BR","Correction: BioSenic S.A.  : Transparency notifications received from François Rieger, Véronique Pomi, FA Dièse 3 SAS and Capital Grand Est SAS","https://www.globenewswire.com/news-release/2023/10/17/2761355/0/en/Correction-BioSenic-S-A-Transparency-notifications-received-from-Fran%C3%A7ois-Rieger-V%C3%A9ronique-Pomi-FA-Di%C3%A8se-3-SAS-and-Capital-Grand-Est-SAS.html","European Regulatory News","2023-10-17 07:00:00","pre_market",0,0,436,433,0,-0,0,"long","long",NaN
390,"BIOS.BR","BioSenic soutient la prochaine conférence européenne sur la maladie du greffon contre l'hôte","https://www.globenewswire.com/news-release/2024/01/31/2820799/0/fr/BioSenic-soutient-la-prochaine-conf%C3%A9rence-europ%C3%A9enne-sur-la-maladie-du-greffon-contre-l-h%C3%B4te.html","European Regulatory News","2024-01-31 04:30:00","pre_market",0,0,491,489,0,-0,0,"long","long",NaN
391,"BIOS.BR","BioSenic signe un nouvel accord de souscription pour un maximum de 1,2 M€ en obligations convertibles","https://www.globenewswire.com/news-release/2024/01/08/2805699/0/fr/BioSenic-signe-un-nouvel-accord-de-souscription-pour-un-maximum-de-1-2-M-en-obligations-convertibles.html","European Regulatory News","2024-01-08 12:00:00","market_open",0,0,468,475,0,0,-0,"short","short",NaN
386,"BIOR","Biora Therapeutics Announces New Patent for its NaviCap™ Targeted Oral Delivery Platform","https://www.globenewswire.com/news-release/2023/12/19/2798488/0/en/Biora-Therapeutics-Announces-New-Patent-for-its-NaviCap-Targeted-Oral-Delivery-Platform.html","Patents","2023-12-19 08:00:00","pre_market",1,1,472,473,0,0,0,"long","long",NaN
392,"BIOS.BR","BioSenic lève 500 000 euros dans le cadre d'un placement privé d'actions nouvelles auprès de nouveaux investisseurs établis","https://www.globenewswire.com/news-release/2024/02/02/2822980/0/fr/BioSenic-l%C3%A8ve-500-000-euros-dans-le-cadre-d-un-placement-priv%C3%A9-d-actions-nouvelles-aupr%C3%A8s-de-nouveaux-investisseurs-%C3%A9tablis.html","European Regulatory News","2024-02-02 11:30:00","market_open",0,0,490,494,0,0,-0,"short","short",NaN
393,"BIOS.BR","BioSenic signs a new subscription agreement for a maximum of EUR 1.2M in convertible bonds","https://www.globenewswire.com/news-release/2024/01/08/2805699/0/en/BioSenic-signs-a-new-subscription-agreement-for-a-maximum-of-EUR-1-2M-in-convertible-bonds.html","European Regulatory News","2024-01-08 12:00:00","market_open",0,0,468,475,0,0,-0,"short","short",NaN
394,"BIOS.BR","BioSenic provides support to forthcoming European conference on graft-versus-host disease","https://www.globenewswire.com/news-release/2024/01/31/2820799/0/en/BioSenic-provides-support-to-forthcoming-European-conference-on-graft-versus-host-disease.html","European Regulatory News","2024-01-31 04:30:00","pre_market",0,0,491,489,0,-0,0,"long","long",NaN
395,"BIOS.BR","BioSenic raises €500,000 in private placement of new shares with established new investors","https://www.globenewswire.com/news-release/2024/02/02/2822980/0/en/BioSenic-raises-500-000-in-private-placement-of-new-shares-with-established-new-investors.html","European Regulatory News","2024-02-02 11:30:00","market_open",0,0,490,494,0,0,-0,"short","long",NaN
387,"BIOR","Biora Therapeutics Announces Initiation of Phase 1 Clinical Study of BT-600","https://www.globenewswire.com/news-release/2024/01/08/2805368/0/en/Biora-Therapeutics-Announces-Initiation-of-Phase-1-Clinical-Study-of-BT-600.html","Clinical Study","2024-01-08 08:00:00","pre_market",1,1,468,468,0,0,0,"long","long",NaN
388,"BIOR","Biora Therapeutics Accelerates Debt Reduction and Raises Capital with Large Institutional Investors","https://www.globenewswire.com/news-release/2023/12/18/2797800/0/en/Biora-Therapeutics-Accelerates-Debt-Reduction-and-Raises-Capital-with-Large-Institutional-Investors.html","Health","2023-12-18 08:00:00","pre_market",1,1,469,471,-0,0,-0,"short","short",NaN
404,"BIVI","BioVie Announces Data from Phase 2 Parkinson’s Disease Trial Accepted for Presentation at AD/PD 2023","https://www.globenewswire.com/news-release/2023/03/21/2631261/0/en/BioVie-Announces-Data-from-Phase-2-Parkinson-s-Disease-Trial-Accepted-for-Presentation-at-AD-PD-2023.html","Health","2023-03-21 08:01:00","pre_market",9,9,394,397,0,0,0,"long","long",NaN
405,"BIVI","BioVie to Present Blinded Data on NE3107 in the Treatment of Mild to Moderate Alzheimer’s Disease at CTAD","https://www.globenewswire.com/news-release/2023/10/19/2763073/0/en/BioVie-to-Present-Blinded-Data-on-NE3107-in-the-Treatment-of-Mild-to-Moderate-Alzheimer-s-Disease-at-CTAD.html","Clinical Study","2023-10-19 07:30:00","pre_market",3,3,430,431,-0,0,-0,"short","short",NaN
406,"BIVI","BioVie Hosting Virtual KOL Event on NE3107 in Alzheimer’s Disease Today, September 7, 2023","https://www.globenewswire.com/news-release/2023/09/07/2739254/0/en/BioVie-Hosting-Virtual-KOL-Event-on-NE3107-in-Alzheimer-s-Disease-Today-September-7-2023.html","Conference Calls/ Webcasts","2023-09-07 08:00:00","pre_market",3,3,446,443,0,-0,0,"long","long",NaN
407,"BIVI","BioVie Presents Data Highlighting Role of Insulin Resistance and Neuroinflammation in the Development of Mild to Moderate in Alzheimer’s Disease","https://www.globenewswire.com/news-release/2023/06/26/2694368/0/en/BioVie-Presents-Data-Highlighting-Role-of-Insulin-Resistance-and-Neuroinflammation-in-the-Development-of-Mild-to-Moderate-in-Alzheimer-s-Disease.html","Calendar of Events","2023-06-26 08:00:00","pre_market",6,6,433,433,-0,-0,-0,"short","short",NaN
408,"BIVI","BioVie Presents Data for NE3107 at 2023 International Congress of Parkinson’s Disease and Movement Disorders","https://www.globenewswire.com/news-release/2023/08/28/2732542/0/en/BioVie-Presents-Data-for-NE3107-at-2023-International-Congress-of-Parkinson-s-Disease-and-Movement-Disorders.html","Health","2023-08-28 08:00:00","pre_market",3,3,440,442,0,0,-0,"short","short",NaN
410,"BIVI","BioVie to Participate in the Cantor Fitzgerald Global Healthcare Conference","https://www.globenewswire.com/news-release/2023/09/19/2745513/0/en/BioVie-to-Participate-in-the-Cantor-Fitzgerald-Global-Healthcare-Conference.html","Conference Calls/ Webcasts","2023-09-19 08:00:00","pre_market",3,3,444,443,0,-0,0,"long","long",NaN
411,"BIVI","BioVie Announces Efficacy Data from Phase 3 Trial of NE3107 in Patients with Mild to Moderate Alzheimer’s Disease","https://www.globenewswire.com/news-release/2023/11/29/2787674/0/en/BioVie-Announces-Efficacy-Data-from-Phase-3-Trial-of-NE3107-in-Patients-with-Mild-to-Moderate-Alzheimer-s-Disease.html","Clinical Study","2023-11-29 08:00:00","pre_market",5,2,455,457,-1,0,-1,"short","short",NaN
412,"BIVI","BioVie to Host Conference Call and Webcast Wednesday November 1, 2023 at 8:00 AM ET","https://www.globenewswire.com/news-release/2023/10/30/2769132/0/en/BioVie-to-Host-Conference-Call-and-Webcast-Wednesday-November-1-2023-at-8-00-AM-ET.html","Conference Calls/ Webcasts","2023-10-30 08:00:00","pre_market",3,3,411,414,-0,0,-0,"short","short",NaN
413,"BIVI","BioVie Announces Registration Details for ""BioVie Day"" Webinar","https://www.globenewswire.com/news-release/2023/03/14/2626541/0/en/BioVie-Announces-Registration-Details-for-BioVie-Day-Webinar.html","Calendar of Events","2023-03-14 08:00:00","pre_market",8,9,385,390,0,0,0,"long","long",NaN
414,"BIVI","BioVie Presents Data Highlighting Baseline Characteristics of Study Population in Phase 3 Trial of NE3107 in Mild to Moderate Alzheimer’s Disease","https://www.globenewswire.com/news-release/2023/09/11/2740752/0/en/BioVie-Presents-Data-Highlighting-Baseline-Characteristics-of-Study-Population-in-Phase-3-Trial-of-NE3107-in-Mild-to-Moderate-Alzheimer-s-Disease.html","Clinical Study","2023-09-11 08:00:00","pre_market",3,4,446,448,0,0,0,"long","short",NaN
415,"BIVI","BioVie to Participate in the Oppenheimer 33rd Annual Healthcare Conference","https://www.globenewswire.com/news-release/2023/03/09/2624028/0/en/BioVie-to-Participate-in-the-Oppenheimer-33rd-Annual-Healthcare-Conference.html","Conference Calls/ Webcasts","2023-03-09 08:00:00","pre_market",9,9,399,400,-0,0,-0,"short","short",NaN
416,"BIVI","BioVie Announces the Pausing of Patient Enrollment in Ascites Phase 2b Trial, Encouraging Efficacy Data is Announced, Initiating FDA Discussions to Conduct Pivotal Registrational Trial","https://www.globenewswire.com/news-release/2023/03/13/2625654/0/en/BioVie-Announces-the-Pausing-of-Patient-Enrollment-in-Ascites-Phase-2b-Trial-Encouraging-Efficacy-Data-is-Announced-Initiating-FDA-Discussions-to-Conduct-Pivotal-Registrational-Tri.html","Product / Services Announcement","2023-03-13 08:00:00","pre_market",8,8,386,382,-0,-0,-0,"short","short",NaN
417,"BIVI","BioVie Issues Letter to Shareholders","https://www.globenewswire.com/news-release/2023/07/18/2706267/0/en/BioVie-Issues-Letter-to-Shareholders.html","Advisory","2023-07-18 07:00:00","pre_market",5,5,451,450,0,-0,0,"long","long",NaN
418,"BIVI","BioVie Announces Completion of Last Patient Treatment Visit in Phase 3 Trial of NE3107 in Mild to Moderate Alzheimer's Disease","https://www.globenewswire.com/news-release/2023/09/26/2749457/0/en/BioVie-Announces-Completion-of-Last-Patient-Treatment-Visit-in-Phase-3-Trial-of-NE3107-in-Mild-to-Moderate-Alzheimer-s-Disease.html","Clinical Study","2023-09-26 08:00:00","pre_market",3,3,432,429,0,-0,0,"long","short",NaN
419,"BIVI","BioVie Presents Data Showing How NE3107 May Potentially Regulate DNA Methylation of Specific Genes in a Manner Highly Correlated to Observed Improvements in Cognition and Biomarkers of Disease","https://www.globenewswire.com/news-release/2023/07/17/2705478/0/en/BioVie-Presents-Data-Showing-How-NE3107-May-Potentially-Regulate-DNA-Methylation-of-Specific-Genes-in-a-Manner-Highly-Correlated-to-Observed-Improvements-in-Cognition-and-Biomarker.html","Clinical Study","2023-07-17 07:00:00","pre_market",5,5,449,449,-0,-0,-0,"short","short",NaN
423,"BMRA","Biomerica Announces Pricing of $8 Million Underwritten Public Offering of Common Stock","https://www.globenewswire.com/news-release/2023/03/03/2620157/0/en/Biomerica-Announces-Pricing-of-8-Million-Underwritten-Public-Offering-of-Common-Stock.html","Prospectus/Announcement of Prospectus","2023-03-03 07:30:00","pre_market",3,2,398,400,-0,0,-0,"short","short",NaN
454,"BNOX","Bionomics Provides a Review of 2023 and of 2024 Plans","https://www.globenewswire.com/news-release/2024/01/22/2812832/0/en/Bionomics-Provides-a-Review-of-2023-and-of-2024-Plans.html","Clinical Study","2024-01-22 06:00:00","pre_market",1,1,482,484,-0,0,-0,"short","short",NaN
425,"BMRA","Walmart to Expand Sales of Biomerica’s Aware® Breast Self Exam; Product will now be available in over 2400 Walmart stores","https://www.globenewswire.com/news-release/2022/10/14/2534713/0/en/Walmart-to-Expand-Sales-of-Biomerica-s-Aware-Breast-Self-Exam-Product-will-now-be-available-in-over-2400-Walmart-stores.html","Product / Services Announcement","2022-10-14 09:18:00","pre_market",4,5,366,369,0,0,0,"long","long",NaN
426,"BMRA","Biomerica Appoints Mayo Clinic Gastroenterologist, Dr. Brian E. Lacy, to the Company’s Scientific Advisory Board","https://www.globenewswire.com/news-release/2023/01/10/2586154/0/en/Biomerica-Appoints-Mayo-Clinic-Gastroenterologist-Dr-Brian-E-Lacy-to-the-Company-s-Scientific-Advisory-Board.html","Health","2023-01-10 08:19:00","pre_market",3,3,388,387,0,-0,0,"long","long",NaN
427,"BMRA","Biomerica Receives Notice of Patent Allowance in China for a Potential Innovative Technology That Includes an Artificial Intelligence (AI) Claim for Predicting Foods That Contain Ingredients That Cause Adverse Reactions in Patients","https://www.globenewswire.com/news-release/2023/06/21/2691993/0/en/Biomerica-Receives-Notice-of-Patent-Allowance-in-China-for-a-Potential-Innovative-Technology-That-Includes-an-Artificial-Intelligence-AI-Claim-for-Predicting-Foods-That-Contain-Ing.html","Patents","2023-06-21 08:19:00","pre_market",2,2,437,436,0,-0,0,"long","long",NaN
428,"BMRA","Biomerica Receives KFDA and Ministry of Health Approval for Colorectal Screening and Breast Screening Tests in Saudi Arabia and UAE","https://www.globenewswire.com/news-release/2022/12/08/2570250/0/en/Biomerica-Receives-KFDA-and-Ministry-of-Health-Approval-for-Colorectal-Screening-and-Breast-Screening-Tests-in-Saudi-Arabia-and-UAE.html","Product / Services Announcement","2022-12-08 08:19:00","pre_market",4,4,393,395,0,0,0,"long","long",NaN
430,"BMRA","REPEAT - Biomerica Reports First Quarter 2024 Financial Results","https://www.globenewswire.com/news-release/2023/10/13/2760118/0/en/REPEAT-Biomerica-Reports-First-Quarter-2024-Financial-Results.html","Earnings Releases and Operating Results","2023-10-13 13:10:00","market_open",1,1,435,432,0,-0,0,"long","long",NaN
431,"BMRA","Biomerica InFoods® IBS Data Presented at the 2022 American College of Gastroenterology (ACG) Annual Scientific Meeting","https://www.globenewswire.com/news-release/2022/11/02/2546506/0/en/Biomerica-InFoods-IBS-Data-Presented-at-the-2022-American-College-of-Gastroenterology-ACG-Annual-Scientific-Meeting.html","Clinical Study","2022-11-02 08:19:00","pre_market",3,3,385,384,-0,-0,-0,"short","short",NaN
432,"BMRA","Biomerica’s inFoods® IBS test is now available at Gastro Health, providing a revolutionary new treatment for patients suffering from Irritable Bowel Syndrome (IBS).","https://www.globenewswire.com/news-release/2023/04/17/2647830/0/en/Biomerica-s-inFoods-IBS-test-is-now-available-at-Gastro-Health-providing-a-revolutionary-new-treatment-for-patients-suffering-from-Irritable-Bowel-Syndrome-IBS.html","Product / Services Announcement","2023-04-17 07:47:00","pre_market",2,2,412,412,-0,-0,-0,"short","short",NaN
433,"BMRA","inFoods® IBS Test Now Validated for Use with Simple Finger Stick Whole Blood Collection Technology","https://www.globenewswire.com/news-release/2023/05/18/2671867/0/en/inFoods-IBS-Test-Now-Validated-for-Use-with-Simple-Finger-Stick-Whole-Blood-Collection-Technology.html","Clinical Study","2023-05-18 08:19:00","pre_market",1,1,415,415,-0,-0,-0,"short","short",NaN
434,"BMRA","Biomerica to Participate in 14th Annual Craig-Hallum Alpha Select Conference on November 16","https://www.globenewswire.com/news-release/2023/11/10/2778299/0/en/Biomerica-to-Participate-in-14th-Annual-Craig-Hallum-Alpha-Select-Conference-on-November-16.html","Calendar of Events","2023-11-10 08:19:00","pre_market",1,1,434,436,0,0,0,"long","long",NaN
435,"BMRA","Diagnostics Industry Leader Jack Kenny Joins Biomerica’s Board of Directors","https://www.globenewswire.com/news-release/2023/08/28/2732577/0/en/Diagnostics-Industry-Leader-Jack-Kenny-Joins-Biomerica-s-Board-of-Directors.html","Directors and Officers","2023-08-28 08:19:00","pre_market",1,1,440,442,0,0,-0,"short","short",NaN
436,"BMRA","Biomerica Reports First Quarter 2024 Financial Results","https://www.globenewswire.com/news-release/2023/10/13/2759856/0/en/Biomerica-Reports-First-Quarter-2024-Financial-Results.html","Earnings Releases and Operating Results","2023-10-13 06:39:00","pre_market",1,1,434,435,-0,0,-0,"short","short",NaN
420,"BIVI","BioVie to Host Virtual KOL Event on NE3107 in Alzheimer’s Disease on September 7, 2023","https://www.globenewswire.com/news-release/2023/08/31/2735173/0/en/BioVie-to-Host-Virtual-KOL-Event-on-NE3107-in-Alzheimer-s-Disease-on-September-7-2023.html","Health","2023-08-31 08:00:00","pre_market",3,3,451,452,0,0,0,"long","long",NaN
421,"BIVI","BioVie to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference","https://www.globenewswire.com/news-release/2024/02/06/2824283/0/en/BioVie-to-Participate-in-the-Oppenheimer-34th-Annual-Healthcare-Life-Sciences-Conference.html","Conference Calls/ Webcasts","2024-02-06 08:00:00","pre_market",1,1,493,494,0,0,0,"long","long",NaN
452,"BNOX","Bionomics Completes Last Patient Last Visit in the Phase 2b ATTUNE Study for Post-Traumatic Stress Disorder (PTSD) and Confirms Expected 2023 Milestones with its Lead Asset BNC210","https://www.globenewswire.com/news-release/2023/08/23/2730217/0/en/Bionomics-Completes-Last-Patient-Last-Visit-in-the-Phase-2b-ATTUNE-Study-for-Post-Traumatic-Stress-Disorder-PTSD-and-Confirms-Expected-2023-Milestones-with-its-Lead-Asset-BNC210.html","Product / Services Announcement","2023-08-23 06:00:00","pre_market",1,1,438,439,0,0,0,"long","long",NaN
450,"BNOX","Bionomics Announces the Completion of Enrollment in Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Post-Traumatic Stress Disorder (PTSD)","https://www.globenewswire.com/news-release/2023/04/27/2656035/0/en/Bionomics-Announces-the-Completion-of-Enrollment-in-Phase-2b-ATTUNE-Clinical-Trial-of-BNC210-in-Patients-with-Post-Traumatic-Stress-Disorder-PTSD.html","Clinical Study","2023-04-27 06:00:00","pre_market",2,2,404,407,0,0,-0,"short","short",NaN
448,"BNOX","Quarterly Activities and Cashflow Report","https://www.globenewswire.com/news-release/2023/07/31/2714666/0/en/Quarterly-Activities-and-Cashflow-Report.html","Management statements","2023-07-31 06:00:00","pre_market",2,1,457,457,-0,0,-0,"short","short",NaN
437,"BMRA","Biomerica announces the Launch of InFoods IBS as a Laboratory Developed Test (LDT); First patient samples have been processed","https://www.globenewswire.com/news-release/2023/03/08/2623008/0/en/Biomerica-announces-the-Launch-of-InFoods-IBS-as-a-Laboratory-Developed-Test-LDT-First-patient-samples-have-been-processed.html","Health","2023-03-08 08:19:00","pre_market",2,2,398,398,0,0,0,"long","long",NaN
444,"BNOX","Quarterly Activities and Cashflow Report","https://www.globenewswire.com/news-release/2023/04/28/2657250/0/en/Quarterly-Activities-and-Cashflow-Report.html","Management statements","2023-04-28 06:00:00","pre_market",2,2,412,411,0,-0,0,"long","short",NaN
453,"BNOX","Bionomics Presents Detailed Data on the Validity and Reliability of the Subjective Units of Distress Scale at the 2023 American College of Neuropsychopharmacology Annual Meeting","https://www.globenewswire.com/news-release/2023/12/06/2791725/0/en/Bionomics-Presents-Detailed-Data-on-the-Validity-and-Reliability-of-the-Subjective-Units-of-Distress-Scale-at-the-2023-American-College-of-Neuropsychopharmacology-Annual-Meeting.html","Health","2023-12-06 08:00:00","pre_market",1,1,457,459,0,0,0,"long","long",NaN
443,"BNOX","Bionomics to Present at Upcoming June Investor Conferences","https://www.globenewswire.com/news-release/2023/06/15/2688829/0/en/Bionomics-to-Present-at-Upcoming-June-Investor-Conferences.html","Calendar of Events","2023-06-15 08:00:00","pre_market",2,2,437,436,0,-0,0,"long","long",NaN
442,"BNOX","Bionomics Announces Accepted Abstract and Upcoming Poster Presentations at the American College of Neuropsychopharmacology (ACNP) 2022 Annual Meeting","https://www.globenewswire.com/news-release/2022/12/02/2566521/0/en/Bionomics-Announces-Accepted-Abstract-and-Upcoming-Poster-Presentations-at-the-American-College-of-Neuropsychopharmacology-ACNP-2022-Annual-Meeting.html","Health","2022-12-02 06:00:00","pre_market",7,7,407,402,0,-0,0,"long","long",NaN
447,"BNOX","Bionomics Announces Key Leadership Updates to Drive U.S.-Focused Transformation and Next Stage of Strategic Growth","https://www.globenewswire.com/news-release/2023/07/03/2698382/0/en/Bionomics-Announces-Key-Leadership-Updates-to-Drive-U-S-Focused-Transformation-and-Next-Stage-of-Strategic-Growth.html","Management Changes","2023-07-03 06:00:00","pre_market",2,2,443,443,0,-0,0,"long","long",NaN
445,"BNOX","Bionomics Announces Update on the α7 Nicotinic Acetylcholine Receptor (nAChR) Positive Allosteric Modulator (PAM) Collaboration with MSD","https://www.globenewswire.com/news-release/2023/09/14/2743067/0/en/Bionomics-Announces-Update-on-the-%CE%B17-Nicotinic-Acetylcholine-Receptor-nAChR-Positive-Allosteric-Modulator-PAM-Collaboration-with-MSD.html","Product / Services Announcement","2023-09-14 06:00:00","pre_market",2,1,447,449,-0,0,-0,"short","long",NaN
446,"BNOX","Bionomics Announces Positive Topline Results from the Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Post-Traumatic Stress Disorder (PTSD)","https://www.globenewswire.com/news-release/2023/09/28/2751004/0/en/Bionomics-Announces-Positive-Topline-Results-from-the-Phase-2b-ATTUNE-Clinical-Trial-of-BNC210-in-Patients-with-Post-Traumatic-Stress-Disorder-PTSD.html","Clinical Study","2023-09-28 06:00:00","pre_market",1,6,426,425,5,-0,5,"long","long",NaN
449,"BNOX","Bionomics Limited to Participate in Upcoming November Investor Conferences","https://www.globenewswire.com/news-release/2022/11/02/2546246/0/en/Bionomics-Limited-to-Participate-in-Upcoming-November-Investor-Conferences.html","Calendar of Events","2022-11-02 06:00:00","pre_market",8,7,385,384,-0,-0,-0,"short","long",NaN
451,"BNOX","Bionomics’ Half-Year Report","https://www.globenewswire.com/news-release/2023/02/23/2614019/0/en/Bionomics-Half-Year-Report.html","Earnings Releases and Operating Results","2023-02-23 06:00:00","pre_market",3,3,399,402,0,0,0,"long","short",NaN
438,"BMRA","Diagnostics Industry Leader Jack Kenny Appointed as Chairman of the Board at Biomerica","https://www.globenewswire.com/news-release/2024/01/23/2814070/0/en/Diagnostics-Industry-Leader-Jack-Kenny-Appointed-as-Chairman-of-the-Board-at-Biomerica.html","Directors and Officers","2024-01-23 08:19:00","pre_market",1,1,483,484,0,0,-0,"short","short",NaN
439,"BMRA","Biomerica Received US FDA 510(k) Clearance for Their Hp Detect™ ELISA Test Product Designed to Detect the Presence of the H. pylori Bacteria That infects Approximately 35% of the U.S. Population","https://www.globenewswire.com/news-release/2023/12/18/2797746/0/en/Biomerica-Received-US-FDA-510-k-Clearance-for-Their-Hp-Detect-ELISA-Test-Product-Designed-to-Detect-the-Presence-of-the-H-pylori-Bacteria-That-infects-Approximately-35-of-the-U-S-P.html","Product / Services Announcement","2023-12-18 07:47:00","pre_market",1,2,469,471,1,0,1,"long","long",NaN
468,"BNTX","BioNTech schließt Übernahme von InstaDeep ab","https://www.globenewswire.com/news-release/2023/07/31/2714822/0/de/BioNTech-schlie%C3%9Ft-%C3%9Cbernahme-von-InstaDeep-ab.html","Press releases","2023-07-31 08:00:00","pre_market",107,108,457,457,0,0,0,"long","long",NaN
464,"BNTX","Pfizer und BioNTech erhalten positive CHMP-Empfehlung für an Omikron XBB.1.5 angepassten COVID-19-Impfstoff in der Europäischen Union","https://www.globenewswire.com/news-release/2023/08/30/2734517/0/de/Pfizer-und-BioNTech-erhalten-positive-CHMP-Empfehlung-f%C3%BCr-an-Omikron-XBB-1-5-angepassten-COVID-19-Impfstoff-in-der-Europ%C3%A4ischen-Union.html","Company Announcement","2023-08-30 10:00:00","market_open",122,125,450,451,0,0,0,"long","long",NaN
457,"BNTX","BioNTech Presents Positive Phase 1/2 Data Update for  CAR-T Cell Therapy Candidate BNT211 in Advanced Solid Tumors at ESMO Congress 2023","https://www.globenewswire.com/news-release/2023/10/23/2764948/0/en/BioNTech-Presents-Positive-Phase-1-2-Data-Update-for-CAR-T-Cell-Therapy-Candidate-BNT211-in-Advanced-Solid-Tumors-at-ESMO-Congress-2023.html","Company Announcement","2023-10-23 11:30:00","market_open",89,93,420,420,0,0,0,"long","long",NaN
466,"BNTX","Pfizer and BioNTech Receive Health Canada Authorization for  XBB.1.5-Adapted Monovalent COVID-19 Vaccine","https://www.globenewswire.com/news-release/2023/09/28/2751493/0/en/Pfizer-and-BioNTech-Receive-Health-Canada-Authorization-for-XBB-1-5-Adapted-Monovalent-COVID-19-Vaccine.html","Company Announcement","2023-09-28 12:24:00","market_open",103,102,425,429,-0,0,-0,"short","short",NaN
458,"BNTX","BioNTech erweitert fortgeschrittenes klinisches Onkologie-Portfolio: Weiterer Phase-2-Studienstart mit mRNA-basierter individualisierter Neoantigen-spezifischer Immuntherapie  in neuer Krebsindikation","https://www.globenewswire.com/news-release/2023/10/19/2763018/0/de/BioNTech-erweitert-fortgeschrittenes-klinisches-Onkologie-Portfolio-Weiterer-Phase-2-Studienstart-mit-mRNA-basierter-individualisierter-Neoantigen-spezifischer-Immuntherapie-in-neu.html","Press releases","2023-10-19 06:45:00","pre_market",94,94,430,431,-0,0,-0,"short","short",NaN
456,"BNTX","BioNTech veröffentlicht am 6. November 2023 Ergebnisse des dritten Quartals und informiert zur Geschäftsentwicklung und lädt zum „Innovation Series Day“ am 7. November 2023 ein","https://www.globenewswire.com/news-release/2023/10/23/2764554/0/de/BioNTech-ver%C3%B6ffentlicht-am-6-November-2023-Ergebnisse-des-dritten-Quartals-und-informiert-zur-Gesch%C3%A4ftsentwicklung-und-l%C3%A4dt-zum-Innovation-Series-Day-am-7-November-2023-ein.html","Press releases","2023-10-23 06:45:00","pre_market",91,89,421,420,-0,-0,-0,"short","short",NaN
459,"BNTX","Pfizer and BioNTech Announce Positive Topline Data for mRNA-based Combination Vaccine Program Against Influenza and COVID-19","https://www.globenewswire.com/news-release/2023/10/26/2767318/0/en/Pfizer-and-BioNTech-Announce-Positive-Topline-Data-for-mRNA-based-Combination-Vaccine-Program-Against-Influenza-and-COVID-19.html","Company Announcement","2023-10-26 06:45:00","pre_market",95,96,418,416,0,-0,0,"long","long",NaN
461,"BNTX","BioNTech veröffentlicht Ergebnisse des dritten Quartals 2023 und Informationen zur Geschäftsentwicklung","https://www.globenewswire.com/news-release/2023/11/06/2773898/0/de/BioNTech-ver%C3%B6ffentlicht-Ergebnisse-des-dritten-Quartals-2023-und-Informationen-zur-Gesch%C3%A4ftsentwicklung.html","Earnings Releases and Operating Results","2023-11-06 06:45:00","pre_market",96,101,435,435,0,0,0,"long","long",NaN
463,"BNTX","BioNTech präsentiert positives Daten-Update aus der Phase-1/2-Studie mit dem CAR-T-Zelltherapiekandidat BNT211 bei fortgeschrittenen soliden Tumoren auf dem ESMO-Kongress 2023","https://www.globenewswire.com/news-release/2023/10/23/2764948/0/de/BioNTech-pr%C3%A4sentiert-positives-Daten-Update-aus-der-Phase-1-2-Studie-mit-dem-CAR-T-Zelltherapiekandidat-BNT211-bei-fortgeschrittenen-soliden-Tumoren-auf-dem-ESMO-Kongress-2023.html","Company Announcement","2023-10-23 11:30:00","market_open",89,93,420,420,0,0,0,"long","long",NaN
460,"BNTX","BioNTech and CEPI Announce Partnership to Advance mRNA Mpox Vaccine Development and Support CEPI’s 100 Days Mission","https://www.globenewswire.com/news-release/2023/09/18/2744601/0/en/BioNTech-and-CEPI-Announce-Partnership-to-Advance-mRNA-Mpox-Vaccine-Development-and-Support-CEPI-s-100-Days-Mission.html","Company Announcement","2023-09-18 06:45:00","pre_market",113,113,443,443,0,-0,0,"long","long",NaN
467,"BNTX","BioNTech und CEPI geben Partnerschaft zur Entwicklung eines mRNA-Mpox-Impfstoffs und zur Unterstützung von CEPIs 100-Tage-Ziel bekannt","https://www.globenewswire.com/news-release/2023/09/18/2744601/0/de/BioNTech-und-CEPI-geben-Partnerschaft-zur-Entwicklung-eines-mRNA-Mpox-Impfstoffs-und-zur-Unterst%C3%BCtzung-von-CEPIs-100-Tage-Ziel-bekannt.html","Company Announcement","2023-09-18 06:45:00","pre_market",113,113,443,443,0,-0,0,"long","long",NaN
469,"BNTX","Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron XBB.1.5-adapted COVID-19 Vaccine in the European Union","https://www.globenewswire.com/news-release/2023/08/30/2734517/0/en/Pfizer-and-BioNTech-Receive-Positive-CHMP-Opinion-for-Omicron-XBB-1-5-adapted-COVID-19-Vaccine-in-the-European-Union.html","Company Announcement","2023-08-30 10:00:00","market_open",122,125,450,451,0,0,0,"long","long",NaN
455,"BNOX","Bionomics to Present at Biotech Showcase™ 2024","https://www.globenewswire.com/news-release/2024/01/05/2804526/0/en/Bionomics-to-Present-at-Biotech-Showcase-2024.html","Calendar of Events","2024-01-05 06:00:00","pre_market",1,1,467,467,0,0,0,"long","long",NaN
470,"BNTX","BioNTech Expands Management Board by Appointing James Ryan as Chief Legal Officer","https://www.globenewswire.com/news-release/2023/08/14/2724220/0/en/BioNTech-Expands-Management-Board-by-Appointing-James-Ryan-as-Chief-Legal-Officer.html","Company Announcement","2023-08-14 06:45:00","pre_market",107,107,446,445,-0,-0,0,"long","long",NaN
471,"BNTX","BioNTech Completes Acquisition of InstaDeep","https://www.globenewswire.com/news-release/2023/07/31/2714822/0/en/BioNTech-Completes-Acquisition-of-InstaDeep.html","Press releases","2023-07-31 08:00:00","pre_market",107,108,457,457,0,0,0,"long","long",NaN
474,"BNTX","BioNTech und DualityBio erhalten Breakthrough-Therapy-Status der FDA für ADC-Kandidaten BNT323/DB-1303 zur Behandlung von Gebärmutterkrebs","https://www.globenewswire.com/news-release/2023/12/21/2799939/0/de/BioNTech-und-DualityBio-erhalten-Breakthrough-Therapy-Status-der-FDA-f%C3%BCr-ADC-Kandidaten-BNT323-DB-1303-zur-Behandlung-von-Geb%C3%A4rmutterkrebs.html","Press releases","2023-12-21 08:00:00","pre_market",103,103,468,471,0,0,0,"long","long",NaN
473,"BNTX","BioNTech Announces Third Quarter 2023 Financial Results and Corporate Update","https://www.globenewswire.com/news-release/2023/11/06/2773898/0/en/BioNTech-Announces-Third-Quarter-2023-Financial-Results-and-Corporate-Update.html","Earnings Releases and Operating Results","2023-11-06 06:45:00","pre_market",96,101,435,435,0,0,0,"long","long",NaN
475,"BNTX","BioNTech und Autolus schließen strategische Kollaboration zur Weiterentwicklung der Pipeline und Ausbau fortgeschrittener CAR-T-Zelltherapie-Programme","https://www.globenewswire.com/news-release/2024/02/08/2825809/0/de/BioNTech-und-Autolus-schlie%C3%9Fen-strategische-Kollaboration-zur-Weiterentwicklung-der-Pipeline-und-Ausbau-fortgeschrittener-CAR-T-Zelltherapie-Programme.html","Press releases","2024-02-08 05:45:00","pre_market",95,95,498,498,0,0,0,"long","long",NaN
476,"BNTX","BioNTech and DualityBio Receive FDA Breakthrough Therapy Designation for Antibody-Drug Conjugate Candidate BNT323/DB-1303 in Endometrial Cancer","https://www.globenewswire.com/news-release/2023/12/21/2799939/0/en/BioNTech-and-DualityBio-Receive-FDA-Breakthrough-Therapy-Designation-for-Antibody-Drug-Conjugate-Candidate-BNT323-DB-1303-in-Endometrial-Cancer.html","Press releases","2023-12-21 08:00:00","pre_market",103,103,468,471,0,0,0,"long","long",NaN
477,"BNTX","BioNTech Outlines 2024 Strategic Priorities at the 42nd Annual J.P. Morgan Healthcare Conference","https://www.globenewswire.com/news-release/2024/01/09/2806101/0/en/BioNTech-Outlines-2024-Strategic-Priorities-at-the-42nd-Annual-J-P-Morgan-Healthcare-Conference.html","Company Announcement","2024-01-09 06:45:00","pre_market",112,109,475,472,-0,-0,-0,"short","short",NaN
478,"BNTX","BioNTech Achieves Milestone at mRNA-based Vaccine Manufacturing Site in Rwanda","https://www.globenewswire.com/news-release/2023/12/18/2798070/0/en/BioNTech-Achieves-Milestone-at-mRNA-based-Vaccine-Manufacturing-Site-in-Rwanda.html","Company Announcement","2023-12-18 13:15:00","market_open",102,104,471,472,0,0,0,"long","long",NaN
479,"BNTX","BioNTech und DualityBio erhalten Fast-Track-Status der FDA für innovativen Antikörper-Wirkstoff-Konjugat-Kandidat BNT325/DB-1305","https://www.globenewswire.com/news-release/2024/01/31/2820922/0/de/BioNTech-und-DualityBio-erhalten-Fast-Track-Status-der-FDA-f%C3%BCr-innovativen-Antik%C3%B6rper-Wirkstoff-Konjugat-Kandidat-BNT325-DB-1305.html","Company Announcement","2024-01-31 06:45:00","pre_market",95,94,491,489,-0,-0,-0,"short","short",NaN
480,"BNTX","BioNTech erreicht Meilenstein in der Errichtung einer Produktionsstätte für mRNA-basierte Impfstoffe in Ruanda","https://www.globenewswire.com/news-release/2023/12/18/2798070/0/de/BioNTech-erreicht-Meilenstein-in-der-Errichtung-einer-Produktionsst%C3%A4tte-f%C3%BCr-mRNA-basierte-Impfstoffe-in-Ruanda.html","Company Announcement","2023-12-18 13:15:00","market_open",102,104,471,472,0,0,0,"long","long",NaN
481,"BNTX","BioNTech and DualityBio Receive FDA Fast Track Designation for Next-Generation Antibody-Drug Conjugate Candidate BNT325/DB-1305","https://www.globenewswire.com/news-release/2024/01/31/2820922/0/en/BioNTech-and-DualityBio-Receive-FDA-Fast-Track-Designation-for-Next-Generation-Antibody-Drug-Conjugate-Candidate-BNT325-DB-1305.html","Company Announcement","2024-01-31 06:45:00","pre_market",95,94,491,489,-0,-0,-0,"short","short",NaN
482,"BNTX","BioNTech weiht am 18. Dezember 2023 ersten afrikanischen Standort ein","https://www.globenewswire.com/news-release/2023/12/12/2794577/0/de/BioNTech-weiht-am-18-Dezember-2023-ersten-afrikanischen-Standort-ein.html","Press releases","2023-12-12 06:45:00","pre_market",100,100,462,462,-0,-0,-0,"short","short",NaN
483,"BNTX","BioNTech and DualityBio Initiate Pivotal Phase 3 Trial  Of Antibody-Drug Conjugate Candidate BNT323/DB-1303  in Metastatic Breast Cancer","https://www.globenewswire.com/news-release/2024/01/22/2812878/0/en/BioNTech-and-DualityBio-Initiate-Pivotal-Phase-3-Trial-Of-Antibody-Drug-Conjugate-Candidate-BNT323-DB-1303-in-Metastatic-Breast-Cancer.html","Company Announcement","2024-01-22 06:45:00","pre_market",98,98,482,484,0,0,-0,"short","short",NaN
485,"BNTX","BioNTech stellt strategische Prioritäten für 2024 auf der 42. jährlichen J.P. Morgan Healthcare-Konferenz vor","https://www.globenewswire.com/news-release/2024/01/09/2806101/0/de/BioNTech-stellt-strategische-Priorit%C3%A4ten-f%C3%BCr-2024-auf-der-42-j%C3%A4hrlichen-J-P-Morgan-Healthcare-Konferenz-vor.html","Company Announcement","2024-01-09 06:45:00","pre_market",112,109,475,472,-0,-0,-0,"short","short",NaN
486,"BNTX","BioNTech to Inaugurate First African Site on December 18, 2023","https://www.globenewswire.com/news-release/2023/12/12/2794577/0/en/BioNTech-to-Inaugurate-First-African-Site-on-December-18-2023.html","Press releases","2023-12-12 06:45:00","pre_market",100,100,462,462,-0,-0,-0,"short","long",NaN
487,"BNTX","BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs","https://www.globenewswire.com/news-release/2024/02/08/2825809/0/en/BioNTech-and-Autolus-Announce-Strategic-CAR-T-Cell-Therapy-Collaboration-to-Advance-Pipeline-and-Expand-Late-Stage-Programs.html","Press releases","2024-02-08 05:45:00","pre_market",95,95,498,498,0,0,0,"long","long",NaN
489,"BTAI","BioXcel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Highlights","https://www.globenewswire.com/news-release/2023/03/09/2623898/0/en/BioXcel-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2022-Financial-Results-and-Recent-Operational-Highlights.html","Earnings Releases and Operating Results","2023-03-09 07:00:00","pre_market",28,27,399,400,-0,0,-0,"short","short",NaN
490,"BTAI","BioXcel Therapeutics Announces Positive Findings from Independent Third Party Audit of Data Integrity at TRANQUILITY II Phase 3 Trial Site","https://www.globenewswire.com/news-release/2023/10/25/2766353/0/en/BioXcel-Therapeutics-Announces-Positive-Findings-from-Independent-Third-Party-Audit-of-Data-Integrity-at-TRANQUILITY-II-Phase-3-Trial-Site.html","Clinical Study","2023-10-25 07:00:00","pre_market",2,3,424,422,0,-0,0,"long","long",NaN
492,"BTAI","BioXcel Therapeutics Reports Positive Overall Survival Results from Single-Arm, Open-Label Phase 2 Trial of BXCL701 in Patients with Small Cell Neuroendocrine Prostate Cancer","https://www.globenewswire.com/news-release/2023/10/10/2757315/0/en/BioXcel-Therapeutics-Reports-Positive-Overall-Survival-Results-from-Single-Arm-Open-Label-Phase-2-Trial-of-BXCL701-in-Patients-with-Small-Cell-Neuroendocrine-Prostate-Cancer.html","Clinical Study","2023-10-10 07:00:00","pre_market",3,3,432,433,0,0,0,"long","long",NaN
519,"BXRX","Baudax Bio Reports Second Quarter 2023 Financial Results and Provides Business Update","https://www.globenewswire.com/news-release/2023/08/16/2726283/0/en/Baudax-Bio-Reports-Second-Quarter-2023-Financial-Results-and-Provides-Business-Update.html","Earnings Releases and Operating Results","2023-08-16 08:00:00","pre_market",1,1,443,442,0,-0,0,"long","long",NaN
493,"BTAI","BioXcel Therapeutics to Participate at Two Upcoming Investor Conferences","https://www.globenewswire.com/news-release/2023/06/01/2680145/0/en/BioXcel-Therapeutics-to-Participate-at-Two-Upcoming-Investor-Conferences.html","Calendar of Events","2023-06-01 07:00:00","pre_market",18,18,418,418,-0,0,-0,"short","short",NaN
494,"BTAI","BioXcel Therapeutics to Report Second Quarter 2023 Financial Results on August 14, 2023","https://www.globenewswire.com/news-release/2023/07/31/2714718/0/en/BioXcel-Therapeutics-to-Report-Second-Quarter-2023-Financial-Results-on-August-14-2023.html","Conference Calls/ Webcasts","2023-07-31 07:00:00","pre_market",10,10,457,457,0,0,0,"long","long",NaN
495,"BTAI","BioXcel Therapeutics Announces Promising Topline Results from Part 1 of Pivotal SERENITY III Trial of BXCL501 for At-Home Use in Acute Treatment of Agitation in Bipolar Disorders or Schizophrenia","https://www.globenewswire.com/news-release/2023/05/25/2675983/0/en/BioXcel-Therapeutics-Announces-Promising-Topline-Results-from-Part-1-of-Pivotal-SERENITY-III-Trial-of-BXCL501-for-At-Home-Use-in-Acute-Treatment-of-Agitation-in-Bipolar-Disorders-o.html","Health","2023-05-25 07:00:00","pre_market",26,26,411,415,-0,0,-0,"short","long",NaN
496,"BTAI","BioXcel Therapeutics Aligns with FDA Recommendation for Phase 3 Trial for TRANQUILITY Program, Provides Update on Strategic Financing, and Reports Third Quarter 2023 Financial Results","https://www.globenewswire.com/news-release/2023/11/14/2779919/0/en/BioXcel-Therapeutics-Aligns-with-FDA-Recommendation-for-Phase-3-Trial-for-TRANQUILITY-Program-Provides-Update-on-Strategic-Financing-and-Reports-Third-Quarter-2023-Financial-Result.html","Conference Calls/ Webcasts","2023-11-14 07:00:00","pre_market",6,4,440,446,-0,0,-0,"short","short",NaN
497,"BTAI","BioXcel Therapeutics Reports First Quarter 2023 Financial Results and Recent Operational Highlights","https://www.globenewswire.com/news-release/2023/05/08/2663157/0/en/BioXcel-Therapeutics-Reports-First-Quarter-2023-Financial-Results-and-Recent-Operational-Highlights.html","Earnings Releases and Operating Results","2023-05-08 07:00:00","pre_market",23,21,413,413,-0,0,-0,"short","short",NaN
498,"BTAI","BioXcel Therapeutics to Present at the BofA Securities 2023 Health Care Conference","https://www.globenewswire.com/news-release/2023/05/02/2658961/0/en/BioXcel-Therapeutics-to-Present-at-the-BofA-Securities-2023-Health-Care-Conference.html","Trade Show","2023-05-02 07:00:00","pre_market",21,21,416,415,0,-0,0,"long","long",NaN
499,"BTAI","BioXcel Therapeutics Announces Promising Top-Line Results from Phase 2 Trial of BXCL701 in Aggressive Form of Rare Prostate Cancer","https://www.globenewswire.com/news-release/2023/01/11/2586890/0/en/BioXcel-Therapeutics-Announces-Promising-Top-Line-Results-from-Phase-2-Trial-of-BXCL701-in-Aggressive-Form-of-Rare-Prostate-Cancer.html","Clinical Study","2023-01-11 07:00:00","pre_market",24,24,391,392,0,0,0,"long","long",NaN
500,"BTAI","BioXcel Therapeutics Announces Positive Top-Line Data from Repeat Dosing of BXCL501 in Phase 1b Multiple Ascending Dose Trial in Healthy Volunteers for Major Depressive Disorder (MDD) Program","https://www.globenewswire.com/news-release/2023/05/16/2669821/0/en/BioXcel-Therapeutics-Announces-Positive-Top-Line-Data-from-Repeat-Dosing-of-BXCL501-in-Phase-1b-Multiple-Ascending-Dose-Trial-in-Healthy-Volunteers-for-Major-Depressive-Disorder-MD.html","Health","2023-05-16 07:00:00","pre_market",27,27,413,412,0,-0,0,"long","long",NaN
501,"BTAI","BioXcel Therapeutics to Report Third Quarter 2023 Financial Results on November 14, 2023","https://www.globenewswire.com/news-release/2023/10/31/2769984/0/en/BioXcel-Therapeutics-to-Report-Third-Quarter-2023-Financial-Results-on-November-14-2023.html","Calendar of Events","2023-10-31 07:00:00","pre_market",4,4,416,416,-0,0,-0,"short","short",NaN
502,"BTAI","BioXcel Therapeutics Announces First Patient Dosed in TRANQUILITY III Phase 3 Trial for Acute Treatment of Agitation in Patients with Alzheimer’s Disease","https://www.globenewswire.com/news-release/2022/12/19/2576149/0/en/BioXcel-Therapeutics-Announces-First-Patient-Dosed-in-TRANQUILITY-III-Phase-3-Trial-for-Acute-Treatment-of-Agitation-in-Patients-with-Alzheimer-s-Disease.html","Clinical Study","2022-12-19 07:00:00","pre_market",20,20,383,383,0,0,0,"long","long",NaN
518,"BXRX","Baudax Bio Announces Additional, Positive Top-Line Results From Phase 2 Randomized Clinical Trial of BX1000","https://www.globenewswire.com/news-release/2023/06/07/2683858/0/en/Baudax-Bio-Announces-Additional-Positive-Top-Line-Results-From-Phase-2-Randomized-Clinical-Trial-of-BX1000.html","Clinical Study","2023-06-07 09:21:00","pre_market",1,1,428,428,0,0,0,"long","long",NaN
520,"BXRX","Baudax Bio Acquires TeraImmune, Inc.","https://www.globenewswire.com/news-release/2023/06/30/2697710/0/en/Baudax-Bio-Acquires-TeraImmune-Inc.html","Mergers and Acquisitions","2023-06-30 08:00:00","pre_market",1,1,438,441,0,0,0,"long","long",NaN
505,"BTAI","BioXcel Therapeutics Receives Permanent J-Code for IGALMI™ (dexmedetomidine) Sublingual Film from Centers for Medicare & Medicaid Services","https://www.globenewswire.com/news-release/2023/10/30/2769033/0/en/BioXcel-Therapeutics-Receives-Permanent-J-Code-for-IGALMI-dexmedetomidine-Sublingual-Film-from-Centers-for-Medicare-Medicaid-Services.html","Health","2023-10-30 07:00:00","pre_market",3,3,411,414,0,0,-0,"short","long",NaN
506,"BTAI","BioXcel Therapeutics Announces Update on NIDA-funded Trial of BXCL501 (sublingual dexmedetomidine) for Potential Treatment of Opioid Use Disorder (OUD)","https://www.globenewswire.com/news-release/2023/11/06/2773940/0/en/BioXcel-Therapeutics-Announces-Update-on-NIDA-funded-Trial-of-BXCL501-sublingual-dexmedetomidine-for-Potential-Treatment-of-Opioid-Use-Disorder-OUD.html","Health","2023-11-06 07:00:00","pre_market",5,5,435,435,0,0,0,"long","long",NaN
507,"BTAI","BioXcel Therapeutics to Host Virtual Neuroscience R&D Day on Dec. 12, 2023","https://www.globenewswire.com/news-release/2023/11/30/2788461/0/en/BioXcel-Therapeutics-to-Host-Virtual-Neuroscience-R-D-Day-on-Dec-12-2023.html","Conference Calls/ Webcasts","2023-11-30 07:00:00","pre_market",4,4,455,455,-0,0,-0,"short","long",NaN
508,"BTAI","BioXcel Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on March 9, 2023","https://www.globenewswire.com/news-release/2023/02/23/2614089/0/en/BioXcel-Therapeutics-to-Report-Fourth-Quarter-and-Full-Year-2022-Financial-Results-on-March-9-2023.html","Calendar of Events","2023-02-23 07:00:00","pre_market",29,29,399,402,0,0,0,"long","long",NaN
509,"BTAI","BioXcel Therapeutics to Report First Quarter 2023 Financial Results on May 8, 2023","https://www.globenewswire.com/news-release/2023/04/24/2652526/0/en/BioXcel-Therapeutics-to-Report-First-Quarter-2023-Financial-Results-on-May-8-2023.html","Conference Calls/ Webcasts","2023-04-24 07:00:00","pre_market",22,22,412,412,-0,-0,-0,"short","short",NaN
510,"BTAI","BioXcel Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference","https://www.globenewswire.com/news-release/2022/12/22/2578481/0/en/BioXcel-Therapeutics-to-Present-at-41st-Annual-J-P-Morgan-Healthcare-Conference.html","Calendar of Events","2022-12-22 07:00:00","pre_market",21,21,386,383,-0,-0,0,"long","long",NaN
511,"BTAI","BioXcel Therapeutics Reports Positive Overall Survival Results from Single-Arm, Open-Label Phase 2 Trial of BXCL701 in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) of Adenocarcinoma Phenotype","https://www.globenewswire.com/news-release/2023/11/08/2776064/0/en/BioXcel-Therapeutics-Reports-Positive-Overall-Survival-Results-from-Single-Arm-Open-Label-Phase-2-Trial-of-BXCL701-in-Patients-with-Metastatic-Castration-Resistant-Prostate-Cancer-.html","Clinical Study","2023-11-08 07:00:00","pre_market",5,5,437,438,0,0,0,"long","long",NaN
512,"BTAI","BioXcel Therapeutics Announces Termination of Proposed Public Offering","https://www.globenewswire.com/news-release/2024/02/13/2828330/0/en/BioXcel-Therapeutics-Announces-Termination-of-Proposed-Public-Offering.html","Financing Agreements","2024-02-13 09:00:00","pre_market",2,3,501,495,0,-0,0,"long","long",NaN
513,"BTAI","BioXcel Therapeutics Strengthens Clinical Development Leadership to Advance Late-Stage Programs","https://www.globenewswire.com/news-release/2023/12/11/2793729/0/en/BioXcel-Therapeutics-Strengthens-Clinical-Development-Leadership-to-Advance-Late-Stage-Programs.html","Corporate Action","2023-12-11 07:00:00","pre_market",3,3,460,460,0,-0,0,"long","long",NaN
514,"BTAI","BioXcel Therapeutics Hosting Virtual Neuroscience R&D Day Today","https://www.globenewswire.com/news-release/2023/12/12/2794604/0/en/BioXcel-Therapeutics-Hosting-Virtual-Neuroscience-R-D-Day-Today.html","Product / Services Announcement","2023-12-12 07:00:00","pre_market",3,3,462,462,0,-0,0,"long","long",NaN
515,"BTAI","BioXcel Therapeutics Receives FDA Fast Track Designation for BXCL701 for Treatment of Small Cell Neuroendocrine Prostate Cancer (SCNC)","https://www.globenewswire.com/news-release/2024/02/12/2827423/0/en/BioXcel-Therapeutics-Receives-FDA-Fast-Track-Designation-for-BXCL701-for-Treatment-of-Small-Cell-Neuroendocrine-Prostate-Cancer-SCNC.html","Health","2024-02-12 07:14:00","pre_market",2,2,501,501,0,-0,0,"long","long",NaN
516,"BTAI","BioXcel Therapeutics Announces USPTO’s Allowance of Patent Application for Method of Treating Agitation in Alzheimer’s Disease Using Oromucosal Formulations of Dexmedetomidine","https://www.globenewswire.com/news-release/2024/02/05/2823402/0/en/BioXcel-Therapeutics-Announces-USPTO-s-Allowance-of-Patent-Application-for-Method-of-Treating-Agitation-in-Alzheimer-s-Disease-Using-Oromucosal-Formulations-of-Dexmedetomidine.html","Patents","2024-02-05 07:00:00","pre_market",3,3,494,494,0,-0,0,"long","long",NaN
517,"BTAI","BioXcel Therapeutics Announces Completion of Patient Enrollment in Safety Portion of Investigator-Sponsored Phase 2 Relapsed Pancreatic Cancer Trial of BXCL701 in Combination with KEYTRUDA®","https://www.globenewswire.com/news-release/2024/02/06/2824137/0/en/BioXcel-Therapeutics-Announces-Completion-of-Patient-Enrollment-in-Safety-Portion-of-Investigator-Sponsored-Phase-2-Relapsed-Pancreatic-Cancer-Trial-of-BXCL701-in-Combination-with-.html","Clinical Study","2024-02-06 07:00:00","pre_market",4,4,493,494,-0,0,-0,"short","short",NaN
528,"CADL","Candel Therapeutics to Participate in the Canaccord Genuity 43rd Annual Growth Conference","https://www.globenewswire.com/news-release/2023/08/02/2716816/0/en/Candel-Therapeutics-to-Participate-in-the-Canaccord-Genuity-43rd-Annual-Growth-Conference.html","Health","2023-08-02 08:00:00","pre_market",1,1,456,453,0,-0,0,"long","long",NaN
529,"CADL","Candel Therapeutics Announces New Data from Ongoing Phase 1 Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting","https://www.globenewswire.com/news-release/2023/05/19/2672581/0/en/Candel-Therapeutics-Announces-New-Data-from-Ongoing-Phase-1-Clinical-Trial-of-CAN-3110-in-Recurrent-High-Grade-Glioma-at-the-American-Society-of-Gene-Cell-Therapy-ASGCT-26th-Annual.html","Clinical Study","2023-05-19 09:00:00","pre_market",2,2,419,420,0,0,0,"long","long",NaN
530,"CADL","Candel Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference","https://www.globenewswire.com/news-release/2023/09/06/2738304/0/en/Candel-Therapeutics-to-Participate-in-the-H-C-Wainwright-25th-Annual-Global-Investment-Conference.html","Conference Calls/ Webcasts","2023-09-06 08:00:00","pre_market",1,1,449,448,-0,-0,-0,"short","short",NaN
531,"CADL","Candel Therapeutics Announces Restructuring to Prioritize Resources on Key Value Drivers for Expanded Development of CAN-3110, the enLIGHTEN™ Discovery Platform, and Key Clinical Readouts for CAN-2409","https://www.globenewswire.com/news-release/2023/11/28/2787049/0/en/Candel-Therapeutics-Announces-Restructuring-to-Prioritize-Resources-on-Key-Value-Drivers-for-Expanded-Development-of-CAN-3110-the-enLIGHTEN-Discovery-Platform-and-Key-Clinical-Read.html","Clinical Study","2023-11-28 09:00:00","pre_market",1,1,454,454,0,-0,0,"long","long",NaN
533,"CADL","Candel Therapeutics to Participate in the 2023 Jefferies Healthcare Conference","https://www.globenewswire.com/news-release/2023/06/05/2681910/0/en/Candel-Therapeutics-to-Participate-in-the-2023-Jefferies-Healthcare-Conference.html","Calendar of Events","2023-06-05 08:00:00","pre_market",2,2,428,428,0,0,0,"long","long",NaN
534,"CADL","Candel Therapeutics Receives FDA Fast Track Designation for CAN-2409 in Non-Small Cell Lung Cancer","https://www.globenewswire.com/news-release/2023/04/17/2647879/0/en/Candel-Therapeutics-Receives-FDA-Fast-Track-Designation-for-CAN-2409-in-Non-Small-Cell-Lung-Cancer.html","Regulatory information","2023-04-17 08:00:00","pre_market",1,2,412,412,0,-0,0,"long","long",NaN
535,"CADL","Candel Therapeutics Announces It Expects to Report Topline Data from its Phase 2 Clinical Trial of CAN-2409 in Non-Small Cell Lung Cancer in the Second Quarter of 2024","https://www.globenewswire.com/news-release/2023/06/13/2687074/0/en/Candel-Therapeutics-Announces-It-Expects-to-Report-Topline-Data-from-its-Phase-2-Clinical-Trial-of-CAN-2409-in-Non-Small-Cell-Lung-Cancer-in-the-Second-Quarter-of-2024.html","Clinical Study","2023-06-13 08:00:00","pre_market",2,2,434,435,-0,0,-0,"short","short",NaN
536,"CADL","Candel Therapeutics Appoints Experienced Manufacturing Leader Nicoletta Loggia, PhD, RPh to its Board of Directors","https://www.globenewswire.com/news-release/2023/06/08/2684701/0/en/Candel-Therapeutics-Appoints-Experienced-Manufacturing-Leader-Nicoletta-Loggia-PhD-RPh-to-its-Board-of-Directors.html","Directors and Officers","2023-06-08 08:00:00","pre_market",2,2,427,427,0,0,0,"long","long",NaN
537,"CADL","Candel Therapeutics to Participate in Guggenheim Healthcare Talks 2023 Oncology Day","https://www.globenewswire.com/news-release/2023/02/01/2599407/0/en/Candel-Therapeutics-to-Participate-in-Guggenheim-Healthcare-Talks-2023-Oncology-Day.html","Conference Calls/ Webcasts","2023-02-01 08:00:00","pre_market",3,3,406,405,0,-0,0,"long","long",NaN
521,"BXRX","Baudax Bio Announces Orphan Drug Designation Granted by U.S. FDA for TI-168 for the Treatment of Hemophilia A with Inhibitors","https://www.globenewswire.com/news-release/2023/09/28/2751180/0/en/Baudax-Bio-Announces-Orphan-Drug-Designation-Granted-by-U-S-FDA-for-TI-168-for-the-Treatment-of-Hemophilia-A-with-Inhibitors.html","Environmental, Social, and Governance Criteria","2023-09-28 08:00:00","pre_market",0,1,426,425,1,-0,1,"long","long",NaN
522,"BXRX","Baudax Bio Announces Date of Reconvened Annual Meeting","https://www.globenewswire.com/news-release/2023/06/06/2682905/0/en/Baudax-Bio-Announces-Date-of-Reconvened-Annual-Meeting.html","Calendar of Events","2023-06-06 09:00:00","pre_market",1,1,427,427,0,-0,0,"long","long",NaN
523,"BXRX","Baudax Bio Announces $1.9 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules","https://www.globenewswire.com/news-release/2023/08/17/2727199/0/en/Baudax-Bio-Announces-1-9-Million-Registered-Direct-Offering-Priced-At-The-Market-under-Nasdaq-Rules.html","Warrants and Certificates","2023-08-17 08:00:00","pre_market",1,1,440,441,-0,0,-0,"short","short",NaN
524,"BXRX","Baudax Bio to Participate in the H.C. Wainwright Global Investment Conference","https://www.globenewswire.com/news-release/2023/09/07/2739292/0/en/Baudax-Bio-to-Participate-in-the-H-C-Wainwright-Global-Investment-Conference.html","Calendar of Events","2023-09-07 08:00:00","pre_market",0,0,446,443,-0,-0,-0,"short","short",NaN
525,"BXRX","Baudax Bio Announces Distribution of Series C Preferred Stock to Holders of its Common Stock","https://www.globenewswire.com/news-release/2023/08/23/2730353/0/en/Baudax-Bio-Announces-Distribution-of-Series-C-Preferred-Stock-to-Holders-of-its-Common-Stock.html","Dividend Reports and Estimates","2023-08-23 08:00:00","pre_market",0,0,438,439,0,0,0,"long","long",NaN
526,"BXRX","Baudax Bio Announces Corporate Update","https://www.globenewswire.com/news-release/2023/10/18/2762296/0/en/Baudax-Bio-Announces-Corporate-Update.html","Corporate Action","2023-10-18 08:00:00","pre_market",0,0,436,434,0,-0,0,"long","long",NaN
553,"CAPR","Capricor Therapeutics Announces Appointment of Paul Auwaerter, M.D. to its Board of Directors","https://www.globenewswire.com/news-release/2023/07/13/2704319/0/en/Capricor-Therapeutics-Announces-Appointment-of-Paul-Auwaerter-M-D-to-its-Board-of-Directors.html","Directors and Officers","2023-07-13 08:30:00","pre_market",4,4,446,448,0,0,0,"long","long",NaN
547,"CADL","Candel Therapeutics to Host Virtual R&D Day on December 6, 2022","https://www.globenewswire.com/news-release/2022/11/29/2563926/0/en/Candel-Therapeutics-to-Host-Virtual-R-D-Day-on-December-6-2022.html","Calendar of Events","2022-11-29 08:00:00","pre_market",2,2,396,396,0,0,0,"long","long",NaN
539,"CADL","Candel Therapeutics Reports Encouraging Initial Survival Data from Phase 2 Clinical Trial of CAN-2409 in Non-Small Cell Lung Cancer","https://www.globenewswire.com/news-release/2023/09/26/2749459/0/en/Candel-Therapeutics-Reports-Encouraging-Initial-Survival-Data-from-Phase-2-Clinical-Trial-of-CAN-2409-in-Non-Small-Cell-Lung-Cancer.html","Clinical Study","2023-09-26 08:00:00","pre_market",1,1,432,429,0,-0,0,"long","long",NaN
540,"CADL","Candel Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights","https://www.globenewswire.com/news-release/2023/08/10/2722588/0/en/Candel-Therapeutics-Reports-Second-Quarter-2023-Financial-Results-and-Recent-Corporate-Highlights.html","Earnings Releases and Operating Results","2023-08-10 08:00:00","pre_market",1,1,446,448,-0,0,-0,"short","short",NaN
542,"CADL","Candel Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights","https://www.globenewswire.com/news-release/2023/11/09/2777291/0/en/Candel-Therapeutics-Reports-Third-Quarter-2023-Financial-Results-and-Recent-Corporate-Highlights.html","Clinical Study","2023-11-09 08:00:00","pre_market",1,1,437,438,0,0,0,"long","long",NaN
543,"CADL","Candel Therapeutics Announces Initial Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer","https://www.globenewswire.com/news-release/2023/11/03/2773326/0/en/Candel-Therapeutics-Announces-Initial-Positive-Interim-Data-from-Randomized-Phase-2-Clinical-Trial-of-CAN-2409-in-Non-Metastatic-Pancreatic-Cancer.html","Clinical Study","2023-11-03 12:00:00","market_open",1,1,433,435,-0,0,-0,"short","short",NaN
544,"CADL","Candel Therapeutics Announces Three Abstracts Accepted for Poster Presentations at SITC 2023 Annual Meeting","https://www.globenewswire.com/news-release/2023/09/27/2750513/0/en/Candel-Therapeutics-Announces-Three-Abstracts-Accepted-for-Poster-Presentations-at-SITC-2023-Annual-Meeting.html","Clinical Study","2023-09-27 09:40:00","market_open",1,1,427,426,-0,-0,-0,"short","short",NaN
545,"CADL","Candel Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights","https://www.globenewswire.com/news-release/2023/05/11/2666694/0/en/Candel-Therapeutics-Reports-First-Quarter-2023-Financial-Results-and-Recent-Corporate-Highlights.html","Earnings Releases and Operating Results","2023-05-11 08:00:00","pre_market",2,2,413,412,-0,-0,-0,"short","short",NaN
546,"CADL","Candel Therapeutics Announces Late-Breaking Oral Presentation at SITC Annual Meeting with Data on CAN-2409 in Combination with Nivolumab in a Phase 1 Mechanistic Clinical Trial in Patients with High-Grade Glioma","https://www.globenewswire.com/news-release/2022/11/11/2554350/0/en/Candel-Therapeutics-Announces-Late-Breaking-Oral-Presentation-at-SITC-Annual-Meeting-with-Data-on-CAN-2409-in-Combination-with-Nivolumab-in-a-Phase-1-Mechanistic-Clinical-Trial-in-.html","Product / Services Announcement","2022-11-11 12:00:00","market_open",2,2,396,399,0,0,0,"long","long",NaN
571,"CBAY","CymaBay Announces Proposed $150 Million Public Offering of Common Stock and Pre-Funded Warrants","https://www.globenewswire.com/news-release/2023/09/11/2740591/37067/en/CymaBay-Announces-Proposed-150-Million-Public-Offering-of-Common-Stock-and-Pre-Funded-Warrants.html","Warrants and Certificates","2023-09-11 06:00:00","pre_market",16,16,446,448,-0,0,-0,"short","short",NaN
548,"CADL","Candel Therapeutics to Participate in Upcoming B. Riley Oncology Conference","https://www.globenewswire.com/news-release/2023/01/12/2587826/0/en/Candel-Therapeutics-to-Participate-in-Upcoming-B-Riley-Oncology-Conference.html","Conference Calls/ Webcasts","2023-01-12 08:00:00","pre_market",2,2,396,397,0,0,0,"long","long",NaN
549,"CADL","Candel Therapeutics Sets Path to Success: Recent Achievements Pave the Way for a Promising 2024 Propelled by Key Value Drivers and Catalysts","https://www.globenewswire.com/news-release/2024/02/05/2823461/0/en/Candel-Therapeutics-Sets-Path-to-Success-Recent-Achievements-Pave-the-Way-for-a-Promising-2024-Propelled-by-Key-Value-Drivers-and-Catalysts.html","Product / Services Announcement","2024-02-05 08:00:00","pre_market",1,1,494,494,0,-0,0,"long","long",NaN
550,"CADL","Candel Therapeutics Receives FDA Fast Track Designation for CAN-2409 in Pancreatic Cancer","https://www.globenewswire.com/news-release/2023/12/12/2794671/0/en/Candel-Therapeutics-Receives-FDA-Fast-Track-Designation-for-CAN-2409-in-Pancreatic-Cancer.html","Product / Services Announcement","2023-12-12 08:00:00","pre_market",1,1,462,462,1,-0,1,"long","long",NaN
551,"CADL","CAN-3110 Receives FDA Fast Track Designation for Treatment of Recurrent High-Grade Glioma","https://www.globenewswire.com/news-release/2024/02/13/2828140/0/en/CAN-3110-Receives-FDA-Fast-Track-Designation-for-Treatment-of-Recurrent-High-Grade-Glioma.html","Health","2024-02-13 07:30:00","pre_market",1,1,501,495,0,-0,0,"long","long",NaN
569,"CBAY","CymaBay Therapeutics to Present at the SVB Securities Global Biopharma Conference","https://www.globenewswire.com/news-release/2023/02/06/2602017/37067/en/CymaBay-Therapeutics-to-Present-at-the-SVB-Securities-Global-Biopharma-Conference.html","Conference Calls/ Webcasts","2023-02-06 08:00:00","pre_market",9,9,412,410,0,-0,0,"long","long",NaN
570,"CBAY","CymaBay Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference","https://www.globenewswire.com/news-release/2023/03/01/2618131/37067/en/CymaBay-Therapeutics-to-Present-at-the-Oppenheimer-33rd-Annual-Healthcare-Conference.html","Trade Show","2023-03-01 08:00:00","pre_market",8,8,396,395,0,-0,0,"long","short",NaN
555,"CAPR","Capricor Therapeutics Appoints Michael Kelliher to Board of Directors","https://www.globenewswire.com/news-release/2023/09/06/2738485/0/en/Capricor-Therapeutics-Appoints-Michael-Kelliher-to-Board-of-Directors.html","Directors and Officers","2023-09-06 09:00:00","pre_market",6,6,449,448,0,-0,0,"long","short",NaN
556,"CAPR","Capricor Therapeutics Announces Positive Type-B Meeting with the FDA to Discuss Pathway to BLA for CAP-1002 in Duchenne Muscular Dystrophy","https://www.globenewswire.com/news-release/2023/09/29/2751919/0/en/Capricor-Therapeutics-Announces-Positive-Type-B-Meeting-with-the-FDA-to-Discuss-Pathway-to-BLA-for-CAP-1002-in-Duchenne-Muscular-Dystrophy.html","Conference Calls/ Webcasts","2023-09-29 07:30:00","pre_market",6,4,429,432,-0,0,-0,"short","short",NaN
557,"CAPR","Capricor Therapeutics to Present Third Quarter 2023 Financial Results and Recent Corporate Update on November 14","https://www.globenewswire.com/news-release/2023/11/07/2775233/0/en/Capricor-Therapeutics-to-Present-Third-Quarter-2023-Financial-Results-and-Recent-Corporate-Update-on-November-14.html","Conference Calls/ Webcasts","2023-11-07 09:15:00","pre_market",3,3,436,436,-0,0,-0,"short","short",NaN
558,"CAPR","Capricor Therapeutics to Present Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Update on March 15","https://www.globenewswire.com/news-release/2023/03/08/2623124/0/en/Capricor-Therapeutics-to-Present-Fourth-Quarter-and-Full-Year-2022-Financial-Results-and-Recent-Corporate-Update-on-March-15.html","Conference Calls/ Webcasts","2023-03-08 09:00:00","pre_market",5,5,398,398,0,0,0,"long","long",NaN
559,"CAPR","Capricor Announces Peer-Reviewed Publication Demonstrating the Therapeutic Potential of Exosome-Based Multivalent Vaccine Developed from its StealthX™ Platform","https://www.globenewswire.com/news-release/2023/04/27/2656431/0/en/Capricor-Announces-Peer-Reviewed-Publication-Demonstrating-the-Therapeutic-Potential-of-Exosome-Based-Multivalent-Vaccine-Developed-from-its-StealthX-Platform.html","Product / Services Announcement","2023-04-27 09:00:00","pre_market",4,4,404,407,0,0,0,"long","long",NaN
560,"CAPR","Capricor Therapeutics Announces Late-Breaking Presentations at 28th Annual Congress of the World Muscle Society","https://www.globenewswire.com/news-release/2023/10/10/2757546/0/en/Capricor-Therapeutics-Announces-Late-Breaking-Presentations-at-28th-Annual-Congress-of-the-World-Muscle-Society.html","Health","2023-10-10 09:00:00","pre_market",3,3,432,433,-0,0,-0,"short","short",NaN
561,"CAPR","Capricor Therapeutics to Present First Quarter 2023 Financial Results and Recent Corporate Update on May 11","https://www.globenewswire.com/news-release/2023/05/04/2661614/0/en/Capricor-Therapeutics-to-Present-First-Quarter-2023-Financial-Results-and-Recent-Corporate-Update-on-May-11.html","Calendar of Events","2023-05-04 09:00:00","pre_market",4,4,408,407,-0,-0,-0,"short","short",NaN
562,"CAPR","Capricor Therapeutics to Present 24-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy","https://www.globenewswire.com/news-release/2023/06/13/2687234/0/en/Capricor-Therapeutics-to-Present-24-Month-Results-from-Ongoing-HOPE-2-Open-Label-Extension-Study-of-CAP-1002-in-Duchenne-Muscular-Dystrophy.html","Conference Calls/ Webcasts","2023-06-13 09:15:00","pre_market",5,5,434,435,0,0,0,"long","long",NaN
563,"CAPR","Capricor Therapeutics Announces Appointment of Philip J. Gotwals, Ph.D. to its Board of Directors","https://www.globenewswire.com/news-release/2023/07/24/2709506/0/en/Capricor-Therapeutics-Announces-Appointment-of-Philip-J-Gotwals-Ph-D-to-its-Board-of-Directors.html","Management Changes","2023-07-24 08:30:00","pre_market",5,5,452,453,0,0,0,"long","short",NaN
564,"CAPR","Capricor Therapeutics Receives Clinical Research Forum’s 2023 Top Ten Clinical Research Achievement Award","https://www.globenewswire.com/news-release/2023/03/02/2619446/0/en/Capricor-Therapeutics-Receives-Clinical-Research-Forum-s-2023-Top-Ten-Clinical-Research-Achievement-Award.html","Contests/Awards","2023-03-02 09:15:00","pre_market",5,5,395,393,0,-0,0,"long","long",NaN
565,"CAPR","Capricor Therapeutics Announces $23 Million Registered Direct Offering","https://www.globenewswire.com/news-release/2023/09/29/2751922/0/en/Capricor-Therapeutics-Announces-23-Million-Registered-Direct-Offering.html","Partnerships","2023-09-29 07:35:00","pre_market",6,4,429,432,-0,0,-0,"short","short",NaN
566,"CAPR","Capricor Therapeutics Announces Collaboration with the National Institutes of Health for Clinical Trial of Novel Exosome-Based Multivalent Vaccine for SARS-CoV-2","https://www.globenewswire.com/news-release/2024/01/24/2815446/0/en/Capricor-Therapeutics-Announces-Collaboration-with-the-National-Institutes-of-Health-for-Clinical-Trial-of-Novel-Exosome-Based-Multivalent-Vaccine-for-SARS-CoV-2.html","Clinical Study","2024-01-24 09:15:00","pre_market",4,4,485,488,0,0,0,"long","long",NaN
567,"CAPR","Capricor Therapeutics Announces Continuation of Phase 3 HOPE-3 Trial of CAP-1002 in Duchenne Muscular Dystrophy Based on Completion of Interim Futility Analysis","https://www.globenewswire.com/news-release/2023/12/11/2793907/0/en/Capricor-Therapeutics-Announces-Continuation-of-Phase-3-HOPE-3-Trial-of-CAP-1002-in-Duchenne-Muscular-Dystrophy-Based-on-Completion-of-Interim-Futility-Analysis.html","Product / Services Announcement","2023-12-11 09:00:00","pre_market",4,4,460,460,0,-0,0,"long","long",NaN
584,"CCCC","C4 Therapeutics Appoints Experienced Clinical Development Leaders Laura Bessen, M.D. and Donna Grogan, M.D. to Board of Directors","https://www.globenewswire.com/news-release/2022/08/02/2490309/0/en/C4-Therapeutics-Appoints-Experienced-Clinical-Development-Leaders-Laura-Bessen-M-D-and-Donna-Grogan-M-D-to-Board-of-Directors.html","Directors and Officers","2022-08-02 08:00:00","pre_market",9,9,411,409,-0,-0,-0,"short","short",NaN
585,"CCCC","C4 Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights","https://www.globenewswire.com/news-release/2023/05/04/2661295/0/en/C4-Therapeutics-Reports-First-Quarter-2023-Financial-Results-and-Recent-Business-Highlights.html","Earnings Releases and Operating Results","2023-05-04 07:00:00","pre_market",3,3,408,407,0,-0,0,"long","long",NaN
586,"CCCC","C4 Therapeutics Announces Upcoming Data Presentations for CFT8634, an Orally Bioavailable BiDAC™ Degrader in Development for Synovial Sarcoma and SMARCB1-Null Tumors, and CFT7455, an Orally Bioavailable MonoDAC™ Degrader in Development for Multiple Myeloma and Non-Hodgkin’s Lymphoma","https://www.globenewswire.com/news-release/2023/10/11/2758207/0/en/C4-Therapeutics-Announces-Upcoming-Data-Presentations-for-CFT8634-an-Orally-Bioavailable-BiDAC-Degrader-in-Development-for-Synovial-Sarcoma-and-SMARCB1-Null-Tumors-and-CFT7455-an-O.html","Health","2023-10-11 07:00:00","pre_market",2,2,435,436,0,0,0,"long","long",NaN
587,"CCCC","C4 Therapeutics to Present at Bank of America Securities Precision Oncology Conference 2022","https://www.globenewswire.com/news-release/2022/09/26/2522365/0/en/C4-Therapeutics-to-Present-at-Bank-of-America-Securities-Precision-Oncology-Conference-2022.html","Calendar of Events","2022-09-26 07:00:00","pre_market",9,9,368,366,0,-0,0,"long","long",NaN
572,"CBAY","Seladelpar Granted Revised Breakthrough Therapy Designation for the Treatment of Primary Biliary Cholangitis Including Pruritus in Patients Without Cirrhosis or With Compensated Cirrhosis","https://www.globenewswire.com/news-release/2023/10/23/2764648/37067/en/Seladelpar-Granted-Revised-Breakthrough-Therapy-Designation-for-the-Treatment-of-Primary-Biliary-Cholangitis-Including-Pruritus-in-Patients-Without-Cirrhosis-or-With-Compensated-Ci.html","Research Analysis and Reports","2023-10-23 08:00:00","pre_market",14,14,421,420,-0,-0,0,"long","long",NaN
573,"CBAY","CymaBay Names Harish Shantharam Chief Financial Officer","https://www.globenewswire.com/news-release/2023/05/09/2664385/37067/en/CymaBay-Names-Harish-Shantharam-Chief-Financial-Officer.html","Directors and Officers","2023-05-09 08:00:00","pre_market",10,10,413,411,-0,-0,-0,"short","short",NaN
574,"CBAY","CymaBay’s RESPONSE Phase 3 Data Evaluating Seladelpar for Primary Biliary Cholangitis to be Featured in an Oral Late-Breaking Presentation at The Liver Meeting® 2023","https://www.globenewswire.com/news-release/2023/10/18/2762280/37067/en/CymaBay-s-RESPONSE-Phase-3-Data-Evaluating-Seladelpar-for-Primary-Biliary-Cholangitis-to-be-Featured-in-an-Oral-Late-Breaking-Presentation-at-The-Liver-Meeting-2023.html","Clinical Study","2023-10-18 08:00:00","pre_market",14,14,436,434,-0,-0,-0,"short","short",NaN
575,"CBAY","CymaBay Therapeutics to Report First Quarter of 2023 Financial Results on Monday, May 15, 2023","https://www.globenewswire.com/news-release/2023/05/10/2665485/37067/en/CymaBay-Therapeutics-to-Report-First-Quarter-of-2023-Financial-Results-on-Monday-May-15-2023.html","Calendar of Events","2023-05-10 08:00:00","pre_market",10,10,411,414,0,0,-0,"short","long",NaN
576,"CBAY","CymaBay Therapeutics Announces Publication of Results From the ENHANCE, Phase 3 Study of Seladelpar in Patients with Primary Biliary Cholangitis (PBC)","https://www.globenewswire.com/news-release/2023/04/21/2651878/37067/en/CymaBay-Therapeutics-Announces-Publication-of-Results-From-the-ENHANCE-Phase-3-Study-of-Seladelpar-in-Patients-with-Primary-Biliary-Cholangitis-PBC.html","Research Analysis and Reports","2023-04-21 08:00:00","pre_market",10,10,412,412,0,0,0,"long","long",NaN
577,"CBAY","CymaBay Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ","https://www.globenewswire.com/news-release/2023/04/17/2647862/37067/en/CymaBay-Therapeutics-to-Present-at-the-H-C-Wainwright-BioConnect-Investor-Conference-at-NASDAQ.html","Trade Show","2023-04-17 08:00:00","pre_market",9,9,412,412,0,-0,0,"long","short",NaN
578,"CBAY","CymaBay Announces Publication of Two-year Safety and Efficacy Results of Seladelpar in Patients with Primary Biliary Cholangitis","https://www.globenewswire.com/news-release/2023/11/01/2771113/37067/en/CymaBay-Announces-Publication-of-Two-year-Safety-and-Efficacy-Results-of-Seladelpar-in-Patients-with-Primary-Biliary-Cholangitis.html","Clinical Study","2023-11-01 08:00:00","pre_market",16,16,418,419,0,0,-0,"short","short",NaN
579,"CBAY","CymaBay Therapeutics to Present at the Cantor Global Healthcare Conference","https://www.globenewswire.com/news-release/2023/09/15/2743947/37067/en/CymaBay-Therapeutics-to-Present-at-the-Cantor-Global-Healthcare-Conference.html","Conference Calls/ Webcasts","2023-09-15 08:00:00","pre_market",17,17,450,447,0,-0,0,"long","long",NaN
580,"CBAY","CymaBay Initiates AFFIRM, a Phase 3b/4 Study Evaluating the Effect of Seladelpar on Clinical Outcomes in Patients with Cirrhosis due to Primary Biliary Cholangitis","https://www.globenewswire.com/news-release/2023/09/21/2747218/37067/en/CymaBay-Initiates-AFFIRM-a-Phase-3b-4-Study-Evaluating-the-Effect-of-Seladelpar-on-Clinical-Outcomes-in-Patients-with-Cirrhosis-due-to-Primary-Biliary-Cholangitis.html","Clinical Study","2023-09-21 08:00:00","pre_market",15,14,439,436,-0,-0,-0,"short","short",NaN
581,"CBAY","CymaBay Therapeutics to Participate in Upcoming Investment Conferences","https://www.globenewswire.com/news-release/2024/01/31/2821052/37067/en/CymaBay-Therapeutics-to-Participate-in-Upcoming-Investment-Conferences.html","Conference Calls/ Webcasts","2024-01-31 08:00:00","pre_market",24,24,491,489,0,-0,0,"long","long",NaN
588,"CCCC","C4 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights","https://www.globenewswire.com/news-release/2023/11/01/2770978/0/en/C4-Therapeutics-Reports-Third-Quarter-2023-Financial-Results-and-Recent-Business-Highlights.html","Earnings Releases and Operating Results","2023-11-01 07:00:00","pre_market",1,2,418,419,0,0,0,"long","long",NaN
589,"CCCC","C4 Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights","https://www.globenewswire.com/news-release/2022/08/04/2492273/0/en/C4-Therapeutics-Reports-Second-Quarter-2022-Financial-Results-and-Recent-Business-Highlights.html","Earnings Releases and Operating Results","2022-08-04 08:00:00","pre_market",11,11,414,414,-0,-0,-0,"short","short",NaN
591,"CCCC","C4 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights","https://www.globenewswire.com/news-release/2023/02/23/2614105/0/en/C4-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2022-Financial-Results-and-Recent-Business-Highlights.html","Calendar of Events","2023-02-23 07:00:00","pre_market",6,6,399,402,-0,0,-0,"short","short",NaN
592,"CCCC","C4 Therapeutics Receives Study May Proceed Letter from U.S. FDA to Initiate Phase 1/2 Clinical Trial of CFT1946, an Orally Bioavailable BiDAC™ Degrader, in BRAF-V600 Mutant Solid Cancers","https://www.globenewswire.com/news-release/2022/09/29/2525008/0/en/C4-Therapeutics-Receives-Study-May-Proceed-Letter-from-U-S-FDA-to-Initiate-Phase-1-2-Clinical-Trial-of-CFT1946-an-Orally-Bioavailable-BiDAC-Degrader-in-BRAF-V600-Mutant-Solid-Cance.html","Regulatory information","2022-09-29 07:00:00","pre_market",9,9,371,367,-0,-0,-0,"short","short",NaN
593,"CCCC","C4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","https://www.globenewswire.com/news-release/2023/07/17/2705168/0/en/C4-Therapeutics-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html","Management statements","2023-07-17 07:00:00","pre_market",3,3,449,449,0,-0,0,"long","short",NaN
594,"CCCC","C4 Therapeutics Strengthens Board of Directors with Owen Hughes Appointment","https://www.globenewswire.com/news-release/2023/11/20/2783101/0/en/C4-Therapeutics-Strengthens-Board-of-Directors-with-Owen-Hughes-Appointment.html","Directors and Officers","2023-11-20 07:00:00","pre_market",2,2,451,451,0,-0,0,"long","long",NaN
595,"CCCC","C4 Therapeutics Announces 2023 Strategic Priorities to Advance Portfolio of Targeted Protein Degradation Medicines","https://www.globenewswire.com/news-release/2023/01/09/2585029/0/en/C4-Therapeutics-Announces-2023-Strategic-Priorities-to-Advance-Portfolio-of-Targeted-Protein-Degradation-Medicines.html","Research Analysis and Reports","2023-01-09 07:00:00","pre_market",7,7,388,390,0,0,0,"long","long",NaN
596,"CCCC","C4 Therapeutics to Host Webcast to Present New Dose Escalation Data from CFT7455 Phase 1 Study in Relapsed/Refractory Multiple Myeloma","https://www.globenewswire.com/news-release/2023/11/28/2786797/0/en/C4-Therapeutics-to-Host-Webcast-to-Present-New-Dose-Escalation-Data-from-CFT7455-Phase-1-Study-in-Relapsed-Refractory-Multiple-Myeloma.html","Clinical Study","2023-11-28 07:00:00","pre_market",2,2,454,454,0,-0,0,"long","long",NaN
597,"CCCC","C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT1946, an Orally Bioavailable BiDAC™ Degrader, in BRAF V600 Mutant Solid Tumors","https://www.globenewswire.com/news-release/2023/01/30/2597422/0/en/C4-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1-2-Clinical-Trial-Evaluating-CFT1946-an-Orally-Bioavailable-BiDAC-Degrader-in-BRAF-V600-Mutant-Solid-Tumors.html","Clinical Study","2023-01-30 07:00:00","pre_market",8,8,406,403,-0,-0,-0,"short","short",NaN
598,"CCCC","C4 Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights","https://www.globenewswire.com/news-release/2022/11/03/2547375/0/en/C4-Therapeutics-Reports-Third-Quarter-2022-Financial-Results-and-Recent-Business-Highlights.html","Earnings Releases and Operating Results","2022-11-03 07:00:00","pre_market",10,9,375,371,-0,-0,-0,"short","long",NaN
599,"CCCC","C4 Therapeutics to Present at Two Virtual February 2023 Conferences","https://www.globenewswire.com/news-release/2023/02/08/2603789/0/en/C4-Therapeutics-to-Present-at-Two-Virtual-February-2023-Conferences.html","Calendar of Events","2023-02-08 07:00:00","pre_market",6,6,415,413,0,-0,0,"long","long",NaN
600,"CCCC","C4 Therapeutics Announces License and Research Collaboration with Merck to Discover and Develop Degrader-Antibody Conjugates (DACs)","https://www.globenewswire.com/news-release/2023/12/12/2794588/0/en/C4-Therapeutics-Announces-License-and-Research-Collaboration-with-Merck-to-Discover-and-Develop-Degrader-Antibody-Conjugates-DACs.html","Product / Services Announcement","2023-12-12 07:00:00","pre_market",1,2,462,462,1,-0,1,"long","long",NaN
601,"CCCC","C4 Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference","https://www.globenewswire.com/news-release/2024/01/04/2803847/0/en/C4-Therapeutics-to-Present-at-the-42nd-Annual-J-P-Morgan-Healthcare-Conference.html","Conference Calls/ Webcasts","2024-01-04 07:00:00","pre_market",6,6,469,468,0,-0,0,"long","short",NaN
610,"CDTX","Cidara Therapeutics Receives U.S. FDA Fast Track Designation for CD388, a Novel Drug-Fc Conjugate Targeting Influenza A and B","https://www.globenewswire.com/news-release/2023/06/22/2692856/0/en/Cidara-Therapeutics-Receives-U-S-FDA-Fast-Track-Designation-for-CD388-a-Novel-Drug-Fc-Conjugate-Targeting-Influenza-A-and-B.html","Product / Services Announcement","2023-06-22 08:00:00","pre_market",1,1,435,434,0,-0,0,"long","long",NaN
611,"CDTX","Cidara Therapeutics to Present New Data on Novel drug-Fc conjugate CD388 at IDWeek 2023","https://www.globenewswire.com/news-release/2023/09/27/2750330/0/en/Cidara-Therapeutics-to-Present-New-Data-on-Novel-drug-Fc-conjugate-CD388-at-IDWeek-2023.html","Calendar of Events","2023-09-27 08:00:00","pre_market",1,1,426,427,-0,0,-0,"short","short",NaN
612,"CDTX","Cidara Therapeutics and Mundipharma receive positive CHMP opinion for rezafungin for the treatment of Invasive Candidiasis in adults(1)","https://www.globenewswire.com/news-release/2023/10/13/2760048/0/en/Cidara-Therapeutics-and-Mundipharma-receive-positive-CHMP-opinion-for-rezafungin-for-the-treatment-of-Invasive-Candidiasis-in-adults-1.html","Product / Services Announcement","2023-10-13 10:34:00","market_open",1,1,435,432,0,-0,0,"long","long",NaN
613,"CDTX","Cidara Therapeutics to Present New Preclinical Data on Novel Dual-Acting Drug-Fc Conjugates at ESMO Immuno-Oncology Annual Congress","https://www.globenewswire.com/news-release/2023/11/30/2788520/0/en/Cidara-Therapeutics-to-Present-New-Preclinical-Data-on-Novel-Dual-Acting-Drug-Fc-Conjugates-at-ESMO-Immuno-Oncology-Annual-Congress.html","Product / Services Announcement","2023-11-30 08:00:00","pre_market",1,1,455,455,0,0,0,"long","long",NaN
614,"CDTX","Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results","https://www.globenewswire.com/news-release/2023/03/23/2633001/0/en/Cidara-Therapeutics-Provides-Corporate-Update-and-Reports-Fourth-Quarter-and-Full-Year-2022-Financial-Results.html","Earnings Releases and Operating Results","2023-03-23 07:12:00","pre_market",2,2,392,395,-0,0,-0,"short","long",NaN
615,"CDTX","Cidara Therapeutics to Present Ongoing Development of Drug-Fc Conjugates (DFC) Including CD73-Targeting DFC From Its Cloudbreak® Platform at Adenosine-Pathway Targeted Cancer Immunotherapy Summit","https://www.globenewswire.com/news-release/2023/06/20/2691268/0/en/Cidara-Therapeutics-to-Present-Ongoing-Development-of-Drug-Fc-Conjugates-DFC-Including-CD73-Targeting-DFC-From-Its-Cloudbreak-Platform-at-Adenosine-Pathway-Targeted-Cancer-Immunoth.html","Clinical Study","2023-06-20 09:55:00","market_open",1,1,437,437,0,-0,0,"long","long",NaN
616,"CDTX","Cidara Therapeutics Named as a San Diego Metro Area Top Workplace","https://www.globenewswire.com/news-release/2023/11/20/2783213/0/en/Cidara-Therapeutics-Named-as-a-San-Diego-Metro-Area-Top-Workplace.html","Contests/Awards","2023-11-20 08:00:00","pre_market",1,1,451,451,-0,-0,-0,"short","short",NaN
617,"CDTX","Cidara Therapeutics to Present at Adenosine Pathway Targeted Cancer Immunotherapy Summit","https://www.globenewswire.com/news-release/2023/06/13/2687061/0/en/Cidara-Therapeutics-to-Present-at-Adenosine-Pathway-Targeted-Cancer-Immunotherapy-Summit.html","Health","2023-06-13 08:00:00","pre_market",1,1,434,435,-0,0,-0,"short","short",NaN
618,"CDTX","Cidara Therapeutics Announces Janssen’s Election to Proceed Under its License Agreement Relating to Novel Drug-Fc Conjugates Targeting Influenza","https://www.globenewswire.com/news-release/2023/09/06/2738348/0/en/Cidara-Therapeutics-Announces-Janssen-s-Election-to-Proceed-Under-its-License-Agreement-Relating-to-Novel-Drug-Fc-Conjugates-Targeting-Influenza.html","Business Contracts","2023-09-06 08:00:00","pre_market",1,1,449,448,0,-0,0,"long","long",NaN
619,"CDTX","Cidara Therapeutics to Host Virtual Research & Development Day on its Cloudbreak® Development Pipeline on September 21, 2023","https://www.globenewswire.com/news-release/2023/09/07/2739260/0/en/Cidara-Therapeutics-to-Host-Virtual-Research-Development-Day-on-its-Cloudbreak-Development-Pipeline-on-September-21-2023.html","Calendar of Events","2023-09-07 08:00:00","pre_market",1,1,446,443,-0,-0,-0,"short","short",NaN
620,"CDTX","Cidara Therapeutics Presents New Preclinical and Clinical Data on Novel Drug-Fc Conjugate CD388 at IDWeek 2023","https://www.globenewswire.com/news-release/2023/10/11/2758360/0/en/Cidara-Therapeutics-Presents-New-Preclinical-and-Clinical-Data-on-Novel-Drug-Fc-Conjugate-CD388-at-IDWeek-2023.html","Health","2023-10-11 08:30:00","pre_market",1,1,435,436,0,0,0,"long","long",NaN
605,"CDMO","Avid Bioservices Unveils Completed Mammalian Cell Facilities Expansion Providing Significantly Increased Capacity for Existing and Future Customers","https://www.globenewswire.com/news-release/2023/04/04/2640637/0/en/Avid-Bioservices-Unveils-Completed-Mammalian-Cell-Facilities-Expansion-Providing-Significantly-Increased-Capacity-for-Existing-and-Future-Customers.html","Health","2023-04-04 08:05:00","pre_market",19,19,411,412,0,0,0,"long","long",NaN
621,"CDTX","Cidara Therapeutics Receives $20 Million Milestone Payment Following FDA Approval of REZZAYO™","https://www.globenewswire.com/news-release/2023/04/24/2652645/0/en/Cidara-Therapeutics-Receives-20-Million-Milestone-Payment-Following-FDA-Approval-of-REZZAYO.html","Product / Services Announcement","2023-04-24 08:00:00","pre_market",1,1,412,412,0,-0,0,"long","long",NaN
606,"CDMO","Avid Bioservices Partners With California Institute for Regenerative Medicine (CIRM) to Provide CDMO Services for Cell and Gene Therapy (CGT) Programs","https://www.globenewswire.com/news-release/2023/11/08/2776212/0/en/Avid-Bioservices-Partners-With-California-Institute-for-Regenerative-Medicine-CIRM-to-Provide-CDMO-Services-for-Cell-and-Gene-Therapy-CGT-Programs.html","Product / Services Announcement","2023-11-08 08:05:00","pre_market",6,6,437,438,0,0,0,"long","long",NaN
607,"CDMO","Avid Bioservices Appoints Oksana Lukash as Vice President, People","https://www.globenewswire.com/news-release/2022/11/16/2557167/0/en/Avid-Bioservices-Appoints-Oksana-Lukash-as-Vice-President-People.html","Management statements","2022-11-16 08:05:00","pre_market",16,15,398,397,-0,-0,-0,"short","short",NaN
629,"CELU","Celularity Inc. Announces $6 Million Registered Direct Offering","https://www.globenewswire.com/news-release/2023/04/05/2641778/0/en/Celularity-Inc-Announces-6-Million-Registered-Direct-Offering.html","Financing Agreements","2023-04-05 09:00:00","pre_market",1,1,409,408,-0,-0,-0,"short","short",NaN
630,"CELU","Celularity Announces Commercial Biomaterial Products Receive Saudi Food and Drug Authority (SFDA) Product Classification","https://www.globenewswire.com/news-release/2023/10/18/2762428/0/en/Celularity-Announces-Commercial-Biomaterial-Products-Receive-Saudi-Food-and-Drug-Authority-SFDA-Product-Classification.html","Regulatory information","2023-10-18 09:00:00","pre_market",0,0,436,434,-0,-0,0,"long","long",NaN
631,"CELU","Celularity Receives U.S. Food And Drug Administration (FDA) Preliminary Assessment For Celularity’s Investigational Fuse Bone Void Filler To Be Regulated As A Device By FDA’s Center For Devices And Radiological Health","https://www.globenewswire.com/news-release/2023/04/03/2639651/0/en/Celularity-Receives-U-S-Food-And-Drug-Administration-FDA-Preliminary-Assessment-For-Celularity-s-Investigational-Fuse-Bone-Void-Filler-To-Be-Regulated-As-A-Device-By-FDA-s-Center-F.html","Product / Services Announcement","2023-04-03 09:00:00","pre_market",1,1,409,409,0,-0,0,"long","long",NaN
632,"CELU","Celularity’s Dr. Robert Hariri To Co-Chair The 2023 International Precision Medicine Center (IPMC) Conference “Beyond Longevity: Live 120 Like 50™”","https://www.globenewswire.com/news-release/2023/04/12/2645388/0/en/Celularity-s-Dr-Robert-Hariri-To-Co-Chair-The-2023-International-Precision-Medicine-Center-IPMC-Conference-Beyond-Longevity-Live-120-Like-50.html","Calendar of Events","2023-04-12 09:00:00","pre_market",1,1,410,412,0,0,0,"long","long",NaN
633,"CELU","Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing","https://www.globenewswire.com/news-release/2023/11/24/2785689/0/en/Celularity-Inc-Announces-Receipt-of-Nasdaq-Notice-Regarding-Late-Form-10-Q-Filing.html","Exchange Members","2023-11-24 13:15:00","market_open",0,0,455,455,0,0,0,"long","short",NaN
634,"CELU","Celularity Announces Clinical Data on  Human Placental-Derived Unmodified Allogeneic Natural Killer Cell Therapy Candidate Cynk-001 in Adult Patients With Relapsed Refractory and Measurable Residual Disease-Positive Acute Myeloid Leukemia","https://www.globenewswire.com/news-release/2023/04/27/2656412/0/en/Celularity-Announces-Clinical-Data-on-Human-Placental-Derived-Unmodified-Allogeneic-Natural-Killer-Cell-Therapy-Candidate-Cynk-001-in-Adult-Patients-With-Relapsed-Refractory-and-Me.html","Clinical Study","2023-04-27 09:00:00","pre_market",1,1,404,407,0,0,0,"long","long",NaN
635,"CELU","Celularity and Verséa Ophthalmics Announce Exclusive U.S. Commercialization Agreement to Distribute Biovance® and Biovance® 3l Ocular For Ophthalmic Applications","https://www.globenewswire.com/news-release/2023/07/27/2712254/0/en/Celularity-and-Vers%C3%A9a-Ophthalmics-Announce-Exclusive-U-S-Commercialization-Agreement-to-Distribute-Biovance-and-Biovance-3l-Ocular-For-Ophthalmic-Applications.html","Product / Services Announcement","2023-07-27 09:00:00","pre_market",0,0,456,459,-0,0,-0,"short","short",NaN
636,"CELU","Celularity Announces Acceptance of Poster Presentation at 2023 Society for Biomaterials Annual Meeting","https://www.globenewswire.com/news-release/2023/04/04/2640787/0/en/Celularity-Announces-Acceptance-of-Poster-Presentation-at-2023-Society-for-Biomaterials-Annual-Meeting.html","Calendar of Events","2023-04-04 09:00:00","pre_market",1,1,411,412,0,0,0,"long","long",NaN
637,"CELU","Celularity Inc. Announces $3 Million Registered Direct Offering","https://www.globenewswire.com/news-release/2023/07/27/2712276/0/en/Celularity-Inc-Announces-3-Million-Registered-Direct-Offering.html","Stock Market News","2023-07-27 09:07:00","pre_market",0,0,456,459,-0,0,-0,"short","short",NaN
622,"CDTX","Cidara Therapeutics Announces Appointment of Nicole Davarpanah, M.D., J.D., as Senior Vice President of Translational Research & Development","https://www.globenewswire.com/news-release/2023/08/16/2726300/0/en/Cidara-Therapeutics-Announces-Appointment-of-Nicole-Davarpanah-M-D-J-D-as-Senior-Vice-President-of-Translational-Research-Development.html","Company Announcement","2023-08-16 08:00:00","pre_market",1,1,443,442,-0,-0,-0,"short","short",NaN
623,"CDTX","Cidara Therapeutics Presents New Promising Preclincal Data on Novel Dual-Acting Drug-Fc Conjugates at ESMO Immuno-Oncology Annual Congress","https://www.globenewswire.com/news-release/2023/12/07/2792476/0/en/Cidara-Therapeutics-Presents-New-Promising-Preclincal-Data-on-Novel-Dual-Acting-Drug-Fc-Conjugates-at-ESMO-Immuno-Oncology-Annual-Congress.html","Clinical Study","2023-12-07 08:00:00","pre_market",1,1,455,457,0,0,0,"long","long",NaN
624,"CDTX","Cidara Therapeutics to Participate in Upcoming Investor Conferences","https://www.globenewswire.com/news-release/2023/03/31/2638585/0/en/Cidara-Therapeutics-to-Participate-in-Upcoming-Investor-Conferences.html","Calendar of Events","2023-03-31 08:00:00","pre_market",1,1,404,405,-0,0,-0,"short","short",NaN
625,"CDTX","Cidara Therapeutics Announces Completion of Enrollment in Phase 3 Restore Trial of Rezafungin in China","https://www.globenewswire.com/news-release/2023/12/06/2791705/0/en/Cidara-Therapeutics-Announces-Completion-of-Enrollment-in-Phase-3-Restore-Trial-of-Rezafungin-in-China.html","Product / Services Announcement","2023-12-06 08:00:00","pre_market",1,1,457,459,-0,0,-0,"short","short",NaN
626,"CDTX","Cidara Therapeutics Receives $11.14 Million Milestone Payment Following European Approval of REZZAYO","https://www.globenewswire.com/news-release/2024/02/12/2827490/0/en/Cidara-Therapeutics-Receives-11-14-Million-Milestone-Payment-Following-European-Approval-of-REZZAYO.html","Health","2024-02-12 08:00:00","pre_market",1,1,501,501,0,-0,0,"long","long",NaN
627,"CDTX","Cidara Therapeutics Announces European Approval of REZZAYO® (rezafungin) for the Treatment of Invasive Candidiasis in Adults","https://www.globenewswire.com/news-release/2023/12/22/2800553/0/en/Cidara-Therapeutics-Announces-European-Approval-of-REZZAYO-rezafungin-for-the-Treatment-of-Invasive-Candidiasis-in-Adults.html","Clinical Study","2023-12-22 07:30:00","pre_market",1,1,473,474,0,0,0,"long","long",NaN
650,"CERT","Certara Announces 300th Regulatory Submission Milestone Using its Technology-enabled Services and Software","https://www.globenewswire.com/news-release/2023/09/19/2745582/0/en/Certara-Announces-300th-Regulatory-Submission-Milestone-Using-its-Technology-enabled-Services-and-Software.html","Management statements","2023-09-19 08:15:00","pre_market",14,14,444,443,0,-0,0,"long","long",NaN
652,"CERT","Arsenal Capital Partners Increases Investment in Global Biosimulation Leader Certara with $449M Stock Purchase","https://www.globenewswire.com/news-release/2022/11/07/2549670/0/en/Arsenal-Capital-Partners-Increases-Investment-in-Global-Biosimulation-Leader-Certara-with-449M-Stock-Purchase.html","Changes in company's own shares","2022-11-07 08:00:00","pre_market",11,12,376,378,0,0,0,"long","long",NaN
653,"CERT","Certara Customers Received 90 Percent of US FDA Novel Drug Approvals for 9th Consecutive Year","https://www.globenewswire.com/news-release/2023/04/27/2656261/0/en/Certara-Customers-Received-90-Percent-of-US-FDA-Novel-Drug-Approvals-for-9th-Consecutive-Year.html","Health","2023-04-27 08:00:00","pre_market",24,24,404,407,0,0,0,"long","long",NaN
638,"CELU","Celularity Human Placental-Derived  Advanced Biomaterials Demonstrate Superior Biocompatibility and Better Support Differentiated Cell Functions in Studies","https://www.globenewswire.com/news-release/2023/07/18/2706479/0/en/Celularity-Human-Placental-Derived-Advanced-Biomaterials-Demonstrate-Superior-Biocompatibility-and-Better-Support-Differentiated-Cell-Functions-in-Studies.html","Clinical Study","2023-07-18 09:00:00","pre_market",0,0,451,450,0,-0,0,"long","long",NaN
639,"CELU","Celularity Announces Multi-Year Research Collaboration Services Agreement With Regeneron","https://www.globenewswire.com/news-release/2023/08/29/2733451/0/en/Celularity-Announces-Multi-Year-Research-Collaboration-Services-Agreement-With-Regeneron.html","Calendar of Events","2023-08-29 09:00:00","pre_market",0,0,443,443,0,-0,0,"long","long",NaN
640,"CELU","Celularity Announces Advisory Guidance From Tamer Group Regarding Anticipated 2023 Purchase Orders for Celularity Branded Halal-Certified Biomaterial Products","https://www.globenewswire.com/news-release/2023/05/10/2665590/0/en/Celularity-Announces-Advisory-Guidance-From-Tamer-Group-Regarding-Anticipated-2023-Purchase-Orders-for-Celularity-Branded-Halal-Certified-Biomaterial-Products.html","Management statements","2023-05-10 09:00:00","pre_market",0,0,411,414,0,0,0,"long","long",NaN
641,"CELU","Celularity Announces Agreement with AD Ports Group for Exclusive Product Distribution in Various Territories in the Gulf Cooperation Council Regions and Egypt","https://www.globenewswire.com/news-release/2023/03/28/2635736/0/en/Celularity-Announces-Agreement-with-AD-Ports-Group-for-Exclusive-Product-Distribution-in-Various-Territories-in-the-Gulf-Cooperation-Council-Regions-and-Egypt.html","Partnerships","2023-03-28 09:00:00","pre_market",1,1,396,396,0,-0,0,"long","long",NaN
642,"CELU","Correcting & Replacing -- Celularity Receives Preliminary Assessment of Product Classification and Jurisdiction for Its Investigational Celularity Tendon Wrap (CTW) to be Regulated  as a Device Within U.S. Food and Drug Administration (FDA) Center for Devices and Radiological Health (CDRH)","https://www.globenewswire.com/news-release/2023/02/02/2600378/0/en/Correcting-Replacing-Celularity-Receives-Preliminary-Assessment-of-Product-Classification-and-Jurisdiction-for-Its-Investigational-Celularity-Tendon-Wrap-CTW-to-be-Regulated-as-a-D.html","Licensing Agreements","2023-02-02 07:53:00","pre_market",1,1,411,415,-0,0,-0,"short","short",NaN
643,"CELU","Celularity Tissue Factor Gene Knockout of Allogeneic Stromal Cells Significantly Lowers Thrombotic Effects; Study Highlights Critical Importance of Gene Editing Capability","https://www.globenewswire.com/news-release/2023/06/01/2680450/0/en/Celularity-Tissue-Factor-Gene-Knockout-of-Allogeneic-Stromal-Cells-Significantly-Lowers-Thrombotic-Effects-Study-Highlights-Critical-Importance-of-Gene-Editing-Capability.html","Clinical Study","2023-06-01 09:15:00","pre_market",1,1,418,418,0,0,0,"long","long",NaN
644,"CELU","Celularity Announces Net Sales Expectations for First Quarter 2024 and Full Year 2024, Reiterates Advanced Biomaterial Product Commercial and Development Pipeline","https://www.globenewswire.com/news-release/2024/02/01/2822062/0/en/Celularity-Announces-Net-Sales-Expectations-for-First-Quarter-2024-and-Full-Year-2024-Reiterates-Advanced-Biomaterial-Product-Commercial-and-Development-Pipeline.html","Health","2024-02-01 09:00:00","pre_market",0,0,483,485,0,0,0,"long","long",NaN
645,"CELU","Celularity Releases CEO Letter to Shareholders","https://www.globenewswire.com/news-release/2024/01/18/2811877/0/en/Celularity-Releases-CEO-Letter-to-Shareholders.html","Major shareholder announcements","2024-01-18 13:40:00","market_open",0,0,474,476,0,0,0,"long","long",NaN
646,"CELU","Celularity Announces Net Sales and Total Revenue Expectations for Fourth Quarter 2023 and Full Year 2023","https://www.globenewswire.com/news-release/2024/01/03/2803517/0/en/Celularity-Announces-Net-Sales-and-Total-Revenue-Expectations-for-Fourth-Quarter-2023-and-Full-Year-2023.html","Pre-Release Comments","2024-01-03 12:00:00","market_open",0,0,470,469,0,-0,0,"long","long",NaN
647,"CELU","Celularity and Genting Leaders Comments on Closing $21 Million Financing Transactions","https://www.globenewswire.com/news-release/2024/01/25/2816813/0/en/Celularity-and-Genting-Leaders-Comments-on-Closing-21-Million-Financing-Transactions.html","Financing Agreements","2024-01-25 09:00:00","pre_market",0,0,485,488,-0,0,-0,"short","short",NaN
648,"CELU","Celularity Confirms Commercialization Agreement with BioCellgraft for the Manufacture and Distribution of Advanced Biomaterial Products for Use in Oral Healthcare","https://www.globenewswire.com/news-release/2024/01/04/2804245/0/en/Celularity-Confirms-Commercialization-Agreement-with-BioCellgraft-for-the-Manufacture-and-Distribution-of-Advanced-Biomaterial-Products-for-Use-in-Oral-Healthcare.html","Partnerships","2024-01-04 13:00:00","market_open",0,0,468,467,-0,-0,-0,"short","short",NaN
657,"CHRS","Coherus and Superior Biologics Announce National Distribution Agreement for YUSIMRY™","https://www.globenewswire.com/news-release/2023/07/13/2704318/33333/en/Coherus-and-Superior-Biologics-Announce-National-Distribution-Agreement-for-YUSIMRY.html","Product / Services Announcement","2023-07-13 08:30:00","pre_market",4,5,446,448,0,0,0,"long","long",NaN
659,"CHRS","Coherus and Junshi Biosciences Announce FDA Approval of LOQTORZI™ (toripalimab-tpzi) in All Lines of Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)","https://www.globenewswire.com/news-release/2023/10/27/2768663/33333/en/Coherus-and-Junshi-Biosciences-Announce-FDA-Approval-of-LOQTORZI-toripalimab-tpzi-in-All-Lines-of-Treatment-for-Recurrent-or-Metastatic-Nasopharyngeal-Carcinoma-NPC.html","Clinical Study","2023-10-27 15:07:00","market_open",3,3,414,411,-0,-0,-0,"short","long",NaN
660,"CHRS","Coherus Completes Surface Oncology Acquisition","https://www.globenewswire.com/news-release/2023/09/08/2740124/33333/en/Coherus-Completes-Surface-Oncology-Acquisition.html","Mergers and Acquisitions","2023-09-08 09:05:00","pre_market",5,5,445,445,0,0,0,"long","long",NaN
661,"CHRS","Coherus to Acquire Surface Oncology","https://www.globenewswire.com/news-release/2023/06/16/2689648/33333/en/Coherus-to-Acquire-Surface-Oncology.html","Mergers and Acquisitions","2023-06-16 07:01:00","pre_market",5,5,443,443,-0,0,-0,"short","short",NaN
662,"CHRS","CIMERLI® (ranibizumab-eqrn) Sales Exceed 100,000 Doses in First Year of Launch","https://www.globenewswire.com/news-release/2023/10/04/2754586/33333/en/CIMERLI-ranibizumab-eqrn-Sales-Exceed-100-000-Doses-in-First-Year-of-Launch.html","Product / Services Announcement","2023-10-04 08:30:00","pre_market",3,3,422,422,0,0,0,"long","long",NaN
663,"CHRS","Coherus Announces Three Presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)","https://www.globenewswire.com/news-release/2023/09/27/2750480/33333/en/Coherus-Announces-Three-Presentations-at-the-38th-Annual-Meeting-of-the-Society-for-Immunotherapy-of-Cancer-SITC.html","Health","2023-09-27 09:10:00","pre_market",4,4,426,427,0,0,0,"long","long",NaN
654,"CERT","Certara Acquires Vyasa, an Artificial Intelligence Company that Delivers Predictions to Accelerate Scientific Innovation","https://www.globenewswire.com/news-release/2023/01/04/2582816/0/en/Certara-Acquires-Vyasa-an-Artificial-Intelligence-Company-that-Delivers-Predictions-to-Accelerate-Scientific-Innovation.html","Mergers and Acquisitions","2023-01-04 07:31:00","pre_market",16,17,381,383,0,0,0,"long","long",NaN
664,"CHRS","Coherus Applauds Congressional Designation of September 30th as Rare Cancer Day","https://www.globenewswire.com/news-release/2023/10/02/2752800/33333/en/Coherus-Applauds-Congressional-Designation-of-September-30th-as-Rare-Cancer-Day.html","Health","2023-10-02 09:00:00","pre_market",4,4,427,427,0,-0,0,"long","long",NaN
665,"CHRS","Mark Cuban Cost Plus Drug Company joins forces with Coherus to make YUSIMRY™, a HUMIRA® biosimilar, available to patients","https://www.globenewswire.com/news-release/2023/06/01/2680351/33333/en/Mark-Cuban-Cost-Plus-Drug-Company-joins-forces-with-Coherus-to-make-YUSIMRY-a-HUMIRA-biosimilar-available-to-patients.html","Product / Services Announcement","2023-06-01 08:33:00","pre_market",4,4,418,418,0,0,0,"long","long",NaN
655,"CERT","Certara Simcyp™ Group Awarded Two New Grants from US FDA","https://www.globenewswire.com/news-release/2023/08/29/2733376/0/en/Certara-Simcyp-Group-Awarded-Two-New-Grants-from-US-FDA.html","Health","2023-08-29 08:15:00","pre_market",16,16,443,443,-0,-0,-0,"short","short",NaN
666,"CHRS","Coherus Announces Resubmission of Biologics License Application (BLA) Supplement for UDENYCA® ONBODY™","https://www.globenewswire.com/news-release/2023/10/05/2755393/33333/en/Coherus-Announces-Resubmission-of-Biologics-License-Application-BLA-Supplement-for-UDENYCA-ONBODY.html","Product / Services Announcement","2023-10-05 08:30:00","pre_market",3,3,425,424,0,-0,0,"long","long",NaN
667,"CHRS","Coherus Presents Data from Next-generation Immuno-oncology Programs at 38th Annual Meeting of Society for Immunotherapy of Cancer (SITC)","https://www.globenewswire.com/news-release/2023/11/03/2773176/33333/en/Coherus-Presents-Data-from-Next-generation-Immuno-oncology-Programs-at-38th-Annual-Meeting-of-Society-for-Immunotherapy-of-Cancer-SITC.html","Health","2023-11-03 08:30:00","pre_market",3,3,431,433,0,0,0,"long","long",NaN
668,"CHRS","Coherus and Junshi Biosciences Announce Publication of Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Trial Evaluating LOQTORZI™ (toripalimab-tpzi) as Treatment for Nasopharyngeal Carcinoma, in the Journal of the American Medical Association","https://www.globenewswire.com/news-release/2023/11/28/2787206/33333/en/Coherus-and-Junshi-Biosciences-Announce-Publication-of-Positive-Final-Overall-Survival-Results-of-JUPITER-02-a-Phase-3-Trial-Evaluating-LOQTORZI-toripalimab-tpzi-as-Treatment-for-N.html","Clinical Study","2023-11-28 11:16:00","market_open",2,2,454,455,0,0,0,"long","long",NaN
669,"CHRS","Coherus Amends Term Loan Agreement with Pharmakon Advisors, LP","https://www.globenewswire.com/news-release/2024/02/05/2823475/33333/en/Coherus-Amends-Term-Loan-Agreement-with-Pharmakon-Advisors-LP.html","Financing Agreements","2024-02-05 08:00:00","pre_market",2,2,494,494,-0,-0,-0,"short","short",NaN
670,"CHRS","Coherus Presents Phase 1/2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2023 ESMO Immuno-Oncology Congress","https://www.globenewswire.com/news-release/2023/12/06/2791515/33333/en/Coherus-Presents-Phase-1-2-Clinical-Data-on-Casdozokitug-a-First-in-Class-IL-27-Targeted-Antibody-at-the-2023-ESMO-Immuno-Oncology-Congress.html","Clinical Study","2023-12-06 04:00:00","pre_market",2,2,457,459,0,0,-0,"short","short",NaN
675,"CKPT","Checkpoint Therapeutics to Participate in the Cantor Global Healthcare Conference","https://www.globenewswire.com/news-release/2023/09/21/2747284/36989/en/Checkpoint-Therapeutics-to-Participate-in-the-Cantor-Global-Healthcare-Conference.html","Conference Calls/ Webcasts","2023-09-21 08:30:00","pre_market",2,2,439,436,-0,-0,-0,"short","short",NaN
739,"CRSP","CRISPR Therapeutics Announces Departure of Board Member","https://www.globenewswire.com/news-release/2023/03/29/2636608/0/en/CRISPR-Therapeutics-Announces-Departure-of-Board-Member.html","Directors and Officers","2023-03-29 08:00:00","pre_market",44,44,396,400,0,0,0,"long","long",NaN
676,"CKPT","Checkpoint Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference","https://www.globenewswire.com/news-release/2023/09/06/2738401/36989/en/Checkpoint-Therapeutics-to-Present-at-H-C-Wainwright-25th-Annual-Global-Investment-Conference.html","Calendar of Events","2023-09-06 08:30:00","pre_market",2,2,449,448,-0,-0,-0,"short","short",NaN
677,"CKPT","Checkpoint Therapeutics Announces $7.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules","https://www.globenewswire.com/news-release/2022/12/15/2574533/36989/en/Checkpoint-Therapeutics-Announces-7-5-Million-Registered-Direct-Offering-Priced-At-the-Market-Under-Nasdaq-Rules.html","Stock Market News","2022-12-15 08:00:00","pre_market",5,4,399,394,-0,-0,-0,"short","short",NaN
678,"CKPT","Checkpoint Therapeutics Announces Publication of Cosibelimab Pivotal Trial Results in the Journal for ImmunoTherapy of Cancer","https://www.globenewswire.com/news-release/2023/10/18/2762378/36989/en/Checkpoint-Therapeutics-Announces-Publication-of-Cosibelimab-Pivotal-Trial-Results-in-the-Journal-for-ImmunoTherapy-of-Cancer.html","Clinical Study","2023-10-18 08:30:00","pre_market",2,2,436,434,0,-0,0,"long","long",NaN
679,"CKPT","Checkpoint Therapeutics Announces $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules","https://www.globenewswire.com/news-release/2023/05/23/2674331/36989/en/Checkpoint-Therapeutics-Announces-10-Million-Registered-Direct-Offering-Priced-At-the-Market-Under-Nasdaq-Rules.html","Stock Market News","2023-05-23 08:30:00","pre_market",3,3,419,417,-0,-0,-0,"short","short",NaN
681,"CKPT","Checkpoint Therapeutics to Participate in Two Upcoming Investor Conferences","https://www.globenewswire.com/news-release/2022/09/22/2521006/36989/en/Checkpoint-Therapeutics-to-Participate-in-Two-Upcoming-Investor-Conferences.html","Calendar of Events","2022-09-22 08:30:00","pre_market",11,11,377,377,0,-0,0,"long","long",NaN
682,"CKPT","Checkpoint Therapeutics Submits Biologics License Application to FDA for Cosibelimab as a Treatment for Patients with Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma","https://www.globenewswire.com/news-release/2023/01/04/2582863/36989/en/Checkpoint-Therapeutics-Submits-Biologics-License-Application-to-FDA-for-Cosibelimab-as-a-Treatment-for-Patients-with-Metastatic-or-Locally-Advanced-Cutaneous-Squamous-Cell-Carcino.html","Company Announcement","2023-01-04 08:00:00","pre_market",6,6,381,383,0,0,0,"long","long",NaN
683,"CKPT","Checkpoint Therapeutics Announces FDA Filing Acceptance of Biologics License Application for Cosibelimab in Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma","https://www.globenewswire.com/news-release/2023/03/02/2619118/36989/en/Checkpoint-Therapeutics-Announces-FDA-Filing-Acceptance-of-Biologics-License-Application-for-Cosibelimab-in-Metastatic-or-Locally-Advanced-Cutaneous-Squamous-Cell-Carcinoma.html","Health","2023-03-02 07:00:00","pre_market",5,5,395,393,0,-0,0,"long","long",NaN
684,"CKPT","Checkpoint Therapeutics Announces Exercise of Warrants for $11.13 Million in Gross Proceeds","https://www.globenewswire.com/news-release/2023/10/02/2753067/36989/en/Checkpoint-Therapeutics-Announces-Exercise-of-Warrants-for-11-13-Million-in-Gross-Proceeds.html","Financing Agreements","2023-10-02 12:53:00","market_open",2,2,427,427,-0,0,-0,"short","short",NaN
685,"CKPT","Checkpoint Therapeutics Announces Presentation of New Cosibelimab Pharmacokinetic Data Supporting Extended-Interval Dosing","https://www.globenewswire.com/news-release/2023/06/28/2696124/36989/en/Checkpoint-Therapeutics-Announces-Presentation-of-New-Cosibelimab-Pharmacokinetic-Data-Supporting-Extended-Interval-Dosing.html","Clinical Study","2023-06-28 08:00:00","pre_market",2,2,436,435,0,-0,0,"long","long",NaN
686,"CKPT","Checkpoint Therapeutics to Participate in the B. Riley Securities 4th Annual Oncology Conference","https://www.globenewswire.com/news-release/2024/01/11/2807906/36989/en/Checkpoint-Therapeutics-to-Participate-in-the-B-Riley-Securities-4th-Annual-Oncology-Conference.html","Health","2024-01-11 08:15:00","pre_market",2,2,477,478,0,0,0,"long","long",NaN
671,"CHRS","Coherus Announces Updated NCCN Clinical Practice Guidelines Positioning LOQTORZI™ (toripalimab-tpzi) as Preferred Category 1 Regimen for First-Line Treatment of Cancer of the Nasopharynx","https://www.globenewswire.com/news-release/2023/12/11/2793856/33333/en/Coherus-Announces-Updated-NCCN-Clinical-Practice-Guidelines-Positioning-LOQTORZI-toripalimab-tpzi-as-Preferred-Category-1-Regimen-for-First-Line-Treatment-of-Cancer-of-the-Nasophar.html","Clinical Study","2023-12-11 08:30:00","pre_market",2,2,460,460,0,-0,0,"long","long",NaN
672,"CHRS","Coherus BioSciences Management to Present at the 42nd Annual J.P. Morgan Healthcare Conference","https://www.globenewswire.com/news-release/2024/01/03/2803378/33333/en/Coherus-BioSciences-Management-to-Present-at-the-42nd-Annual-J-P-Morgan-Healthcare-Conference.html","Conference Calls/ Webcasts","2024-01-03 09:00:00","pre_market",3,3,473,470,-0,-0,-0,"short","short",NaN
694,"CNTG","CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders","https://www.globenewswire.com/news-release/2023/04/11/2644190/0/en/CENTOGENE-Extends-Strategic-Partnership-With-Takeda-to-Continue-Providing-Access-to-Genetic-Testing-for-Patients-With-Lysosomal-Storage-Disorders.html","Clinical Study","2023-04-11 06:30:00","pre_market",1,1,410,410,0,0,0,"long","long",NaN
687,"CKPT","Checkpoint Therapeutics Strengthens Intellectual Property Protection for Cosibelimab with New U.S. Patent Issuance","https://www.globenewswire.com/news-release/2023/12/05/2790924/36989/en/Checkpoint-Therapeutics-Strengthens-Intellectual-Property-Protection-for-Cosibelimab-with-New-U-S-Patent-Issuance.html","Patents","2023-12-05 08:30:00","pre_market",3,3,457,455,-0,-0,-0,"short","long",NaN
693,"CNTG","CENTOGENE and Lifera, a Biopharma Company Owned by the PIF, Enter Strategic Collaboration – Forming Saudi Arabian Joint Venture to Increase Access to Leading Data-Driven Multiomic Testing and Securing CENTOGENE $30 Million Investment","https://www.globenewswire.com/news-release/2023/06/27/2695202/0/en/CENTOGENE-and-Lifera-a-Biopharma-Company-Owned-by-the-PIF-Enter-Strategic-Collaboration-Forming-Saudi-Arabian-Joint-Venture-to-Increase-Access-to-Leading-Data-Driven-Multiomic-Test.html","Financing Agreements","2023-06-27 07:30:00","pre_market",1,1,431,432,0,0,0,"long","long",NaN
816,"DBVT","Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF","https://www.globenewswire.com/news-release/2024/01/16/2810343/0/en/Half-Year-Report-on-the-DBV-Technologies-Liquidity-Contract-with-ODDO-BHF.html","European Regulatory News","2024-01-16 16:30:00","after_hours",(null),(null),(null),(null),(null),(null),(null),(null),"long",NaN
695,"CNTG","CENTOGENE Accelerates Global Genetic Data Interpretation, Launching FilterTool Application as Accessory to CentoCloud® Bioinformatics Pipeline","https://www.globenewswire.com/news-release/2023/04/26/2655078/0/en/CENTOGENE-Accelerates-Global-Genetic-Data-Interpretation-Launching-FilterTool-Application-as-Accessory-to-CentoCloud-Bioinformatics-Pipeline.html","Product / Services Announcement","2023-04-26 08:30:00","pre_market",2,2,406,407,0,0,0,"long","long",NaN
696,"CNTG","CENTOGENE to Participate in Upcoming Conferences in April","https://www.globenewswire.com/news-release/2023/04/14/2647012/0/en/CENTOGENE-to-Participate-in-Upcoming-Conferences-in-April.html","Calendar of Events","2023-04-14 08:00:00","pre_market",1,1,413,413,0,-0,0,"long","long",NaN
703,"CNTG","CENTOGENE Regains Compliance With Nasdaq Listing Requirements","https://www.globenewswire.com/news-release/2023/07/14/2704894/0/en/CENTOGENE-Regains-Compliance-With-Nasdaq-Listing-Requirements.html","Stock Market News","2023-07-14 06:30:00","pre_market",1,2,450,450,0,0,0,"long","long",NaN
700,"CNTG","CENTOGENE Receives Nasdaq Non-Compliance Notice","https://www.globenewswire.com/news-release/2023/04/28/2657282/0/en/CENTOGENE-Receives-Nasdaq-Non-Compliance-Notice.html","Stock Market News","2023-04-28 06:30:00","pre_market",1,1,412,411,-0,-0,-0,"short","short",NaN
688,"CKPT","U.S. Food and Drug Administration Issues Complete Response Letter for Cosibelimab Solely Due to Inspection Findings at Third-Party Manufacturer","https://www.globenewswire.com/news-release/2023/12/18/2797694/36989/en/U-S-Food-and-Drug-Administration-Issues-Complete-Response-Letter-for-Cosibelimab-Solely-Due-to-Inspection-Findings-at-Third-Party-Manufacturer.html","Clinical Study","2023-12-18 07:00:00","pre_market",3,2,469,471,-1,0,-1,"short","short",NaN
697,"CNTG","CENTOGENE to Participate in Upcoming Conferences in August","https://www.globenewswire.com/news-release/2023/08/07/2719533/0/en/CENTOGENE-to-Participate-in-Upcoming-Conferences-in-August.html","Health","2023-08-07 06:30:00","pre_market",1,1,447,449,-0,0,-0,"short","short",NaN
702,"CNTG","CENTOGENE, University College London, and Global Team of Researchers Discover Gene Associated With New Neurodevelopmental Disease Linked to Early-Onset Dystonia and Parkinsonism","https://www.globenewswire.com/news-release/2023/11/14/2780103/0/en/CENTOGENE-University-College-London-and-Global-Team-of-Researchers-Discover-Gene-Associated-With-New-Neurodevelopmental-Disease-Linked-to-Early-Onset-Dystonia-and-Parkinsonism.html","Clinical Study","2023-11-14 08:30:00","pre_market",1,1,440,446,0,0,0,"long","long",NaN
692,"CNTG","CENTOGENE Expands Multiomic Diagnostic Portfolio With Newly-Launched Transcriptomic Offering","https://www.globenewswire.com/news-release/2023/10/10/2757274/0/en/CENTOGENE-Expands-Multiomic-Diagnostic-Portfolio-With-Newly-Launched-Transcriptomic-Offering.html","Product / Services Announcement","2023-10-10 06:30:00","pre_market",1,1,432,433,-0,0,-0,"short","short",NaN
701,"CNTG","CENTOGENE to Participate in Upcoming Conferences in May","https://www.globenewswire.com/news-release/2023/05/05/2662386/0/en/CENTOGENE-to-Participate-in-Upcoming-Conferences-in-May.html","Conference Calls/ Webcasts","2023-05-05 06:30:00","pre_market",1,1,405,409,-0,0,-0,"short","short",NaN
689,"CKPT","Checkpoint Therapeutics Announces $14 Million Registered Direct Offering Priced At-the-Market","https://www.globenewswire.com/news-release/2024/01/29/2818873/36989/en/Checkpoint-Therapeutics-Announces-14-Million-Registered-Direct-Offering-Priced-At-the-Market.html","Financing Agreements","2024-01-29 08:00:00","pre_market",2,2,487,488,0,0,0,"long","short",NaN
712,"CRBP","Corbus Pharmaceuticals to Report Third Quarter Results on November 10, 2020","https://www.globenewswire.com/news-release/2020/11/03/2119282/0/en/Corbus-Pharmaceuticals-to-Report-Third-Quarter-Results-on-November-10-2020.html","Press releases","2020-11-03 08:05:00","pre_market",31,31,330,334,0,0,-0,"short","short",NaN
713,"CRBP","Corbus Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update","https://www.globenewswire.com/news-release/2023/11/07/2775041/0/en/Corbus-Pharmaceuticals-Reports-Third-Quarter-2023-Financial-Results-and-Provides-Corporate-Update.html","Earnings Releases and Operating Results","2023-11-07 08:00:00","pre_market",5,5,436,436,-0,0,-0,"short","short",NaN
714,"CRBP","Corbus Pharmaceuticals Presents Additional Data from RESOLVE-1 Study in Systemic Sclerosis","https://www.globenewswire.com/news-release/2020/11/09/2122759/0/en/Corbus-Pharmaceuticals-Presents-Additional-Data-from-RESOLVE-1-Study-in-Systemic-Sclerosis.html","Press releases","2020-11-09 08:05:00","pre_market",34,35,350,364,0,0,-0,"short","short",NaN
715,"CRBP","Corbus Pharmaceuticals to Report Fourth Quarter and Year-End 2020 Results on March 15, 2021","https://www.globenewswire.com/news-release/2021/03/08/2188695/0/en/Corbus-Pharmaceuticals-to-Report-Fourth-Quarter-and-Year-End-2020-Results-on-March-15-2021.html","Press releases","2021-03-08 08:05:00","pre_market",56,56,384,385,0,0,-0,"short","short",NaN
716,"CRBP","CORBUS PHARMACEUTICALS ANNOUNCES ADJOURNMENT OF ANNUAL MEETING","https://www.globenewswire.com/news-release/2021/05/19/2232608/0/en/CORBUS-PHARMACEUTICALS-ANNOUNCES-ADJOURNMENT-OF-ANNUAL-MEETING.html","Press releases","2021-05-19 09:20:00","pre_market",49,47,412,407,-0,-0,-0,"short","short",NaN
717,"CRBP","Corbus Pharmaceuticals Announces Publication of Two Abstracts at EULAR 2021 Virtual Congress","https://www.globenewswire.com/news-release/2021/05/25/2235486/0/en/Corbus-Pharmaceuticals-Announces-Publication-of-Two-Abstracts-at-EULAR-2021-Virtual-Congress.html","Press releases","2021-05-25 08:05:00","pre_market",51,51,419,420,0,0,-0,"short","short",NaN
718,"CRBP","Corbus Pharmaceuticals Announces Presentations at the New York Academy of Sciences Webinar on Targeting the Endocannabinoid System to Treat Human Diseases","https://www.globenewswire.com/news-release/2021/01/20/2161391/0/en/Corbus-Pharmaceuticals-Announces-Presentations-at-the-New-York-Academy-of-Sciences-Webinar-on-Targeting-the-Endocannabinoid-System-to-Treat-Human-Diseases.html","Press releases","2021-01-20 08:05:00","pre_market",52,52,379,381,0,0,-0,"short","short",NaN
719,"CRBP","Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences","https://www.globenewswire.com/news-release/2021/03/09/2189519/0/en/Corbus-Pharmaceuticals-to-Present-at-Two-Upcoming-Investor-Conferences.html","Press releases","2021-03-09 08:05:00","pre_market",56,58,382,386,0,0,0,"long","long",NaN
720,"CRBP","Corbus Pharmaceuticals to Present at Three Upcoming Investor Conferences","https://www.globenewswire.com/news-release/2021/05/11/2227201/0/en/Corbus-Pharmaceuticals-to-Present-at-Three-Upcoming-Investor-Conferences.html","Press releases","2021-05-11 08:05:00","pre_market",47,43,418,413,-0,-0,-0,"short","long",NaN
721,"CRBP","Corbus Pharmaceuticals Presents the First Pre-Clinical Characterization of its Next Generation Nectin-4 ADC CRB-701","https://www.globenewswire.com/news-release/2023/10/16/2760607/0/en/Corbus-Pharmaceuticals-Presents-the-First-Pre-Clinical-Characterization-of-its-Next-Generation-Nectin-4-ADC-CRB-701.html","Health","2023-10-16 08:00:00","pre_market",6,6,432,434,0,0,0,"long","long",NaN
704,"CNTG","CENTOGENE Announces Publication Establishing Lyso-Gb1 as a Predictive Biomarker for Gaucher Disease Patients","https://www.globenewswire.com/news-release/2023/09/01/2735986/0/en/CENTOGENE-Announces-Publication-Establishing-Lyso-Gb1-as-a-Predictive-Biomarker-for-Gaucher-Disease-Patients.html","Clinical Study","2023-09-01 08:00:00","pre_market",1,1,450,453,0,0,0,"long","long",NaN
705,"CNTG","CENTOGENE Announces Voting Results of Extraordinary General Meeting","https://www.globenewswire.com/news-release/2023/12/19/2798385/0/en/CENTOGENE-Announces-Voting-Results-of-Extraordinary-General-Meeting.html","Annual Meetings & Shareholder Rights","2023-12-19 06:30:00","pre_market",1,1,472,473,-0,0,-0,"short","short",NaN
706,"CNTG","CENTOGENE Announces Preliminary Full Year 2023 Revenue","https://www.globenewswire.com/news-release/2024/01/18/2811370/0/en/CENTOGENE-Announces-Preliminary-Full-Year-2023-Revenue.html","Management statements","2024-01-18 06:30:00","pre_market",1,1,472,474,-0,0,-0,"short","short",NaN
707,"CNTG","CENTOGENE’s Frontotemporal Dementia (FTD) Genetic Study, EFRONT, Reaches Initial Patient Enrollment Milestone","https://www.globenewswire.com/news-release/2023/12/13/2795390/0/en/CENTOGENE-s-Frontotemporal-Dementia-FTD-Genetic-Study-EFRONT-Reaches-Initial-Patient-Enrollment-Milestone.html","Clinical Study","2023-12-13 06:30:00","pre_market",1,1,464,464,-0,0,-0,"short","long",NaN
708,"CNTG","CENTOGENE Receives French Research Tax Credit Accreditation","https://www.globenewswire.com/news-release/2024/01/24/2815050/0/en/CENTOGENE-Receives-French-Research-Tax-Credit-Accreditation.html","Management statements","2024-01-24 06:30:00","pre_market",1,1,485,488,-0,0,-0,"short","short",NaN
709,"CNTG","CENTOGENE and the Laboratory of Human Genetics of Infectious Diseases at Institut Imagine Announce Rare Disease Research Collaboration","https://www.globenewswire.com/news-release/2024/01/25/2816524/0/en/CENTOGENE-and-the-Laboratory-of-Human-Genetics-of-Infectious-Diseases-at-Institut-Imagine-Announce-Rare-Disease-Research-Collaboration.html","Health","2024-01-25 06:30:00","pre_market",1,1,485,488,-0,0,-0,"short","long",NaN
710,"CNTG","CENTOGENE and The Michael J. Fox Foundation Announce Research Project to Validate Genetic Risk Factors of Parkinson’s Disease Using Multiomics","https://www.globenewswire.com/news-release/2024/01/23/2813910/0/en/CENTOGENE-and-The-Michael-J-Fox-Foundation-Announce-Research-Project-to-Validate-Genetic-Risk-Factors-of-Parkinson-s-Disease-Using-Multiomics.html","Clinical Study","2024-01-23 06:30:00","pre_market",1,1,483,484,0,0,-0,"short","short",NaN
723,"CRBP","Corbus Pharmaceuticals to Host Virtual ‘Meet the Expert’ Series (Session 2) on CRB-701 on October 10, 2023","https://www.globenewswire.com/news-release/2023/10/03/2753553/0/en/Corbus-Pharmaceuticals-to-Host-Virtual-Meet-the-Expert-Series-Session-2-on-CRB-701-on-October-10-2023.html","Calendar of Events","2023-10-03 08:00:00","pre_market",6,6,427,425,0,-0,0,"long","long",NaN
724,"CRBP","Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2020 Financial Results","https://www.globenewswire.com/news-release/2021/03/15/2192661/0/en/Corbus-Pharmaceuticals-Reports-Fourth-Quarter-and-Year-End-2020-Financial-Results.html","Press releases","2021-03-15 07:05:00","pre_market",70,72,394,394,0,0,0,"long","long",NaN
726,"CRBP","Corbus Pharmaceuticals Announces Presentation of Data from its Phase 2b Study in Cystic Fibrosis at NACFC 2020","https://www.globenewswire.com/news-release/2020/10/23/2113631/0/en/Corbus-Pharmaceuticals-Announces-Presentation-of-Data-from-its-Phase-2b-Study-in-Cystic-Fibrosis-at-NACFC-2020.html","Press releases","2020-10-23 08:05:00","pre_market",31,31,345,346,-0,0,-0,"short","short",NaN
727,"CRBP","Corbus Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Updates","https://www.globenewswire.com/news-release/2021/05/13/2229088/0/en/Corbus-Pharmaceuticals-Reports-First-Quarter-2021-Financial-Results-and-Provides-Corporate-Updates.html","Press releases","2021-05-13 08:05:00","pre_market",45,44,405,407,-0,0,-0,"short","short",NaN
728,"CRBP","Corbus Pharmaceuticals Reports Third Quarter Financial Results and Provides Corporate Updates","https://www.globenewswire.com/news-release/2020/11/10/2123642/0/en/Corbus-Pharmaceuticals-Reports-Third-Quarter-Financial-Results-and-Provides-Corporate-Updates.html","Press releases","2020-11-10 07:05:00","pre_market",37,36,355,353,-0,-0,-0,"short","short",NaN
729,"CRBP","Corbus Pharmaceuticals Presents Results of Two Pre-Clinical Studies on its Anti-αVβ8 Monoclonal Antibody (CRB-601) at the 2023 SITC Annual Meeting","https://www.globenewswire.com/news-release/2023/11/02/2772252/0/en/Corbus-Pharmaceuticals-Presents-Results-of-Two-Pre-Clinical-Studies-on-its-Anti-%CE%B1V%CE%B28-Monoclonal-Antibody-CRB-601-at-the-2023-SITC-Annual-Meeting.html","Clinical Study","2023-11-02 08:00:00","pre_market",5,5,423,427,0,0,0,"long","long",NaN
730,"CRBP","Corbus Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Updates","https://www.globenewswire.com/news-release/2021/08/12/2279756/0/en/Corbus-Pharmaceuticals-Reports-Second-Quarter-2021-Financial-Results-and-Provides-Corporate-Updates.html","Press releases","2021-08-12 08:05:00","pre_market",40,40,444,444,-0,-0,-0,"short","short",NaN
1819,"ORPHA.CO","Insiders handel med selskabets aktier","https://www.globenewswire.com/news-release/2023/12/08/2793205/0/da/Insiders-handel-med-selskabets-aktier.html","European Regulatory News","2023-12-08 08:40:00","pre_market",677,676,458,457,-0,-0,0,"long","long",NaN
731,"CRBP","Corbus Pharmaceuticals Announces Completion of Enrollment in NIH-Sponsored Phase 2 Study of Lenabasum for Treatment of Systemic Lupus Erythematosus (SLE)","https://www.globenewswire.com/news-release/2021/04/20/2213251/0/en/Corbus-Pharmaceuticals-Announces-Completion-of-Enrollment-in-NIH-Sponsored-Phase-2-Study-of-Lenabasum-for-Treatment-of-Systemic-Lupus-Erythematosus-SLE.html","Press releases","2021-04-20 08:05:00","pre_market",49,49,415,414,0,-0,0,"long","short",NaN
732,"CRBP","Corbus Pharmaceuticals to Present at the Jefferies Virtual London Healthcare Conference","https://www.globenewswire.com/news-release/2020/11/12/2125597/0/en/Corbus-Pharmaceuticals-to-Present-at-the-Jefferies-Virtual-London-Healthcare-Conference.html","Press releases","2020-11-12 08:05:00","pre_market",37,37,357,356,0,-0,0,"long","long",NaN
733,"CRBP","Phase 1 Clinical Data for SYS6002 (CRB-701) to be presented at 2024 ASCO GU","https://www.globenewswire.com/news-release/2024/01/23/2814050/0/en/Phase-1-Clinical-Data-for-SYS6002-CRB-701-to-be-presented-at-2024-ASCO-GU.html","Clinical Study","2024-01-23 08:00:00","pre_market",8,8,483,484,0,0,0,"long","long",NaN
734,"CRBP","Corbus Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference","https://www.globenewswire.com/news-release/2024/02/06/2824475/0/en/Corbus-Pharmaceuticals-to-Present-at-the-Oppenheimer-34th-Annual-Healthcare-Life-Sciences-Conference.html","Conference Calls/ Webcasts","2024-02-06 09:50:00","market_open",25,26,494,494,0,0,0,"long","long",NaN
735,"CRBP","CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting Antibody Drug Conjugate Demonstrates Encouraging Safety and Efficacy in Patients with Nectin-4 Positive Tumors in First-In-Human Study Presented at ASCO-GU 2024","https://www.globenewswire.com/news-release/2024/01/26/2817869/0/en/CRB-701-SYS6002-A-Next-Generation-Nectin-4-Targeting-Antibody-Drug-Conjugate-Demonstrates-Encouraging-Safety-and-Efficacy-in-Patients-with-Nectin-4-Positive-Tumors-in-First-In-Huma.html","Clinical Study","2024-01-26 07:30:00","pre_market",8,17,488,488,1,-0,1,"long","long",NaN
736,"CRBP","Corbus Pharmaceuticals Announces Pricing of Public Offering","https://www.globenewswire.com/news-release/2024/01/31/2821248/0/en/Corbus-Pharmaceuticals-Announces-Pricing-of-Public-Offering.html","Changes in company's own shares","2024-01-31 09:19:00","pre_market",25,28,491,489,0,-0,0,"long","long",NaN
737,"CRBP","Corbus Pharmaceuticals Announces FDA Clearance of IND Application for its anti-αvβ8 monoclonal antibody (CRB-601)","https://www.globenewswire.com/news-release/2024/01/09/2806222/0/en/Corbus-Pharmaceuticals-Announces-FDA-Clearance-of-IND-Application-for-its-anti-%CE%B1v%CE%B28-monoclonal-antibody-CRB-601.html","Product / Services Announcement","2024-01-09 08:00:00","pre_market",7,7,475,472,0,-0,0,"long","long",NaN
738,"CRBP","Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO GU","https://www.globenewswire.com/news-release/2023/12/18/2797790/0/en/Corbus-Pharmaceuticals-Announces-Abstract-Accepted-for-Presentation-at-2024-ASCO-GU.html","Product / Services Announcement","2023-12-18 08:00:00","pre_market",6,6,469,471,0,0,-0,"short","short",NaN
740,"CRSP","CRISPR Therapeutics to Present at the 2022 BMO Growth & ESG Conference","https://www.globenewswire.com/news-release/2022/12/01/2565896/0/en/CRISPR-Therapeutics-to-Present-at-the-2022-BMO-Growth-ESG-Conference.html","Calendar of Events","2022-12-01 08:00:00","pre_market",55,54,408,409,-0,0,-0,"short","short",NaN
741,"CRSP","CRISPR Therapeutics to Participate in Upcoming Investor Conferences","https://www.globenewswire.com/news-release/2023/02/08/2603890/0/en/CRISPR-Therapeutics-to-Participate-in-Upcoming-Investor-Conferences.html","Calendar of Events","2023-02-08 08:00:00","pre_market",56,56,415,413,0,-0,0,"long","long",NaN
742,"CRSP","CRISPR Therapeutics to Participate in the 43rd Annual Cowen Health Care Conference","https://www.globenewswire.com/news-release/2023/02/27/2616052/0/en/CRISPR-Therapeutics-to-Participate-in-the-43rd-Annual-Cowen-Health-Care-Conference.html","Health","2023-02-27 08:00:00","pre_market",48,49,396,400,0,0,0,"long","long",NaN
743,"CRSP","CRISPR Therapeutics to Present at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting","https://www.globenewswire.com/news-release/2023/09/27/2750466/0/en/CRISPR-Therapeutics-to-Present-at-the-Society-for-Immunotherapy-of-Cancer-SITC-38th-Annual-Meeting.html","Calendar of Events","2023-09-27 09:01:00","pre_market",46,47,426,427,0,0,0,"long","short",NaN
744,"CRSP","CRISPR Therapeutics to Participate in B. Riley Securities’ 3rd Annual Oncology Conference","https://www.globenewswire.com/news-release/2023/01/11/2586996/0/en/CRISPR-Therapeutics-to-Participate-in-B-Riley-Securities-3rd-Annual-Oncology-Conference.html","Conference Calls/ Webcasts","2023-01-11 08:00:00","pre_market",48,49,391,392,0,0,0,"long","long",NaN
745,"CRSP","CRISPR Therapeutics to Participate in Goldman Sachs 44th Annual Global Healthcare Conference","https://www.globenewswire.com/news-release/2023/06/13/2687207/0/en/CRISPR-Therapeutics-to-Participate-in-Goldman-Sachs-44th-Annual-Global-Healthcare-Conference.html","Conference Calls/ Webcasts","2023-06-13 09:00:00","pre_market",60,60,434,435,0,0,-0,"short","short",NaN
746,"CRSP","CRISPR Therapeutics Announces Leadership Transition","https://www.globenewswire.com/news-release/2023/09/07/2739361/0/en/CRISPR-Therapeutics-Announces-Leadership-Transition.html","Directors and Officers","2023-09-07 08:30:00","pre_market",51,49,446,443,-0,-0,-0,"short","short",NaN
747,"CRSP","CRISPR Therapeutics Proposes New Appointment to the Board of Directors","https://www.globenewswire.com/news-release/2023/10/16/2760571/0/en/CRISPR-Therapeutics-Proposes-New-Appointment-to-the-Board-of-Directors.html","Directors and Officers","2023-10-16 08:00:00","pre_market",44,44,432,434,0,0,-0,"short","long",NaN
748,"CRSP","CRISPR Therapeutics to Participate in Citi's 18th Annual Biopharma Conference","https://www.globenewswire.com/news-release/2023/08/30/2734284/0/en/CRISPR-Therapeutics-to-Participate-in-Citi-s-18th-Annual-Biopharma-Conference.html","Calendar of Events","2023-08-30 08:00:00","pre_market",51,51,449,450,-0,0,-0,"short","short",NaN
749,"CRSP","CRISPR Therapeutics Provides Update on Its Ongoing Phase 1 CARBON™ Trial of CTX110®","https://www.globenewswire.com/news-release/2022/12/12/2572040/0/en/CRISPR-Therapeutics-Provides-Update-on-Its-Ongoing-Phase-1-CARBON-Trial-of-CTX110.html","Clinical Study","2022-12-12 10:00:00","market_open",49,51,394,399,0,0,0,"long","long",NaN
750,"CRSP","CRISPR Therapeutics Announces the Appointment of Alex Harding, M.D., M.B.A., as Head of Business Development","https://www.globenewswire.com/news-release/2022/12/19/2576318/0/en/CRISPR-Therapeutics-Announces-the-Appointment-of-Alex-Harding-M-D-M-B-A-as-Head-of-Business-Development.html","Directors and Officers","2022-12-19 08:30:00","pre_market",46,46,383,383,0,0,0,"long","long",NaN
754,"CRSP","CRISPR Therapeutics to Present at the Citi 2024 Virtual Oncology Leadership Summit","https://www.globenewswire.com/news-release/2024/02/15/2829970/0/en/CRISPR-Therapeutics-to-Present-at-the-Citi-2024-Virtual-Oncology-Leadership-Summit.html","Calendar of Events","2024-02-15 08:30:00","pre_market",79,80,499,499,0,0,0,"long","long",NaN
752,"CRSP","CRISPR Therapeutics to Participate Upcoming Investor Conferences","https://www.globenewswire.com/news-release/2023/05/02/2659065/0/en/CRISPR-Therapeutics-to-Participate-Upcoming-Investor-Conferences.html","Conference Calls/ Webcasts","2023-05-02 08:00:00","pre_market",49,49,416,415,-0,-0,0,"long","long",NaN
751,"CRSP","CRISPR Therapeutics Announces Preclinical Data at the American Heart Association (AHA) Scientific Sessions 2023","https://www.globenewswire.com/news-release/2023/11/06/2773808/0/en/CRISPR-Therapeutics-Announces-Preclinical-Data-at-the-American-Heart-Association-AHA-Scientific-Sessions-2023.html","Product / Services Announcement","2023-11-06 05:01:00","pre_market",51,53,435,435,0,0,0,"long","long",NaN
755,"CRSP","CRISPR Therapeutics Announces $280 Million Registered Direct Offering","https://www.globenewswire.com/news-release/2024/02/13/2828258/0/en/CRISPR-Therapeutics-Announces-280-Million-Registered-Direct-Offering.html","Changes in company's own shares","2024-02-13 08:30:00","pre_market",76,72,501,495,-0,-0,-0,"short","short",NaN
756,"CRSP","CRISPR Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference","https://www.globenewswire.com/news-release/2024/01/03/2803326/0/en/CRISPR-Therapeutics-to-Present-at-the-42nd-Annual-J-P-Morgan-Healthcare-Conference.html","Conference Calls/ Webcasts","2024-01-03 08:30:00","pre_market",66,65,473,470,-0,-0,-0,"short","short",NaN
757,"CRSP","CRISPR Therapeutics Highlights Strategic Priorities and 2024 Outlook","https://www.globenewswire.com/news-release/2024/01/08/2805274/0/en/CRISPR-Therapeutics-Highlights-Strategic-Priorities-and-2024-Outlook.html","Clinical Study","2024-01-08 07:00:00","pre_market",61,61,468,468,-0,0,-0,"short","long",NaN
768,"CTMX","CytomX Therapeutics to Present at Upcoming November Investor Conferences","https://www.globenewswire.com/news-release/2023/11/01/2771110/37704/en/CytomX-Therapeutics-to-Present-at-Upcoming-November-Investor-Conferences.html","Calendar of Events","2023-11-01 08:00:00","pre_market",1,1,418,419,-0,0,-0,"short","short",NaN
760,"CTKB","Cytek® Biosciences Marks Shipment of Its 100th Cell Sorter as the Company Continues to Lead Cell Analysis Forward","https://www.globenewswire.com/news-release/2023/05/16/2669891/0/en/Cytek-Biosciences-Marks-Shipment-of-Its-100th-Cell-Sorter-as-the-Company-Continues-to-Lead-Cell-Analysis-Forward.html","Product / Services Announcement","2023-05-16 08:00:00","pre_market",7,7,413,412,-0,-0,-0,"short","short",NaN
761,"CTKB","Cytek Biosciences Announces $50 Million Stock Repurchase Program","https://www.globenewswire.com/news-release/2023/05/19/2672579/0/en/Cytek-Biosciences-Announces-50-Million-Stock-Repurchase-Program.html","Stock Market News","2023-05-19 09:00:00","pre_market",7,7,419,420,0,0,0,"long","short",NaN
769,"CTMX","CytomX Therapeutics Announces New Employment Inducement Grants","https://www.globenewswire.com/news-release/2023/07/20/2708270/37704/en/CytomX-Therapeutics-Announces-New-Employment-Inducement-Grants.html","Changes in company's own shares","2023-07-20 09:00:00","pre_market",2,2,455,454,0,-0,0,"long","long",NaN
770,"CTMX","CytomX Therapeutics Announces $30 Million Private Placement from BVF Partners L.P.","https://www.globenewswire.com/news-release/2023/06/30/2697718/37704/en/CytomX-Therapeutics-Announces-30-Million-Private-Placement-from-BVF-Partners-L-P.html","Management statements","2023-06-30 08:00:00","pre_market",1,2,438,441,0,0,0,"long","long",NaN
762,"CTKB","Cytek® Biosciences Cell Analysis Solutions Take Center Stage at Upcoming Clinical Conferences in the US and Europe","https://www.globenewswire.com/news-release/2023/09/20/2746504/0/en/Cytek-Biosciences-Cell-Analysis-Solutions-Take-Center-Stage-at-Upcoming-Clinical-Conferences-in-the-US-and-Europe.html","Health","2023-09-20 09:00:00","pre_market",6,6,443,444,0,0,0,"long","long",NaN
771,"CTMX","CytomX Therapeutics Announces Milestone Achievement in Probody® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas","https://www.globenewswire.com/news-release/2023/01/26/2595893/37704/en/CytomX-Therapeutics-Announces-Milestone-Achievement-in-Probody-T-Cell-Engaging-Bispecific-TCB-Collaboration-with-Astellas.html","Health","2023-01-26 07:00:00","pre_market",3,3,400,403,0,0,0,"long","long",NaN
772,"CTMX","CytomX Therapeutics to Present Preclinical Data for Conditionally Activated Interferon Alpha-2b at the SITC 2023 Annual Meeting","https://www.globenewswire.com/news-release/2023/10/30/2769158/37704/en/CytomX-Therapeutics-to-Present-Preclinical-Data-for-Conditionally-Activated-Interferon-Alpha-2b-at-the-SITC-2023-Annual-Meeting.html","Calendar of Events","2023-10-30 08:00:00","pre_market",1,1,411,414,0,0,0,"long","long",NaN
763,"CTKB","Sale of Flow Cytometry and Imaging Business From DiaSorin to Cytek® Biosciences Completed","https://www.globenewswire.com/news-release/2023/02/28/2617240/0/en/Sale-of-Flow-Cytometry-and-Imaging-Business-From-DiaSorin-to-Cytek-Biosciences-Completed.html","Mergers and Acquisitions","2023-02-28 09:21:00","pre_market",11,11,398,397,0,-0,0,"long","long",NaN
773,"CTMX","CytomX Therapeutics Appoints Yu-Waye (Wayne) Chu, M.D., as Chief Medical Officer","https://www.globenewswire.com/news-release/2023/07/17/2705602/37704/en/CytomX-Therapeutics-Appoints-Yu-Waye-Wayne-Chu-M-D-as-Chief-Medical-Officer.html","Directors and Officers","2023-07-17 08:00:00","pre_market",2,2,449,449,0,-0,0,"long","long",NaN
774,"CTMX","CytomX Therapeutics to Report Second Quarter 2023 Financial Results on August 8, 2023","https://www.globenewswire.com/news-release/2023/08/01/2715756/37704/en/CytomX-Therapeutics-to-Report-Second-Quarter-2023-Financial-Results-on-August-8-2023.html","Conference Calls/ Webcasts","2023-08-01 08:00:00","pre_market",2,2,458,456,-0,-0,-0,"short","long",NaN
764,"CTKB","Cytek® Biosciences Launches Educational Roadshow Focused on Spectral Flow Cytometry","https://www.globenewswire.com/news-release/2023/09/14/2743290/0/en/Cytek-Biosciences-Launches-Educational-Roadshow-Focused-on-Spectral-Flow-Cytometry.html","Calendar of Events","2023-09-14 09:00:00","pre_market",7,7,447,449,0,0,0,"long","long",NaN
775,"CTMX","CytomX Therapeutics to Report Third Quarter 2023 Financial Results on November 7, 2023","https://www.globenewswire.com/news-release/2023/10/31/2770106/37704/en/CytomX-Therapeutics-to-Report-Third-Quarter-2023-Financial-Results-on-November-7-2023.html","Conference Calls/ Webcasts","2023-10-31 08:00:00","pre_market",1,1,416,416,-0,0,-0,"short","short",NaN
765,"CTKB","Cytek® Biosciences Achieves ISO 13485 Certification at Headquarters","https://www.globenewswire.com/news-release/2023/09/27/2750427/0/en/Cytek-Biosciences-Achieves-ISO-13485-Certification-at-Headquarters.html","Company Announcement","2023-09-27 09:00:00","pre_market",6,6,426,427,0,0,0,"long","long",NaN
766,"CTKB","Cytek Biosciences Announces Preliminary Full Year 2023 Revenue Results","https://www.globenewswire.com/news-release/2024/01/08/2805518/0/en/Cytek-Biosciences-Announces-Preliminary-Full-Year-2023-Revenue-Results.html","Management statements","2024-01-08 09:00:00","pre_market",8,8,468,468,-0,0,-0,"short","short",NaN
767,"CTKB","Cytek® Biosciences Introduces the Cytek Orion™ Reagent Cocktail Preparation System, the First-of-its-Kind Automated Cocktail Preparation Instrument for Flow Cytometry","https://www.globenewswire.com/news-release/2023/12/21/2800056/0/en/Cytek-Biosciences-Introduces-the-Cytek-Orion-Reagent-Cocktail-Preparation-System-the-First-of-its-Kind-Automated-Cocktail-Preparation-Instrument-for-Flow-Cytometry.html","Product / Services Announcement","2023-12-21 09:00:00","pre_market",9,9,468,471,0,0,0,"long","long",NaN
781,"DBVT","DBV Technologies to Participate in Upcoming Investor Conference","https://www.globenewswire.com/news-release/2023/06/06/2683358/0/en/DBV-Technologies-to-Participate-in-Upcoming-Investor-Conference.html","European Regulatory News","2023-06-06 17:00:00","after_hours",(null),(null),(null),(null),(null),(null),(null),(null),"long",NaN
782,"DBVT","Bilan semestriel du contrat de liquidité DBV Technologies avec ODDO BHF","https://www.globenewswire.com/news-release/2023/07/10/2702197/0/fr/Bilan-semestriel-du-contrat-de-liquidit%C3%A9-DBV-Technologies-avec-ODDO-BHF.html","European Regulatory News","2023-07-10 16:30:00","after_hours",(null),(null),(null),(null),(null),(null),(null),(null),"long",NaN
783,"DBVT","DBV Technologies participera au prochain congrès de l’EAACI 2023","https://www.globenewswire.com/news-release/2023/06/08/2685215/0/fr/DBV-Technologies-participera-au-prochain-congr%C3%A8s-de-l-EAACI-2023.html","European Regulatory News","2023-06-08 16:30:00","after_hours",(null),(null),(null),(null),(null),(null),(null),(null),"long",NaN
784,"DBVT","DBV Technologies to Participate in Upcoming EAACI Congress 2023","https://www.globenewswire.com/news-release/2023/06/08/2685215/0/en/DBV-Technologies-to-Participate-in-Upcoming-EAACI-Congress-2023.html","European Regulatory News","2023-06-08 16:30:00","after_hours",(null),(null),(null),(null),(null),(null),(null),(null),"long",NaN
785,"DBVT","DBV Technologies va présenter de nouvelles données à l’ACAAI 2023","https://www.globenewswire.com/news-release/2023/11/02/2772870/0/fr/DBV-Technologies-va-pr%C3%A9senter-de-nouvelles-donn%C3%A9es-%C3%A0-l-ACAAI-2023.html","European Regulatory News","2023-11-02 16:30:00","after_hours",(null),(null),(null),(null),(null),(null),(null),(null),"long",NaN
786,"DBVT","DBV Technologies to Present New Data at ACAAI 2023","https://www.globenewswire.com/news-release/2023/11/02/2772870/0/en/DBV-Technologies-to-Present-New-Data-at-ACAAI-2023.html","European Regulatory News","2023-11-02 16:30:00","after_hours",(null),(null),(null),(null),(null),(null),(null),(null),"long",NaN
795,"DBVT","Information mensuelle relative au nombre total des droits de vote et  d’actions composant le capital social au 31 octobre 2023","https://www.globenewswire.com/news-release/2023/11/06/2774558/0/fr/Information-mensuelle-relative-au-nombre-total-des-droits-de-vote-et-d-actions-composant-le-capital-social-au-31-octobre-2023.html","European Regulatory News","2023-11-06 16:30:00","after_hours",(null),(null),(null),(null),(null),(null),(null),(null),"long",NaN
788,"DBVT","DBV Technologies to Report Third Quarter 2023 Financial Results and Business Update","https://www.globenewswire.com/news-release/2023/10/27/2768706/0/en/DBV-Technologies-to-Report-Third-Quarter-2023-Financial-Results-and-Business-Update.html","European Regulatory News","2023-10-27 16:30:00","after_hours",(null),(null),(null),(null),(null),(null),(null),(null),"long",NaN
789,"DBVT","DBV Technologies Receives Requested Feedback from FDA on Protocol Design Elements for COMFORT Safety Studies and Reports Third Quarter 2023 Financial Results","https://www.globenewswire.com/news-release/2023/10/31/2770671/0/en/DBV-Technologies-Receives-Requested-Feedback-from-FDA-on-Protocol-Design-Elements-for-COMFORT-Safety-Studies-and-Reports-Third-Quarter-2023-Financial-Results.html","European Regulatory News","2023-10-31 16:30:00","after_hours",(null),(null),(null),(null),(null),(null),(null),(null),"long",NaN
790,"DBVT","Monthly information regarding the total number of voting rights and  total number of shares of the Company as of May 31, 2023","https://www.globenewswire.com/news-release/2023/06/16/2689932/0/en/Monthly-information-regarding-the-total-number-of-voting-rights-and-total-number-of-shares-of-the-Company-as-of-May-31-2023.html","European Regulatory News","2023-06-16 16:30:00","after_hours",(null),(null),(null),(null),(null),(null),(null),(null),"long",NaN
791,"DBVT","DBV Technologies a reçu la réponse attendue de la FDA sur certains éléments de conception du protocole pour les études de sécurité COMFORT et publie ses résultats financiers du troisième trimestre 2023","https://www.globenewswire.com/news-release/2023/10/31/2770671/0/fr/DBV-Technologies-a-re%C3%A7u-la-r%C3%A9ponse-attendue-de-la-FDA-sur-certains-%C3%A9l%C3%A9ments-de-conception-du-protocole-pour-les-%C3%A9tudes-de-s%C3%A9curit%C3%A9-COMFORT-et-publie-ses-r%C3%A9sultats-financiers-du-tro.html","European Regulatory News","2023-10-31 16:30:00","after_hours",(null),(null),(null),(null),(null),(null),(null),(null),"long",NaN
787,"DBVT","DBV Technologies annonce la nomination de Virginie Boucinha au poste de Directrice Financière","https://www.globenewswire.com/news-release/2023/10/16/2760299/0/fr/DBV-Technologies-annonce-la-nomination-de-Virginie-Boucinha-au-poste-de-Directrice-Financi%C3%A8re.html","European Regulatory News","2023-10-16 02:00:00","no_market",(null),(null),(null),(null),(null),(null),(null),(null),"long",NaN
796,"DBVT","Information relative au nombre total des droits de vote et  d’actions composant le capital social au 30 novembre 2023","https://www.globenewswire.com/news-release/2023/12/04/2790484/0/fr/Information-relative-au-nombre-total-des-droits-de-vote-et-d-actions-composant-le-capital-social-au-30-novembre-2023.html","European Regulatory News","2023-12-04 16:30:00","after_hours",(null),(null),(null),(null),(null),(null),(null),(null),"long",NaN
793,"DBVT","DBV Technologies Announces Appointment of Virginie Boucinha as Chief Financial Officer","https://www.globenewswire.com/news-release/2023/10/16/2760299/0/en/DBV-Technologies-Announces-Appointment-of-Virginie-Boucinha-as-Chief-Financial-Officer.html","European Regulatory News","2023-10-16 02:00:00","overnight",(null),(null),(null),(null),(null),(null),(null),(null),"long",NaN
794,"DBVT","DBV Technologies Announces Appointment of Virginie Boucinha as Chief Financial Officer","https://www.globenewswire.com/news-release/2023/10/16/2760299/0/en/DBV-Technologies-Announces-Appointment-of-Virginie-Boucinha-as-Chief-Financial-Officer.html","European Regulatory News","2023-10-16 02:00:00","no_market",(null),(null),(null),(null),(null),(null),(null),(null),"long",NaN
902,"ELTX","Angion Biomedia Corp. Announces 1-for-10 Reverse Stock Split","https://www.globenewswire.com/news-release/2023/06/01/2680276/0/en/Angion-Biomedia-Corp-Announces-1-for-10-Reverse-Stock-Split.html","Major shareholder announcements","2023-06-01 08:00:00","pre_market",10,11,418,418,0,0,0,"long","long",NaN
777,"CTMX","CytomX Therapeutics Outlines 2024 Company Priorities and Milestones","https://www.globenewswire.com/news-release/2024/01/04/2803919/37704/en/CytomX-Therapeutics-Outlines-2024-Company-Priorities-and-Milestones.html","Product / Services Announcement","2024-01-04 08:00:00","pre_market",2,2,469,468,0,-0,0,"long","long",NaN
778,"CTMX","CytomX Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference","https://www.globenewswire.com/news-release/2023/12/21/2799945/37704/en/CytomX-Therapeutics-to-Present-at-the-42nd-Annual-J-P-Morgan-Healthcare-Conference.html","Calendar of Events","2023-12-21 08:00:00","pre_market",1,1,468,471,-0,0,-0,"short","long",NaN
779,"CTMX","CytomX Therapeutics to Present at the B. Riley Securities Virtual Annual Oncology Conference","https://www.globenewswire.com/news-release/2024/01/12/2808578/37704/en/CytomX-Therapeutics-to-Present-at-the-B-Riley-Securities-Virtual-Annual-Oncology-Conference.html","Calendar of Events","2024-01-12 08:00:00","pre_market",2,2,476,478,0,0,-0,"short","short",NaN
804,"DBVT","DBV Technologies invitée à participer à une prochaine Conférence Investisseur","https://www.globenewswire.com/news-release/2023/09/05/2737908/0/fr/DBV-Technologies-invit%C3%A9e-%C3%A0-participer-%C3%A0-une-prochaine-Conf%C3%A9rence-Investisseur.html","European Regulatory News","2023-09-05 16:30:00","after_hours",(null),(null),(null),(null),(null),(null),(null),(null),"long",NaN
805,"DBVT","Information mensuelle relative au nombre total des droits de vote et  d’actions composant le capital social au 30 juin 2023","https://www.globenewswire.com/news-release/2023/07/19/2707774/0/fr/Information-mensuelle-relative-au-nombre-total-des-droits-de-vote-et-d-actions-composant-le-capital-social-au-30-juin-2023.html","European Regulatory News","2023-07-19 16:30:00","after_hours",(null),(null),(null),(null),(null),(null),(null),(null),"long",NaN
806,"DBVT","Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF","https://www.globenewswire.com/news-release/2023/07/10/2702197/0/en/Half-Year-Report-on-the-DBV-Technologies-Liquidity-Contract-with-ODDO-BHF.html","European Regulatory News","2023-07-10 16:30:00","after_hours",(null),(null),(null),(null),(null),(null),(null),(null),"long",NaN
807,"DBVT","Information mensuelle relative au nombre total des droits de vote et  d’actions composant le capital social au 30 septembre 2023","https://www.globenewswire.com/news-release/2023/10/05/2755807/0/fr/Information-mensuelle-relative-au-nombre-total-des-droits-de-vote-et-d-actions-composant-le-capital-social-au-30-septembre-2023.html","European Regulatory News","2023-10-05 16:30:00","after_hours",(null),(null),(null),(null),(null),(null),(null),(null),"long",NaN
808,"DBVT","DBV Technologies présente ses résultats financiers du premier semestre 2023 et fait le point sur ses activités","https://www.globenewswire.com/news-release/2023/07/25/2710899/0/fr/DBV-Technologies-pr%C3%A9sente-ses-r%C3%A9sultats-financiers-du-premier-semestre-2023-et-fait-le-point-sur-ses-activit%C3%A9s.html","European Regulatory News","2023-07-25 16:30:00","after_hours",(null),(null),(null),(null),(null),(null),(null),(null),"long",NaN
809,"DBVT","Information mensuelle relative au nombre total des droits de vote et  d’actions composant le capital social au 31 mai 2023","https://www.globenewswire.com/news-release/2023/06/16/2689932/0/fr/Information-mensuelle-relative-au-nombre-total-des-droits-de-vote-et-d-actions-composant-le-capital-social-au-31-mai-2023.html","European Regulatory News","2023-06-16 16:30:00","after_hours",(null),(null),(null),(null),(null),(null),(null),(null),"long",NaN
810,"DBVT","DBV Technologies to Participate in Upcoming Investor Conference","https://www.globenewswire.com/news-release/2023/09/05/2737908/0/en/DBV-Technologies-to-Participate-in-Upcoming-Investor-Conference.html","European Regulatory News","2023-09-05 16:30:00","after_hours",(null),(null),(null),(null),(null),(null),(null),(null),"long",NaN
811,"DBVT","DBV Technologies Announces New England Journal of Medicine Publication of Phase 3 EPITOPE Trial Data Evaluating Viaskin™ Peanut in Toddlers","https://www.globenewswire.com/news-release/2023/05/10/2666153/0/en/DBV-Technologies-Announces-New-England-Journal-of-Medicine-Publication-of-Phase-3-EPITOPE-Trial-Data-Evaluating-Viaskin-Peanut-in-Toddlers.html","European Regulatory News","2023-05-10 17:30:00","after_hours",(null),(null),(null),(null),(null),(null),(null),(null),"long",NaN
812,"DBVT","DBV Technologies to Report First Half 2023 Financial Results and Provide a Corporate Update","https://www.globenewswire.com/news-release/2023/07/25/2710899/0/en/DBV-Technologies-to-Report-First-Half-2023-Financial-Results-and-Provide-a-Corporate-Update.html","European Regulatory News","2023-07-25 16:30:00","after_hours",(null),(null),(null),(null),(null),(null),(null),(null),"long",NaN
813,"DBVT","DBV Technologies invitée à participer à une prochaine Conférence Investisseur","https://www.globenewswire.com/news-release/2023/06/06/2683358/0/fr/DBV-Technologies-invit%C3%A9e-%C3%A0-participer-%C3%A0-une-prochaine-Conf%C3%A9rence-Investisseur.html","European Regulatory News","2023-06-06 17:00:00","after_hours",(null),(null),(null),(null),(null),(null),(null),(null),"long",NaN
814,"DBVT","DBV Technologies présente ses résultats financiers du troisième trimestre 2023 et fait le point sur ses activités","https://www.globenewswire.com/news-release/2023/10/27/2768706/0/fr/DBV-Technologies-pr%C3%A9sente-ses-r%C3%A9sultats-financiers-du-troisi%C3%A8me-trimestre-2023-et-fait-le-point-sur-ses-activit%C3%A9s.html","European Regulatory News","2023-10-27 16:30:00","after_hours",(null),(null),(null),(null),(null),(null),(null),(null),"long",NaN
815,"DBVT","Bilan semestriel du contrat de liquidité DBV Technologies avec ODDO BHF","https://www.globenewswire.com/news-release/2024/01/16/2810343/0/fr/Bilan-semestriel-du-contrat-de-liquidit%C3%A9-DBV-Technologies-avec-ODDO-BHF.html","European Regulatory News","2024-01-16 16:30:00","after_hours",(null),(null),(null),(null),(null),(null),(null),(null),"long",NaN
819,"DYAI","Dyadic Attends Investor Events in December","https://www.globenewswire.com/news-release/2023/11/30/2788573/0/en/Dyadic-Attends-Investor-Events-in-December.html","Calendar of Events","2023-11-30 08:30:00","pre_market",2,2,455,455,0,0,0,"long","long",NaN
821,"DYAI","Dyadic and bYoRNA Announce a Collaboration Targeting the Production of Abundant, Low-Cost mRNA From C1-Cells","https://www.globenewswire.com/news-release/2023/09/26/2749502/0/en/Dyadic-and-bYoRNA-Announce-a-Collaboration-Targeting-the-Production-of-Abundant-Low-Cost-mRNA-From-C1-Cells.html","Partnerships","2023-09-26 08:30:00","pre_market",2,2,432,429,0,-0,0,"long","long",NaN
822,"DYAI","Dyadic to Present at World Vaccine Congress Washington 2023","https://www.globenewswire.com/news-release/2023/03/30/2637625/0/en/Dyadic-to-Present-at-World-Vaccine-Congress-Washington-2023.html","Calendar of Events","2023-03-30 08:30:00","pre_market",1,2,401,404,0,0,0,"long","long",NaN
823,"DYAI","Dyadic to Participate at Two Industry Events in May","https://www.globenewswire.com/news-release/2023/05/10/2665543/0/en/Dyadic-to-Participate-at-Two-Industry-Events-in-May.html","Product / Services Announcement","2023-05-10 08:30:00","pre_market",2,2,411,414,-0,0,-0,"short","short",NaN
824,"DYAI","Dyadic to Present at Industry and Investor Events in October","https://www.globenewswire.com/news-release/2023/09/29/2751979/0/en/Dyadic-to-Present-at-Industry-and-Investor-Events-in-October.html","Product / Services Announcement","2023-09-29 08:30:00","pre_market",2,2,429,432,0,0,-0,"short","short",NaN
825,"DYAI","Dyadic Announces Continued Progress Towards Commercialization of Animal-Free Recombinant Serum Albumin","https://www.globenewswire.com/news-release/2023/08/07/2719707/0/en/Dyadic-Announces-Continued-Progress-Towards-Commercialization-of-Animal-Free-Recombinant-Serum-Albumin.html","Product / Services Announcement","2023-08-07 08:30:00","pre_market",2,2,447,449,-0,0,-0,"short","long",NaN
826,"DYAI","Dyadic Announces Expanded Licensing Agreement to Develop and Commercialize Vaccines and Biologics for African Continent","https://www.globenewswire.com/news-release/2023/04/12/2645288/0/en/Dyadic-Announces-Expanded-Licensing-Agreement-to-Develop-and-Commercialize-Vaccines-and-Biologics-for-African-Continent.html","Licensing Agreements","2023-04-12 08:00:00","pre_market",2,2,410,412,0,0,0,"long","short",NaN
827,"DYAI","Dyadic Announces Top-Line Results from its Successful Phase 1 Clinical Trial for a First-in-Human Filamentous Fungal-Based Vaccine Candidate","https://www.globenewswire.com/news-release/2023/11/29/2787745/0/en/Dyadic-Announces-Top-Line-Results-from-its-Successful-Phase-1-Clinical-Trial-for-a-First-in-Human-Filamentous-Fungal-Based-Vaccine-Candidate.html","Clinical Study","2023-11-29 08:30:00","pre_market",2,2,455,457,-0,0,-0,"short","short",NaN
828,"DYAI","Dyadic Receives U.S. Patent for Manufacturing Seasonal and Pandemic Influenza Vaccines from its Proprietary C1 Protein Production Platform","https://www.globenewswire.com/news-release/2023/04/18/2649016/0/en/Dyadic-Receives-U-S-Patent-for-Manufacturing-Seasonal-and-Pandemic-Influenza-Vaccines-from-its-Proprietary-C1-Protein-Production-Platform.html","Patents","2023-04-18 08:30:00","pre_market",2,2,414,416,0,0,0,"long","long",NaN
829,"DYAI","Dyadic Announces Development and License Agreement to Commercialize Animal-Free Alternative Proteins Using Dapibus™","https://www.globenewswire.com/news-release/2023/09/19/2745544/0/en/Dyadic-Announces-Development-and-License-Agreement-to-Commercialize-Animal-Free-Alternative-Proteins-Using-Dapibus.html","Licensing Agreements","2023-09-19 08:00:00","pre_market",2,2,444,443,-0,-0,-0,"short","short",NaN
830,"DYAI","Dyadic Announces Collaboration to Commercialize Animal-Free Alternative Proteins Using Dapibus™","https://www.globenewswire.com/news-release/2023/05/08/2663306/0/en/Dyadic-Announces-Collaboration-to-Commercialize-Animal-Free-Alternative-Proteins-Using-Dapibus.html","Health","2023-05-08 08:30:00","pre_market",2,2,413,413,0,0,0,"long","long",NaN
831,"DYAI","Dyadic Appoints Doug Pace to Its Executive Leadership Team","https://www.globenewswire.com/news-release/2023/10/09/2756672/0/en/Dyadic-Appoints-Doug-Pace-to-Its-Executive-Leadership-Team.html","Health","2023-10-09 08:30:00","pre_market",2,2,430,428,-0,-0,-0,"short","short",NaN
832,"DYAI","Dyadic to Participate at Upcoming Events in June","https://www.globenewswire.com/news-release/2023/06/01/2680321/0/en/Dyadic-to-Participate-at-Upcoming-Events-in-June.html","Calendar of Events","2023-06-01 08:30:00","pre_market",2,2,418,418,-0,0,-0,"short","short",NaN
833,"DYAI","Dyadic Provides Phase 1 Clinical Trial Update for its Recombinant Protein RBD Vaccine Candidate","https://www.globenewswire.com/news-release/2023/07/24/2709514/0/en/Dyadic-Provides-Phase-1-Clinical-Trial-Update-for-its-Recombinant-Protein-RBD-Vaccine-Candidate.html","Clinical Study","2023-07-24 08:30:00","pre_market",2,2,452,453,0,0,0,"long","long",NaN
834,"DYAI","Dyadic Announced an MoU with Bangladesh’s State-Owned Pharmaceutical Company to Facilitate Biopharmaceutical Research and Biomanufacturing Capacity","https://www.globenewswire.com/news-release/2023/06/21/2692028/0/en/Dyadic-Announced-an-MoU-with-Bangladesh-s-State-Owned-Pharmaceutical-Company-to-Facilitate-Biopharmaceutical-Research-and-Biomanufacturing-Capacity.html","Business Contracts","2023-06-21 08:33:00","pre_market",2,2,437,436,0,-0,0,"long","long",NaN
817,"DBVT","Information regarding the total number of voting rights and  total number of shares of the Company as of November 30, 2023","https://www.globenewswire.com/news-release/2023/12/04/2790484/0/en/Information-regarding-the-total-number-of-voting-rights-and-total-number-of-shares-of-the-Company-as-of-November-30-2023.html","European Regulatory News","2023-12-04 16:30:00","after_hours",(null),(null),(null),(null),(null),(null),(null),(null),"long",NaN
840,"ECOR","electroCore Announces Two-Year Extension of gammaCore™ Device Listing in the NHS Supply Chain Catalogue","https://www.globenewswire.com/news-release/2023/10/17/2761421/0/en/electroCore-Announces-Two-Year-Extension-of-gammaCore-Device-Listing-in-the-NHS-Supply-Chain-Catalogue.html","Government News","2023-10-17 08:00:00","pre_market",5,5,436,433,0,-0,0,"long","long",NaN
841,"ECOR","electroCore, Inc. Announces Distribution Agreement with Reliefband Technologies, LLC","https://www.globenewswire.com/news-release/2023/07/13/2704254/0/en/electroCore-Inc-Announces-Distribution-Agreement-with-Reliefband-Technologies-LLC.html","Partnerships","2023-07-13 08:00:00","pre_market",5,5,446,448,-0,0,-0,"short","short",NaN
843,"ECOR","electroCore to Announce Second Quarter Financial Results on Wednesday, August 9","https://www.globenewswire.com/news-release/2023/08/01/2715804/0/en/electroCore-to-Announce-Second-Quarter-Financial-Results-on-Wednesday-August-9.html","Conference Calls/ Webcasts","2023-08-01 08:00:00","pre_market",4,4,458,456,-0,-0,-0,"short","short",NaN
844,"ECOR","electroCore to Participate in the Lytham Partners Fall 2023 Virtual Investor Conference","https://www.globenewswire.com/news-release/2023/10/05/2755341/0/en/electroCore-to-Participate-in-the-Lytham-Partners-Fall-2023-Virtual-Investor-Conference.html","Calendar of Events","2023-10-05 08:00:00","pre_market",6,6,425,424,0,-0,0,"long","long",NaN
845,"ECOR","TAC-STIM™ Non-Invasive Vagal Nerve Stimulation Selected for Inclusion in the Air Force Research Laboratories Real-Time Assessing and Augmenting Cognitive Performance in Extreme Environments Project","https://www.globenewswire.com/news-release/2023/06/27/2695227/0/en/TAC-STIM-Non-Invasive-Vagal-Nerve-Stimulation-Selected-for-Inclusion-in-the-Air-Force-Research-Laboratories-Real-Time-Assessing-and-Augmenting-Cognitive-Performance-in-Extreme-Envi.html","Product / Services Announcement","2023-06-27 08:00:00","pre_market",4,4,431,432,-0,0,-0,"short","short",NaN
846,"ECOR","electroCore to Present at iAccess Alpha’s – Top 10 Best Ideas from the Buyside Virtual Conference","https://www.globenewswire.com/news-release/2023/09/21/2747197/0/en/electroCore-to-Present-at-iAccess-Alpha-s-Top-10-Best-Ideas-from-the-Buyside-Virtual-Conference.html","Calendar of Events","2023-09-21 08:00:00","pre_market",5,5,439,436,-0,-0,-0,"short","short",NaN
847,"ECOR","electroCore Expands Intellectual Property Portfolio for Non-Invasive Vagus Nerve Stimulation (nVNS) Technology","https://www.globenewswire.com/news-release/2023/10/11/2758277/0/en/electroCore-Expands-Intellectual-Property-Portfolio-for-Non-Invasive-Vagus-Nerve-Stimulation-nVNS-Technology.html","Product / Services Announcement","2023-10-11 08:00:00","pre_market",5,5,435,436,-0,0,-0,"short","short",NaN
848,"ECOR","electroCore to Participate in Canaccord Genuity’s MedTech, Diagnostics and Digital Health & Services Forum","https://www.globenewswire.com/news-release/2023/11/07/2775044/0/en/electroCore-to-Participate-in-Canaccord-Genuity-s-MedTech-Diagnostics-and-Digital-Health-Services-Forum.html","Health","2023-11-07 08:00:00","pre_market",6,6,436,436,-0,0,-0,"short","short",NaN
849,"ECOR","electroCore to Participate in the H.C. Wainwright 25th Annual Global Investment Conference","https://www.globenewswire.com/news-release/2023/09/07/2739252/0/en/electroCore-to-Participate-in-the-H-C-Wainwright-25th-Annual-Global-Investment-Conference.html","Calendar of Events","2023-09-07 08:00:00","pre_market",6,6,446,443,-0,-0,0,"long","long",NaN
850,"ECOR","electroCore Announces Dismissal of All Litigation Related to Its 2018 Initial Public Offering","https://www.globenewswire.com/news-release/2023/08/23/2730348/0/en/electroCore-Announces-Dismissal-of-All-Litigation-Related-to-Its-2018-Initial-Public-Offering.html","Initial Public Offerings","2023-08-23 08:00:00","pre_market",5,5,438,439,-0,0,-0,"short","short",NaN
851,"ECOR","electroCore Expands Intellectual Property Portfolio for Non-Invasive Vagus Nerve Stimulation (nVNS) Technology","https://www.globenewswire.com/news-release/2023/09/26/2749414/0/en/electroCore-Expands-Intellectual-Property-Portfolio-for-Non-Invasive-Vagus-Nerve-Stimulation-nVNS-Technology.html","Patents","2023-09-26 08:00:00","pre_market",5,5,432,429,0,-0,0,"long","short",NaN
903,"ELTX","Elicio Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference","https://www.globenewswire.com/news-release/2023/09/06/2738299/0/en/Elicio-Therapeutics-to-Present-at-the-H-C-Wainwright-25th-Annual-Global-Investment-Conference.html","Calendar of Events","2023-09-06 08:00:00","pre_market",8,9,449,448,0,-0,0,"long","long",NaN
835,"DYAI","Dyadic’s C1 Platform to be Used to Produce Vaccines for Humans and Animals in Africa","https://www.globenewswire.com/news-release/2023/11/20/2783242/0/en/Dyadic-s-C1-Platform-to-be-Used-to-Produce-Vaccines-for-Humans-and-Animals-in-Africa.html","Product / Services Announcement","2023-11-20 08:30:00","pre_market",2,2,451,451,0,-0,0,"long","long",NaN
836,"DYAI","Dyadic to Attend BIO CEO & Investor Conference and European Industry Events","https://www.globenewswire.com/news-release/2024/02/01/2821988/0/en/Dyadic-to-Attend-BIO-CEO-Investor-Conference-and-European-Industry-Events.html","Calendar of Events","2024-02-01 08:30:00","pre_market",1,1,483,485,-0,0,-0,"short","short",NaN
837,"DYAI","Dyadic Announces Research and Development Collaboration Agreement with Global Biopharmaceutical Company","https://www.globenewswire.com/news-release/2024/02/06/2824325/0/en/Dyadic-Announces-Research-and-Development-Collaboration-Agreement-with-Global-Biopharmaceutical-Company.html","Partnerships","2024-02-06 08:30:00","pre_market",1,1,493,494,0,0,0,"long","long",NaN
838,"DYAI","Dyadic and Cygnus Technologies Announce Partnership To Provide C1 HCP ELISA Assay to Enhance Quality Assurance in Biomanufacturing","https://www.globenewswire.com/news-release/2024/02/13/2828243/0/en/Dyadic-and-Cygnus-Technologies-Announce-Partnership-To-Provide-C1-HCP-ELISA-Assay-to-Enhance-Quality-Assurance-in-Biomanufacturing.html","Partnerships","2024-02-13 08:30:00","pre_market",1,1,501,495,0,-0,0,"long","long",NaN
865,"EDIT","Editas Medicine Announces Third Quarter 2023 Results and Business Updates","https://www.globenewswire.com/news-release/2023/11/03/2773078/0/en/Editas-Medicine-Announces-Third-Quarter-2023-Results-and-Business-Updates.html","Earnings Releases and Operating Results","2023-11-03 07:00:00","pre_market",7,7,431,433,0,0,0,"long","long",NaN
866,"EDIT","Editas Medicine Reports Inducement Grant to New Chief Scientific Officer","https://www.globenewswire.com/news-release/2023/07/25/2710379/0/en/Editas-Medicine-Reports-Inducement-Grant-to-New-Chief-Scientific-Officer.html","Contests/Awards","2023-07-25 08:00:00","pre_market",9,9,454,454,0,-0,0,"long","long",NaN
868,"EDIT","Editas Medicine to Host Virtual Event to Discuss EDIT-301 Clinical Data from the RUBY Trial for Severe Sickle Cell Disease and the EDITHAL Trial for Transfusion-dependent Beta Thalassemia","https://www.globenewswire.com/news-release/2023/06/06/2682746/0/en/Editas-Medicine-to-Host-Virtual-Event-to-Discuss-EDIT-301-Clinical-Data-from-the-RUBY-Trial-for-Severe-Sickle-Cell-Disease-and-the-EDITHAL-Trial-for-Transfusion-dependent-Beta-Thal.html","Clinical Study","2023-06-06 08:00:00","pre_market",9,9,427,427,0,-0,0,"long","long",NaN
869,"EDIT","Editas Medicine Announces Upcoming Investor Events","https://www.globenewswire.com/news-release/2023/08/30/2734405/0/en/Editas-Medicine-Announces-Upcoming-Investor-Events.html","Conference Calls/ Webcasts","2023-08-30 09:00:00","pre_market",9,9,449,450,0,0,0,"long","long",NaN
852,"ECOR","Data Highlighting Non-invasive Vagus Nerve Stimulation (nVNS) for Treatment of Symptoms of Gastroparesis Presented at 2023 American College of Gastroenterology Annual Meeting","https://www.globenewswire.com/news-release/2023/10/24/2765530/0/en/Data-Highlighting-Non-invasive-Vagus-Nerve-Stimulation-nVNS-for-Treatment-of-Symptoms-of-Gastroparesis-Presented-at-2023-American-College-of-Gastroenterology-Annual-Meeting.html","Research Analysis and Reports","2023-10-24 08:00:00","pre_market",5,5,420,423,-0,0,-0,"short","short",NaN
853,"ECOR","electroCore to Announce Third Quarter Financial Results on Wednesday, November 8","https://www.globenewswire.com/news-release/2023/10/09/2756628/0/en/electroCore-to-Announce-Third-Quarter-Financial-Results-on-Wednesday-November-8.html","Conference Calls/ Webcasts","2023-10-09 08:00:00","pre_market",6,6,430,428,-0,-0,-0,"short","short",NaN
854,"ECOR","gammaCore Non-Invasive Vagus Nerve Stimulation (nVNS) Improves Attention and Working Memory in Patients with Post Traumatic Stress Disorder (PTSD)","https://www.globenewswire.com/news-release/2023/09/27/2750322/0/en/gammaCore-Non-Invasive-Vagus-Nerve-Stimulation-nVNS-Improves-Attention-and-Working-Memory-in-Patients-with-Post-Traumatic-Stress-Disorder-PTSD.html","Product / Services Announcement","2023-09-27 08:00:00","pre_market",6,6,426,427,0,0,0,"long","long",NaN
855,"ECOR","Dr. Peter Staats to Host Analyst Day on the Science Behind gammaCore™ Non-Invasive Vagus Nerve Stimulation (nVNS) on Tuesday, November 21, 2023","https://www.globenewswire.com/news-release/2023/11/15/2781017/0/en/Dr-Peter-Staats-to-Host-Analyst-Day-on-the-Science-Behind-gammaCore-Non-Invasive-Vagus-Nerve-Stimulation-nVNS-on-Tuesday-November-21-2023.html","Calendar of Events","2023-11-15 08:15:00","pre_market",6,6,449,450,-0,0,-0,"short","short",NaN
856,"ECOR","electroCore to Participate in the LD Micro Main Event XVI Conference","https://www.globenewswire.com/news-release/2023/09/25/2748582/0/en/electroCore-to-Participate-in-the-LD-Micro-Main-Event-XVI-Conference.html","Conference Calls/ Webcasts","2023-09-25 08:00:00","pre_market",5,5,430,429,-0,-0,-0,"short","long",NaN
857,"ECOR","Data Highlighting Non-Invasive Vagus Nerve Stimulation (nVNS) for Treatment of Acute Neurological Injury Presented at 2023 World Stroke Congress","https://www.globenewswire.com/news-release/2023/10/10/2757401/0/en/Data-Highlighting-Non-Invasive-Vagus-Nerve-Stimulation-nVNS-for-Treatment-of-Acute-Neurological-Injury-Presented-at-2023-World-Stroke-Congress.html","Clinical Study","2023-10-10 08:00:00","pre_market",6,6,432,433,-0,0,-0,"short","short",NaN
858,"ECOR","electroCore Provides Select Second Quarter 2023 Financial Guidance","https://www.globenewswire.com/news-release/2023/07/11/2702564/0/en/electroCore-Provides-Select-Second-Quarter-2023-Financial-Guidance.html","Pre-Release Comments","2023-07-11 08:00:00","pre_market",5,5,440,440,0,0,0,"long","short",NaN
859,"ECOR","gammaCore™ Non-Invasive Vagal Nerve Stimulation Selected for Study Funded by the National Football League (NFL) and National Football League Players Association (NFLPA) on Alleviating Concussion Symptoms","https://www.globenewswire.com/news-release/2023/07/06/2700272/0/en/gammaCore-Non-Invasive-Vagal-Nerve-Stimulation-Selected-for-Study-Funded-by-the-National-Football-League-NFL-and-National-Football-League-Players-Association-NFLPA-on-Alleviating-C.html","Product / Services Announcement","2023-07-06 08:00:00","pre_market",5,5,443,439,-0,-0,0,"long","long",NaN
860,"ECOR","electroCore Expands Intellectual Patent Portfolio for nVNS Technology","https://www.globenewswire.com/news-release/2023/07/18/2706335/0/en/electroCore-Expands-Intellectual-Patent-Portfolio-for-nVNS-Technology.html","Patents","2023-07-18 08:00:00","pre_market",5,5,451,450,-0,-0,-0,"short","short",NaN
861,"ECOR","electroCore Expands Intellectual Property Portfolio","https://www.globenewswire.com/news-release/2024/02/06/2824242/0/en/electroCore-Expands-Intellectual-Property-Portfolio.html","Patents","2024-02-06 08:00:00","pre_market",7,7,493,494,-0,0,-0,"short","short",NaN
862,"ECOR","electroCore Expands Intellectual Property Portfolio","https://www.globenewswire.com/news-release/2024/01/09/2806206/0/en/electroCore-Expands-Intellectual-Property-Portfolio.html","Patents","2024-01-09 08:00:00","pre_market",6,6,475,472,0,-0,0,"long","short",NaN
863,"ECOR","electroCore Expands Intellectual Property Portfolio for Nerve Stimulation Technology","https://www.globenewswire.com/news-release/2023/12/12/2794664/0/en/electroCore-Expands-Intellectual-Property-Portfolio-for-Nerve-Stimulation-Technology.html","Patents","2023-12-12 08:00:00","pre_market",5,5,462,462,-0,-0,-0,"short","short",NaN
885,"ELOX","Eloxx Pharmaceuticals Reports Second Quarter 2023 Financial and Operating Results and Provides Business Update","https://www.globenewswire.com/news-release/2023/08/14/2724500/0/en/Eloxx-Pharmaceuticals-Reports-Second-Quarter-2023-Financial-and-Operating-Results-and-Provides-Business-Update.html","Earnings Releases and Operating Results","2023-08-14 08:30:00","pre_market",5,5,446,445,0,-0,0,"long","long",NaN
886,"ELOX","Eloxx Pharmaceuticals to Host Investor and Analyst Call on Alport Syndrome","https://www.globenewswire.com/news-release/2023/06/21/2692434/0/en/Eloxx-Pharmaceuticals-to-Host-Investor-and-Analyst-Call-on-Alport-Syndrome.html","Health","2023-06-21 13:30:00","market_open",5,4,436,435,-0,-0,-0,"short","long",NaN
871,"EDIT","Editas Medicine Announces Second Quarter 2023 Results Conference Call and Corporate Update","https://www.globenewswire.com/news-release/2023/07/26/2711149/0/en/Editas-Medicine-Announces-Second-Quarter-2023-Results-Conference-Call-and-Corporate-Update.html","Conference Calls/ Webcasts","2023-07-26 07:00:00","pre_market",9,9,455,454,-0,-0,-0,"short","short",NaN
872,"EDIT","Editas Medicine Announces Third Quarter 2023 Results Conference Call and Upcoming Investor Events","https://www.globenewswire.com/news-release/2023/10/27/2768274/0/en/Editas-Medicine-Announces-Third-Quarter-2023-Results-Conference-Call-and-Upcoming-Investor-Events.html","Conference Calls/ Webcasts","2023-10-27 07:00:00","pre_market",7,7,413,414,0,0,0,"long","long",NaN
873,"EDIT","Editas Medicine Strengthens Executive Leadership Team with Appointment of Linda C. Burkly, Ph.D., as Chief Scientific Officer","https://www.globenewswire.com/news-release/2023/07/24/2709396/0/en/Editas-Medicine-Strengthens-Executive-Leadership-Team-with-Appointment-of-Linda-C-Burkly-Ph-D-as-Chief-Scientific-Officer.html","Directors and Officers","2023-07-24 07:00:00","pre_market",9,9,452,453,-0,0,-0,"short","short",NaN
874,"EDIT","Editas Medicine Receives FDA Orphan Drug Designation for EDIT-301 for the Treatment of Sickle Cell Disease","https://www.globenewswire.com/news-release/2023/04/27/2656430/0/en/Editas-Medicine-Receives-FDA-Orphan-Drug-Designation-for-EDIT-301-for-the-Treatment-of-Sickle-Cell-Disease.html","Clinical Study","2023-04-27 09:00:00","pre_market",8,8,404,407,0,0,0,"long","long",NaN
875,"EDIT","Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of EDIT-301 at the ASH 2023 Annual Meeting and in a Company-sponsored Webinar","https://www.globenewswire.com/news-release/2023/11/02/2772452/0/en/Editas-Medicine-to-Present-Clinical-Data-from-the-RUBY-and-EdiTHAL-Trials-of-EDIT-301-at-the-ASH-2023-Annual-Meeting-and-in-a-Company-sponsored-Webinar.html","Product / Services Announcement","2023-11-02 09:12:00","pre_market",7,7,423,427,0,0,0,"long","long",NaN
876,"EDIT","Editas Medicine Announces Second Quarter 2023 Results and Business Updates","https://www.globenewswire.com/news-release/2023/08/02/2716708/0/en/Editas-Medicine-Announces-Second-Quarter-2023-Results-and-Business-Updates.html","Earnings Releases and Operating Results","2023-08-02 07:00:00","pre_market",9,8,456,453,-0,-0,-0,"short","short",NaN
877,"EDIT","Editas Medicine Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for EDIT-301 for the Treatment of Severe Sickle Cell Disease","https://www.globenewswire.com/news-release/2023/10/16/2760573/0/en/Editas-Medicine-Granted-FDA-Regenerative-Medicine-Advanced-Therapy-RMAT-Designation-for-EDIT-301-for-the-Treatment-of-Severe-Sickle-Cell-Disease.html","Health","2023-10-16 08:00:00","pre_market",7,7,432,434,-0,0,-0,"short","short",NaN
878,"EDIT","Editas Medicine and Azzur Group Expand Partnership to Accelerate Editas’ Manufacturing Capabilities for Advancing the EDIT-301 Program Through Approval to Commercialization","https://www.globenewswire.com/news-release/2023/07/27/2712247/0/en/Editas-Medicine-and-Azzur-Group-Expand-Partnership-to-Accelerate-Editas-Manufacturing-Capabilities-for-Advancing-the-EDIT-301-Program-Through-Approval-to-Commercialization.html","Partnerships","2023-07-27 09:00:00","pre_market",9,9,456,459,0,0,0,"long","long",NaN
879,"EDIT","Editas Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference","https://www.globenewswire.com/news-release/2024/01/03/2803160/0/en/Editas-Medicine-to-Present-at-the-42nd-Annual-J-P-Morgan-Healthcare-Conference.html","Calendar of Events","2024-01-03 07:00:00","pre_market",10,10,473,470,-0,-0,-0,"short","short",NaN
880,"EDIT","Editas Medicine Highlights 2024 Anticipated Milestones and Strategic Priorities at the J.P. Morgan Healthcare Conference","https://www.globenewswire.com/news-release/2024/01/08/2805430/0/en/Editas-Medicine-Highlights-2024-Anticipated-Milestones-and-Strategic-Priorities-at-the-J-P-Morgan-Healthcare-Conference.html","Calendar of Events","2024-01-08 08:15:00","pre_market",9,9,468,468,-0,0,-0,"short","short",NaN
881,"EDIT","Editas Medicine and Vertex Pharmaceuticals Enter into Non-exclusive License Agreement for Cas9","https://www.globenewswire.com/news-release/2023/12/13/2795602/0/en/Editas-Medicine-and-Vertex-Pharmaceuticals-Enter-into-Non-exclusive-License-Agreement-for-Cas9.html","Licensing Agreements","2023-12-13 09:00:00","pre_market",10,10,464,464,0,0,0,"long","long",NaN
882,"EDIT","Editas Medicine to Participate in Upcoming Investor Conferences","https://www.globenewswire.com/news-release/2024/01/31/2821218/0/en/Editas-Medicine-to-Participate-in-Upcoming-Investor-Conferences.html","Conference Calls/ Webcasts","2024-01-31 09:00:00","pre_market",7,7,491,489,0,-0,0,"long","long",NaN
883,"EDIT","Editas Medicine Announces New EDIT-301 Safety and Efficacy Data in 17 Patients, Presented Today at the American Society of Hematology (ASH) Annual Meeting and in a Company-sponsored Webinar","https://www.globenewswire.com/news-release/2023/12/11/2794110/0/en/Editas-Medicine-Announces-New-EDIT-301-Safety-and-Efficacy-Data-in-17-Patients-Presented-Today-at-the-American-Society-of-Hematology-ASH-Annual-Meeting-and-in-a-Company-sponsored-W.html","Clinical Study","2023-12-11 12:00:00","market_open",10,10,460,462,-0,0,-0,"short","short",NaN
887,"ELOX","Eloxx Pharmaceuticals Intends to Advance ELX-02 into Pivotal Trial for the Treatment of Alport Syndrome with Nonsense Mutations Following Achievement of Remission in Patient in Phase 2 Study","https://www.globenewswire.com/news-release/2023/05/24/2675190/0/en/Eloxx-Pharmaceuticals-Intends-to-Advance-ELX-02-into-Pivotal-Trial-for-the-Treatment-of-Alport-Syndrome-with-Nonsense-Mutations-Following-Achievement-of-Remission-in-Patient-in-Pha.html","Clinical Study","2023-05-24 08:00:00","pre_market",9,8,414,412,-0,-0,-0,"short","short",NaN
899,"ELTX","Elicio Therapeutics Announces Appointment of Megan Filoon as General Counsel and Dr. Thian Kheoh as Senior Vice President of Biometrics","https://www.globenewswire.com/news-release/2023/08/28/2732545/0/en/Elicio-Therapeutics-Announces-Appointment-of-Megan-Filoon-as-General-Counsel-and-Dr-Thian-Kheoh-as-Senior-Vice-President-of-Biometrics.html","Directors and Officers","2023-08-28 08:00:00","pre_market",10,10,440,442,-0,0,-0,"short","long",NaN
888,"ELOX","Eloxx Pharmaceuticals Highlights Recent Alport Syndrome Natural History Data Presented at 60th ERA Congress","https://www.globenewswire.com/news-release/2023/06/21/2692112/0/en/Eloxx-Pharmaceuticals-Highlights-Recent-Alport-Syndrome-Natural-History-Data-Presented-at-60th-ERA-Congress.html","Clinical Study","2023-06-21 09:00:00","pre_market",5,5,437,436,0,-0,0,"long","long",NaN
889,"ELOX","Eloxx Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules","https://www.globenewswire.com/news-release/2023/09/19/2745534/0/en/Eloxx-Pharmaceuticals-Announces-2-Million-Registered-Direct-Offering-Priced-At-the-Market-Under-Nasdaq-Rules.html","Prospectus/Announcement of Prospectus","2023-09-19 08:00:00","pre_market",5,5,444,443,-0,-0,0,"long","long",NaN
890,"ELOX","Eloxx Pharmaceuticals Reports Independent Confirmation of Positive Biopsy Results in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome","https://www.globenewswire.com/news-release/2023/09/18/2744637/0/en/Eloxx-Pharmaceuticals-Reports-Independent-Confirmation-of-Positive-Biopsy-Results-in-All-Patients-Treated-with-ELX-02-in-Phase-2-Clinical-Study-for-Alport-Syndrome.html","Clinical Study","2023-09-18 07:00:00","pre_market",6,6,443,443,0,-0,0,"long","long",NaN
891,"ELOX","Eloxx Pharmaceuticals Provides Program Updates on ELX-02 and ZKN-013","https://www.globenewswire.com/news-release/2023/09/07/2739454/0/en/Eloxx-Pharmaceuticals-Provides-Program-Updates-on-ELX-02-and-ZKN-013.html","Clinical Study","2023-09-07 09:00:00","pre_market",5,6,446,443,0,-0,0,"long","short",NaN
892,"ELOX","Eloxx Pharmaceuticals Reports Drug Response in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome","https://www.globenewswire.com/news-release/2023/08/14/2724338/0/en/Eloxx-Pharmaceuticals-Reports-Drug-Response-in-All-Patients-Treated-with-ELX-02-in-Phase-2-Clinical-Study-for-Alport-Syndrome.html","Clinical Study","2023-08-14 08:00:00","pre_market",5,5,446,445,0,-0,0,"long","long",NaN
893,"ELOX","Eloxx Pharmaceuticals Granted Extension by Nasdaq to Regain Compliance with the Market Value of Listed Securities Continued Listing Requirement","https://www.globenewswire.com/news-release/2023/06/06/2682826/0/en/Eloxx-Pharmaceuticals-Granted-Extension-by-Nasdaq-to-Regain-Compliance-with-the-Market-Value-of-Listed-Securities-Continued-Listing-Requirement.html","Exchange Members","2023-06-06 08:30:00","pre_market",7,7,427,427,0,-0,0,"long","long",NaN
894,"ELOX","Eloxx Pharmaceuticals Announces Publication Demonstrating the Power of its TURBO-ZM™ Platform to Target the Human Ribosome for Therapeutic Benefit","https://www.globenewswire.com/news-release/2023/07/10/2701816/0/en/Eloxx-Pharmaceuticals-Announces-Publication-Demonstrating-the-Power-of-its-TURBO-ZM-Platform-to-Target-the-Human-Ribosome-for-Therapeutic-Benefit.html","Product / Services Announcement","2023-07-10 09:00:00","pre_market",4,4,439,438,0,-0,0,"long","long",NaN
895,"ELOX","Eloxx Pharmaceuticals Reports Additional Confirmation that All Nonsense Mutation Alport Syndrome Patients Treated with ELX-02 in Phase 2 Study had Improvement in Kidney Morphology and Clinical Benefit of Reduction or Stabilization of Proteinuria","https://www.globenewswire.com/news-release/2023/10/09/2756643/0/en/Eloxx-Pharmaceuticals-Reports-Additional-Confirmation-that-All-Nonsense-Mutation-Alport-Syndrome-Patients-Treated-with-ELX-02-in-Phase-2-Study-had-Improvement-in-Kidney-Morphology-.html","Health","2023-10-09 08:00:00","pre_market",4,4,430,428,-0,-0,-0,"short","short",NaN
896,"ELOX","Eloxx Pharmaceuticals Key Opinion Leader Event Highlights Significant Unmet Need in Treatment of Alport Syndrome Patients with Nonsense Mutations and Additional Positive Results from Phase 2 Clinical Study Evaluating ELX-02","https://www.globenewswire.com/news-release/2023/06/28/2696256/0/en/Eloxx-Pharmaceuticals-Key-Opinion-Leader-Event-Highlights-Significant-Unmet-Need-in-Treatment-of-Alport-Syndrome-Patients-with-Nonsense-Mutations-and-Additional-Positive-Results-fr.html","Clinical Study","2023-06-28 09:00:00","pre_market",4,4,436,435,-0,-0,-0,"short","short",NaN
897,"ELOX","Eloxx Pharmaceuticals Reports Fourth Quarter 2022 Financial and Operating Results and Provides Business Update","https://www.globenewswire.com/news-release/2023/04/03/2639530/0/en/Eloxx-Pharmaceuticals-Reports-Fourth-Quarter-2022-Financial-and-Operating-Results-and-Provides-Business-Update.html","Earnings Releases and Operating Results","2023-04-03 08:00:00","pre_market",3,3,409,409,0,-0,0,"long","long",NaN
914,"ENTX","Interim Results from Ongoing Clinical Study Confirm EB613 Optimized Profile for Osteoporosis Treatment and Potential for Entera’s Next Generation Oral Peptide Platform","https://www.globenewswire.com/news-release/2023/11/29/2787754/0/en/Interim-Results-from-Ongoing-Clinical-Study-Confirm-EB613-Optimized-Profile-for-Osteoporosis-Treatment-and-Potential-for-Entera-s-Next-Generation-Oral-Peptide-Platform.html","Health","2023-11-29 08:30:00","pre_market",1,1,455,457,0,0,0,"long","long",NaN
915,"ENTX","Entera Bio Reports Rapid Pharmacodynamic (PD) Response and Consistent Pharmacokinetic (PK) Data for its First-in-Class Oral PTH(1-34) Mini Tablets at the ASBMR 2023 Annual Meeting","https://www.globenewswire.com/news-release/2023/10/16/2760611/0/en/Entera-Bio-Reports-Rapid-Pharmacodynamic-PD-Response-and-Consistent-Pharmacokinetic-PK-Data-for-its-First-in-Class-Oral-PTH-1-34-Mini-Tablets-at-the-ASBMR-2023-Annual-Meeting.html","Health","2023-10-16 08:00:00","pre_market",1,1,432,434,0,0,0,"long","long",NaN
916,"ENTX","Entera Bio to Participate in the SVB Securities Global Biopharma Conference","https://www.globenewswire.com/news-release/2023/02/13/2606702/0/en/Entera-Bio-to-Participate-in-the-SVB-Securities-Global-Biopharma-Conference.html","Calendar of Events","2023-02-13 09:00:00","pre_market",1,1,408,409,-0,0,-0,"short","short",NaN
917,"ENTX","Entera Bio Hosting Key Opinion Leader Webinar on the Treatment Landscape for Osteoporosis and EB613’s Potential Impact on Wednesday, September 28th @ 10am ET","https://www.globenewswire.com/news-release/2022/09/21/2520186/0/en/Entera-Bio-Hosting-Key-Opinion-Leader-Webinar-on-the-Treatment-Landscape-for-Osteoporosis-and-EB613-s-Potential-Impact-on-Wednesday-September-28th-10am-ET.html","Calendar of Events","2022-09-21 08:30:00","pre_market",1,1,384,386,0,0,-0,"short","long",NaN
918,"ENTX","Entera Bio Reports Q3 2023 Financial Results, Highlights Transformational Steps and Unveils Vision as Premier Oral Peptide Company with Five Potential Programs in Development","https://www.globenewswire.com/news-release/2023/11/14/2779971/0/en/Entera-Bio-Reports-Q3-2023-Financial-Results-Highlights-Transformational-Steps-and-Unveils-Vision-as-Premier-Oral-Peptide-Company-with-Five-Potential-Programs-in-Development.html","Earnings Releases and Operating Results","2023-11-14 07:30:00","pre_market",1,1,440,446,0,0,-0,"short","long",NaN
919,"ENTX","Entera Bio Adds Sanofi Commercial Leader, Haya Taitel to its Board of Directors","https://www.globenewswire.com/news-release/2023/06/07/2683653/0/en/Entera-Bio-Adds-Sanofi-Commercial-Leader-Haya-Taitel-to-its-Board-of-Directors.html","Directors and Officers","2023-06-07 07:30:00","pre_market",1,1,428,428,0,0,0,"long","long",NaN
904,"ELTX","Elicio Therapeutics Receives $2.6 Million Grant from the Gastro-Intestinal (GI) Research Foundation to Fund Research for Two Therapeutic Cancer Vaccines","https://www.globenewswire.com/news-release/2023/09/07/2739266/0/en/Elicio-Therapeutics-Receives-2-6-Million-Grant-from-the-Gastro-Intestinal-GI-Research-Foundation-to-Fund-Research-for-Two-Therapeutic-Cancer-Vaccines.html","Product / Services Announcement","2023-09-07 08:00:00","pre_market",8,9,446,443,0,-0,0,"long","long",NaN
905,"ELTX","Elicio Therapeutics to Present at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference","https://www.globenewswire.com/news-release/2023/12/04/2789966/0/en/Elicio-Therapeutics-to-Present-at-the-H-C-Wainwright-4th-Annual-Precision-Oncology-Virtual-Conference.html","Conference Calls/ Webcasts","2023-12-04 08:00:00","pre_market",6,6,459,456,0,-0,0,"long","long",NaN
906,"ELTX","Nature Medicine Publishes Updated Preliminary Phase 1 Data From Elicio Therapeutic’s AMPLIFY-201 Phase 1 Solid Tumor Study of ELI-002","https://www.globenewswire.com/news-release/2024/01/09/2806073/0/en/Nature-Medicine-Publishes-Updated-Preliminary-Phase-1-Data-From-Elicio-Therapeutic-s-AMPLIFY-201-Phase-1-Solid-Tumor-Study-of-ELI-002.html","Health","2024-01-09 06:00:00","pre_market",8,8,475,472,0,-0,0,"long","long",NaN
907,"ELTX","Elicio Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference","https://www.globenewswire.com/news-release/2024/02/05/2823522/0/en/Elicio-Therapeutics-to-Present-at-the-Oppenheimer-34th-Annual-Healthcare-Life-Sciences-Conference.html","Calendar of Events","2024-02-05 08:30:00","pre_market",4,4,494,494,0,-0,0,"long","long",NaN
908,"ELTX","Elicio Therapeutics Announces $7.0 Million Private Placement Financing","https://www.globenewswire.com/news-release/2023/12/22/2800613/0/en/Elicio-Therapeutics-Announces-7-0-Million-Private-Placement-Financing.html","Financing Agreements","2023-12-22 09:00:00","pre_market",6,6,473,474,-0,0,-0,"short","short",NaN
909,"ELTX","Elicio Therapeutics Announces First Patient Dosed in Randomized Phase 2 Pancreatic Cancer Study","https://www.globenewswire.com/news-release/2024/01/11/2807912/0/en/Elicio-Therapeutics-Announces-First-Patient-Dosed-in-Randomized-Phase-2-Pancreatic-Cancer-Study.html","Health","2024-01-11 08:30:00","pre_market",6,5,477,478,-0,0,-0,"short","short",NaN
910,"ELTX","Elicio Therapeutics to Present ELI-002 7P (AMPLIFY-7P) Trial in Progress Poster on Phase 1/2 Study of Lymph Node-Targeted Vaccine at ASCO GI Symposium","https://www.globenewswire.com/news-release/2024/01/17/2810706/0/en/Elicio-Therapeutics-to-Present-ELI-002-7P-AMPLIFY-7P-Trial-in-Progress-Poster-on-Phase-1-2-Study-of-Lymph-Node-Targeted-Vaccine-at-ASCO-GI-Symposium.html","Calendar of Events","2024-01-17 08:30:00","pre_market",5,5,475,472,0,-0,0,"long","long",NaN
929,"ETNB","89bio Announces U.S. FDA has Granted Breakthrough Therapy Designation for Pegozafermin in Nonalcoholic Steatohepatitis (NASH)","https://www.globenewswire.com/news-release/2023/09/21/2747202/0/en/89bio-Announces-U-S-FDA-has-Granted-Breakthrough-Therapy-Designation-for-Pegozafermin-in-Nonalcoholic-Steatohepatitis-NASH.html","Company Announcement","2023-09-21 08:00:00","pre_market",15,15,439,436,0,-0,0,"long","long",NaN
930,"ETNB","89bio to Participate in Upcoming Investor Conferences","https://www.globenewswire.com/news-release/2023/05/02/2659103/0/en/89bio-to-Participate-in-Upcoming-Investor-Conferences.html","Trade Show","2023-05-02 08:00:00","pre_market",17,17,416,415,0,-0,0,"long","long",NaN
931,"ETNB","89bio Initiates Phase 3 ENTRUST Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG)","https://www.globenewswire.com/news-release/2023/05/23/2674259/0/en/89bio-Initiates-Phase-3-ENTRUST-Trial-of-Pegozafermin-in-Patients-with-Severe-Hypertriglyceridemia-SHTG.html","Clinical Study","2023-05-23 08:00:00","pre_market",17,17,419,417,0,-0,0,"long","long",NaN
932,"ETNB","89bio to Participate in the 2023 Cantor Global Healthcare Conference","https://www.globenewswire.com/news-release/2023/09/20/2746391/0/en/89bio-to-Participate-in-the-2023-Cantor-Global-Healthcare-Conference.html","Conference Calls/ Webcasts","2023-09-20 08:00:00","pre_market",17,17,443,444,0,0,-0,"short","short",NaN
933,"ETNB","89bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update","https://www.globenewswire.com/news-release/2023/03/10/2624905/0/en/89bio-Reports-Fourth-Quarter-and-Full-Year-2022-Financial-Results-and-Provides-Corporate-Update.html","Earnings Releases and Operating Results","2023-03-10 08:00:00","pre_market",13,13,392,391,0,-0,0,"long","long",NaN
920,"ENTX","Entera Bio Announces FDA Agreement for a Single Phase 3 Clinical Trial to Support an NDA for EB613 for the Treatment of Osteoporosis","https://www.globenewswire.com/news-release/2022/10/06/2529359/0/en/Entera-Bio-Announces-FDA-Agreement-for-a-Single-Phase-3-Clinical-Trial-to-Support-an-NDA-for-EB613-for-the-Treatment-of-Osteoporosis.html","Clinical Study","2022-10-06 07:00:00","pre_market",1,1,377,376,0,-0,0,"long","long",NaN
934,"ETNB","89bio’s Phase 2b ENLIVEN Trial of Pegozafermin in Nonalcoholic Steatohepatitis (NASH) Achieved High Statistical Significance on Both Primary Histology Endpoints with Weekly (QW) and Every-Two-Week (Q2W) Dosing at 24 Weeks","https://www.globenewswire.com/news-release/2023/03/22/2632062/0/en/89bio-s-Phase-2b-ENLIVEN-Trial-of-Pegozafermin-in-Nonalcoholic-Steatohepatitis-NASH-Achieved-High-Statistical-Significance-on-Both-Primary-Histology-Endpoints-with-Weekly-QW-and-Ev.html","Health","2023-03-22 07:00:00","pre_market",11,15,399,399,0,-0,0,"long","long",NaN
921,"ENTX","Entera Bio Provides Guidance from FDA Type D Meeting Related to EB613 Pivotal Program","https://www.globenewswire.com/news-release/2023/04/03/2639415/0/en/Entera-Bio-Provides-Guidance-from-FDA-Type-D-Meeting-Related-to-EB613-Pivotal-Program.html","Health","2023-04-03 07:00:00","pre_market",1,1,409,409,0,-0,0,"long","long",NaN
935,"ETNB","89bio Announces New Positive Long-Term Data from the ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis (NASH)","https://www.globenewswire.com/news-release/2023/11/27/2786131/0/en/89bio-Announces-New-Positive-Long-Term-Data-from-the-ENLIVEN-Phase-2b-Trial-of-Pegozafermin-in-Patients-with-Nonalcoholic-Steatohepatitis-NASH.html","Clinical Study","2023-11-27 08:00:00","pre_market",8,8,455,455,-0,-0,-0,"short","long",NaN
922,"ENTX","Entera Bio Reports Key Milestone Relating to Oral PTH (1-34) Peptide (EB613) Phase 3 Program: ASBMR-SABRE Has Submitted to FDA the Full Qualification Plan to Approve BMD as a Surrogate Endpoint for Osteoporosis","https://www.globenewswire.com/news-release/2023/11/09/2777730/0/en/Entera-Bio-Reports-Key-Milestone-Relating-to-Oral-PTH-1-34-Peptide-EB613-Phase-3-Program-ASBMR-SABRE-Has-Submitted-to-FDA-the-Full-Qualification-Plan-to-Approve-BMD-as-a-Surrogate-.html","Clinical Study","2023-11-09 14:30:00","market_open",1,1,438,434,0,-0,0,"long","long",NaN
923,"ENTX","Entera Bio Announces Collaboration with OPKO Biologics to Develop Oral Peptide Tablet Formulations for Obesity and Intestinal Malabsorption Syndromes","https://www.globenewswire.com/news-release/2023/09/12/2741673/0/en/Entera-Bio-Announces-Collaboration-with-OPKO-Biologics-to-Develop-Oral-Peptide-Tablet-Formulations-for-Obesity-and-Intestinal-Malabsorption-Syndromes.html","Partnerships","2023-09-12 08:30:00","pre_market",1,1,448,447,0,-0,0,"long","long",NaN
925,"ENTX","Entera’s Oral Delivery of GLP-2 Pre-Clinical Data to be Published in Peer Reviewed, International Journal of Peptide Research and Therapeutics","https://www.globenewswire.com/news-release/2023/05/03/2660482/0/en/Entera-s-Oral-Delivery-of-GLP-2-Pre-Clinical-Data-to-be-Published-in-Peer-Reviewed-International-Journal-of-Peptide-Research-and-Therapeutics.html","Clinical Study","2023-05-03 09:34:00","market_open",1,1,411,408,0,-0,0,"long","long",NaN
926,"ENTX","Entera Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference","https://www.globenewswire.com/news-release/2024/01/30/2820007/0/en/Entera-Bio-to-Present-at-the-Oppenheimer-34th-Annual-Healthcare-Life-Sciences-Conference.html","Calendar of Events","2024-01-30 08:30:00","pre_market",1,1,491,491,-0,-0,-0,"short","short",NaN
927,"ENTX","Entera Bio Receives Extension from Nasdaq to Regain Compliance with Minimum Bid Price Rule","https://www.globenewswire.com/news-release/2024/01/03/2803257/0/en/Entera-Bio-Receives-Extension-from-Nasdaq-to-Regain-Compliance-with-Minimum-Bid-Price-Rule.html","Management statements","2024-01-03 08:00:00","pre_market",1,1,473,470,0,-0,0,"long","long",NaN
943,"EVAX","Evaxion präsentiert neueste klinische Daten der Phase II von EVX-01 in einem Webinar mit dem Key Opinion Leader Adnan Khattak","https://www.globenewswire.com/news-release/2023/11/07/2775301/0/de/Evaxion-pr%C3%A4sentiert-neueste-klinische-Daten-der-Phase-II-von-EVX-01-in-einem-Webinar-mit-dem-Key-Opinion-Leader-Adnan-Khattak.html","Calendar of Events","2023-11-07 10:15:00","market_open",12,12,436,437,-0,0,-0,"short","short",NaN
944,"EVAX","Evaxion Announces Encouraging Initial Phase 2 Clinical Data on Its Personalized Cancer Vaccine EVX-01","https://www.globenewswire.com/news-release/2023/10/31/2770437/0/en/Evaxion-Announces-Encouraging-Initial-Phase-2-Clinical-Data-on-Its-Personalized-Cancer-Vaccine-EVX-01.html","Clinical Study","2023-10-31 11:15:00","market_open",10,11,416,418,0,0,0,"long","short",NaN
945,"EVAX","Evaxion expands preclinical bacterial vaccine pipeline in collaboration with leading pharmaceutical company","https://www.globenewswire.com/news-release/2023/09/18/2744760/0/en/Evaxion-expands-preclinical-bacterial-vaccine-pipeline-in-collaboration-with-leading-pharmaceutical-company.html","Partnerships","2023-09-18 08:23:00","pre_market",8,7,443,443,-0,-0,-0,"short","short",NaN
946,"EVAX","Révolutionner la découverte de vaccins : De nouvelles données valident la plateforme d'intelligence artificielle d'Evaxion, promettant de réduire les risques et les coûts dans le développement de vaccins contre les maladies infectieuses","https://www.globenewswire.com/news-release/2023/09/12/2741564/0/fr/R%C3%A9volutionner-la-d%C3%A9couverte-de-vaccins-De-nouvelles-donn%C3%A9es-valident-la-plateforme-d-intelligence-artificielle-d-Evaxion-promettant-de-r%C3%A9duire-les-risques-et-les-co%C3%BBts-dans-le-d%C3%A9ve.html","Research Analysis and Reports","2023-09-12 07:59:00","pre_market",8,8,448,447,0,-0,0,"long","long",NaN
947,"EVAX","Evaxion Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency","https://www.globenewswire.com/news-release/2023/10/05/2755383/0/en/Evaxion-Receives-Nasdaq-Notification-Regarding-Minimum-Bid-Price-Deficiency.html","Major shareholder announcements","2023-10-05 08:30:00","pre_market",9,8,425,424,-0,-0,-0,"short","short",NaN
948,"EVAX","Evaxion präsentiert Proof-of-Principle für sein einzigartiges KI-Modell zur Vorhersage des Ansprechens auf Krebsimmuntherapie","https://www.globenewswire.com/news-release/2023/11/16/2781872/0/de/Evaxion-pr%C3%A4sentiert-Proof-of-Principle-f%C3%BCr-sein-einzigartiges-KI-Modell-zur-Vorhersage-des-Ansprechens-auf-Krebsimmuntherapie.html","Health","2023-11-16 08:52:00","pre_market",7,7,450,449,-0,-0,-0,"short","short",NaN
949,"EVAX","Evaxion Presents Proof-of-Principle for Its Unique AI Model Predicting Responses to Cancer Immunotherapy","https://www.globenewswire.com/news-release/2023/11/15/2780971/0/en/Evaxion-Presents-Proof-of-Principle-for-Its-Unique-AI-Model-Predicting-Responses-to-Cancer-Immunotherapy.html","Health","2023-11-15 08:00:00","pre_market",7,8,449,450,0,0,0,"long","long",NaN
950,"EVAX","Revolutionizing Vaccine Discovery: New Data Validates Evaxion AI Platform, Offering Promise to Reduce Risk and Cost in Infectious Disease Vaccine Development","https://www.globenewswire.com/news-release/2023/09/11/2740790/0/en/Revolutionizing-Vaccine-Discovery-New-Data-Validates-Evaxion-AI-Platform-Offering-Promise-to-Reduce-Risk-and-Cost-in-Infectious-Disease-Vaccine-Development.html","Research Analysis and Reports","2023-09-11 08:17:00","pre_market",7,7,446,448,0,0,0,"long","long",NaN
1820,"ORPHA.CO","Storaktionærmeddelelse","https://www.globenewswire.com/news-release/2023/12/08/2793179/0/da/Storaktion%C3%A6rmeddelelse.html","European Regulatory News","2023-12-08 08:12:00","pre_market",677,676,458,457,-0,-0,0,"long","long",NaN
936,"ETNB","89bio, Inc. Announces Upsized Pricing of $275 Million Public Offering of Common Stock","https://www.globenewswire.com/news-release/2023/03/24/2633885/0/en/89bio-Inc-Announces-Upsized-Pricing-of-275-Million-Public-Offering-of-Common-Stock.html","Stock Market News","2023-03-24 07:00:00","pre_market",17,17,393,392,0,-0,0,"long","long",NaN
937,"ETNB","89bio Reaches Alignment with the FDA and EMA on Phase 3 Program for Pegozafermin in Nonalcoholic Steatohepatitis (NASH); Program Initiation Planned in the First Half of 2024","https://www.globenewswire.com/news-release/2023/12/04/2789876/0/en/89bio-Reaches-Alignment-with-the-FDA-and-EMA-on-Phase-3-Program-for-Pegozafermin-in-Nonalcoholic-Steatohepatitis-NASH-Program-Initiation-Planned-in-the-First-Half-of-2024.html","Clinical Study","2023-12-04 07:00:00","pre_market",8,9,459,456,0,-0,0,"long","long",NaN
938,"ETNB","89bio to Participate in the H.C. Wainwright 7ᵗʰ Annual NASH Investor Conference","https://www.globenewswire.com/news-release/2023/10/17/2761468/0/en/89bio-to-Participate-in-the-H-C-Wainwright-7%E1%B5%97%CA%B0-Annual-NASH-Investor-Conference.html","Conference Calls/ Webcasts","2023-10-17 08:00:00","pre_market",7,7,436,433,-0,-0,-0,"short","short",NaN
939,"ETNB","89bio Announces Closing of its Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares","https://www.globenewswire.com/news-release/2023/12/12/2794645/0/en/89bio-Announces-Closing-of-its-Upsized-Public-Offering-and-Full-Exercise-of-Underwriters-Option-to-Purchase-Additional-Shares.html","Major shareholder announcements","2023-12-12 07:30:00","pre_market",10,9,462,462,-0,-0,-0,"short","short",NaN
940,"ETNB","89bio, Inc. Announces Upsized Pricing of $150.0 Million Public Offering of Common Stock and Pre-Funded Warrants","https://www.globenewswire.com/news-release/2023/12/07/2792370/0/en/89bio-Inc-Announces-Upsized-Pricing-of-150-0-Million-Public-Offering-of-Common-Stock-and-Pre-Funded-Warrants.html","Warrants and Certificates","2023-12-07 07:00:00","pre_market",10,10,455,457,-0,0,-0,"short","short",NaN
952,"EVAX","Evaxion announces Executive Management Changes to strengthen the AI-strategy","https://www.globenewswire.com/news-release/2023/08/29/2733405/0/en/Evaxion-announces-Executive-Management-Changes-to-strengthen-the-AI-strategy.html","Management Changes","2023-08-29 08:30:00","pre_market",9,9,443,443,0,-0,0,"long","short",NaN
953,"EVAX","Evaxion présente les dernières données cliniques de la phase II d’EVX-01 à l’occasion d’un webinaire organisé en présence du leader d’opinion Adnan Khattak","https://www.globenewswire.com/news-release/2023/11/07/2775301/0/fr/Evaxion-pr%C3%A9sente-les-derni%C3%A8res-donn%C3%A9es-cliniques-de-la-phase-II-d-EVX-01-%C3%A0-l-occasion-d-un-webinaire-organis%C3%A9-en-pr%C3%A9sence-du-leader-d-opinion-Adnan-Khattak.html","Calendar of Events","2023-11-07 10:15:00","market_open",12,12,436,437,-0,0,-0,"short","short",NaN
955,"EVAX","De nouvelles données cliniques passionnantes sur les vaccins anticancéreux individualisés d'Evaxion et basés sur l'AI-Immunology™ seront bientôt présentées","https://www.globenewswire.com/news-release/2023/10/27/2768411/0/fr/De-nouvelles-donn%C3%A9es-cliniques-passionnantes-sur-les-vaccins-anticanc%C3%A9reux-individualis%C3%A9s-d-Evaxion-et-bas%C3%A9s-sur-l-AI-Immunology-seront-bient%C3%B4t-pr%C3%A9sent%C3%A9es.html","Calendar of Events","2023-10-27 08:48:00","pre_market",8,8,413,414,0,0,0,"long","long",NaN
956,"EVAX","Evaxion va lever le voile sur un concept potentiellement révolutionnaire de vaccin précis contre le cancer alimenté par sa plateforme IA-Immunology™","https://www.globenewswire.com/news-release/2023/11/29/2787781/0/fr/Evaxion-va-lever-le-voile-sur-un-concept-potentiellement-r%C3%A9volutionnaire-de-vaccin-pr%C3%A9cis-contre-le-cancer-aliment%C3%A9-par-sa-plateforme-IA-Immunology.html","Product / Services Announcement","2023-11-29 08:55:00","pre_market",8,8,455,457,-0,0,-0,"short","short",NaN
957,"EVAX","Evaxion stellt potenziell bahnbrechendes Konzept für AI-Immunology™-gestützen Präzisions-Krebsimpfstoff vor","https://www.globenewswire.com/news-release/2023/11/29/2787781/0/de/Evaxion-stellt-potenziell-bahnbrechendes-Konzept-f%C3%BCr-AI-Immunology-gest%C3%BCtzen-Pr%C3%A4zisions-Krebsimpfstoff-vor.html","Product / Services Announcement","2023-11-29 08:55:00","pre_market",8,8,455,457,-0,0,-0,"short","short",NaN
958,"EVAX","Evaxion geht Partnerschaft mit dem Pharmaunternehmen Afrigen Biologics zur Entwicklung eines neuartigen mRNA-Impfstoffs gegen Gonorrhoe ein","https://www.globenewswire.com/news-release/2023/09/20/2755536/0/de/Evaxion-geht-Partnerschaft-mit-dem-Pharmaunternehmen-Afrigen-Biologics-zur-Entwicklung-eines-neuartigen-mRNA-Impfstoffs-gegen-Gonorrhoe-ein.html","Partnerships","2023-09-20 08:26:00","pre_market",5,6,443,444,0,0,0,"long","long",NaN
960,"EVAX","Evaxion Shares Latest EVX-01 Phase 2 Clinical Data in Webinar with Key Opinion Leader Adnan Khattak","https://www.globenewswire.com/news-release/2023/11/06/2774255/0/en/Evaxion-Shares-Latest-EVX-01-Phase-2-Clinical-Data-in-Webinar-with-Key-Opinion-Leader-Adnan-Khattak.html","Calendar of Events","2023-11-06 10:12:00","market_open",12,11,435,436,-0,0,-0,"short","short",NaN
961,"EVAX","Revolution in der Entdeckung von Impfstoffen: Neue Daten validieren die KI-Plattform von Evaxion und versprechen Senkung der Risiken und Kosten bei der Entwicklung von Impfstoffen gegen Infektionskrankheiten","https://www.globenewswire.com/news-release/2023/09/12/2741564/0/de/Revolution-in-der-Entdeckung-von-Impfstoffen-Neue-Daten-validieren-die-KI-Plattform-von-Evaxion-und-versprechen-Senkung-der-Risiken-und-Kosten-bei-der-Entwicklung-von-Impfstoffen-g.html","Research Analysis and Reports","2023-09-12 07:59:00","pre_market",8,8,448,447,0,-0,0,"long","long",NaN
962,"EVAX","Evaxion gibt ermutigende erste klinische Daten der Phase II zu seinem personalisierten Krebsimpfstoff EVX-01 bekannt","https://www.globenewswire.com/news-release/2023/11/01/2771615/0/de/Evaxion-gibt-ermutigende-erste-klinische-Daten-der-Phase-II-zu-seinem-personalisierten-Krebsimpfstoff-EVX-01-bekannt.html","Clinical Study","2023-11-01 13:45:00","market_open",12,11,419,423,-0,0,-0,"short","short",NaN
963,"EVAX","Evaxion presents promising results on EVX-B1, an AI-designed vaccine against Staphylococcus aureus","https://www.globenewswire.com/news-release/2023/07/31/2714741/0/en/Evaxion-presents-promising-results-on-EVX-B1-an-AI-designed-vaccine-against-Staphylococcus-aureus.html","Clinical Study","2023-07-31 07:00:00","pre_market",13,12,457,457,-0,0,-0,"short","short",NaN
964,"EVAX","Evaxion s'associe à la société pharmaceutique Afrigen Biologics pour développer un nouveau vaccin à ARN messager contre la gonorrhée","https://www.globenewswire.com/news-release/2023/09/20/2755536/0/fr/Evaxion-s-associe-%C3%A0-la-soci%C3%A9t%C3%A9-pharmaceutique-Afrigen-Biologics-pour-d%C3%A9velopper-un-nouveau-vaccin-%C3%A0-ARN-messager-contre-la-gonorrh%C3%A9e.html","Partnerships","2023-09-20 08:26:00","pre_market",5,6,443,444,0,0,0,"long","long",NaN
965,"EVAX","Evaxion Partners With Pharmaceutical Company Afrigen Biologics to Develop Novel mRNA Vaccine Against Gonorrhea","https://www.globenewswire.com/news-release/2023/09/20/2746452/0/en/Evaxion-Partners-With-Pharmaceutical-Company-Afrigen-Biologics-to-Develop-Novel-mRNA-Vaccine-Against-Gonorrhea.html","Partnerships","2023-09-20 08:26:00","pre_market",5,6,443,444,0,0,0,"long","long",NaN
966,"EVAX","Neue und aufregende klinische Daten zu AI-Immunology™-basierten personalisierten Krebsimpfstoffen von Evaxion werden präsentiert","https://www.globenewswire.com/news-release/2023/10/27/2768411/0/de/Neue-und-aufregende-klinische-Daten-zu-AI-Immunology-basierten-personalisierten-Krebsimpfstoffen-von-Evaxion-werden-pr%C3%A4sentiert.html","Calendar of Events","2023-10-27 08:48:00","pre_market",8,8,413,414,0,0,0,"long","long",NaN
968,"EVAX","Evaxion to Develop Tailored Novel Cancer Vaccines Based upon a New Untapped Source of AI-Discovered Targets","https://www.globenewswire.com/news-release/2024/01/24/2815320/0/en/Evaxion-to-Develop-Tailored-Novel-Cancer-Vaccines-Based-upon-a-New-Untapped-Source-of-AI-Discovered-Targets.html","Product / Services Announcement","2024-01-24 08:30:00","pre_market",5,9,485,488,1,0,1,"long","short",NaN
969,"EVAX","Evaxion répond de nouveau aux exigences du Nasdaq en matière de prix minimum de l'offre","https://www.globenewswire.com/news-release/2024/02/08/2825836/0/fr/Evaxion-r%C3%A9pond-de-nouveau-aux-exigences-du-Nasdaq-en-mati%C3%A8re-de-prix-minimum-de-l-offre.html","Financing Agreements","2024-02-08 06:20:00","pre_market",4,4,498,498,0,0,0,"long","short",NaN
970,"EVAX","Evaxion Biotech gibt Preisfestsetzung für Emission in Höhe von 15 Mio. USD bekannt","https://www.globenewswire.com/news-release/2024/02/02/2822861/0/de/Evaxion-Biotech-gibt-Preisfestsetzung-f%C3%BCr-Emission-in-H%C3%B6he-von-15-Mio-USD-bekannt.html","Initial Public Offerings","2024-02-02 08:57:00","pre_market",5,5,489,490,0,0,-0,"short","short",NaN
971,"EVAX","Evaxion kündigt Plan zur Änderung des ADS-Verhältnisses an","https://www.globenewswire.com/news-release/2024/01/09/2806034/0/de/Evaxion-k%C3%BCndigt-Plan-zur-%C3%84nderung-des-ADS-Verh%C3%A4ltnisses-an.html","Changes in company's own shares","2024-01-09 04:43:00","pre_market",8,7,475,472,-0,-0,-0,"short","short",NaN
972,"EVAX","Evaxion Announces Plan to Implement ADS Ratio Change","https://www.globenewswire.com/news-release/2024/01/08/2805439/0/en/Evaxion-Announces-Plan-to-Implement-ADS-Ratio-Change.html","Changes in company's own shares","2024-01-08 08:30:00","pre_market",8,8,468,468,0,0,0,"long","long",NaN
973,"EVAX","Evaxion présente la preuve de concept de son modèle unique d’IA prédisant les réponses à l’immunothérapie du cancer","https://www.globenewswire.com/news-release/2023/11/16/2781872/0/fr/Evaxion-pr%C3%A9sente-la-preuve-de-concept-de-son-mod%C3%A8le-unique-d-IA-pr%C3%A9disant-les-r%C3%A9ponses-%C3%A0-l-immunoth%C3%A9rapie-du-cancer.html","Health","2023-11-16 08:52:00","pre_market",7,7,450,449,-0,-0,-0,"short","short",NaN
974,"EVAX","Evaxion Biotech gibt Abschluss einer Privatplatzierung bekannt","https://www.globenewswire.com/news-release/2023/12/22/2800800/0/de/Evaxion-Biotech-gibt-Abschluss-einer-Privatplatzierung-bekannt.html","Health","2023-12-22 15:13:00","market_open",7,7,474,474,0,-0,0,"long","long",NaN
975,"EVAX","Evaxion gibt den Abschluss seiner Emission in Höhe von 15 Mio. USD bekannt","https://www.globenewswire.com/news-release/2024/02/07/2825018/0/de/Evaxion-gibt-den-Abschluss-seiner-Emission-in-H%C3%B6he-von-15-Mio-USD-bekannt.html","Initial Public Offerings","2024-02-07 06:13:00","pre_market",4,4,494,496,0,0,-0,"short","short",NaN
976,"EVAX","Evaxion entwickelt maßgeschneiderte neuartige Krebsimpfstoffe auf der Grundlage einer neuen, bisher ungenutzten Quelle von durch KI entdeckten Targets","https://www.globenewswire.com/news-release/2024/01/25/2816750/0/de/Evaxion-entwickelt-ma%C3%9Fgeschneiderte-neuartige-Krebsimpfstoffe-auf-der-Grundlage-einer-neuen-bisher-ungenutzten-Quelle-von-durch-KI-entdeckten-Targets.html","Product / Services Announcement","2024-01-25 08:22:00","pre_market",11,11,485,488,0,0,-0,"short","long",NaN
977,"EVAX","Evaxion erfüllt wieder die Anforderungen der Nasdaq an den Mindestangebotspreis","https://www.globenewswire.com/news-release/2024/02/08/2825836/0/de/Evaxion-erf%C3%BCllt-wieder-die-Anforderungen-der-Nasdaq-an-den-Mindestangebotspreis.html","Financing Agreements","2024-02-08 06:20:00","pre_market",4,4,498,498,0,0,0,"long","short",NaN
978,"EVAX","Clôture du financement par placement privé pour Evaxion Biotech","https://www.globenewswire.com/news-release/2023/12/22/2800800/0/fr/Cl%C3%B4ture-du-financement-par-placement-priv%C3%A9-pour-Evaxion-Biotech.html","Health","2023-12-22 15:13:00","market_open",7,7,474,474,0,-0,0,"long","long",NaN
979,"EVAX","Evaxion Biotech Announces Pricing of $15 Million Public Offering","https://www.globenewswire.com/news-release/2024/02/01/2822093/0/en/Evaxion-Biotech-Announces-Pricing-of-15-Million-Public-Offering.html","Initial Public Offerings","2024-02-01 09:20:00","pre_market",4,4,483,485,0,0,0,"long","long",NaN
980,"EVAX","Evaxion annonce la clôture de son offre publique à 15 millions de dollars","https://www.globenewswire.com/news-release/2024/02/07/2825018/0/fr/Evaxion-annonce-la-cl%C3%B4ture-de-son-offre-publique-%C3%A0-15-millions-de-dollars.html","Initial Public Offerings","2024-02-07 06:13:00","pre_market",4,4,494,496,0,0,-0,"short","short",NaN
981,"EVAX","Evaxion Regains Compliance with Nasdaq Minimum Bid Price Requirement","https://www.globenewswire.com/news-release/2024/02/07/2825208/0/en/Evaxion-Regains-Compliance-with-Nasdaq-Minimum-Bid-Price-Requirement.html","Financing Agreements","2024-02-07 08:30:00","pre_market",4,4,494,496,0,0,-0,"short","short",NaN
982,"EVAX","Evaxion Announces Closing of $15 Million Public Offering","https://www.globenewswire.com/news-release/2024/02/06/2824339/0/en/Evaxion-Announces-Closing-of-15-Million-Public-Offering.html","Initial Public Offerings","2024-02-06 08:30:00","pre_market",4,4,493,494,0,0,0,"long","long",NaN
983,"EVAX","Evaxion annonce un plan visant à mettre en œuvre la modification du ratio de ses ADS","https://www.globenewswire.com/news-release/2024/01/09/2806034/0/fr/Evaxion-annonce-un-plan-visant-%C3%A0-mettre-en-%C5%93uvre-la-modification-du-ratio-de-ses-ADS.html","Changes in company's own shares","2024-01-09 04:43:00","pre_market",8,7,475,472,-0,-0,-0,"short","short",NaN
984,"EVAX","Evaxion announces financing commitments totaling up to USD 20 million with Negma Group","https://www.globenewswire.com/news-release/2023/08/01/2715621/0/en/Evaxion-announces-financing-commitments-totaling-up-to-USD-20-million-with-Negma-Group.html","Financing Agreements","2023-08-01 07:00:00","pre_market",12,12,458,456,-0,-0,-0,"short","short",NaN
985,"EVAX","Evaxion Biotech fixe le prix de son offre publique à 15 millions de dollars","https://www.globenewswire.com/news-release/2024/02/02/2822861/0/fr/Evaxion-Biotech-fixe-le-prix-de-son-offre-publique-%C3%A0-15-millions-de-dollars.html","Initial Public Offerings","2024-02-02 08:57:00","pre_market",5,5,489,490,0,0,-0,"short","short",NaN
1003,"EYEN","Eyenovia to Report Second Quarter 2023 Results on Thursday, August 10","https://www.globenewswire.com/news-release/2023/08/07/2719644/0/en/Eyenovia-to-Report-Second-Quarter-2023-Results-on-Thursday-August-10.html","Calendar of Events","2023-08-07 08:00:00","pre_market",2,2,447,449,0,0,0,"long","long",0
987,"EVLO","Evelo Biosciences Provides Clinical and Business Updates","https://www.globenewswire.com/news-release/2023/02/01/2599332/0/en/Evelo-Biosciences-Provides-Clinical-and-Business-Updates.html","Annual report","2023-02-01 07:30:00","pre_market",21,16,406,405,-0,-0,-0,"short","long",NaN
988,"EVLO","Evelo Biosciences Announces Reverse Stock Split Effective","https://www.globenewswire.com/news-release/2023/06/29/2697068/0/en/Evelo-Biosciences-Announces-Reverse-Stock-Split-Effective.html","Changes in company's own shares","2023-06-29 09:00:00","pre_market",5,4,436,436,-0,-0,-0,"short","long",NaN
989,"EVLO","Evelo Biosciences Provides Clinical Updates","https://www.globenewswire.com/news-release/2023/04/26/2654930/0/en/Evelo-Biosciences-Provides-Clinical-Updates.html","Health","2023-04-26 07:30:00","pre_market",3,3,406,407,-0,0,-0,"short","long",NaN
1004,"EYEN","Eyenovia to Present Data on Preservative-Free Microbial Integrity of the Optejet®","https://www.globenewswire.com/news-release/2023/10/09/2756566/0/en/Eyenovia-to-Present-Data-on-Preservative-Free-Microbial-Integrity-of-the-Optejet.html","Clinical Study","2023-10-09 07:00:00","pre_market",2,2,430,428,0,-0,0,"long","long",NaN
990,"EVLO","Evelo Biosciences Announces Second Quarter Financial Results and Recent Business Highlights","https://www.globenewswire.com/news-release/2023/08/14/2724292/0/en/Evelo-Biosciences-Announces-Second-Quarter-Financial-Results-and-Recent-Business-Highlights.html","Earnings Releases and Operating Results","2023-08-14 07:30:00","pre_market",10,10,446,445,-0,-0,-0,"short","short",NaN
1005,"EYEN","Eyenovia Acquires U.S. Commercial Rights to APP13007 (Clobetasol Propionate Ophthalmic Nanosuspension, 0.05%) from Formosa Pharmaceuticals","https://www.globenewswire.com/news-release/2023/08/16/2726141/0/en/Eyenovia-Acquires-U-S-Commercial-Rights-to-APP13007-Clobetasol-Propionate-Ophthalmic-Nanosuspension-0-05-from-Formosa-Pharmaceuticals.html","Mergers and Acquisitions","2023-08-16 06:00:00","pre_market",2,2,443,442,0,-0,0,"long","long",NaN
1006,"EYEN","Eyenovia Announces Development Collaboration Agreement with Formosa Pharmaceuticals","https://www.globenewswire.com/news-release/2023/02/15/2608912/0/en/Eyenovia-Announces-Development-Collaboration-Agreement-with-Formosa-Pharmaceuticals.html","Health","2023-02-15 09:51:00","market_open",3,3,410,414,0,0,0,"long","long",NaN
1001,"EVLO","Evelo Biosciences Reports that EDP2939, its First Oral Extracellular Vesicle Product Candidate, Commenced Dosing in a Phase 2 Psoriasis Trial","https://www.globenewswire.com/news-release/2023/02/27/2615820/0/en/Evelo-Biosciences-Reports-that-EDP2939-its-First-Oral-Extracellular-Vesicle-Product-Candidate-Commenced-Dosing-in-a-Phase-2-Psoriasis-Trial.html","Clinical Study","2023-02-27 06:00:00","pre_market",13,13,396,400,0,0,0,"long","long",NaN
993,"EVLO","Evelo Biosciences Announces Succession Plan","https://www.globenewswire.com/news-release/2022/08/11/2496459/0/en/Evelo-Biosciences-Announces-Succession-Plan.html","Directors and Officers","2022-08-11 06:01:00","pre_market",59,59,420,423,0,0,-0,"short","short",NaN
992,"EVLO","Evelo Biosciences to Participate in Morgan Stanley 20th Annual Global Health Care Conference","https://www.globenewswire.com/news-release/2022/09/01/2508294/0/en/Evelo-Biosciences-to-Participate-in-Morgan-Stanley-20th-Annual-Global-Health-Care-Conference.html","Calendar of Events","2022-09-01 06:00:00","pre_market",44,43,395,393,-0,-0,-0,"short","long",NaN
994,"EVLO","Evelo Biosciences Announces $25.5 Million Private Placement","https://www.globenewswire.com/news-release/2023/07/10/2701677/0/en/Evelo-Biosciences-Announces-25-5-Million-Private-Placement.html","Stock Market News","2023-07-10 07:30:00","pre_market",2,2,439,438,0,-0,0,"long","long",NaN
991,"EVLO","Evelo Biosciences to Present at the 2022 Jefferies London Healthcare Conference","https://www.globenewswire.com/news-release/2022/11/08/2550584/0/en/Evelo-Biosciences-to-Present-at-the-2022-Jefferies-London-Healthcare-Conference.html","Calendar of Events","2022-11-08 06:00:00","pre_market",39,39,380,381,0,0,0,"long","short",NaN
996,"EVLO","Evelo Biosciences Announces Top-Line Results From its Phase 2 Clinical Study with EDP2939 in Moderate Psoriasis","https://www.globenewswire.com/news-release/2023/10/17/2761342/0/en/Evelo-Biosciences-Announces-Top-Line-Results-From-its-Phase-2-Clinical-Study-with-EDP2939-in-Moderate-Psoriasis.html","Clinical Study","2023-10-17 07:00:00","pre_market",3,1,436,433,-1,-0,-1,"short","short",NaN
997,"EVLO","Evelo Biosciences Closes $25.5 Million Private Placement","https://www.globenewswire.com/news-release/2023/07/12/2703423/0/en/Evelo-Biosciences-Closes-25-5-Million-Private-Placement.html","Financing Agreements","2023-07-12 07:30:00","pre_market",3,3,442,446,0,0,-0,"short","short",NaN
998,"EVLO","Evelo Biosciences Announces Second Quarter 2022 Financial Results and Business Highlights","https://www.globenewswire.com/news-release/2022/08/11/2496455/0/en/Evelo-Biosciences-Announces-Second-Quarter-2022-Financial-Results-and-Business-Highlights.html","Health","2022-08-11 06:00:00","pre_market",59,59,420,423,0,0,-0,"short","long",NaN
1000,"EVLO","Evelo Biosciences to Participate in the Cowen 43rd Annual Health Care Conference","https://www.globenewswire.com/news-release/2023/03/01/2617946/0/en/Evelo-Biosciences-to-Participate-in-the-Cowen-43rd-Annual-Health-Care-Conference.html","Conference Calls/ Webcasts","2023-03-01 06:00:00","pre_market",12,12,396,395,-0,-0,-0,"short","short",NaN
1022,"FARON.HE","Faron Pharmaceuticals Announces Board Changes","https://www.globenewswire.com/news-release/2023/09/22/2748072/0/en/Faron-Pharmaceuticals-Announces-Board-Changes.html","Directors and Officers","2023-09-22 11:00:00","market_open",4,4,432,430,-0,-0,-0,"short","short",NaN
1008,"EYEN","Eyenovia Announces First Commercial Sale of Mydcombi™","https://www.globenewswire.com/news-release/2023/08/03/2717937/0/en/Eyenovia-Announces-First-Commercial-Sale-of-Mydcombi.html","Product / Services Announcement","2023-08-03 08:00:00","pre_market",2,2,450,448,0,-0,0,"long","long",NaN
1007,"EYEN","Eyenovia Announces Addition to Russell 2000® and Russell 3000® Indexes","https://www.globenewswire.com/news-release/2023/06/26/2694372/0/en/Eyenovia-Announces-Addition-to-Russell-2000-and-Russell-3000-Indexes.html","Trading information","2023-06-26 08:00:00","pre_market",2,2,433,433,0,-0,0,"long","short",NaN
1023,"FARON.HE","Faron to Hold Conference Call to Discuss New Positive Clinical Data from Phase I/II BEXMAB Study of Bexmarilimab in Relapsed/Refractory AML and MDS","https://www.globenewswire.com/news-release/2023/07/19/2707037/0/en/Faron-to-Hold-Conference-Call-to-Discuss-New-Positive-Clinical-Data-from-Phase-I-II-BEXMAB-Study-of-Bexmarilimab-in-Relapsed-Refractory-AML-and-MDS.html","Calendar of Events","2023-07-19 04:54:00","pre_market",3,3,454,455,0,0,0,"long","long",NaN
1009,"EYEN","Eyenovia to Participate in Panel Discussion at Cantor Global Healthcare Conference","https://www.globenewswire.com/news-release/2023/09/21/2747224/0/en/Eyenovia-to-Participate-in-Panel-Discussion-at-Cantor-Global-Healthcare-Conference.html","Calendar of Events","2023-09-21 08:00:00","pre_market",2,2,439,436,-0,-0,-0,"short","long",NaN
1010,"EYEN","Eyenovia to Report Fourth Quarter and Full-Year 2022 Results on Thursday, March 30","https://www.globenewswire.com/news-release/2023/03/23/2633055/0/en/Eyenovia-to-Report-Fourth-Quarter-and-Full-Year-2022-Results-on-Thursday-March-30.html","Conference Calls/ Webcasts","2023-03-23 08:00:00","pre_market",3,3,392,395,0,0,0,"long","short",NaN
1011,"EYEN","Eyenovia to Present at Upcoming H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference","https://www.globenewswire.com/news-release/2023/08/09/2721562/0/en/Eyenovia-to-Present-at-Upcoming-H-C-Wainwright-3rd-Annual-Ophthalmology-Virtual-Conference.html","Conference Calls/ Webcasts","2023-08-09 08:00:00","pre_market",2,2,449,449,0,0,0,"long","long",NaN
1014,"EYEN","Eyenovia Reveals Positive Evidence That Optejet® Delivery Technology Decreased Inflammation From Preserved Glaucoma Solutions Compared to Drops","https://www.globenewswire.com/news-release/2023/01/12/2587812/0/en/Eyenovia-Reveals-Positive-Evidence-That-Optejet-Delivery-Technology-Decreased-Inflammation-From-Preserved-Glaucoma-Solutions-Compared-to-Drops.html","Product / Services Announcement","2023-01-12 08:00:00","pre_market",2,2,396,397,0,0,0,"long","long",NaN
1015,"EYEN","Eyenovia to Present at Upcoming H.C. Wainwright 25th Annual Global Investment Conference","https://www.globenewswire.com/news-release/2023/09/07/2739251/0/en/Eyenovia-to-Present-at-Upcoming-H-C-Wainwright-25th-Annual-Global-Investment-Conference.html","Calendar of Events","2023-09-07 08:00:00","pre_market",2,2,446,443,0,-0,0,"long","long",NaN
1016,"EYEN","Eyenovia Announces Poster Presentation at ARVO 2023","https://www.globenewswire.com/news-release/2023/04/24/2652646/0/en/Eyenovia-Announces-Poster-Presentation-at-ARVO-2023.html","Product / Services Announcement","2023-04-24 08:00:00","pre_market",5,5,412,412,-0,-0,-0,"short","short",NaN
1017,"EYEN","Eyenovia Announces Presentation at the OCTANE Ophthalmology Tech Forum 2023","https://www.globenewswire.com/news-release/2023/06/01/2680264/0/en/Eyenovia-Announces-Presentation-at-the-OCTANE-Ophthalmology-Tech-Forum-2023.html","Calendar of Events","2023-06-01 08:00:00","pre_market",3,3,418,418,-0,0,-0,"short","short",NaN
1018,"EYEN","Eyenovia Announces FDA Approval of Redwood City as Commercial Manufacturing Facility","https://www.globenewswire.com/news-release/2024/02/13/2828089/0/en/Eyenovia-Announces-FDA-Approval-of-Redwood-City-as-Commercial-Manufacturing-Facility.html","Product / Services Announcement","2024-02-13 07:00:00","pre_market",2,2,501,495,0,-0,0,"long","long",NaN
1019,"EYEN","Eyenovia Announces FDA Approval of Coastline International as Contract Manufacturer to Initiate Mydcombi Commercial Production","https://www.globenewswire.com/news-release/2023/11/02/2772116/0/en/Eyenovia-Announces-FDA-Approval-of-Coastline-International-as-Contract-Manufacturer-to-Initiate-Mydcombi-Commercial-Production.html","Product / Services Announcement","2023-11-02 07:00:00","pre_market",1,1,423,427,0,0,0,"long","long",NaN
1020,"EYEN","Eyenovia to Sponsor Course on Drug Delivery Innovation at IJCAHPO’s 51st Annual Continuing Education (ACE) Program","https://www.globenewswire.com/news-release/2023/10/30/2769019/0/en/Eyenovia-to-Sponsor-Course-on-Drug-Delivery-Innovation-at-IJCAHPO-s-51st-Annual-Continuing-Education-ACE-Program.html","Clinical Study","2023-10-30 07:00:00","pre_market",1,1,411,414,0,0,0,"long","long",NaN
1029,"FBIO","Helocyte Announces $3.22 Million Grant from the National Cancer Institute for Triplex Phase 2 Clinical Trial Program","https://www.globenewswire.com/news-release/2023/06/15/2688861/28889/en/Helocyte-Announces-3-22-Million-Grant-from-the-National-Cancer-Institute-for-Triplex-Phase-2-Clinical-Trial-Program.html","Clinical Study","2023-06-15 08:00:00","pre_market",9,9,437,436,0,-0,0,"long","long",NaN
1031,"FBIO","Urica Therapeutics Announces Topline Data from the Phase 1 Clinical Trial Evaluating Dotinurad in Healthy Volunteers in the United States","https://www.globenewswire.com/news-release/2023/06/29/2696949/28889/en/Urica-Therapeutics-Announces-Topline-Data-from-the-Phase-1-Clinical-Trial-Evaluating-Dotinurad-in-Healthy-Volunteers-in-the-United-States.html","Clinical Study","2023-06-29 08:00:00","pre_market",8,8,436,436,0,-0,0,"long","long",NaN
1025,"FARON.HE","Faron to Participate in Fireside Chat at the Canaccord Genuity 43rd Annual Growth Conference","https://www.globenewswire.com/news-release/2023/08/02/2716788/0/en/Faron-to-Participate-in-Fireside-Chat-at-the-Canaccord-Genuity-43rd-Annual-Growth-Conference.html","Calendar of Events","2023-08-02 08:00:00","pre_market",3,3,456,453,0,-0,0,"long","long",NaN
1032,"FBIO","Aevitas Therapeutics, a Fortress Biotech Subsidiary, Announces Asset Purchase Agreement with 4D Molecular Therapeutics for World-Wide Rights to Aevitas’ Short-Form Human Complement Factor H","https://www.globenewswire.com/news-release/2023/04/24/2652668/28889/en/Aevitas-Therapeutics-a-Fortress-Biotech-Subsidiary-Announces-Asset-Purchase-Agreement-with-4D-Molecular-Therapeutics-for-World-Wide-Rights-to-Aevitas-Short-Form-Human-Complement-Fa.html","Health","2023-04-24 08:00:00","pre_market",11,10,412,412,-0,-0,-0,"short","short",NaN
1033,"FBIO","Helocyte, Inc. Announces Positive Data from Stem Cell Transplant Donor Vaccination Trial to be Presented at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR","https://www.globenewswire.com/news-release/2023/02/16/2609775/28889/en/Helocyte-Inc-Announces-Positive-Data-from-Stem-Cell-Transplant-Donor-Vaccination-Trial-to-be-Presented-at-the-2023-Tandem-Meetings-Transplantation-Cellular-Therapy-Meetings-of-ASTC.html","Clinical Study","2023-02-16 08:30:00","pre_market",11,11,414,409,0,-0,0,"long","long",NaN
1034,"FBIO","Fortress Biotech Announces Pricing of $10.0 Million Public Offering","https://www.globenewswire.com/news-release/2023/11/10/2778298/28889/en/Fortress-Biotech-Announces-Pricing-of-10-0-Million-Public-Offering.html","Management statements","2023-11-10 08:15:00","pre_market",2,1,434,436,-0,0,-0,"short","short",NaN
1035,"FBIO","Fortress Biotech Announces Reverse Stock Split","https://www.globenewswire.com/news-release/2023/10/09/2756959/28889/en/Fortress-Biotech-Announces-Reverse-Stock-Split.html","Changes in share capital and votes","2023-10-09 12:50:00","market_open",5,4,428,432,-0,0,-0,"short","long",NaN
1036,"FBIO","Fortress Biotech to Participate in Two March 2023 Investor Conferences","https://www.globenewswire.com/news-release/2023/03/07/2622003/28889/en/Fortress-Biotech-to-Participate-in-Two-March-2023-Investor-Conferences.html","Conference Calls/ Webcasts","2023-03-07 08:00:00","pre_market",12,12,404,404,0,-0,0,"long","long",NaN
1037,"FBIO","Fortress Biotech Announces Timing of Regular Monthly Dividend for October, November and December 2022 for its 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock","https://www.globenewswire.com/news-release/2022/10/05/2528702/28889/en/Fortress-Biotech-Announces-Timing-of-Regular-Monthly-Dividend-for-October-November-and-December-2022-for-its-9-375-Series-A-Cumulative-Redeemable-Perpetual-Preferred-Stock.html","Stock Market News","2022-10-05 08:30:00","pre_market",13,13,378,373,0,-0,0,"long","long",NaN
1038,"FBIO","Fortress Biotech to Present at the BTIG Virtual Biotechnology Conference 2023","https://www.globenewswire.com/news-release/2023/08/03/2718058/28889/en/Fortress-Biotech-to-Present-at-the-BTIG-Virtual-Biotechnology-Conference-2023.html","Calendar of Events","2023-08-03 08:30:00","pre_market",9,9,450,448,0,-0,0,"long","short",NaN
1039,"FBIO","Fortress Biotech Announces Closing of $13.9 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules","https://www.globenewswire.com/news-release/2023/02/10/2606152/28889/en/Fortress-Biotech-Announces-Closing-of-13-9-Million-Registered-Direct-Offering-Priced-At-the-Market-under-Nasdaq-Rules.html","Stock Market News","2023-02-10 12:50:00","market_open",11,11,406,408,0,0,0,"long","short",NaN
1040,"FBIO","Cyprium Therapeutics, a Fortress Biotech Subsidiary Company, Completes Asset Transfer of CUTX-101 Copper Histidinate Product Candidate for Treatment of Menkes Disease, to Sentynl Therapeutics, a Wholly-owned Subsidiary of Zydus Lifesciences Ltd.","https://www.globenewswire.com/news-release/2023/12/06/2791767/28889/en/Cyprium-Therapeutics-a-Fortress-Biotech-Subsidiary-Company-Completes-Asset-Transfer-of-CUTX-101-Copper-Histidinate-Product-Candidate-for-Treatment-of-Menkes-Disease-to-Sentynl-Ther.html","Health","2023-12-06 08:30:00","pre_market",3,3,457,459,0,0,0,"long","long",NaN
1026,"FARON.HE","Inside information: Faron Announces Positive BEXMAB Study Update in Relapsed/Refractory AML and HMA-Refractory MDS Patients","https://www.globenewswire.com/news-release/2023/10/11/2758195/0/en/Inside-information-Faron-Announces-Positive-BEXMAB-Study-Update-in-Relapsed-Refractory-AML-and-HMA-Refractory-MDS-Patients.html","Health","2023-10-11 07:00:00","pre_market",4,4,435,436,0,0,0,"long","long",NaN
1027,"FARON.HE","Faron Pharmaceuticals Ltd Results of the Extraordinary General Meeting","https://www.globenewswire.com/news-release/2023/09/22/2747864/0/en/Faron-Pharmaceuticals-Ltd-Results-of-the-Extraordinary-General-Meeting.html","Annual Meetings & Shareholder Rights","2023-09-22 06:33:00","pre_market",4,4,431,432,0,0,0,"long","long",NaN
1041,"FBIO","Urica Therapeutics Expands Exclusive License Agreement with Fuji Yakuhin Co. Ltd. to Develop Dotinurad in Additional Territories Including Turkey and the Middle East and North Africa","https://www.globenewswire.com/news-release/2022/12/14/2573643/28889/en/Urica-Therapeutics-Expands-Exclusive-License-Agreement-with-Fuji-Yakuhin-Co-Ltd-to-Develop-Dotinurad-in-Additional-Territories-Including-Turkey-and-the-Middle-East-and-North-Africa.html","Partnerships","2022-12-14 08:00:00","pre_market",10,10,402,402,0,-0,0,"long","long",NaN
1042,"FBIO","Fortress Biotech Subsidiary Helocyte Announces Option Agreement with City of Hope for Exclusive Worldwide Rights to use a Novel Bispecific CMV/HIV CAR T Cell Therapy (optionally in combination with Triplex) for the Treatment of Adults Living with HIV-1","https://www.globenewswire.com/news-release/2023/10/16/2760729/28889/en/Fortress-Biotech-Subsidiary-Helocyte-Announces-Option-Agreement-with-City-of-Hope-for-Exclusive-Worldwide-Rights-to-use-a-Novel-Bispecific-CMV-HIV-CAR-T-Cell-Therapy-optionally-in-.html","Product / Services Announcement","2023-10-16 09:00:00","pre_market",3,3,432,434,0,0,-0,"short","short",NaN
1043,"FBIO","Fortress Biotech to Present at H.C. Wainwright 25th Annual Global Investment Conference","https://www.globenewswire.com/news-release/2023/09/07/2739367/28889/en/Fortress-Biotech-to-Present-at-H-C-Wainwright-25th-Annual-Global-Investment-Conference.html","Calendar of Events","2023-09-07 08:30:00","pre_market",6,6,446,443,-0,-0,-0,"short","short",NaN
1044,"FBIO","Fortress Biotech to Participate in Cantor Medical & Aesthetic Dermatology, Ophthalmology & MedTech/Diagnostic Conference","https://www.globenewswire.com/news-release/2022/12/06/2568308/28889/en/Fortress-Biotech-to-Participate-in-Cantor-Medical-Aesthetic-Dermatology-Ophthalmology-MedTech-Diagnostic-Conference.html","Trade Show","2022-12-06 08:30:00","pre_market",10,10,400,399,-0,-0,-0,"short","short",NaN
1045,"FBIO","Fortress Biotech Appoints Lucy Lu, M.D., to its Board of Directors","https://www.globenewswire.com/news-release/2022/12/19/2576277/28889/en/Fortress-Biotech-Appoints-Lucy-Lu-M-D-to-its-Board-of-Directors.html","Directors and Officers","2022-12-19 08:00:00","pre_market",9,9,383,383,0,0,0,"long","long",NaN
1049,"FGEN","FibroGen to Report First Quarter 2023 Financial Results","https://www.globenewswire.com/news-release/2023/04/24/2652535/33525/en/FibroGen-to-Report-First-Quarter-2023-Financial-Results.html","Conference Calls/ Webcasts","2023-04-24 07:00:00","pre_market",20,20,412,412,-0,-0,-0,"short","short",NaN
1050,"FGEN","FibroGen Announces Leadership Transition","https://www.globenewswire.com/news-release/2023/07/25/2710270/33525/en/FibroGen-Announces-Leadership-Transition.html","Directors and Officers","2023-07-25 07:00:00","pre_market",2,2,454,454,-0,-0,-0,"short","short",NaN
1051,"FGEN","FibroGen Announces Topline Results from LELANTOS-1 Phase 3 Clinical Study of Pamrevlumab in Non-Ambulatory Patients with Duchenne Muscular Dystrophy","https://www.globenewswire.com/news-release/2023/06/07/2683598/33525/en/FibroGen-Announces-Topline-Results-from-LELANTOS-1-Phase-3-Clinical-Study-of-Pamrevlumab-in-Non-Ambulatory-Patients-with-Duchenne-Muscular-Dystrophy.html","Clinical Study","2023-06-07 06:55:00","pre_market",19,19,428,428,-0,0,-0,"short","long",NaN
1052,"FGEN","FibroGen Announces Completion of the Pamrevlumab Arm in Precision Promise, Pancreatic Cancer Action Network’s Phase 2/3 Adaptive Platform Trial for Metastatic Pancreatic Cancer","https://www.globenewswire.com/news-release/2024/01/25/2816553/33525/en/FibroGen-Announces-Completion-of-the-Pamrevlumab-Arm-in-Precision-Promise-Pancreatic-Cancer-Action-Network-s-Phase-2-3-Adaptive-Platform-Trial-for-Metastatic-Pancreatic-Cancer.html","Company Announcement","2024-01-25 07:00:00","pre_market",1,1,485,488,0,0,0,"long","long",NaN
1053,"FGEN","FibroGen to Report Second Quarter 2023 Financial Results","https://www.globenewswire.com/news-release/2023/07/24/2709392/33525/en/FibroGen-to-Report-Second-Quarter-2023-Financial-Results.html","Conference Calls/ Webcasts","2023-07-24 07:00:00","pre_market",2,2,452,453,0,0,0,"long","long",NaN
1046,"FBIO","Fortress Biotech Announces Pricing of $13.9 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules","https://www.globenewswire.com/news-release/2023/02/08/2603922/28889/en/Fortress-Biotech-Announces-Pricing-of-13-9-Million-Registered-Direct-Offering-Priced-At-the-Market-under-Nasdaq-Rules.html","Prospectus/Announcement of Prospectus","2023-02-08 08:00:00","pre_market",13,11,415,413,-0,-0,-0,"short","short",NaN
1054,"FGEN","FibroGen Announces Completion of Patient Enrollment in ZEPHYRUS-2, a Phase 3 Clinical Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis","https://www.globenewswire.com/news-release/2023/04/03/2639399/33525/en/FibroGen-Announces-Completion-of-Patient-Enrollment-in-ZEPHYRUS-2-a-Phase-3-Clinical-Study-of-Pamrevlumab-in-Idiopathic-Pulmonary-Fibrosis.html","Clinical Study","2023-04-03 07:00:00","pre_market",19,19,409,409,0,-0,0,"long","long",NaN
1055,"FGEN","FibroGen To Host Part I of Virtual KOL Investor Event Series to Review Pamrevlumab Clinical Program in Pancreatic Cancer on February 13, 2024","https://www.globenewswire.com/news-release/2024/02/05/2823393/33525/en/FibroGen-To-Host-Part-I-of-Virtual-KOL-Investor-Event-Series-to-Review-Pamrevlumab-Clinical-Program-in-Pancreatic-Cancer-on-February-13-2024.html","Clinical Study","2024-02-05 07:00:00","pre_market",2,2,494,494,-0,-0,-0,"short","short",NaN
1056,"FGEN","FibroGen Announces Positive Topline Results from China Pivotal Phase 3 Clinical Trial of Roxadustat for the Treatment of Chemotherapy Induced Anemia","https://www.globenewswire.com/news-release/2023/05/18/2671783/33525/en/FibroGen-Announces-Positive-Topline-Results-from-China-Pivotal-Phase-3-Clinical-Trial-of-Roxadustat-for-the-Treatment-of-Chemotherapy-Induced-Anemia.html","Clinical Study","2023-05-18 07:30:00","pre_market",18,18,415,415,0,-0,0,"long","long",NaN
1047,"FBIO","Fortress Biotech Announces Pricing of $11 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules","https://www.globenewswire.com/news-release/2023/12/29/2802052/28889/en/Fortress-Biotech-Announces-Pricing-of-11-Million-Registered-Direct-Offering-Priced-At-the-Market-Under-Nasdaq-Rules.html","Financing Agreements","2023-12-29 08:20:00","pre_market",4,3,477,476,-0,-0,-0,"short","short",NaN
1064,"GLUE","Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update","https://www.globenewswire.com/news-release/2023/03/16/2628536/0/en/Monte-Rosa-Therapeutics-Announces-Fourth-Quarter-and-Full-Year-2022-Financial-Results-and-Provides-Corporate-Update.html","Earnings Releases and Operating Results","2023-03-16 07:30:00","pre_market",7,6,389,387,-0,-0,-0,"short","short",NaN
1065,"GLUE","Monte Rosa Therapeutics Appoints Dr. Jan Skvarka to Board of Directors","https://www.globenewswire.com/news-release/2023/03/23/2633019/0/en/Monte-Rosa-Therapeutics-Appoints-Dr-Jan-Skvarka-to-Board-of-Directors.html","Directors and Officers","2023-03-23 07:30:00","pre_market",7,7,392,395,0,0,0,"long","long",NaN
1066,"GLUE","Monte Rosa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update","https://www.globenewswire.com/news-release/2023/11/09/2777173/0/en/Monte-Rosa-Therapeutics-Announces-Third-Quarter-2023-Financial-Results-and-Provides-Corporate-Update.html","Earnings Releases and Operating Results","2023-11-09 07:00:00","pre_market",4,4,437,438,-0,0,-0,"short","short",NaN
1067,"GLUE","Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2023 Demonstrating Potential of MRT-6160, a VAV1-targeted Molecular Glue Degrader, to Treat Immunological and Inflammatory Diseases","https://www.globenewswire.com/news-release/2023/11/07/2775281/0/en/Monte-Rosa-Therapeutics-Presents-Preclinical-Data-at-ACR-Convergence-2023-Demonstrating-Potential-of-MRT-6160-a-VAV1-targeted-Molecular-Glue-Degrader-to-Treat-Immunological-and-Inf.html","Clinical Study","2023-11-07 10:00:00","market_open",3,4,436,437,0,0,0,"long","long",NaN
1068,"GLUE","Monte Rosa Therapeutics Announces Interim PK/PD and Clinical Data for MRT-2359 in Phase 1/2 Trial for MYC-Driven Solid Tumors","https://www.globenewswire.com/news-release/2023/10/17/2761331/0/en/Monte-Rosa-Therapeutics-Announces-Interim-PK-PD-and-Clinical-Data-for-MRT-2359-in-Phase-1-2-Trial-for-MYC-Driven-Solid-Tumors.html","Conference Calls/ Webcasts","2023-10-17 07:00:00","pre_market",5,5,436,433,0,-0,0,"long","long",NaN
1069,"GLUE","Monte Rosa Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update","https://www.globenewswire.com/news-release/2023/08/10/2722527/0/en/Monte-Rosa-Therapeutics-Announces-Second-Quarter-2023-Financial-Results-and-Provides-Corporate-Update.html","Earnings Releases and Operating Results","2023-08-10 07:15:00","pre_market",7,7,446,448,0,0,0,"long","long",NaN
1070,"GLUE","Monte Rosa Therapeutics to Present at Piper Sandler Healthcare Conference","https://www.globenewswire.com/news-release/2023/11/21/2783927/0/en/Monte-Rosa-Therapeutics-to-Present-at-Piper-Sandler-Healthcare-Conference.html","Calendar of Events","2023-11-21 07:00:00","pre_market",3,3,454,453,-0,-0,-0,"short","long",NaN
1071,"GLUE","Monte Rosa Therapeutics Reports Second Quarter 2022 Financial Results and Business Updates","https://www.globenewswire.com/news-release/2022/08/11/2496663/0/en/Monte-Rosa-Therapeutics-Reports-Second-Quarter-2022-Financial-Results-and-Business-Updates.html","Earnings Releases and Operating Results","2022-08-11 07:30:00","pre_market",9,9,420,423,0,0,0,"long","long",NaN
1072,"GLUE","Monte Rosa Therapeutics Announces First Quarter 2023 Financial Results and Provides Corporate Update","https://www.globenewswire.com/news-release/2023/05/11/2666597/0/en/Monte-Rosa-Therapeutics-Announces-First-Quarter-2023-Financial-Results-and-Provides-Corporate-Update.html","Earnings Releases and Operating Results","2023-05-11 07:30:00","pre_market",6,6,413,412,0,-0,0,"long","short",NaN
1073,"GLUE","Monte Rosa Therapeutics to Present at Upcoming Investor Conferences","https://www.globenewswire.com/news-release/2023/02/03/2601254/0/en/Monte-Rosa-Therapeutics-to-Present-at-Upcoming-Investor-Conferences.html","Calendar of Events","2023-02-03 07:30:00","pre_market",7,7,417,412,0,-0,0,"long","long",NaN
1074,"GLUE","Monte Rosa Therapeutics Advances Second Development Candidate, MRT-6160, a Novel, Highly Selective Molecular Glue Degrader Targeting VAV1 for the Treatment of Autoimmune Diseases","https://www.globenewswire.com/news-release/2023/05/23/2674201/0/en/Monte-Rosa-Therapeutics-Advances-Second-Development-Candidate-MRT-6160-a-Novel-Highly-Selective-Molecular-Glue-Degrader-Targeting-VAV1-for-the-Treatment-of-Autoimmune-Diseases.html","Clinical Study","2023-05-23 07:30:00","pre_market",6,6,419,417,-0,-0,-0,"short","short",NaN
1057,"FGEN","FibroGen to Present at Cowen’s 43rd Annual Health Care Conference","https://www.globenewswire.com/news-release/2023/02/27/2615910/33525/en/FibroGen-to-Present-at-Cowen-s-43rd-Annual-Health-Care-Conference.html","Calendar of Events","2023-02-27 07:00:00","pre_market",22,23,396,400,0,0,0,"long","long",NaN
1058,"FGEN","FibroGen to Report Fourth Quarter and Full Year 2022 Financial Results","https://www.globenewswire.com/news-release/2023/02/17/2610529/33525/en/FibroGen-to-Report-Fourth-Quarter-and-Full-Year-2022-Financial-Results.html","Conference Calls/ Webcasts","2023-02-17 07:00:00","pre_market",24,24,408,406,0,-0,0,"long","long",NaN
1059,"FGEN","FibroGen to Report Third Quarter 2023 Financial Results","https://www.globenewswire.com/news-release/2023/10/23/2764572/33525/en/FibroGen-to-Report-Third-Quarter-2023-Financial-Results.html","Conference Calls/ Webcasts","2023-10-23 07:00:00","pre_market",1,1,421,420,-0,-0,-0,"short","short",NaN
1085,"GMAB","Major Shareholder Announcement","https://www.globenewswire.com/news-release/2023/11/09/2777473/0/en/Major-Shareholder-Announcement.html","European Regulatory News","2023-11-09 09:14:00","pre_market",31,32,437,438,0,0,0,"long","long",NaN
1087,"GMAB","Genmab Announces European Commission Approval of TEPKINLY® (epcoritamab) for Adults with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)","https://www.globenewswire.com/news-release/2023/09/25/2748547/0/en/Genmab-Announces-European-Commission-Approval-of-TEPKINLY-epcoritamab-for-Adults-with-Relapsed-or-Refractory-R-R-Diffuse-Large-B-cell-Lymphoma-DLBCL.html","European Regulatory News","2023-09-25 07:45:00","pre_market",36,36,430,429,-0,-0,0,"long","long",NaN
1088,"GMAB","Grant of Restricted Stock Units and Warrants to Employees in Genmab","https://www.globenewswire.com/news-release/2023/09/28/2751599/0/en/Grant-of-Restricted-Stock-Units-and-Warrants-to-Employees-in-Genmab.html","European Regulatory News","2023-09-28 14:38:00","market_open",36,35,425,429,-0,0,-0,"short","short",NaN
1089,"GMAB","Genmab Announces Financial Results for the First Nine Months of 2023","https://www.globenewswire.com/news-release/2023/11/07/2775338/0/en/Genmab-Announces-Financial-Results-for-the-First-Nine-Months-of-2023.html","European Regulatory News","2023-11-07 11:01:00","market_open",29,30,436,437,0,0,0,"long","long",NaN
1091,"GMAB","Capital Increase in Genmab as a Result of Employee Warrant Exercise","https://www.globenewswire.com/news-release/2023/09/12/2742015/0/en/Capital-Increase-in-Genmab-as-a-Result-of-Employee-Warrant-Exercise.html","European Regulatory News","2023-09-12 14:04:00","market_open",37,37,447,446,0,-0,0,"long","long",NaN
1090,"GMAB","Genmab Announces AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)","https://www.globenewswire.com/news-release/2023/07/21/2708724/0/en/Genmab-Announces-AbbVie-Receives-Positive-CHMP-Opinion-for-Epcoritamab-TEPKINLY-for-the-Treatment-of-Adults-with-Relapsed-Refractory-R-R-Diffuse-Large-B-cell-Lymphoma-DLBCL.html","European Regulatory News","2023-07-21 04:30:00","pre_market",41,41,452,454,-0,0,-0,"short","long",NaN
1092,"GMAB","Major Shareholder Announcement","https://www.globenewswire.com/news-release/2023/11/08/2776465/0/en/Major-Shareholder-Announcement.html","European Regulatory News","2023-11-08 11:09:00","market_open",32,31,438,437,-0,-0,-0,"short","long",NaN
1075,"GLUE","Monte Rosa Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference","https://www.globenewswire.com/news-release/2023/01/04/2582790/0/en/Monte-Rosa-Therapeutics-to-Present-at-the-41st-Annual-J-P-Morgan-Healthcare-Conference.html","Calendar of Events","2023-01-04 07:30:00","pre_market",8,8,381,383,0,0,0,"long","long",NaN
1076,"GLUE","Monte Rosa Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating MRT-2359, a GSPT1-directed Molecular Glue Degrader, for Treatment of MYC-driven Tumors","https://www.globenewswire.com/news-release/2022/11/01/2545357/0/en/Monte-Rosa-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1-2-Clinical-Trial-Evaluating-MRT-2359-a-GSPT1-directed-Molecular-Glue-Degrader-for-Treatment-of-MYC-driven-Tumors.html","Product / Services Announcement","2022-11-01 07:30:00","pre_market",9,9,386,390,0,0,0,"long","long",NaN
1077,"GLUE","Monte Rosa Therapeutics Reports Third Quarter 2022 Financial Results and Business Updates","https://www.globenewswire.com/news-release/2022/11/10/2553073/0/en/Monte-Rosa-Therapeutics-Reports-Third-Quarter-2022-Financial-Results-and-Business-Updates.html","Earnings Releases and Operating Results","2022-11-10 07:30:00","pre_market",8,8,374,388,0,0,-0,"short","short",NaN
1078,"GLUE","Monte Rosa Therapeutics Announces Strategic Collaboration with Roche to Discover Novel Molecular Glue Degraders Targeting Cancer and Neurological Diseases","https://www.globenewswire.com/news-release/2023/10/17/2761334/0/en/Monte-Rosa-Therapeutics-Announces-Strategic-Collaboration-with-Roche-to-Discover-Novel-Molecular-Glue-Degraders-Targeting-Cancer-and-Neurological-Diseases.html","Partnerships","2023-10-17 07:00:00","pre_market",5,5,436,433,0,-0,0,"long","long",NaN
1079,"GLUE","Monte Rosa Therapeutics Appoints Dr. Anthony M. Manning to Board of Directors","https://www.globenewswire.com/news-release/2023/07/26/2711202/0/en/Monte-Rosa-Therapeutics-Appoints-Dr-Anthony-M-Manning-to-Board-of-Directors.html","Directors and Officers","2023-07-26 07:30:00","pre_market",7,7,455,454,-0,-0,0,"long","long",NaN
1080,"GLUE","Monte Rosa Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference","https://www.globenewswire.com/news-release/2024/01/03/2803173/0/en/Monte-Rosa-Therapeutics-to-Present-at-the-42nd-Annual-J-P-Morgan-Healthcare-Conference.html","Calendar of Events","2024-01-03 07:00:00","pre_market",6,6,473,470,0,-0,0,"long","long",NaN
1081,"GLUE","Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2024","https://www.globenewswire.com/news-release/2024/01/08/2805310/0/en/Monte-Rosa-Therapeutics-Provides-Corporate-Update-and-Key-Anticipated-Milestones-for-2024.html","Calendar of Events","2024-01-08 07:15:00","pre_market",6,6,468,468,0,0,0,"long","long",NaN
1082,"GLUE","Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences","https://www.globenewswire.com/news-release/2024/01/31/2820942/0/en/Monte-Rosa-Therapeutics-to-Participate-in-Upcoming-Investor-Conferences.html","Conference Calls/ Webcasts","2024-01-31 07:00:00","pre_market",5,5,491,489,-0,-0,-0,"short","short",NaN
1083,"GLUE","Monte Rosa Therapeutics Outlines Progress Across Portfolio of Molecular Glue Degraders and Key Anticipated Milestones for 2023","https://www.globenewswire.com/news-release/2023/01/09/2585095/0/en/Monte-Rosa-Therapeutics-Outlines-Progress-Across-Portfolio-of-Molecular-Glue-Degraders-and-Key-Anticipated-Milestones-for-2023.html","Stock Market News","2023-01-09 07:30:00","pre_market",8,8,388,390,0,0,0,"long","short",NaN
1094,"GMAB","Genmab Announces Multiple Abstracts to be Presented at the 65th Annual Meeting and Exposition of the American Society of Hematology (ASH)","https://www.globenewswire.com/news-release/2023/11/02/2772431/0/en/Genmab-Announces-Multiple-Abstracts-to-be-Presented-at-the-65th-Annual-Meeting-and-Exposition-of-the-American-Society-of-Hematology-ASH.html","European Regulatory News","2023-11-02 09:05:00","pre_market",29,29,423,427,0,0,-0,"short","short",NaN
1095,"GMAB","Genmab Announces Financial Results for the First Half of 2023","https://www.globenewswire.com/news-release/2023/08/03/2718313/0/en/Genmab-Announces-Financial-Results-for-the-First-Half-of-2023.html","European Regulatory News","2023-08-03 11:01:00","market_open",39,39,448,449,0,0,0,"long","long",NaN
1096,"GMAB","Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons","https://www.globenewswire.com/news-release/2023/06/01/2680792/0/en/Transactions-with-shares-and-linked-securities-in-Genmab-A-S-made-by-managerial-employees-and-their-closely-associated-persons.html","European Regulatory News","2023-06-01 15:40:00","market_open",39,39,418,422,0,0,-0,"short","short",NaN
1097,"GMAB","Transactions with Shares and Linked Securities in Genmab A/S Made By Managerial Employees and Their Closely Associated Persons","https://www.globenewswire.com/news-release/2023/05/31/2679379/0/en/Transactions-with-Shares-and-Linked-Securities-in-Genmab-A-S-Made-By-Managerial-Employees-and-Their-Closely-Associated-Persons.html","European Regulatory News","2023-05-31 08:15:00","pre_market",39,39,420,418,-0,-0,-0,"short","short",NaN
1098,"GMAB","Genmab to Present at Morgan Stanley 21st Annual Global Healthcare Conference","https://www.globenewswire.com/news-release/2023/08/28/2732719/0/en/Genmab-to-Present-at-Morgan-Stanley-21st-Annual-Global-Healthcare-Conference.html","European Regulatory News","2023-08-28 10:06:00","market_open",38,38,442,443,0,0,0,"long","long",NaN
1100,"GMAB","Capital Increase in Genmab as a Result of Employee Warrant Exercise","https://www.globenewswire.com/news-release/2023/06/20/2691549/0/en/Capital-Increase-in-Genmab-as-a-Result-of-Employee-Warrant-Exercise.html","European Regulatory News","2023-06-20 14:45:00","market_open",38,38,437,437,0,-0,0,"long","long",NaN
1101,"GMAB","Genmab Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®/TEPKINLY®) for the Treatment of Relapsed/Refractory Follicular Lymphoma","https://www.globenewswire.com/news-release/2023/11/27/2786009/0/en/Genmab-Announces-Positive-Regulatory-Updates-for-Epcoritamab-EPKINLY-TEPKINLY-for-the-Treatment-of-Relapsed-Refractory-Follicular-Lymphoma.html","European Regulatory News","2023-11-27 07:00:00","pre_market",32,31,455,455,-0,-0,-0,"short","long",NaN
1102,"GMAB","Genmab to Hold 2023 R&D Update and ASH Data Review Meeting","https://www.globenewswire.com/news-release/2023/12/12/2794601/0/en/Genmab-to-Hold-2023-R-D-Update-and-ASH-Data-Review-Meeting.html","European Regulatory News","2023-12-12 07:00:00","pre_market",32,30,462,462,-0,-0,-0,"short","long",NaN
1103,"GMAB","Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2023","https://www.globenewswire.com/news-release/2024/01/23/2813898/0/en/Genmab-Announces-Net-Sales-of-DARZALEX-daratumumab-for-2023.html","European Regulatory News","2024-01-23 06:24:00","pre_market",29,28,483,484,-0,0,-0,"short","short",NaN
1104,"GMAB","Tisotumab Vedotin Marketing Authorization Application Validated by European Medicines Agency for Treatment of Recurrent or Metastatic Cervical Cancer","https://www.globenewswire.com/news-release/2024/02/02/2822739/0/en/Tisotumab-Vedotin-Marketing-Authorization-Application-Validated-by-European-Medicines-Agency-for-Treatment-of-Recurrent-or-Metastatic-Cervical-Cancer.html","European Regulatory News","2024-02-02 06:45:00","pre_market",28,28,489,490,-0,0,-0,"short","short",NaN
1105,"GMAB","Notice to Convene the Annual General Meeting of Genmab A/S","https://www.globenewswire.com/news-release/2024/02/15/2829756/0/en/Notice-to-Convene-the-Annual-General-Meeting-of-Genmab-A-S.html","European Regulatory News","2024-02-15 06:00:00","pre_market",28,29,499,499,0,0,0,"long","long",NaN
1106,"GMAB","TIVDAK® (tisotumab vedotin-tftv) Supplemental Biologics License Application Accepted for Priority Review by U.S. Food and Drug Administration for Patients with Recurrent or Metastatic Cervical Cancer","https://www.globenewswire.com/news-release/2024/01/09/2806100/0/en/TIVDAK-tisotumab-vedotin-tftv-Supplemental-Biologics-License-Application-Accepted-for-Priority-Review-by-U-S-Food-and-Drug-Administration-for-Patients-with-Recurrent-or-Metastatic-.html","European Regulatory News","2024-01-09 06:45:00","pre_market",33,32,475,472,-0,-0,-0,"short","long",NaN
1107,"GMAB","Genmab Files Annual Report with the U.S. Securities and Exchange Commission","https://www.globenewswire.com/news-release/2024/02/14/2829403/0/en/Genmab-Files-Annual-Report-with-the-U-S-Securities-and-Exchange-Commission.html","European Regulatory News","2024-02-14 14:09:00","market_open",27,28,497,499,0,0,0,"long","long",NaN
1108,"GMAB","Genmab Publishes 2023 Annual Report","https://www.globenewswire.com/news-release/2024/02/14/2829266/0/en/Genmab-Publishes-2023-Annual-Report.html","European Regulatory News","2024-02-14 11:02:00","market_open",27,28,497,499,0,0,0,"long","long",NaN
1109,"GMAB","Genmab to Present at the 42nd Annual J.P. Morgan Healthcare Conference","https://www.globenewswire.com/news-release/2024/01/02/2802745/0/en/Genmab-to-Present-at-the-42nd-Annual-J-P-Morgan-Healthcare-Conference.html","European Regulatory News","2024-01-02 09:52:00","market_open",31,32,472,473,0,0,0,"long","long",NaN
1110,"GMAB","Grant of Restricted Stock Units and Warrants to Employees in Genmab","https://www.globenewswire.com/news-release/2024/01/25/2817339/0/en/Grant-of-Restricted-Stock-Units-and-Warrants-to-Employees-in-Genmab.html","European Regulatory News","2024-01-25 14:22:00","market_open",28,28,488,488,0,0,0,"long","short",NaN
1114,"GRFS","GigaGen Doses First Patient in Phase 1 Trial of Recombinant Hyperimmune Polyclonal Antibody GIGA-2050 for COVID-19","https://www.globenewswire.com/news-release/2021/08/11/2278973/0/en/GigaGen-Doses-First-Patient-in-Phase-1-Trial-of-Recombinant-Hyperimmune-Polyclonal-Antibody-GIGA-2050-for-COVID-19.html","Health","2021-08-11 10:26:00","market_open",15,15,444,444,-0,-0,-0,"short","short",NaN
1115,"GRFS","GigaGen Granted Expansion of Contract with US Department of Defense to Develop Synthetic Human Antibody Treatments for Botulinum Neurotoxins","https://www.globenewswire.com/news-release/2023/10/19/2763125/0/en/GigaGen-Granted-Expansion-of-Contract-with-US-Department-of-Defense-to-Develop-Synthetic-Human-Antibody-Treatments-for-Botulinum-Neurotoxins.html","Business Contracts","2023-10-19 08:00:00","pre_market",9,8,430,431,-0,0,-0,"short","long",NaN
1116,"GRFS","GigaGen Awarded Contract by U.S. Department of Defense to Discover Synthetic Human Antibody Treatments for High-Priority Toxins and Pathogens","https://www.globenewswire.com/news-release/2022/09/15/2517071/0/en/GigaGen-Awarded-Contract-by-U-S-Department-of-Defense-to-Discover-Synthetic-Human-Antibody-Treatments-for-High-Priority-Toxins-and-Pathogens.html","Health","2022-09-15 10:29:00","market_open",8,8,393,390,0,-0,0,"long","long",NaN
1117,"GRFS","GigaGen Initiates Development of Recombinant Polyclonal Antibody Therapy for COVID-19","https://www.globenewswire.com/news-release/2020/03/30/2008438/0/en/GigaGen-Initiates-Development-of-Recombinant-Polyclonal-Antibody-Therapy-for-COVID-19.html","Company Announcement","2020-03-30 10:17:00","market_open",20,21,256,262,0,0,-0,"short","short",NaN
1118,"GRFS","GigaGen to Present Poster at the 2021 American Association for Cancer Research (AACR) Virtual Annual Meeting","https://www.globenewswire.com/news-release/2021/03/23/2197847/0/en/GigaGen-to-Present-Poster-at-the-2021-American-Association-for-Cancer-Research-AACR-Virtual-Annual-Meeting.html","Calendar of Events","2021-03-23 10:00:00","market_open",16,17,392,390,0,-0,0,"long","long",NaN
1119,"GRFS","GigaGen Licenses ProteoNic’s 2G UNicTM Technology Platform for High Yield Production of GigaGen’s Mono- and Polyclonal Antibody Drug Candidates","https://www.globenewswire.com/news-release/2021/09/30/2306358/0/en/GigaGen-Licenses-ProteoNic-s-2G-UNicTM-Technology-Platform-for-High-Yield-Production-of-GigaGen-s-Mono-and-Polyclonal-Antibody-Drug-Candidates.html","Product / Services Announcement","2021-09-30 10:17:00","market_open",15,15,436,429,-0,-0,-0,"short","short",NaN
1120,"GRFS","GigaGen Publishes Research Showcasing First-Ever Clinical GMP Manufacturing and IND-Enabling Studies for its New Class of Drugs, Recombinant Polyclonal Antibodies","https://www.globenewswire.com/news-release/2022/07/28/2487786/0/en/GigaGen-Publishes-Research-Showcasing-First-Ever-Clinical-GMP-Manufacturing-and-IND-Enabling-Studies-for-its-New-Class-of-Drugs-Recombinant-Polyclonal-Antibodies.html","Company Announcement","2022-07-28 08:00:00","pre_market",11,10,401,402,-0,0,-0,"short","short",NaN
1121,"GRFS","GigaGen to Present at the Inaugural LifeSci Partners Private Company Virtual Summer Symposium","https://www.globenewswire.com/news-release/2020/07/29/2069535/0/en/GigaGen-to-Present-at-the-Inaugural-LifeSci-Partners-Private-Company-Virtual-Summer-Symposium.html","Company Announcement","2020-07-29 09:30:00","market_open",19,19,322,325,0,0,-0,"short","short",NaN
1123,"GRFS","GigaGen Publishes Research Demonstrating the Potential of its Machine Learning Platform to Improve Antibody Drug Discovery and Development","https://www.globenewswire.com/news-release/2022/05/19/2447167/0/en/GigaGen-Publishes-Research-Demonstrating-the-Potential-of-its-Machine-Learning-Platform-to-Improve-Antibody-Drug-Discovery-and-Development.html","Research Analysis and Reports","2022-05-19 11:39:00","market_open",13,13,389,389,0,0,0,"long","long",NaN
1124,"GRFS","GigaGen Announces Publication in the Peer-Reviewed Journal mAbs","https://www.globenewswire.com/news-release/2020/10/20/2111204/0/en/GigaGen-Announces-Publication-in-the-Peer-Reviewed-Journal-mAbs.html","Health","2020-10-20 10:17:00","market_open",19,20,343,343,0,-0,0,"long","long",NaN
1125,"GRFS","GigaGen Publishes Research Describing Potential New Avenues to Overcome Resistance to anti-PD-L1 Therapies","https://www.globenewswire.com/news-release/2021/05/25/2235723/0/en/GigaGen-Publishes-Research-Describing-Potential-New-Avenues-to-Overcome-Resistance-to-anti-PD-L1-Therapies.html","Research Analysis and Reports","2021-05-25 10:15:00","market_open",18,19,420,418,0,-0,0,"long","long",NaN
1126,"GRFS","GigaGen Publishes Research on Company’s Recombinant Hyperimmunes in Nature Biotechnology","https://www.globenewswire.com/news-release/2021/04/15/2211106/0/en/GigaGen-Publishes-Research-on-Company-s-Recombinant-Hyperimmunes-in-Nature-Biotechnology.html","Health","2021-04-15 11:59:00","market_open",18,18,414,416,0,0,0,"long","long",NaN
1127,"GRFS","GigaGen Presents IND-Enabling Data and Phase 1 Trial Strategy for its Novel Anti-CTLA-4 Oncology Drug Candidate, GIGA-564, at SITC 2023","https://www.globenewswire.com/news-release/2023/11/06/2774078/0/en/GigaGen-Presents-IND-Enabling-Data-and-Phase-1-Trial-Strategy-for-its-Novel-Anti-CTLA-4-Oncology-Drug-Candidate-GIGA-564-at-SITC-2023.html","Product / Services Announcement","2023-11-06 08:00:00","pre_market",9,9,435,435,-0,0,-0,"short","short",NaN
1111,"GMAB","Genmab Announces Initiation of Share Buy-Back Program","https://www.globenewswire.com/news-release/2024/02/14/2829305/0/en/Genmab-Announces-Initiation-of-Share-Buy-Back-Program.html","European Regulatory News","2024-02-14 11:41:00","market_open",27,28,497,499,0,0,0,"long","long",NaN
1132,"GTHX","G1 Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference","https://www.globenewswire.com/news-release/2023/02/28/2617561/0/en/G1-Therapeutics-to-Participate-in-the-Cowen-43rd-Annual-Health-Care-Conference.html","Conference Calls/ Webcasts","2023-02-28 14:10:00","market_open",3,4,397,396,0,-0,0,"long","long",NaN
1133,"GTHX","G1 Therapeutics to Release Second Quarter 2023 Financial Results and Provide Business Update on August 2, 2023","https://www.globenewswire.com/news-release/2023/07/26/2711371/0/en/G1-Therapeutics-to-Release-Second-Quarter-2023-Financial-Results-and-Provide-Business-Update-on-August-2-2023.html","Conference Calls/ Webcasts","2023-07-26 09:00:00","pre_market",2,2,455,454,0,-0,0,"long","long",NaN
1134,"GTHX","G1 Therapeutics to Release First Quarter 2023 Financial Results and Provide Business  Update on May 3, 2023","https://www.globenewswire.com/news-release/2023/04/26/2655500/0/en/G1-Therapeutics-to-Release-First-Quarter-2023-Financial-Results-and-Provide-Business-Update-on-May-3-2023.html","Conference Calls/ Webcasts","2023-04-26 12:45:00","market_open",2,2,407,404,-0,-0,0,"long","long",NaN
1144,"GTHX","New Study Confirms Consistent Risk of Myelosuppression Across All Patients Receiving Chemotherapy for Small Cell Lung Cancer","https://www.globenewswire.com/news-release/2023/05/16/2669845/0/en/New-Study-Confirms-Consistent-Risk-of-Myelosuppression-Across-All-Patients-Receiving-Chemotherapy-for-Small-Cell-Lung-Cancer.html","Health","2023-05-16 07:30:00","pre_market",3,3,413,412,-0,-0,-0,"short","short",NaN
1136,"GTHX","G1 Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference","https://www.globenewswire.com/news-release/2023/09/05/2737611/0/en/G1-Therapeutics-to-Participate-in-the-H-C-Wainwright-25th-Annual-Global-Investment-Conference.html","Conference Calls/ Webcasts","2023-09-05 11:00:00","market_open",2,2,451,449,-0,-0,-0,"short","short",NaN
1137,"GTHX","New Results from Phase 2 Trial Confirm Benefit of Trilaciclib in Reducing Adverse Events Related to an Antibody Drug Conjugate (ADC)","https://www.globenewswire.com/news-release/2023/05/10/2665451/0/en/New-Results-from-Phase-2-Trial-Confirm-Benefit-of-Trilaciclib-in-Reducing-Adverse-Events-Related-to-an-Antibody-Drug-Conjugate-ADC.html","Company Announcement","2023-05-10 07:31:00","pre_market",3,3,411,414,0,0,-0,"short","short",NaN
1138,"GTHX","G1 Therapeutics to Release Third Quarter 2023 Financial Results and Provide Business  Update on November 1, 2023","https://www.globenewswire.com/news-release/2023/10/18/2762229/0/en/G1-Therapeutics-to-Release-Third-Quarter-2023-Financial-Results-and-Provide-Business-Update-on-November-1-2023.html","Conference Calls/ Webcasts","2023-10-18 07:30:00","pre_market",1,1,436,434,0,-0,0,"long","long",NaN
1139,"GTHX","G1 Therapeutics to Participate in Two August Investor Conferences","https://www.globenewswire.com/news-release/2023/07/31/2715254/0/en/G1-Therapeutics-to-Participate-in-Two-August-Investor-Conferences.html","Calendar of Events","2023-07-31 14:30:00","market_open",2,2,457,458,0,0,0,"long","long",NaN
1135,"GTHX","G1 Therapeutics Provides Third Quarter 2023 Financial Results and Operational Highlights","https://www.globenewswire.com/news-release/2023/11/01/2770927/0/en/G1-Therapeutics-Provides-Third-Quarter-2023-Financial-Results-and-Operational-Highlights.html","Earnings Releases and Operating Results","2023-11-01 06:30:00","pre_market",2,1,418,419,-0,0,-0,"short","short",NaN
1141,"GTHX","G1 Therapeutics Announces Upcoming Presentations at the 2023 ASCO Quality Care Symposium","https://www.globenewswire.com/news-release/2023/10/16/2760730/0/en/G1-Therapeutics-Announces-Upcoming-Presentations-at-the-2023-ASCO-Quality-Care-Symposium.html","Product / Services Announcement","2023-10-16 09:00:00","pre_market",1,1,432,434,0,0,0,"long","long",NaN
1142,"GTHX","G1 Therapeutics’ COSELA® (trilaciclib) Recommended in Updated Small Cell Lung Cancer Guidelines from the American Society of Clinical Oncology (ASCO)","https://www.globenewswire.com/news-release/2023/10/18/2762334/0/en/G1-Therapeutics-COSELA-trilaciclib-Recommended-in-Updated-Small-Cell-Lung-Cancer-Guidelines-from-the-American-Society-of-Clinical-Oncology-ASCO.html","Health","2023-10-18 08:00:00","pre_market",1,1,436,434,0,-0,0,"long","long",NaN
1143,"GTHX","New Publication Highlights Real World Impact of Trilaciclib on Myelosuppressive Events in Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC)","https://www.globenewswire.com/news-release/2023/07/31/2714895/0/en/New-Publication-Highlights-Real-World-Impact-of-Trilaciclib-on-Myelosuppressive-Events-in-Patients-with-Extensive-Stage-Small-Cell-Lung-Cancer-ES-SCLC.html","Clinical Study","2023-07-31 08:30:00","pre_market",2,2,457,457,0,0,0,"long","long",NaN
1140,"GTHX","G1 Therapeutics Provides Second Quarter 2023 Financial Results and Operational Highlights","https://www.globenewswire.com/news-release/2023/08/02/2716638/0/en/G1-Therapeutics-Provides-Second-Quarter-2023-Financial-Results-and-Operational-Highlights.html","Earnings Releases and Operating Results","2023-08-02 06:30:00","pre_market",2,2,456,453,0,-0,0,"long","long",NaN
1128,"GRFS","GigaGen Partners with the National Cancer Institute to Advance Oncology Drug Candidate GIGA-564","https://www.globenewswire.com/news-release/2023/09/28/2751133/0/en/GigaGen-Partners-with-the-National-Cancer-Institute-to-Advance-Oncology-Drug-Candidate-GIGA-564.html","Health","2023-09-28 08:00:00","pre_market",9,9,426,425,0,-0,0,"long","long",NaN
1129,"GRFS","GigaGen Receives FDA Clearance of IND to Begin Phase 1 Trial of Oncology Drug Candidate, GIGA-564, in Solid Tumors","https://www.globenewswire.com/news-release/2023/12/12/2794694/0/en/GigaGen-Receives-FDA-Clearance-of-IND-to-Begin-Phase-1-Trial-of-Oncology-Drug-Candidate-GIGA-564-in-Solid-Tumors.html","Clinical Study","2023-12-12 08:00:00","pre_market",10,10,462,462,0,-0,0,"long","long",NaN
1130,"GRFS","GigaGen Initiates Large-Scale Manufacturing of its First-in-Class Recombinant Hyperimmune Drug for COVID-19, GIGA-2050","https://www.globenewswire.com/news-release/2020/09/09/2091073/0/en/GigaGen-Initiates-Large-Scale-Manufacturing-of-its-First-in-Class-Recombinant-Hyperimmune-Drug-for-COVID-19-GIGA-2050.html","Product / Services Announcement","2020-09-09 10:17:00","market_open",16,16,338,340,-0,0,-0,"short","short",NaN
1152,"HARP","Harpoon Therapeutics Announces Completion of Planned Patient Enrollment in Phase 1 Study of HPN217 in Relapsed/Refractory Multiple Myeloma","https://www.globenewswire.com/news-release/2023/06/27/2695191/0/en/Harpoon-Therapeutics-Announces-Completion-of-Planned-Patient-Enrollment-in-Phase-1-Study-of-HPN217-in-Relapsed-Refractory-Multiple-Myeloma.html","Clinical Study","2023-06-27 07:30:00","pre_market",6,6,431,432,0,0,-0,"short","short",NaN
1153,"HARP","Harpoon Therapeutics Appoints Haibo Wang as Senior Vice President of Business Development","https://www.globenewswire.com/news-release/2023/08/01/2715708/0/en/Harpoon-Therapeutics-Appoints-Haibo-Wang-as-Senior-Vice-President-of-Business-Development.html","Management Changes","2023-08-01 07:30:00","pre_market",8,8,458,456,-0,-0,-0,"short","short",NaN
1154,"HARP","Harpoon Therapeutics to Participate in Two Upcoming Investor Conferences in August","https://www.globenewswire.com/news-release/2023/08/03/2717893/0/en/Harpoon-Therapeutics-to-Participate-in-Two-Upcoming-Investor-Conferences-in-August.html","Conference Calls/ Webcasts","2023-08-03 07:30:00","pre_market",7,8,450,448,0,-0,0,"long","long",NaN
1155,"HARP","Harpoon Therapeutics Abstract for HPN217 Accepted for Poster Presentation at the 20th International Myeloma Society Annual Meeting","https://www.globenewswire.com/news-release/2023/09/06/2738263/0/en/Harpoon-Therapeutics-Abstract-for-HPN217-Accepted-for-Poster-Presentation-at-the-20th-International-Myeloma-Society-Annual-Meeting.html","Calendar of Events","2023-09-06 07:30:00","pre_market",8,9,449,448,0,-0,0,"long","short",NaN
1156,"HARP","Harpoon Therapeutics Announces First Patients with Small Cell Lung Cancer Dosed in HPN328 Combination Cohort","https://www.globenewswire.com/news-release/2023/09/15/2743899/0/en/Harpoon-Therapeutics-Announces-First-Patients-with-Small-Cell-Lung-Cancer-Dosed-in-HPN328-Combination-Cohort.html","Clinical Study","2023-09-15 07:15:00","pre_market",5,5,450,447,0,-0,0,"long","long",NaN
1157,"HARP","Harpoon Therapeutics Presents Data for New ProTriTAC™ Development Candidates in TROP2- and ITGB6-expressing Solid Tumors at AACR 2023","https://www.globenewswire.com/news-release/2023/04/17/2648353/0/en/Harpoon-Therapeutics-Presents-Data-for-New-ProTriTAC-Development-Candidates-in-TROP2-and-ITGB6-expressing-Solid-Tumors-at-AACR-2023.html","Clinical Study","2023-04-17 13:30:00","market_open",7,7,412,414,-0,0,-0,"short","short",NaN
1158,"HARP","Harpoon Therapeutics Announces Up to $150 Million Private Placement","https://www.globenewswire.com/news-release/2023/10/23/2764595/0/en/Harpoon-Therapeutics-Announces-Up-to-150-Million-Private-Placement.html","Financing Agreements","2023-10-23 07:17:00","pre_market",7,7,421,420,0,-0,0,"long","long",NaN
1159,"HARP","Harpoon Therapeutics to Participate in the SVB Securities Global Biopharma Conference","https://www.globenewswire.com/news-release/2023/02/07/2602863/0/en/Harpoon-Therapeutics-to-Participate-in-the-SVB-Securities-Global-Biopharma-Conference.html","Calendar of Events","2023-02-07 07:30:00","pre_market",11,11,410,409,0,-0,0,"long","long",NaN
1146,"GTHX","G1 Therapeutics to Participate in the 22nd Annual Needham Virtual Healthcare Conference","https://www.globenewswire.com/news-release/2023/04/11/2644770/0/en/G1-Therapeutics-to-Participate-in-the-22nd-Annual-Needham-Virtual-Healthcare-Conference.html","Conference Calls/ Webcasts","2023-04-11 12:30:00","market_open",3,3,410,410,0,-0,0,"long","long",NaN
1145,"GTHX","G1 Therapeutics Provides First Quarter 2023 Financial Results and Operational Highlights","https://www.globenewswire.com/news-release/2023/05/03/2660123/0/en/G1-Therapeutics-Provides-First-Quarter-2023-Financial-Results-and-Operational-Highlights.html","Earnings Releases and Operating Results","2023-05-03 06:30:00","pre_market",3,3,411,411,0,0,0,"long","short",NaN
1160,"HARP","Harpoon Therapeutics Abstract for HPN217 Accepted for Presentation at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition","https://www.globenewswire.com/news-release/2023/11/02/2772457/0/en/Harpoon-Therapeutics-Abstract-for-HPN217-Accepted-for-Presentation-at-the-65th-American-Society-of-Hematology-ASH-Annual-Meeting-and-Exposition.html","Calendar of Events","2023-11-02 09:15:00","pre_market",5,5,423,427,0,0,-0,"short","short",NaN
1147,"GTHX","G1 Therapeutics Provides Corporate Update at the 42nd Annual J.P. Morgan Healthcare Conference","https://www.globenewswire.com/news-release/2024/01/08/2805234/0/en/G1-Therapeutics-Provides-Corporate-Update-at-the-42nd-Annual-J-P-Morgan-Healthcare-Conference.html","Health","2024-01-08 06:45:00","pre_market",3,3,468,468,0,0,0,"long","long",NaN
1161,"HARP","Harpoon Therapeutics Abstract for HPN328 Accepted for Rapid Oral Presentation at the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium","https://www.globenewswire.com/news-release/2023/12/19/2798452/0/en/Harpoon-Therapeutics-Abstract-for-HPN328-Accepted-for-Rapid-Oral-Presentation-at-the-2024-American-Society-of-Clinical-Oncology-Genitourinary-Cancers-Symposium.html","Calendar of Events","2023-12-19 07:30:00","pre_market",10,11,472,473,0,0,0,"long","long",NaN
